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Abstract
In prostate cancer, chronic administration of cytotoxins leads to systemic cytotoxicity. A 
new prostate-selective delivery system has been designed. Polymeric prodrugs are 
selectively retained in solid tumours by the enhanced permeability and retention effect but 
intracellular drug release is slow. In the designed prodrug, the drug would be released by 
the action of prostate specific antigen (PSA) that is active extracellularly in the tumour site 
only. Tumour-selectivity would be binary. PSA selectively cleaves the peptide sequence 
HSSKLQ.
The PSA-activated prodrug comprises a tripartite system, including a PSA-cleavable 
linker, a molecular clip and a model drug. A model drug (2-(4-nitrophenyl)ethylamine) 
was attached through an amide to the dipeptide molecular clip Xaa-2,2- 
dimethylthiazolidine. A 5,5-dimethylthiaproline (Me2Thiazolidine) forces peptides into the 
cis conformation, enhancing cyclisation, diketopiperazine (DKP) formation and drug 
liberation. Targets with different L-amino-acids (H, CH3, CH(CH3)2, CH2PI1, 
CH2CH(CH3)2) were coupled with R and S Me2Thiazolidines. Cyclisation was faster in the 
L,S compounds. In the L>R series, increasing the side-chain bulkiness slows cyclisation; in 
the L,S compounds, bulky groups speed cyclisation. The initial ring-closure is rate- 
determining.
The structures of the DKPs cyc/o-L-Ala-^-dimethylthiazolidine and cyclo-L-Val-R- 
dimethylthiazolidine were established by X-ray crystallography and by !H NMR. The DKP 
ring was in the boat conformation, with the thiazolidine in a half-chair. The geminal 2,2- 
dimethyl groups are equatorial and axial; the Me and isopropyl side chains are pseudo- 
equatorial, remote in space from the dimethyl. In both DKPs, the solution-phase 
conformation was similar. The DKP rings in cyc/o-L-Val-S-dimethylthiazolidine and 
cyc/0 -L-Leu-S-dimethylthiazolidine were almost planar.
PSA-sensitive prodrugs CbzSKLQVOMe, CbzSSKLQV-Me2ThProNPEA and 
CbzSKLQVMe2ThProNPEA was synthesised using orthogonally protected amino-acid 
active esters in solution-phase coupling. Incubation of the prodrugs with PSA revealed 
cleavage LjQ, rather than the predicted QjV.
A short series of disubstituted thiophenes, carrying thiourea head groups, was synthesised 
and evaluated for inhibition of isoforms of nitric oxide synthase.
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1.1 Male reproductive system
The male reproductive system is essential to the perpetuation of life. It is the means by 
which we propagate and ensure our continued existence. Individual life is possible without 










Figure 1.1 Posterior view o f  the male accessory organs o f  reproduction.
The male reproductive system (Figure 1.1) is composed of essential and accessory organs. 
The essential organs {gonads, testes) produce gametes. The accessory organs include 
genital ducts, glands and supporting structures. The genital ducts serve to convey sperm to 
the outside of the body and include a pair of epididymides, a pair of vasa deferentia, a pair 
of ejaculatory ducts and the urethra. The accessory glands, which include a pair of seminal 
vesicles, one prostate and a pair of bulbourethral (Cowper’s) glands produce secretions that
1
serve to nourish, transport and mature sperm. The supporting structures include the 
scrotum, the penis and a pair of spermatic cords.1
1.1.1 Testes
The male reproductive system normally contains two testes. They are small ovoid glands, 
measure about 4 or 5 cm in length and weigh 10 to 15 g. The left testis is generally located 
about 1 cm lower in the scrotal sac than the right. Each testis is composed of up to 900 
coiled seminiferous tubules, in which spermatogenesis occurs.1,2 The formed sperm would 
then empty into the epididymis, another coiled tube about 6  m long. The epididymis then 
leads into the vas deferens, which enlarges into the ampulla of the vas deferens 
immediately before entering the body of the prostate gland.3 The testes secrete several male 
hormones, which are collectively called androgens. All androgens are steroid compounds, 
as shown by the formulae for testosterone (1) and dihydrotestosterone (2) (Figure 1.2). 
They play a critical role in spermatogenesis, prostate cell growth and are responsible for 
many male features such as lower voice, male hair patterns and the male libido or sexual 
drive.3
CH CH
Figure 1.2 Chemical structures of testosterone (1) and dihydrotestosterone (2).
1.1.2 Seminal vesicles
There are two seminal vesicles. Each is a tortuous, loculated tube lined with a secretary 
epithelium and secrets a mucoid material containing an abundance of fructose and citric 
acid, as well as large quantities of prostaglandins and fibrinogen. They are located on each 
side of the prostate. During emission, each vesicle, together with the ampulla, empties its 
contents into the ejaculatory duct, leading through the body of the prostate gland and then 
emptying into the internal urethra.3
2
1.1.3 Prostate gland
The prostate is a single, muscular, walnut-sized gland, located beneath the urinary bladder 
and in front of the rectum.2 The normal gland weighs about 20 g and it is enclosed in a 
fibrous capsule.4 The gland increases slowly in size from birth to puberty and then expands 
rapidly. However, the size attained by age 30 typically remains stable until about age 45, 
when further enlargement may occur.2
Within the prostate, there are three groups of glands arranged concentrically around the 
urethra: an inner peri-urethral group, the submucosal glands and the external group or main 
prostatic glands. From all three groups, ducts converge and open into the prostatic urethra.3 
The prostate gland secretes a thin, milky fluid that constitutes about 31% of the seminal 
fluid volume.1 This fluid contains several substances, such as citric acid, which is used by 
sperm for ATP production via the Krebs cycle, several proteolytic enzymes, such as 
prostate specific antigen (PSA), pepsinogen, lysozyme, amylase, and hyaluronidase which 
break down the clotting protein from the seminal vesicles, in addition to an acid 
phosphatase whose function is unknown.2
During emission, the capsule of the prostate gland contracts simultaneously with the 
contractions of the vas deferens. Consequently, the prostate gland fluid is added to the bulk 
of the semen.3 For successful fertilization of the ovum, the prostatic fluid should have a 
slight alkaline pH to protect the sperm from the acidic environment in the male urethra and 
female vagina (pH 3.5-4.0) .1,3
1.1.4 Bulbourethral glands (Cowper’s glands)
The paired glands resemble peas in size and shape. They are located below the prostate on 
either side. A duct approximately 2.5 cm long connects them with the penile portion of the 
urethra. During sexual arousal, the glands would secrete an alkaline fluid into the urethra. 
This, consequently, protects the passing sperm by neutralising acids resulting from urine in 
the urethra. Also, they secrete mucus which lubricates the end of the penis and the lining of 
the urethra, thus decreasing the number of sperm damaged during ejaculation.1,2
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1.2 Male Sex Hormone
The sexual function of male is controlled by the release of gonadotropin-releasing 
hormone (GnRH) secreted by the hypothalamus. This hormone, in turn, stimulates the 
gonadotropes cells in the anterior pituitary gland to secrete two other hormones:
1 -Luteinising hormone (LH) which is the primary stimulus for the secretion of testosterone 
by the testes Leydig cells which constitute about 20% of the mass of the adult testes.
2-Follicle-stimulating hormone (FSH) which mainly stimulates spermatogenesis.3
So, in the absence of GnRH, the gonadotropes cells secrete almost no LH or FSH. 
Furthermore, testosterone secreted has a reciprocal effect of inhibiting anterior pituitary 
secretion of LH and FSH. This inhibition results from the direct effect of testosterone on 
the hypothalamus to decrease the secretion of GnRH. Consequently, there is a 
corresponding decrease in the secretion of both LH and FSH. This, in turn, decreases the 
secretion of testosterone. Thus, whenever secretion of testosterone is too high, an 
automatic negative feedback effect will decrease the testosterone secretion back toward the 
required operating level.3
In the prostate gland, the testosterone hormone enters the prostatic cells very quickly 
(usually within a few minutes) after secretion; then it will be converted to 
dihydrotestosterone by the intracellular enzyme 5a-reductase. Dihydrotestosterone, in turn, 
binds with a cytoplasmic receptor protein. This combination then migrates to the cell 
nucleus, where it binds with the nuclear protein and induces DNA-RNA transcription. 
Within 30 min, RNA polymerase becomes activated and the concentration of RNA 
increases in the prostatic cell, followed by a progressive increase in cellular protein. After a 
couple of days, the quantity of DNA increases in the prostate with a simultaneous increase 
in the number of prostatic cells.3
1.3 Incidence of prostate disease
Diseases of the prostate are common causes of urinary problems in men, the incidence of 
which increases with age, especially beyond 60 years.4 The most common types of prostate 
diseases are:
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1.3.1 Benign nodular hyperplasia (BNH)
BNH is a non-neoplastic enlargement of the prostate gland (benign neoplasm).4 It is very 
common and the incidence increases after the age of 50. The cause is obscure but it is 
thought to be related to a hormonal imbalance, although the exact mechanism is uncertain. 
The enlargement of the prostate inside its capsule results in the blockage of the urethra and 
consequently may develop slowness or dribbling in the urinary stream, hesitancy or 
difficulty in starting urination, feeling of urgency to urinate, even when the bladder is 
empty, and frequent urination, especially at night.4,5
1.3.2 Prostatitis
Prostatitis is an infection and / or inflammation of the prostate gland which can be caused 




Figure 1.3 Drawing o f  the normal urethra and the narrowed urethra in prostatitis.
A Acute Prostatitis
It is a bacterial infection, characterised by an acute inflammation of the prostate, which 
usually follows an acute infection in the bladder or urethra.6 It is particularly common 
following urethral catheterisation or endoscopy.4 The common causative micro-organism is
Narrowed Urethra
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E. coli. Furthermore; sexually transmitted diseases, particularly gonococcus and chlamydia 
(a cause of non-gonococcal urethritis) may cause prostatitis.4,6
B Chronic Prostatitis
It is also associated with lower urinary tract infection, results from inadequately treated 
acute prostatitis due to resistance, relapse and short-course therapy.6 The prostate gland 
shows increased stromal fibrosis, with an infiltrate of lymphocytes and plasma cells, 
associated with acinar atrophy 4
C Granulomatous Prostatitis
It is a heterogeneous group of lesions, all of which may cause enlargement of the gland and 
urethral obstruction. The inflammatory component and the associated fibrosis produce a 
firm, indurated gland, which, upon rectal examination, mimics the neoplasm clinically. 
Consequently, it is very important to diagnose this type of Prostatitis correctly.4
1.3.3 Prostatic carcinoma
Prostate cancer is among the most common malignant disease for which health-care 
intervention is sought worldwide.7 It is the most common non-cutaneous cancer in most 
developed countries and could become the commonest male cancer worldwide. In term of 
male cancer deaths, it is the second cause of death after lung cancer.8,9 Prostate cancer is 
diagnosed in a very few people aged younger than 50 years (<0.1% of all patients) .10 
However, the peak incidence is between 60-85 years.4
1.3.3.1 Aetiology
The aetiology of the disease is unknown, although it is probable that hormonal changes, 
which occur with increasing age, are involved. With advancing age, there would be a 
decrease in the circulating androgen levels. This decrease is associated with involution of 
the outer zone of the prostate where most tumours arise.4 However, although common 
lesions prostatic carcinoma and BNH frequently coexist coincidentally in the same gland,
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there is virtually no evidence that BNH is causally related to the development of 
malignancy. Therefore, BNH is not considered a pre-neoplastic lesion.4’5
1.3.3.2 Epidemiology
» Incidence of the disease varies widely between ethnic populations and countries. The 
lowest rate is usually in Asia and the highest rates are in North America and Scandinavia. 
This difference is attributed to a combination of other underlying differences, such as 
genetic susceptibility, exposure to unknown risk factors, or artifactual reasons, such as 
cancer registration and difference in health care.10 Other factors may also attribute and 
include:
A Genetic factors
Genetic factors are the cause behind prostate cancer clustering in families. About 10-15 % 
of patients have at least one relative who is also affected. Furthermore, the risk of 
developing the disease in relatives increases with an increase in the number of affected 
individuals in the family.10
B Dietary factors
Epidemiological studies suggested that prostate cancer is associated with Western lifestyle 
and in particular, diet that includes a high intake of fat, meat, and dairy products.11
C Hormones and other risk factors
Andogens play an important role in the development of healthy prostate and in the 
treatment of the cancer. That is, the hormones influence on the growth of normal prostate 
cells is maintained in malignancy. Withdrawal of these hormones, by surgical or medical 
castration, results in the arrest of prostatic cell multiplication.10 Different ways can be used 
to remove androgens from the body. These methods include the removal of man's testes 
(called an orchiectomy), drugs that block the production of androgens (called Luteinizing 
Hormone-Releasing Hormone (LHRH) agonists), drugs that block androgen receptors 
(called anti-androgens and oestrogens) .9
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1.3.3.3 Clinicopathology
Two clinicopathological types of prostatic carcinoma are recognised:
A Clinical (symptomatic) carcinoma
The tumour spread within the gland and may cause urethral obstruction. However, most 
active tumours arise in the posterior lobe of the gland, mainly in the subcapsular area. As a 
result, retropubic prostatectomy for BNH dose not remove the posterior zone; this explains 
why carcinoma sometime may develop following such a prostatectomy.4
The large majority of prostatic carcinomas are adenocarcinomas, usually well 
differentiated, forming acini, tubules or a cribriform pattern. The convoluted outline of the 
glands is lost and neoplastic acini are formed 4,5 Also, it has been found that the tumour 
may metastasize to adjacent tissue widely and silently. This spread may be; (A)-lymphatic, 
initially to presacral, iliac and para-aortic lymph nodes, but often extending widely; (B) 
retrograde venous, to the lumber spine; (C) by the blood stream causing widespread 
metastases, with a marked predilection for the skeleton.4,5
B Latent (incidental) carcinoma
Microscopic foci of carcinoma are found incidentally on histological examination of 
prostatectomy specimens or in the prostate at autopsy. The incidence of these foci depends 
largely on the age of the patient. In addition, such foci are found in about 30% of prostate 
glands over the age of 50 and about 80% of the glands over the age of 75. It is, therefore, 
much commoner than the clinically symptomatic form of the disease 4,5
Latent tumours are adenocarcinomas (like symptomatic lesion). The concept of this tumour
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has been questioned, with the recognition that some of them eventually progress and 
metastasise. The disease progression occurs in about 30% of the patients after 10 years. 
However, the majority probably remain as latent or dormant lesions and, in practical terms, 
the presence of minute tumour foci in the prostatectomy specimen is not an indication for 
immediate hormonal therapy.4
Unfortunately, to date, there are no laboratory techniques available to identify which of 
these microscopic tumour foci will progress, so that, most surgeons will choose to follow 
up the patient without any initial therapy.4
1.3.3.4 Clinical features
a
The clinical features of prostatic carcinoma include:
-Urinary outflow obstructive symptoms such as difficulty or increased frequency of 
nicturition and urinary retention.
-Digital rectal examination would reveal hard craggy prostate.
-Bone metastases often present as localised bone pain, pathological fracture and anaemia. 
-Lymph node metastases due to metastatic prostate carcinoma.4
1.3.3.5 Gleason grading system
After prostate cancer diagnosis, determination of the stage of the cancer is important for 
planning the appropriate treatment. Staging indicates the size and location of the cancer 
and if the cancer has been metastasised beyond the prostate.
12The gleason grading system is the most frequently used system (Figure 1.4). In this 
system, the prognosis of the cancer is considered to be the intermediate between the grade 
of the most predominant pattern of cancer seen in microscopic sample and the grade of the 
second most predominant pattern. Each of these patterns are identified and graded 
separately from 1 (almost normal) to 5 (very abnormal). The two grades are then added 
together.13
Data from the Veterans Administration Cooperative Urological Research Group study 
indicate that clinical staging and histological grading can be combined to provide increased 
discrimination in predicting the biological malignancy of prostatic carcinoma. Therefore, 
prostatic carcinoma was classified according to gleason grading system into: (A) Gleason 
grade 2-4 in which prostatic tumour tend to grow slowly and takes long time to become 
clinically significant. The time required for the tumour to be doubled in size is measured in 
terms of years; (B) Gleason grade of 5 or 6 in which prostatic tumours are clinically 
significant if they occur in younger men below the age of 70-75. Over the age of 80, the
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patient is more likely to die of other causes than prostate cancer; (C) Gleason grades 8, 9, 
or 10, which is very aggressive and the time required for the tumour to be doubled in size 
is measured in terms of weeks or months; (D) Gleason Grade 7 in which cancers act in 
between the moderate and high grade cancers and must be considered significant but not 
incurable.13,14
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Figure 1.4 Prostatic carcinoma grades. This illustration shows Dr. Gleason's own 
simplified drawing o f the five Gleason grades o f prostate cancer. Grade 1 appears on 
the fa r  left and grade 5 on the fa r  right.12
1.3.3.6 Diagnosis
Useful diagnostic investigations include diagnostic imaging such as ultrasound, cytoscopy 
such as transurethral resection and chemical pathology which include the presence of high 
levels of serum acid phosphatase in patients with associated bone metastases,3 high level of 
serum alkaline phosphate n patient with osteosclerotic bone metastases as a result of 
osteoblast proliferation15 and high level of prostate specific antigen present in malignant 
prostatic epithelium.16 Other diagnostic investigations include haematology, such as 
leukoerythroblastic anaemia, which develops upon widespread carcinomatous infiltration 
of the bone marrow and evinced by the presence of primitive red and white cell precursors 




In surgery, the coqcept of treatment is simple. If the cancer is localised within the prostate 
gland and the gland is removed, the cancer is cured. The most common known surgical 
procedure is radical prostatectomy.17 Radical prostatectomy can be divided into retropubic 
and perineal. In radical retropubic prostatectomy, the lymph node can be dissected and the 
prostate is removed in a single incision, whereas, in radical perineal prostatectomy, a 
separate incision is required for lymph-node dissection and for prostatectomy.7 It is 
noteworthy that prostatectomy, in the early stages of the cancer when it is localised, helps 
85% -90% of the patient to survive for up to 15 year after operation.
Following prostatectomy, PSA is expected to be undetectable. However, any rise will be a
suspicious sign for local recurrence. As a result, patients with a local recurrence after
18prostatectomy require an adjuvant radiation therapy.
Unfortunately, urinary incontinence will develop after radical prostatectomy. Urinary 
incontinence definition ranging from the occurrence of urinary dribbling during stressful 
activity to the requirement of urinary pads.19 The incidence of incontinence is quite high, 
immediately after surgery, but decreases with time. About 2 - 5 %  of patients suffer from 
severe incontinence 6 months after surgery.20 Additionally, potency could be diminished 
after surgery. This is because the neurovascular bundles are manipulated or severed. 
However, to date, new surgical approaches which spare the neurovascular bundle through 
unilateral or bilateral nerve-sparing techniques have reduced impotence rates.21
1.4.2 Radiation
Extemal-beam radiotherapy has undergone a technological revolution. It is virtuous in the 
treatment of localised prostate cancer and has the following advantages; (A) unlike 
surgery, no anaesthetic is required. As a result, it is used in a wide spectrum of patients; 
(B) accompanied urinary toxic effects can be managed with a-adrenergic blockers; (C) 
potency preservation rates are higher compared to patients who have undergone
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prostatectomy.7 On the other hand, rectal complications usually result from the 
uncontrolled delivery of radiation to the prostate.22
Brachvtherapv is the direct placement of the radioactive beam into the region of interest. It 
is used for the treatment of early-stage prostate cancer. Unlike extemal-beam radiotherapy, 
the incidence of rectal complications is lower due to the localised dose distribution. Also, it 
offers better potency preservation in comparison with radical prostatectomy. On the other 
hand, the trauma of needle placement into the prostate can result in prostate oedema and 
cause urinary toxic effects. These effects are usually treated with a-adrenergic blockers and 
corticosteroids.23
Generally, it has been found that 10-year disease-specific death after radiotherapy ranged 
from 4% to 54%, for well- and poorly-differentiated local disease, respectively.17
1.4.3 Hormones
The prostate is a hormone-responsive organ.7 In the early stages; prostate cancer growth is 
enhanced by androgens. In the majority of the advanced stages, this disease remains 
sensitive to hormone manipulation. The role of hormones on the growth of normal prostate 
cells is maintained in malignancy. The growth of these cells is stimulated by testosterone 
and other androgens produced by the testis and the adrenal glands. Withdrawal of these 
hormones results in the control of prostatic cell proliferation in 75 -  80% of patients with 
advanced prostate cancer.10,24 Consequently, androgen ablation is the mainstay of primary 
therapy.
Previously androgen-ablation therapy was accomplished surgically by orchiectomy. 
Presently, this has been replaced with medical castration.7 Many hormonal agents work at 
different points in the hormone biosynthesis cascade. They either inhibit testosterone 
production or block its action. These include; (A) steroidal anti-androgens, such as the 
progestogens (megestrol acetate) and the imidazole derivative Ketoconazole. The 
progestogen agent suppress Luteinising hormone (LH) release at the level of the 
hypothalamic-pituitary axis and then reduce testosterone levels, block conversion of 
testosterone to dihydrotestosterone and prevent binding of androgens to receptors. 
Imidazole derivatives are adrenal enzyme synthesis inhibitors, block the function of
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cytochrome P-450 and suppress the synthesis of both testicular and adrenal androgens; (B) 
nonsteroidal anti-androgens, such as flutamide, block androgen action at the cellular target 
level, do not alter LH secretion and have the advantage of preserving libido; (C) 
gonadotropin-releasing hormone (GnRH) agonists, down regulate pituitary receptors 
resulting in the loss of normal pituitary secretion and in castration of serum androgen level. 
(D) oestrogens, such as diethylstilboestrol, suppress the hypothalamic secretion of GnRH 
and, consequently, LH secretion.17,25
The relative value of these various methods of achieving androgen ablation does not show 
any preference of one over the other, except with regards to different cost26 About 70% to 
80% of patients initially respond to hormonal manipulation. However, the overall survivals 
range between 24 to 36 months. So, early stage hormone therapy refines the quality of 
patients' life but does not lengthen their survival27
Unfortunately, disseminated prostate cancer will eventually escape the primary 
monotherapy (first-line hormonal therapy) and requires a second line of treatment 
modalities. As an example, the addition of non-steriodal anti-androgen to orchiectomy will 
result in total androgen blockade and consequently increase the survival rate in patients.24 
In addition; combination of hormones with radiotherapy improves survival.7 ■
Hormonal therapies have common side effects which include, hot flushes, loss of libido or 
erectile function, weight gain, gynaecomastia, liver inflammation and osteoporosis. 
Although these side effects are usually mild in case of short-course treatment, they should 
be balanced against the benefit.28 As a conclusion, hormonal ablation therapy is the main 
choice for the treatment of localised and disseminated prostate cancer but, unfortunately, 
after a brief period, prostate cancer commonly recurs and the patients relapse with 
androgen-independent tumours.29
MacNeal has identified premalignant changes in prostate cancer. One of the early 
changes which lead to malignancy is the lack of senescence. This means that prostate 
cancerous cells do not die as normal cells. This lack of cell death results in a greater 
number of cancerous cells. These cells, which do not age normally, can escape the normal
-ia
control mechanisms of hormones. Coffey and Isaacs, have identified three different 
mechanisms for the development of hormone-independent cells;31 (A) the direct mutation
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of DNA; (B) the ability of the cells to adapt to environment changes; in other words, as 
androgens are withdrawn by hormonal therapy, the cells learn to live in a low-androgen 
environment; (C) the hormone independent cells are present since the beginning of the 
growth, albeit in comparatively small numbers, which become obvious after tumour 
treatment with hormone manipulation or other therapeutic modalities.31
ft
Finally, when the tumour is metastatic, the treatment of hormone-refractory prostate cells 
may be accomplished by chemotherapeutics.
1.4.5 Chemotherapy
In 1941, the idea of using chemotherapy in the treatment of malignant disease was bom. In 
the following year,32 Gilman and others started clinical studies on the nitrogen mustards 
and discovered that mechlorethamine was effective against Hodgkins disease and 
lymphosarcoma.33 In the next decade, antimetabolites such as methotrexate (3) (1949), 6- 
mercaptopurine (4) (1952) and 5-fluorouracil (5) (1957) were discovered. Also, alkylating 
agents, such as melphalan (6) and cyclophosphamide (7) were developed. In addition, 
natural products, such as mitomycin C (8) and alkaloids were discovered in this period. 
During the 1960s, progress continued in all these areas with the discovery of doxorubicin 
(9).34 It is noteworthy that there are many other chemotherapeutic agents present but I will 
discuss the most principle ones.
1.4.5.1 Alkylating agents
Melphalan (6) Cyclophosphamide (7)
They are highly reactive agents; form covalent links with biomolecules containing -SH, 
NH2 and OH nucleophiles, such as nucleic acids and proteins. The alkylation of nucleic 
acids involves a substitution reaction in which a nucleophilic atom (Nu) of the biopolymer 
displaces a leaving group from the alkylating agent.34
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Nu-H + Alkyl-Y ► Alkyl-Nu + H+ + Y"
Alkylating agents cause different types of damage to DNA, which include; (A) single 
alkylation of a base leading to errors in DNA function; (B) alkylation of two bases to 
cross-link them, either within the same or different strands; (C) single or double strand 
breaks. A consequent physiological repair process will take place. However, it is not 
efficient in highly alkylated and cross-linked regions. So, DNA damage will give rise to a 
chain breaks and faulty transcription of the information in the DNA.35
It is noteworthy that mitomycin C (8) is commonly listed among the antibiotics although 
its mechanism of action is reductive-activated alkylation °
1.4.5.2 Antimetabolites
Antimetabolites are compounds that prevent the biosynthesis of cellular metabolites by 
acting as enzyme inhibitors or by preventing their utilisation by acting as analogues. For 
example:
Methotrexate (3) stops DNA synthesis by acting as a potent inhibitor of the enzyme 
dihydrofolate reductase, which is essential in the synthesis of tetrahydrofolate needed for 
the biosynthesis of both thymidylate and h 2n
process is very limited; as a result, high doses of drug are required. The resulting high 
plasma level will increase the rate of passive diffusion process and, consequently elevate 
intracellular concentrations, resulting in sustained inhibition of DNA synthesis. However,
and strand breakage of treated DNA.35
o c o n h 2
Mitomycin C (8)
purine. There are two processes by which 
this drug enters the cell, active transport 
and passive diffusion. The former
COOH
Methotrexate (3)
such high level results in highly toxic side effects.34,35
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6-Mercaptopurine (4) is a purine analogue, converted into its ribonucleotide by the 
enzyme hypoxanthine-guanine phosphoribosyltransferase. This nucleotide inhibits the first 
step in the pathway of purine biosynthesis, the formation of 5- 
phosphoribosylamine, as well as later steps in the 
interconversion of various purine nucleotides. Neoplasms that 
lack this enzyme are resistant to the drug. Toxicity takes the 6-Mercaptopurine (4) 
form of bone marrow depression, with a delayed leukopenia and evidence of liver 
damage.34,35
5-Fluorouracil (5) in the form of 5-fluoro-2-deoxyuridylic acid is a powerful competitive 
inhibitor of thymidylate synthetase, the enzyme required for the o
formation of thymidylate. Bone marrow depression is the major 
toxic side effects. Other side effects include diarrhoea, stomatitis, 
ulceration of the gastrointestinal tract, hair loss, dermatitis, 
cerebullar damage as dizziness and ataxia.34,35
1.4.5.3 Antibiotics
Different antibiotics have been established in clinical anticancer therapy. These 
compounds were originally rejected as antibacterial agents because of their cytotoxicity. 
Later on, it has been found that this toxicity could turn into an advantage in cancer 
chemotherapy. There are two major mechanisms for these drugs to deform DNA structure 
and so terminate its biological function; (A) intercalation into the double helix DNA 
strand. This in turn creates local unwinding in DNA helix; (B) Inhibition of the enzyme 
topoisomerase n. This enzyme is fundamental for the regulation of DNA topology in all 
living organisms. It prevents DNA tangling during replication, cleaves DNA strands 
reversibly to create a DNA “gate”, allow the second, nearby double helix to pass through 
this break and then reseal the break and dissociates from the DNA. However, this enzyme 
requires appropriate orientation and separation of DNA strands for their activity.34,36
5-Fluorouracil (5)
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Anthracycline antibiotics, such as doxorubicin (9) and its derivatives, inhibit cell growth
and lead to cell death. They dissociate DNA  
double helix by intercalation resulting in the 
formation o f anthracyclin-DNA complex, inhibit 
topoisomerase II enzyme by forming stable 
DNA-enzyme-drug complexes thus, hindering 
the regulation o f DNA strand by the enzyme and 
resulting in irreversible DNA break which then 
lead to cell death.24,37 Doxorubicin (9)
Doxorubicin (9) is among the most effective chemotherapeutic agents for the treatment of  
advanced hormone-refractory prostate cancer. However, the high incidence o f cardiac 
toxicity persuades many clinicians not to use it in old patients or to use low doses which 
unfortunately, would lower drug efficacy 24,38
1.5 Structure-activity relationships of anthracycline antibiotics
The complete structure o f anthracyclines is a glycoside (sugar + aglycone).34 Recent 
studies indicate the crucial role o f the sugar moiety and cyclohexene ring (A) in their 
action.39,40 These studies examined different analogues, with different substituents at the 3' 
and 4' site o f the sugar moiety and / or the removal o f the methoxy group at position 4, 
with respect to their stimulation o f DNA fragmentation at an equitoxic drug concentration 
(Figure 1.5). It has been found that compound (12) stimulate the largest number o f DNA 
strand break (DSB), compounds (13) and (14) stimulate intermediate amounts o f DSB, 
while the lowest level o f DSB was seen with compounds (9), (10), (11), and (15). 
However, the results corresponding to compound (14) were surprising, because previous 
studies o f the cytotoxic potency o f these compounds showed that it is less potent than (9) 
(Figure 1.5), nevertheless, it stimulates larger amount o f DNA strand breakage. So, there 





Compound R, r 4 R5 * 6 Cytotoxicity
IC5 0 ’ M-M
(9) Doxorubicin o c h 3 OH OH H n h 2 H 0.80
( 1 0 ) Daunorubicin o c h 3 H OH H n h 2 H 0 . 2 0
( 1 1 ) Idarubicin H H OH H n h 2 H 0 . 0 2
( 1 2 ) 4-dem ethoxy-3'-deam ino-3'-hydroxy-4'-epi-
doxorubicin
H OH H OH OH H 0.17
0 3 )
3,-deam ino-4'-deoxy-4'-epi-am ino-idarubicin
H H H n h 2 H H 0.05
(14)
3'-epi-daunorubicin
OCH3 H OH H H n h 2 1.37
0 5 ) 3'-deamino-3'-epi-hydroxy-4'-deoxy-4'-am ino-
daunorubicin
OCH3 H n h 2 H H OH 2.60
Figure 1.5 The chemical structures o f  anthracycline derivatives. IC50 values were 
determined from  the dose-response curves o f  three independent experiments. The cytotoxic 
activity was determined on human HL60 leukemic cells using a cell growth inhibition assay 
after 1 h a t 37° drug exposure.39
Previous studies of anthracyclines which stimulate topoisomerase II-mediated DNA 
cleavage, in a DNA sequence-specific manner, have shown that compound (14) has a 
markedly different sequence-specificity, as compared to the parent drug (9). Compound (9) 
requires an adenine and a thymine at positions -1 and -2, respectively, corresponding to the 
two nucleotides at the 3'-terminus of a strand cut, whereas compound (14) prefers guanine.
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This change in the sequence-specificity is due to the configuration of the amino group of 
the sugar moiety. This amino group interacts strongly with the phosphate backbone of 
nucleic acid. In addition, it is speculated that the OH at C-9 of the ring A is involved in its 
interactions with the enzyme.40
Generally speaking, three distinct functional domains of the anthracycline molecule may 
be defined in the ternary complex (DNA-drug-enzyme): the planar ring system, the sugar 
moiety, and the cyclohexane ring (A). The first two domains are likely to interact with the 




DNA-interacting domain 2 
Figure 1.6 Putative functional domains o f  the anthracyclines molecule.
1.6 Drug targeting
Conventional therapies such as surgery, radiotherapy, hormone-ablation and 
chemotherapy, used to eradicate prostate cancer, have resulted in prolonged survival and 
cure in a few patients. However, relapse and metastases occur in most of the cases and, in 
general, are unresponsive to these treatments any more in the conventional doses. So, to 
overcome this resistance, an aggressive treatment was required, which includes a 
combination of chemotherapeutic agents. This, unfortunately, results in severe side-effects 
and is rarely curative. Therefore, conventional doses of the drug should be delivered to the
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targeted area, so as to decrease the toxic side-effects. This could be achieved by the 
invention of site-specific drug delivery systems.
The degree of specificity achieved by drug targeting is classified according to the level of 
selectivity of the delivery system into; (A) first-order (organ targeting) refers to targeting 
of individual organs or tissue; (B) second-order (cellular targeting) refers to targeting of a 
specific cell type(s) within a tissue; (C) third-order (subcellular targeting) refers to 
targeting of selected intracellular compartment in the target cells. Various delivery systems 
could attain each of these levels but not all the three together. The majority of cytotoxic 
agents act at a variety of subcellular sites, so, a third order level of targeting may be 
necessary to ensure maximum therapeutic efficiency.41
1.6.1 Mode of drug targeting
The systems available for achieving site-specific drug delivery range from direct chemical 
modification of the drug molecule, such as prodrug design.42 to the use of carriers, such as 
macromolecules.43 In general, site-specific drug delivery systems are classified according 
to the methods by which they achieve the target site. They are distinguished into “passive” 
and’“active” drug targeting.
1.6.1.1 Passive targeting
Passive drug targeting refers to the natural distribution pattern of the drug in vivo. The fate 
of drug distribution depends largely on the physicochemical properties of the drug 
particles, such as the number, size, shape, surface characteristics and surface charges. 
Therefore, these properties have been exploited to increase targeting efficiency.43 For 
example:
A Passive lung targeting
Passive lung targeting of anticancer agents depends on the entrapment of large particles 
(>7 pm) in the capillary bed of the lung.
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B Passive reticuloendothelial system (RES)
RES system is a collective name for a group of highly phagocytic cells derived from the 
bone marrow.44 These cells are present either at fixed sites or free in the circulation 
throughout the body. They are found in large concentration in the liver (fixed macrophages 
® called Kupffer cells), spleen and bone marrow. RES-mediated clearance is considered to be 
a major factor in determining biodistribution 41
Macrophages are important part of the host defence mechanism against tumour cells. They 
are activated by lymphokines, such as macrophage activating factors, or synthetic 
compounds, such as muramyl dipeptide. Upon activation, they are capable of killing 
tumour cells via an immunologically non-specific mechanism. However, macrophage- 
mediated destruction of large tumour burdens is not feasible. So, this approach is either 
used to eradicate micrometastases or to remove any residual tumour cells remaining after 
surgery or chemotherapy.41,45
C Passive intra-arterial targeting
In general, intra-arterial injection of large drug particles results in entrapment by the first 
capillary bed encountered. This entrapment would be useful upon injection of antitumour 
agents into the arteries supplying a tumour site. This will result in drug accumulation in the 
tumour site before RES clearance takes effect. For example, starch microspheres, co­
injected with cytotoxic agents, result in the blockage of tumour arterioles and, 
consequently, induce localised hypoxia and high concentration of drug. However, this 
approach is of little or even no value in the treatment of disseminated tumours or 
metastases. It is only useful in case of well-localised solid tumours.41,46,47
1.6.1.2 Active targeting
Active targeting refers to the deliberate modification of the natural distribution pattern of 
the drug, in order to direct it to a specific organ tissues or cells. Modifications, such as 
prodrug design with the trigger-linker-effecter concept, constitute a potential strategy to 
overcome the limitations of chemotherapeutic agents. Prodrugs are comprised of two major 
domains; a “trigger” unit, which is the substrate for the activating enzyme or system, and
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an “effecter” unit (the active drug), which is activated or released by a metabolic process; 
these are sometimes joined by a definable linker. (Figure 1.7). Prodrugs are often divided 
into two groups:
Linker EffectorT rigger
Selective Deactivate Potent & diffusible 
metabolism effector cytotoxic
Figure 1.7 Trigger-linker-effecter concept for prodrug design.
1.6.1.2.1 Prodrugs designed to increase the bioavailability to improve the 
pharmacokinetics of antitumour agents
These prodrugs would overcome the problem associated with numerous antitumour drugs 
that possess a limited bioavailability due to low chemical stability, limited oral absorption 
or rapid breakdown in vivo. The activation process of the prodrugs is preferred to be 
relatively slow in the blood or liver, thus preventing acute toxic effects due to high peak 
concentration of the active drug. After activation, the drug has to be transported via the 
blood stream to the tumour site where it can exert its antitumour action.49
It is noteworthy that the bioavailability of rapidly metabolised antitumour drugs could be 
improved by altering the metabolism system itself, without altering drug design. For 
example, the blockage of RES (especially the Kupffer cells), by the use of RES depressant 
agents, such as dextran sulfate 500, will protect the drug from being captured by these 
cells. Ilium et a l47 have used dextran sulfate to block the RES of rabbits. Upon subsequent 
injection of radiolabelled polystyrene particles, 30% of the injected dose accumulates in 
the liver and spleen, compared with 90% in the unblocked RES animals. The drawback of 
this approach results from the possibility of dose overload upon subsequent dosing. So, the 
use of this technique in clinical trial is doubtful.47
1.6.1.2.2 Prodrugs designed to increase the local delivery of antitumour drugs
The concept of this design is referred to as targeting, organ-specific and tumour-specific 
prodrug activation. In organ-specific targeting approach, prodrug activation is achieved by 
an enzyme selectively presented in the targeted organ, whereas, in the tumour-specific 
targeting approach, the enzyme responsible for prodrug activation should be uniquely
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active in the tumour.50 Another method for tumour-specific targeting is by making use of 
the hypoxic environments present in solid tumours by the synthesis of bioreductively 
activated prodrugs.51 In organ-specific and tumour-specific targeting methods, enzymes of 
high catalytic efficiencies are beneficial, enabling a rapid activation of the prodrug. A 
drawback associated with the tumour-specific targeting approach is that, unlike bacteria 
and viruses, cancer cells do not contain molecular targets which are completely foreign to 
the host.52 Examples of the most common alternative strategies encountered in targeting 
include:
1.6.1.2.2.1 Bioreductive prodrug targeting
In the 1950s, Tomlinson and Gray observed that the diffusion limitation of O2 led to the 
presence of hypoxic cells in tumours. This hypoxic condition has been purported to be an 
important biological factor in the failure of radiotherapy to achieve local control.53 On the 
other hand, it is beneficial in the development of site-specific drug delivery systems. This 
hypoxic condition has been exploited for the development of bioreductively activated drug 
targeting systems. The idea starts with the development of inactive prodrugs, which are 
stable in normoxic tissue and are activated upon bioreduction under the hypoxic condition 
to release the active drug. It is noteworthy that the hypoxic condition is also associated 
with a number of other pathological diseases, such as rheumatoid arthritis, diabetes, renal 
disease and some cardiovascular diseases. As a result, hypoxia-based therapeutic strategies 
become more important day-by-day.54
Hypoxia has been shown to control enzyme expression, via hypoxia-inducible factors, 
which results in the regulation of reductase enzymes required for the activation of inactive 
prodrugs. So, hypoxia has a dual advantage; (A) increase the levels of reductase and so 
enhance activation of inactive prodrug; (B) reduce the concentration of oxygen and so 
facilitate the reduction process.54 Several classes of compounds have been considered for 
the development of hypoxia-selective cytotoxins. For example:
A Nitroheterocycles
In the development of bioreductive delivery systems, nitroheterocycles have a number of 
advantages; (A) they by themselves are used as anti-microbial agents and, in many cases,
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have a limited side-effect profile; (B) they vary greatly in their one-electron reduction 
potentials, thus enhances adaptation for targeting drugs to mammalian tissues; (C) in many 
models of drug conjugation; they have been shown to release the active drug, despite 
having a relatively stable linker bond.55,56
B Indolequinones
The introduction of indolequinones in bioreductive delivery system grew from the research 
done on the use of mitomycin C (8) as an anticancer agent. Their one-electron reduction 
potentials made them suitable for bioreductive targeting to hypoxic tissue. A number of 
structural modification analogues of the base indolequinone have been synthesised and 
used in conjugation with a variety of drugs, such as anti-inflammatory agents57 and anti­
cancer agents.58
C Self-alkylating bioreductives
In many diseases, it was essential to use an inert delivery system. In this system, it was 
essential to avoid the deleterious adduct formation with macromolecules such as DNA 
after drug release following bioreduction. The self-alkylating delivery concept was 
designed to incorporate a nucleophile within the bioreductive prodrug. The nucleophile 
will preferentially react with the bioreduced remnant, through an intramolecular cyclisation 
process, during or after drug release, thus assisting drug release, stabilising the 
bioreductive remnant and preventing DNA adduct formation.54
1.6.1.2.2.2 Antibody-drug conjugates targeting
This strategy involves the conjugation of a number of antitumour drugs, such as 
anthracyclines with antibodies. Antibodies are proteins of the immune system, capable of 
differentiating malignant cells from their normal counterparts. In 1975 a new method to 
produce large quantities of monoclonal antibodies (MoAbs), or antibodies to any antigen 
has been published and showed preferential specificity for tumour cells.59
The most commonly used anthracycline chemotherapeutics in constructing drug-MoAb 
conjugate are daunorubicin and doxorubicin. Both are the best recommended drugs to be
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used in the treatment of advanced stage prostate cancer.59 A number of conjugates prepared 
have shown respectable activity against human tumour xenografts implanted into nude 
mice. However, the few which have undergone clinical evaluation have been disappointing 
in their activity. This could be attributed to the decrease in the potency of doxorubicin (9) 
and daunorubicin (10) as a result of the conjugation with MoAbs, even in the case of the 
most releasable constructs. Furthermore, the amount of MoAb-drug conjugate localised 
within the tumours in a clinical trial is 3 to 4 times lower than in experimental mice, as 
determined by studying radiolabelled MoAbs.59
1.6.1.2.2.3 Antibody-directed enzyme prodrug therapy
The method of ADEPT has been designed in an attempt to improve the outcome of the 
drug-MoAb approach. In this approach, an enzyme is conjugated to MoAb instead of the 
drug. This enzyme-MoAb conjugate is then localised into tumour and, after clearance of 
conjugate from the circulation, anthracycline prodrug would be injected. This prodrug is 
inactive alone but becomes active by the effect of the enzyme.60 (Figure 1.8). An example 
of this approach can be seen in the conjugate between alkaline phosphatase and MoAb. 
The 14-phosphate derivative of doxorubicin was used as a prodrug because it is incapable 
of penetrating cell membranes. Good antitumour activity has been detected, whereas each 
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Figure 1.8 General outlines o f the delivery methods for an enzyme/prodrug cancer 
strategy; divided into two major classes: GDEPT and VDEPT, which refers to the delivery oj 
genes that encode prodrug-activating enzymes into tumour tissues; and ADEPT, which 
deliver active enzymes onto tumour tissue.
1.6.1.2.2.4 Gene-directed enzyme prodrug therapy
Gene therapy is a genetic technology of modifying cells for therapeutic gain. Genetic 
modification is possible on both malignant and non-malignant cells. There are two suicide 
gene approaches. The first approach is termed toxin gene therapy and aims to deliver toxic 
genes to the malignant cells where the protein produced will direct tumour cell killing. The 
second approach is termed gene-directed enzyme prodrug therapy (GDEPT) or virally 
directed enzyme prodrug therapy (VDEPT), where foreign enzymes (non-human) are 
expressed in target cells and activate subsequently administered non-toxic, inactive 
prodrugs into active drugs.62,63 (Figure 1.8)
For successful GDEPT, a number of factors must be accomplished, which include; (A) 
gene, which express an exogenous enzyme or an endogenous enzyme that is poorly 
expressed in tumours and is able to activate a prodrug; (B) a means by which gene would 
be delivered to the target cells; (C) a prodrug.62 The gene should be expressed mainly in 
tumour cells or with relatively high ratio compared to normal cells. The enzyme should be 
able to catalyse different types of reactions, such as scission reactions or redox reactions; 
different from endogenous circulating enzyme, accessible to the prodrug and expressed in
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high amount in the targeted tumour cells. The prodrug should be an efficient and selective 
substrate for the expressed enzyme and diffuse through tumour cell membranes efficiently 
to permit its intracellular activation by the enzyme. The active drug should be an effective 
cytotoxin and have good bystander effects (an ability to diffuse to and kill neighbouring 
tumour cells).62,48
A number of prodrugs have been explored in GDEPT, such as 5-fluorocytosine (5-FC)/£. 
coli cytosine deaminase (CD) therapy. CD is an E. coli enzyme,62 similar to human 
cytidine deaminase but with different substrate specificity. It converts the inactive, non­
toxic 5-FC to 5-fluorouracil, which is a powerful competitive inhibitor of thymidylate 
synthase (TS), a key enzyme in DNA biosynthesis, thus causing cell death. CD/5-FC 
therapy has been tested in vivo and in vitro and has been used for the treatment of 
colorectal carcinoma. It has been found that CD expression increases the sensitivity of 
tumour cells to 5-FC in vitro, by -1000 fold (from IC50 = 26 mM to 27 pM).64 However, in 
mice bearing xenografts expressing CD, 5-FU generated after 5-FC administration could 
be detected in the environment surrounding the tumour and contributed to the bystander 
effect.65
The most significant problem in gene chemotherapy is the prediction of a way to deliver 
therapeutic genes to the tumour. In all currently performed clinical trials, direct 
intratumour injection of the vector is the method. This method has certain limitations 
because it fails to address the problem of delivery to the sites of metastatic spread where 
tumour cells are too numerous and inaccessible with direct injection. Many efforts have 
been made to overcome this problem.66
1.6.1.2.2.5 Enzymatic prodrug delivery targeting
The concept of this approach is not far from what had previously been seen in sections
1.6.1.2.2.1 and I.6.I.2.2.4. In the aforementioned, the prodrugs are converted to then- 
active analogue by direct reduction, whereas in the second the prodrugs are activated by 
exogenous enzymes expressed in tumour cells by the action of the delivered genes. In this 
section the prodrugs are activated by endogenous enzymes expressed selectively in tumour 
cell.
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Figure 1.9 Representative schemes o f enzymatic bipartite and tripartite prodrugs 
targeting approaches.
Prodrugs are agents that undergo chemical or enzymatic transformation to the parent drug 
following delivery, so that the parent drug (metabolic product) can subsequently exert its 
therapeutic effect.67 They are divided into Bipartite or Tripartite systems (Figure 1.9); The 
bipartite prodrug system consist of a trigger (carrier) moiety A and a effector (drug) moiety 
B. Moiety A is the means by which, prodrug would be delivered to a specific site and, 
become a specific substrate for a particular enzyme. Enzymatic hydrolysis of the bond 
between A and B releases effector (active drug) B in the body. In certain cases this basic 
prodrug tactic fails. It is possible that the linker bond between A and B is unstable due to 
its inherent nature or the prodrug A-B is quite stable but the electronic and steric features 
of B hinder the hydrolysis of the linker bond by the target enzyme.
As an example, the enzymatic hydrolysis of peptide-doxorubicin conjugates results in the 
release of a doxorubicin-amino acid conjugate, which had lower activity than the parent
z o
drug. So, to overcome the previous difficulty, a tripartite prodrug tactic (three-component 
system) is designed, where the trigger and the effector are linked together by a special type 
of connecter group (Figure 1.9). Consequently, the enzymatic hydrolysis will occur in the 
A-linker bond rather than the A-B bond. Then linker-B bond would hydrolyze 
spontaneously, under the physiological conditions, to release the active, parent drug B.67
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Several models gave promising results in studies in vitro?*1 This leads to its application in 
site specific prodrug delivery of cytotoxic agents' such as doxorubicin and vinblastine 
(Scheme 1.2) and (Scheme 1.3) respectively.69,70
In the following model (Scheme 1.1), The N“-Boc-Lys (17) is the trigger moiety, the p- 
aminobenzyloxycarbonyl is the linker moiety and /7-nitroaniline (22) is the effector. In the 
presence of trypsin, the tripartite prodrug undergoes rapid hydrolysis and consequently 
releases /?-nitroaniline (22) (t</2 ~11 min at 25°C). This rapid release presumably works 
through a 1,6-elimination process, which gives an unstable carbamic acid that is unstable 
and rapidly loses CO2 to produce /7-nitroaniline (22).6










In the following model (Scheme 1.2), the Cbz-Phe-Lys is the trigger moiety, the 4- 
aminobenzyloxycarbonyl is the linker moiety and doxorubicin (9) is the effector. In the 
presence of cathepsin B, the tripartite prodrug undergoes rapid hydrolysis and 
















Scheme 1.2 Enzymatically activated tripartite prodrug model fo r  doxorubicin (9).
In the following model (Scheme 1.3), the Ac-Hyp-Ser-Ser-Chg-Gln-Ser-Ser is the trigger 
moiety, the proline amino acid is the linker moiety and vinblastine (28) is the effector. In 
the presence of prostate specific antigen (PSA), the tripartite prodrug undergoes rapid
30
cleavage and consequently intramolecular cyclisation to release the drug (t/2 -12  min at
37°C).70
Prostate specific antigen 
*CH2CH3 (PSA)
'CH2CH3




Chemical release in vivo
des.Acetyl.Vin +
(28)
Scheme 1.3 PSA-activated tripartite prodrug fo r  vinblastine.
1.6.1.2.2.6 Water-soluble polymeric prodrug targeting
1.6.1.2.2.6.1 Classification of macromolecular drugs
Kalal et al.71 classified macromlecular drugs into: (A) drugs of polymeric nature, in which 
the therapeutic benefit is solely dependent on their macromolecular properties, such as 
plasma expanders; (B) polymer-bound drugs, in which drugs could exert their therapeutic 
effect without being detached from the polymer. In this prodrug system, the main 
polymeric chain is biologically inert and the therapeutically active group constitutes part of 
that chain; (C) polymer-carried drugs, in which drugs are bound to the polymer and must
71 7 7be detached to exert their therapeutic effect. ’
1.6.1.2.2.6.2 Rationale for the concept of macromolecule-drug conjugates
In chemotherapy, the main objective is to optimise the therapeutic effect of the drugs and 
to reduce or even overcome the toxic side-effects. This could be attained by successful 
site-specific drug delivery and by accumulation of drug into tumour sites. Macromolecular
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prodrugs are of increasing interest in cancer chemotherapy because they manage to fulfil 
the targeting and controlled-release criteria.
In general, most pharmacologically active agents are low molecular weight compounds, 
which penetrate readily into the cells by diffusion and are excreted rapidly from the body. 
Consequently, repeated doses must be given, in order to maintain the therapeutic effects, * 
but this will also increase their cytotoxicity.73 A number of sophisticated approaches 
managed to sort out the targetability point. However, we are still looking toward increasing 
the duration of action, either by the retention of drugs in the tumour site or by decreasing 
their biodegradability.
1.6.1.2.2.6.3 Tumouritropic principles of macromolecular drugs
In cancer, the vasculature characteristics of tumour tissues differ fundamentally from their 
normal counterparts. These include (A) tumour angiogenesis i.e the process by which 
tumours enhance ingrowths of new capillaries resulting in hypervasulature (B) 
hyperpermeability (C) hypoplastic or minimally effective lymphatic system producing 
minimal tumour drainage.43’74
It has been reported that a large number of solid tumours possess blood vessels that are 
relatively permeable to macromolecules. This has been loosely attributed to be related to 
the morphological features of permeability, such as the presence of enlarged 
interendothelial cell junctions in a minority of tumours. Later on, Dvorak et al. 75 have 
established the factors underlying tumour-enhanced permeability of macromolecules. 
They have found that extravasation of large macromolecules was restricted to mature veins 
at the interface of the tumour with normal tissue. The blood capillaries responsible 
appeared morphologically normal, without any sign of a presence of obviously enlarged 
interendothelial cell spaces. So, they have suggested that the phenomenon of increased 
permeability might be mediated by enhanced vesicular transport, rather than simple 
leakage from interendothelial cell junctions 43,75 This phenomenon is widely spread in solid 
tumours.76
Hypoplasticity is another phenomenon characteristic of solid tumours but not normal 
tissues. Hypoplastic or minimally effective lymphatic systems produce minimal tumour
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drainage.43,74 In normal tissue, fluid and small solutes which diffuse from the bloodstream 
into tissue can drain back via postcapillary venules, while macromolecules will drain back 
via the lymphatic system. However, in tumours, fluid and small molecules could either 
feedback into the postcapillary venules or pass through the tumour interstitium while 
macromolecule can only pass through the tumour interstitium (the dead end).74 (Figure 
1.10). Thus, the enhanced permeability and retention (EPR) phenomenon of 
macromolecules in solid tumour is considered the focus of interest in developing new 
tactics in cancer-targeting chemotherapy 43,77,78
Normal cell
Blood stream




















Figure 1.10 Diagrammatic representation o f the enhanced permeability and retention 
effect (EPR).
The drawback associated with polymer drug conjugates arises from the process of their 
cellular uptake. Unlike low molecular weight drugs, in which cellular uptake is limited by 
diffusion, polymer drug conjugate (molecular size above 50,000 Da) uptake is limited by 
endocytosis. Endocytosis can be considered of two types; pinocytosis and phagocytosis.77 
Soluble macromolecules are taken up by pinocytosis and not phagocytosis. However, 
pinocytosis is a relatively slow process and the pinocytised materials will be transferred to 
the lysosomal compartment of the cell via endosomes (receptosomes). Thus, binding of the 
drug to a water soluble-macromolecule will render them lysosomotropic.79
A sophisticated way to overcome the pinocytotic and lysosomotropic processes would be 
by designing a polymeric prodrug system from which the active drug could be released by 
the action of an endogenous enzyme that is catalytically active only in the tumour and is 
located either on the outer surface of the cell or in the extracellular space. The tumour-
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selectivity of the polymeric prodrug delivery system would then be binary, involving; (A) 
the EPR effect; (B) tumour-localisation of the enzyme.
1.6.1.2.2.6.4 Models for macromolecule-drug conjugate
A general scheme of the model is represented in (Figure 1.11). The polymer backbone, 
which is generally biodegradable but sometimes biostable, is modified by three functional 
moieties. One part is used to fix the therapeutic agents via a covalent bond. This bond 
could be permanent or transient depending upon the nature of the drug, whether it is active 
while it is part of the polymer, or it should be released from the polymer to be active. The 
second part is a linker, necessary to provide physical separation between the drug and the 
polymer and so, facilitate their conjugation and the third part is a device to control the 

















Figure 1.11 Model o f  macromolecule-drug conjugate.
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1.6.1.2.2.6.5 Macromolecular carriers
In macromolecule-drug conjugates, the macromolecular carrier is the major determinant 
unit of the pharmacokinetic properties in vivo. Ideal carriers should be easily synthesised, 
accessible to chemical modification, water-soluble, biodegradable, non-toxic and non- 
immunogenic.80 However, at present, no carrier has been found to fulfil all these criteria.77 
A number of naturally occurring and synthetic soluble macromolecular carriers are 
presented in (Figure 1.12).
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Figure 1.12 Classification o f  soluble macromolecular carriers.
1.6.1.2.2.6.6 Clinically active polymeric prodrugs
Examples of some polymeric prodrugs models, which showed activity in clinical trials 
include:
A Mitomycin C polymeric prodrug
The general structure of mitomycin C (MMC)-dextran conjugates is represented in (Figure 
1.13). The drug is attached to the carrier by linkage through the aziridine nitrogen. The 
linker used was 6-aminohexanoic. The choice of the linker is important because of its 
influence on the rate of conjugate cleavage. The studies have shown that MMC-dextran
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conjugate (29) of MW 70 KDa, based on this linker, exert higher antitumour activity when 
compared with free MMC against certain murine model tumours (e.g. Ehrlich ascites) in 
vivo.43 The activity of the conjugate is thought to be mediated by extracellular hydrolytic
O  I











Figure 1.13 General structure o f  mitomycin C (MMC)-dextran conjugates.
B 5-Fluorouracil polymeric prodrug
Several molecular prodrugs of 5-FU have been developed. In most cases, the antitumour
82 83activity results from the non-specific chemical hydrolysis of the ester, carbamate, 
carbamoyl82 or amide bond82 between the active drug and the polymer backbone.
A pro-prodrug polymer conjugate system (multi-prodrug, cascade system) has been 
designed.84 This system will provide a tumour-specific release of 5-FU under the 
environmental conditions o f the tumour cells. The free drug would be released by a step­
wise enzymatic and chemical cleavage of several chemical bonds. The first bond will be 
between the polymer backbone and the prodrug, whereas the second bond is inside the
8Sprodrug system. This system will control the rate and time of the drug release.
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SitNichifor et al. have synthesised a pro-prodrug polymer conjugate of 5-FU by attaching 
oligopeptide chains, having a 2-(5-fluorouracil-l-yl)glycine ethyl ester residue at the C- 
terminus to dextran. This conjugate displayed high cytotoxicity in vitro against murine C26 
cells. In addition, intraparental administration to murine C26 tumour-bearing mice caused
no acute toxicity and increased the life-span of the treated animals.
C Doxorubicin polymeric prodrug
Doxorubicin is the mainstay in clinical treatment of a variety of malignant diseases,
notably in metastatic prostate cancer.24 However, chronic administration of high doses 
leads to severe systemic toxicity. Thus, new studies have been oriented toward the use of 
the soluble macromolecules as a method of selective targeting of doxorubicin.
Doxorubicin (9) is an amphipathic molecule, containing a hydrophobic anthraquinone 
structure and a hydrophilic amino-sugar (daunosamine); thus it is freely soluble in aqueous 
and organic solutions and can readily penetrate the cell membrane. It has been conjugated 
with a range of soluble macromolecules, such as proteins, DNA, dextran, poly(aminoacids) 
and methacrylamide-based copolymers. The chemistry of its derivatisation with the 
carriers has been elucidated carefully and a range of different modes of attachment have 
been used. In considering the reduction of cardiotoxicity, similar results have been 
obtained as with particulate formulations of the drug. However, in term of specific 
therapeutic activity, it has been increased. As a result, the increase in specific activity of a 
polymer-doxorubicin conjugate is independent of the decrease in toxicity, which permits 
the administration of higher drug doses 43
The first observation of increased drug-specific activity has been seen with a dextran- 
daunomycin (DNR) conjugate. This conjugate showed improved therapeutic activity, when 
compared with same dose of free drug.87 Later, DNA-anthracycline and protein- 
anthracycline conjugates (lysosomotropic) have been synthesised. The former conjugate 
was designed to release the drug intracellularly88 but they were poorly stable in plasma.89 
Nevertheless, DOX-DNA and DNR-DNA conjugates showed improved therapeutic 
activity against the model LI210 tumor system.90
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A water-soluble polymer, PK1 [HPMA (±)-N-(2-hydroxypropyl)methacrylamide] was 
conjugated with doxorubicin through a tetrapeptide (GFLG) linker. This polymer-drug 
conjugate was designed to be cleaved intracellularly by cathepsins B, H and l  43,91,92 The 
molecular weight (MW) threshold permitting renal excretion of HPMA homopolymer was
O'!
found to be approximately 45,000 Da. Thus, the developed conjugates were designed to 
use a copolymer backbone of a MW about 20,000 Da. This conjugate system displays 
increased specific drug efficacy, compared with the same dose of the free drug 43
However, this approach is limited by two factors; (A) the sole basis of tumour-selectivity 
of delivery is concentration of the prodrug by the EPR effect. Cells in normal tissue are 
also capable of cleaving the GFLG sequence, thus releasing doxorubicin; (B) the enzyme 
that cleaves the GFLG peptide is lysosomal and thus the whole release mechanism is 
essentially intracellular.
The problem with polymeric prodrugs is associated with the pinocytosis process by which 
they access the cells. Pinocytosis is a relatively slow throughput process. Thus, the release 
of active drug is limited. Much more attractive would be a polymeric prodrug system from 
which the active drug is released by the action of an endogenous enzyme that is 
catalytically active in tumour site only and is located either on the outer surface of the cells 
or on the extracellular space. The tumour-selectivity of drug delivery would then be binary 
(EPR effect and tumour-localisation of the enzyme) and the rate of site-selective drug 
release would be much greater. Prostate specific antigen (PSA) fulfils excellently both 
criteria for an activating enzyme.
1.7 Tumour markers for adenocarcinoma of the prostate
1.7.1 Acid phosphatase
During the past years, acid phosphatase enzyme has been considered the standard marker 
for adenocarcinoma of the prostate. It has been used by urologists in the diagnosis and 
staging of the disease, as well as in monitoring patients' response to therapy. However, 
unfortunately, the inability of this marker to report the serum concentration of the
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isoenzyme produced by prostatic tissue without interference from other isoenzymes 
generated by other body organs, constitutes the major difficulty in its usage.94’95
1.7.2 Prostate specific proteins
Among several prostate-specific proteins, prostate-specific membrane antigen (PSMA) and 
prostate-specific antigen (PSA) are sensitive markers for diagnosis of prostate cancer.96
1.7.2.1 Prostate specific membrane antigen (PSMA)
PSMA is a glutamate carboxypeptidase, membrane-bound glycoprotein, highly restricted 
to prostatic epithelial cells and over-expressed in hormone-refractory disease. The PSMA
97gene encodes PSMA, which is exclusively expressed in metastatic prostate carcinoma. 
PSMA cleaves the terminal y-linked glutamate residue from poly-y-glutamated folates by
no
its carboxypeptidase activity. This process is essential for y-glutamate transport into cells. 
Thus, an approach to target prostate cells that over-express PSMA is by designing a 
prodrug containing H-3 toxin. H-3 is a 25-amino-acid toxin capable of penetrating into the 
lipid bilayers by forming a pore, through which cell macromolecules or electrolyte leak 
resulting in cell death.99 H-3 was inactivated by the addition of two glutamate residues. 
Selective activation of the prodrug would result from the cleavage of the terminal 
glutamates by PSMA. This model prodrug was demonstrated in vitro.100 However, it is 
noteworthy, that PSMA is also expressed in normal brain and salivary gland tissue, i.e it is 
not completely prostate-specific. As a result, it is unclear whether or not it can be used for 
targeting therapy in vivo.101
1.7.2.2 Prostate specific antigen
Recently, prostate specific antigen (PSA) has been identified, characterised and found to be
produced exclusively by the prostatic tissue. In fact, it is the most meaningful and useful
102tumour marker in prostate cancer.
39
1.7.2.2.1 Discovery of PSA
In 1971, Hara et al.m  discovered PSA in seminal plasma. At that time, PSA has been 
referred to as gamma-seminoprotein. Two years later, Li and Beling104 were able to isolate 
this protein from the seminal plasma, identify its molecular weight (31,000 Da) and 
described it as Ei antigen. In 1978, Sensabaugh105 truly characterised this “semen-specific 
protein”. He identified that this protein was highly immunogenic, had several sugar 
moieties, with a molecular weight of 33,000 Da and he referred to it as p30 because of its 
molecular weight. Interestingly, Grave et a/.106 suggested that p30 would be an excellent 
marker for semen identification and so could be used in identification of rape victims. In 
1979 Wang et al.m  identified this antigen to be specific to all types of prostatic tissue 
(normal, benign hyperplasia and malignant) and so it could not be found anywhere else in 
human tissue. As a result, this antigen is termed prostate specific antigen. Finally, 
Papsidero et al.m  identified PSA in human serum and verified that this molecule was 
identical to the one seen in prostatic tissue.
1.7.2.2.2 Biomolecular characteristics
PSA is a member of the human kallikrein family that exhibits serine protease activity.16 It 
is a single-chain glycoprotein with a MW 33,000-34,000 Da, comprising 240 amino acid 
residues (93% w/w ) with four carbohydrate side-chains (7% w/w). Subsequent studies 
have shown that one carbohydrate side-chain exists at the N-side-chain of amino-acid 45 
(asparagine) while the other three exist at the O-side-chain of the amino acids 69 (serine), 
70 (threonine) and 71 (serine). The N-terminal amino-acid of the sequence is isoleucine 
and the C-terminal residue is proline.15
1.7.2.2.3 Function
PSA is produced by the epithelial cells lining the acini and ducts of the prostate gland. It is 
secreted at 0.5-2.0 g L'1 into the seminal plasma. Most PSA passes into the gland lumen, 
where it is involved directly in the liquefaction of the seminal gel-forming proteins, 
semenogelin(Sg) I and II, during ejaculation. Usually, a tiny proportion is absorbed into the 
bloodstream where levels should be <4 ng m l1. In normal men, the prostate capsule creates 
a barrier which will prevent the escape of PSA into the peripheral circulation. However,
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barrier disruption by disease allows PSA into the peripheral circulation. Thus, PSA is used 
as a diagnostic tool for the detection and monitoring of prostate cancer and clinically it is 
the best known serological marker for the presence of prostate cancer. 16,109
1.7.2.2.4 PSA in the staging of prostate cancer
The serum PSA concentration correlates well with the number of malignant prostate cells. 
This is because it is synthesised and secreted in large amounts by malignant prostatic 
epithelial cells and, at a lower level, by corresponding normal cells in the prostate. 110 The 
concentration of PSA in the extracellular fluid of normal human prostate and primary 
human prostate cancer is 1600-2100 nM; 80-90 % of this PSA is enzymatically active. In 
contrast, none of the PSA present in serum is enzymatically active. 111 This is because it 
forms a complex with the serum inhibitory proteins al-antichymotrypsin and a 2 - 
macroglobulin, resulting in a predominant inactive form of PSA in the serum . 112 Thus, it is 
proteolytically active exclusively in the prostate, the target tissue for anti-prostate cancer 
therapy, and is an ideal enzyme for the release of drugs from polymeric prodrugs.
1.7.2.2.5 Substrate-specificity of PSA
On the basis of the PSA cleavage maps for Sg I and II, small peptides were synthesised 
containing the amino-acid sequence proximal to the PSA proteolytic sites113 Coombs et 
al.9i studies have converged on the amino-acid sequence SS(Y/F) YjS(G/S) as a preferred 
subsite occupancy for PSA (Figure 1.14). However, this sequence has been found to be 
cleaved efficiently by chymotrypsin.
P4 Pa P2 P. P.' P f
0 O O O O O
II II II II II II
A Ak A
s ,  S, s,
A AA
S,' S '
Protease > Cleavage between PI and P I '
Figure 1.14 Peptide sequences efficiently cleaved by PSA.
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PSA Chymotrypsin Elastase Trypsin Plasmin hKl hK2
1
KGISSQY 510 4290 3068 658 ND ND UDC
SRKSQQY 234 3630 2788 260 0.4 2.0 UDC
GQKGQHY 49.6 4274 922 122 UD ND UD°
2
EHSSKLQ 31.6 UD UD UD UD UD UDC
QNKISYQ 16.8 9.0 9.0 UD UD ND UD0
ENKISYQ 14.4 3.6 2.6 1.8 0.6 UD ND
ATKSKQH 16.0 38.8 UD UD UD UD ND
HSSKLQ 62.7 UD UD UD UD UD UD
SKLQ 29.6 UD UD UD UD UD ND
KLQ UD 10.6 0.4 UD ND UD ND
LQ UD UD UD UD UD ND ND
Q UD UD 0.7 UD UD ND ND
3
KGLSSQC 13.6 12.2 950 UD UD UD ND
LGGSQQL 6.0 314 94.0 UD UD ND ND
4
QNKGHYQ 1.8 0.2 0.6 UD UD UD ND
TEERQLH 12 48.8 1.0 UD 3.8 UD UDC
GSFSIQH UD 3.6 0.4 0.4 02 ND ND
Table L I  Peptide substrates for assaying PSA activity (UD, undetectable <0.1 pmol 
o f substrate hydrolysis/min/100 pmol o f protease; ND, not done; hkl, human plasma 
kallikrein; hk2, human glandular kallikrein). bSubstrate at 0.2 mM concentration in PSA 
assay buffer.114
Denmeade el al.114 identified four groups o f seven amino-acid substrates based on PSA 
activity and specificity. The first group (KGISSQY, SRKSSQY and GQKGHY) were 
cleaved most efficiently by PSA, but were even better substrates for chymotiypsin and 
elastase. The second group (EHSSKLQ, QNKISYQ, ENKISYQ and ATKSKOH) were 
moderately cleavaged by PSA but with greater specificity. The third group (KGLSSQC 
and LGGSQQL) were also cleaved by PSA but with lower specificity than the second 
group. The fourth group (QNKQHYQ, TEERQLH and GSFSIQH) had little susceptibility 
to all proteases tested. So, it has been noticed that all substrates lacking Tyr at the cleavage 
site had no detectable activity with serum proteases and high activity with PSA, 
chymotrysin, trypsin, elastase enzymes i.e. they are not specific to cleavage by PSA. 
Therefore, a follow-up research on the second group indicated that substrates such as
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(HSSKLQ and SKLQ) are extremely specific to cleavage by PSA irrespective of their low 
rate of cleavage. (Table 1.1)
Also, Denmeade el al.114 have identified that the length of the amino acid sequence plays a 
role in the ability of PSA to cleave the peptide, with at least a tetrapeptide sequence 
required for activity. In a small-molecule study, the arylamine 7-amino-4-methylcoumarin 
(AMC) was attached via an amide bond to the C-terminal carboxy group of Gin in the 
peptide sequence HSSKLQ. The HSSKLQ™—AMC construct was not hydrolysed by a 
panel of purified extracellular proteases except PSA. Thus, HSSKLQ can be used as a 
carrier to target prodrugs for activation within sites of metastatic prostate cancer producing 
enzymatically active PSA.114
A doxorubicin-peptide construct has been built and examined in vitro for its behaviour as a 
targeted prodrug for PSA-secreting tumour cells. Unfortunately, PSA was unable to 
hydrolyze the amide bond between glutamine and Dox. However, a previously described 
doxorubicin derivative consisting of the amino acid L-leucine linked to the primary amine 
of doxorubicin (Leu-Dox) was demonstrated to have activity against cancer cell lines in 
animal models.115 This result has turned the view toward additional incorporation of an
amino acid. The whole construct is now HSSKLQL Dox. PSA then released L-Dox,
rather than the parent drug. As a conclusion, PSA is only capable of hydrolysing amide 
bond adjacent to an aromatic ring or to an aminoacyl group.109,68
1.7.2.2.6 PSA-activated prodrugs
The site-specific release of a high concentration of Leu-Dox in the environment 
surrounding prostate cancer cells by the proteolytic activity of PSA led to the search for 
other cytotoxic agents that might be conjugated to the hydrolysed peptide. For example:
Thapsigargin is a potent inhibitor of the Ca2+ dependent ATPase pump. This inhibition will 
elevate Ca2+ concentration and cause cell death.116,117 Thapsigargin’s cytotoxicity is, 
however, unlikely to be prostate-(or cell-type-) specific, given its mechanism of action; 
therefore, it cannot be administered systemically as a therapeutic agent without encoding 
host toxicity. Ten years ago, a prodrug approach for thapsigargin was based on direct 
coupling of a primary amine-containing thapsigargin analogue to a peptide carrier. The
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resulting water-soluble compound was then delivered systemically. 117 However, this 
prodrug was inactive because the carrier peptide prevents it from invading the cell until the 
thapsigargin analogue is liberated from the carrier peptide by proteolytic degradation.
Therefore, a meaningful strategy was required for the selective targeting of thapsigargin to 
prostate cancer cells only, without harming normal cells. Gaining advantage from the 
existence of PSA, specifically in prostate cancer cells, a new prodrug was designed by 
coupling amine-containing thapsigargin analogue 12ADP to the HSSKLQ peptide 
sequence which is selectively cleaved by PSA. (Scheme 1.4). This prodrug was efficiently 
hydrolysed by PSA and was thus selectively toxic to PSA-producing prostate cancer cells 
in vitro; it was also stable in human plasma. Furthermore, continuous subcutaneous 
administration of the prodrug in mice causes complete growth inhibition of established 
PSA-producing prostate cancer xenograft tumours and had no effect on renal carcinoma 
xenograft tumours which do not produce PSA. As a conclusion, the development of PSA- 
activated thapsigargin prodrugs as a therapy for metastatic prostate cancer is 
warranted. , , 8 ’n 9
PSA Hydrolysis
Mu His Ser Ser Lys Leu Gin 8-0-(12-|L-leucinoylamino|dodecanoyll)-8-0-
debutanoylthapsigargin (Leu-12ADT)
(30)
Scheme 1.4 Chemical structure o f  MuHSSKLQ//Ll2ADT. The arrow indicates the site
o f  prostate-specific antigen (PSA) hydrolysis.
As a single agent, doxorubicin has been one of the best chemotoxins against metastatic 
prostate cancer.24 Advances in the knowledge of the mechanism of action of doxorubicin 
highlight the enzyme DNA topoisomerase II as its primary cellular target. This enzyme is 





M uHSSKLQ + Leu-Dox
(32) (33)
Scheme 1.5 PSA-triggered release o f  doxorubicin from a tripartite prodrug system.
Unfortunately, chronic administration of high doses is usually not possible because of the 
dose-limiting systemic toxicities. Therefore, new strategies, which deliver doxorubicin 
specifically to sites of metastatic prostate cancer while avoiding systemic toxicity, were 
crucial. Doxorubicin targeting by means of a specific antitumour monoclonal antibody has 
been investigated as a means to mitigate toxicity against normal tissue. However, this 
method has some limitations with regards to the effective dose of drug that can be 
delivered per antibody molecule.59 Denmeade et a / . 68 have designed a good inactive 
prodrug of doxorubicin. This prodrug was synthesised by coupling the primary amine of 
doxorubicin to the carboxyl terminal of the HSSKQL peptide carrier. The linker amide 
bond was documented to be hydrolysed specifically by PSA to liberate the active cytotoxin 
Leu-Dox (33) (Scheme 1.5).
The specificity of the cytotoxic response to the prodrug was recognized when 70 nM of the 
prodrug killed 50% of the PSA-producing LNCaP cells, whereas no cytotoxic effect on 
PSA-nonproducing TSU human prostate cancer cells in vitro was seen. Currently, the Mu- 
HSSKLQL-Dox (31) prodrug is in studies in vivo in LNCaP and PC-82 tumour-bearing
A method for Dox drug targeting to the sites of metastatic prostate cancer by the use of the 
polymeric prodrug concept would be useful with the aim of lowering the cardiotoxicity and 
improving the therapeutic index. In this thesis, part of this targeting polymeric prodrug 
design will be addressed. The designed prodrug will ensure the release of the active drug 
without any interfering pendant amino acids. The prodrug was synthesised by coupling of a 
model drug to a PSA-peptide via a self immolative molelecular clip linker to produce « 
CbzSSKLQV-2,2-dimethyl-4-thiazolidine-model drug and CbzSKLQV-2,2-dimethyl-4- 
thiazolidine-model drug. These prodrugs serves as a substrate for PSA. This approach 
permitted efficient conversion of the inactive prodrug back to the active form by the 




2.1 Aim of the research
The aim of this research is to design a novel prodrug that will release doxorubicin 
selectively in prostate tumours through an innovative system. This polymeric prodrug 
system could also deliver other cytotoxins selectively.
2.2 Research proposal
2.2.1 Design of a PSA-activated polymeric prodrug system
The general features of the design for a prostate-specific PSA activated polymeric prodrug 









PSA-cleavable peptide linker self-immolative molecular clip DRUG
solubilising group
solubilising group
Figure 2.1 General structure o f  the proposed polymeric prodrug fo r prostate-specific 
drug release.
The first key feature in the polymeric prodrug is the polymeric backbone, which will be 
polyacrylate similar to that of the poly(HPMA), PK1 [HPMA = (±)-N-(2-hydroxypropyl)- 
methaacrylamide]. As in PK1, simple solubilising groups will occupy many of the sites. 
The homopolymer (poly(HPMA) and PK1 have been demonstrated to be non- 
immunogenic.43
The second key feature is the PSA-cleavable peptide linker. However, based on previous
/ «
work carried out by Denmeade et al. on small-molecule prodrug study, a model drug
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(containing amine) will be attached to a PSA-cleavable peptide linker. This linkage 
substantially inhibits the non-specific toxicity o f the drug. Denmeade and coworkers have 
reported that arylamine 7-amino-4-methylcoumarin (AMC) is released from the peptide 
construct HSSKLQ— AMC. However, HSSKLQ— doxorubicin is not cleaved by PSA. To 
achieve cleavage, the construct HSSKLQL—Dox was used; PSA then released L-Dox, 
rather than parent drug (Dox).
These data strongly indicate the need for the development o f a tripartite prodrug system, 
where the peptide sequence and the drug are linked by a “self-immolative molecular clip”. 
Enzymatic hydrolysis o f the peptide— clip bond will liberate the clip—drug moiety, the 
clip is designed to become detached from the drug spontaneously, through an 
intramolecular cyclisation process, resulting in the release o f free drug without any 
interfering pendant amino acids or short peptide fragments. The self-immolative molecular 
clip is a major point in the construction o f this polymeric prodrug system. The drug for the 
study is doxorubicin, but this innovative design could be applied to other drugs that contain 
amines (e.g. doxazosin, a very recent drug o f interest in prostate cancer). However, 
alternatively, 2-(4-Nitrophenyl)ethylamine (NPEA) is used as a drug model with a primary 
aliphatic amine. Firstly, it is a lot less toxic to deal with; secondly, it is less expensive and, 
thirdly, it has a good UV chromophore, thus facilitating its release detection in HPLC 
studies that would be carried out later on.
Thus, as a means to test the rationale o f the proposed prodrug, putative self- immolative 
molecular clip has to be designed and optimised. The designed work is initially divided 
into two parts:
A Development o f  self-immolative aminoacyl-dimethylthiazolidine molecular clip.
The clip must be peptide-like in structure, to encourage binding to the PSA active site but 
expel the drug rapidly after enzymatic release o f the clip-drug moiety. Prodrug strategies
I
based on intramolecular cyclisation reactions have been reviewed. Several effective 
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Scheme 2.1 A. DKP formation from peptides. B. Design o f  aminoacyl- 
dimethylthiaproline molecular clip.
In peptides with free N-terminal amines, the N-terminal amino acid pair cyclise to give a 
dioxopiperazine (diketopiperazine, DKP); the remainder of the peptide is expelled 
(Scheme 2.1 A). The rate of DKP formation depends on the proportion of the dipeptide in 
the reactive cis conformation. 121 However, most peptide sequences adopt only the trans 
conformation, because it is energetically favourable. The presence of proline at the 
penultimate position greatly enhances the rate of DKP formation and expulsion of the 
amine leaving group, owing to the greater propensity to adopt a ds-amide conformation 
(AlaPro is 13% cis121,122). Interestingly, replacement of Pro with 2,2-dimethyl-4- 
thiazolidine (Me2ThPro) forces peptides into 1 0 0 % cis conformation, 122 owing to the major 
steric clash between the side-chain R of the terminal amino acid and the geminal dimethyl 
groups (Scheme 2.1 B). DKP formation and expulsion of the leaving group (the drug) 
should then be rapid.
Therefore, an aminoacyl-Me2Thiazolidine unit will be used as a molecular clip between the 
PSA-cleavable peptide linker and the model drug. Exposure of the amine by the PSA- 
mediated cleavage should initiate rapid DKP formation and expulsion of the drug.










Optimisation of the function of this molecular clip is the next step forward (Scheme 2.2). 
Aminoacyl-Me2Thiazolidine-NPEA potential clips with different R groups (38) will be 
synthesised; all are protected by f-butoxycarbonyl (Boc) at the N-terminal. The R and S- 
Me2Thiazolidine stereoisomers will be prepared by cyclocondensation of L-Cys and D-Cys 
respectively. 123 Selective deprotection with acid will give the N-protonated species (39). 
These species will then be placed in a buffer solution of different pH values 6.0, 7.0 and 
8.0 at 37°C, mimicking physiological media to give the free amine species (40); the rate of 
formation of DKP (37) and liberation of the model drug NPEA (41) will be then monitored 
by HPLC analysis. Different R substituents are necessary to study the importance o f the 
size of the side-chain in forcing the clip into the reactive cis conformation. Hence, the 
function of the molecular clip will thus be optimised to be used in the subsequent step.
B Synthesis and evaluation o f a monomeric model fo r  PSA triggered release o f  
NPEA.
A complete monomeric prodrug model will be constructed (42) (Scheme 2.3) for the study 
of PSA-triggered release of NPEA. In this model, the benzyloxycarbonyl moiety will be 
linked to the N-terminus of the PSA-sensitive peptide sequence to provide a chromophoric 
tag. Constructs containing two peptide sequences SSKLQ and SKLQ, will be synthesised
/ o
and examined. Actually, Denmeade et al. used HSSKLQ in his monomeric prodrug 







unnecessary.114 The aminoacyl-Me2Thiazolidine molecular clip optimized in the previous
study will then be used. The constructed models CbzSSKLQXMe2ThProNPEA and 
CbzSKLQXMe2ThProNPEA will then be evaluated for cleavage by PSA, liberating 
XMe2ThPro-NPEA and, hence, NPEA. HPLC analysis of the incubation mixtures will be 
facilitated by the chromophoric tag of the benzyoxycarbonyl moiety attached to the 
cleaved peptide (43).
Scheme 2.3 Proposed PSA-triggered release o f  NPEA from the monomeric model.
NH
O peptide
Peptide = SSKLQ, SKLQ
(37)






3.1 Development and optimisation of self-immolative molecular clip
Since the advent of solid phase peptide synthesis (SPPS),124 many efforts have been
a
devoted to achieve successful peptide assembly. However, problems such as poor solvation 
of the growing peptide chain during solid phase synthesis, as well as limited solubility of 
the fully protected peptide fragments in the solution approach resulting from 
intermolecular hydrophobic peptide aggregation, self-association, and P-sheet structure 
formation, often leads to incomplete coupling steps. Reported attempts to overcome these 
undesirable physicochemical problems during aminoacylation reactions were made 
through “external factors”. For example, solvent composition,125 elevated temperature126 
and solubilising protecting groups have been used,127 all of which shown to have variable 
efficiencies.
In proteins, the planar peptide bond (C-N) is known to occur predominantly in the trans 
configuration, often resulting in P-sheet structure formation. In addition, the low 
occurrence of cis amide bonds is due to the steric conflicts between adjacent a-carbon 
substituents. Therefore, it is noteworthy that the undesirable physicochemical problems are 
attributed to the existence of peptide amino acids in the trans conformation. Interestingly, 
proline residue plays a peculiar role in peptide synthesis. It is the only naturally occurring 
cyclic amino acid. Unlike other peptide amino acids, which predominantly adopt the trans - 
amide bond conformation, the imidic bond formed with preceding residue (Xaa-Pro) is 
readily subject to cis/trans isomerisation. The cis and trans states are of similar energies, 
with about a 20 Kcal mol'1 barrier for their interconversion.128’129’130
Proline analogues can be tailor made to fit with the required cis/trans conformation ratio.
For example: (a) 5-Oxoproline (44) exhibits an exclusive trans-amide isomer which is
stabilised by both steric and electronic effects due to the replacement of the tertiary amide
1bond by an imide structure; (b) 5,5-Dimethylproline (45) was shown to exist solely in 
the cw-conformation in the tripeptide Ac-Tyr-5-Me2Pro-Asn (Figure 3.1).128
52
o
N H R NH R
N \ ^  N (44)
Cis conformation Trans conformation
(E n e r g e t ic a l ly  u n fa v o u r a b le )  (E n e r g e t ic a lly  fa v o u r a b le )
NH R
(45)
Cis conformation Trans conformation
(E n e r g e t ic a l ly  fa v o u r a b le )  (E n e r g e t ic a l ly  u n fa v o u r a b le )
Figure 3.1 The cis/trans amide conformations o f  5-oxoproline (44) and 5,5- 
dimethylproline (45).
Recently, Ser/Thr-derived oxazolidine and Cys-derived thiazolidine derivatives {pseudo- 
prolines, vj/Pro) have been reported to induce a “kink” conformation in the peptide 
backbone, originating in the preference for cis-amide bond conformation. Consequently, 
i|/Pro prevents the intermolecular hydrophobic peptide aggregation, self-association, and (3- 
sheet structure formation, thus improving solvation and coupling processes. Such building 
blocks are readily accessible by cyclocondensation of Ser, Thr, or Cys with aldehyde or 
ketones (Scheme 3.1), providing a useful protecting tactic for the parent amino acids. 
Furthermore, different substituents Ri and R2 at position 2 affect the ring stability and 
result in different \j/Pro units with different chemical stability. Actually, these substituents 
provide an efficient synthetic tool to tailor the cis/trans ratio of the amide bond in peptide
synthesis. 132 ,133
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Route A Ser, Thr, Cys = Xaa Route B
I
R
R = Xaa(v|/R>’R* pro)








Scheme 3.1 Pseudo-proline units and overview o f  the if/Pro building block synthesis
cyclocondensation, followed by amino acid fluoride coupling. However, route B proceeds 
firstly by amino acid PFP coupling, followed by the acid-catalyzed cyclocondensation. 
Both routes produce L-serine (X = O, R = H) and L-threonine (X  = O, R = methyl)
S, R = H) derived 4-thiazolidinecarboxylic (C ys(fRl' R2 pro)); R/ and /  or R2 = alkyl, 
aryl].
Synthetic analysis (Scheme 3.2) suggested that Me2Thiazolidine (47) would be prepared 
by cyclocondensation of L-cysteine (46) with acetone in the presence of 2,2-
condensation process usually proceeds in the presence of an acid catalyst. However, L-Cys 
was used in the hydrochloride salt form. Thus, no acid addition is required in this reaction. 
The designed strategy was then to protect the N-terminal by terf-butoxycarbonyl (Boc). 
The electron withdrawing effect of the carbamate group will decrease the nucleophilic 
activity of the nitrogen.
according to routes A and B. Route A proceeds firstly by acid-catalysed
derived 4-oxazolidinecarboxylic acid (Ser(iff1 R2 pro); Thr (iff1, R2pro)); L-cysteine (X =
1
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Scheme 3.2 Synthetic steps toward the formation of (51). (i) (CH3)2 0 0 , DMP; (ii) di-t- 
butyl dicarbonate, Pr^NEt, MeCN; (iii) PFPOH, DCC, EtOAc; (iv) 4- 
Nitrophenylethylamine hydrochloride, EtjN, CH2CI2; (v) 20% CF3CO2H /  CH2CI2,’ (vi) 
Boc-Gly-OPFP or Boc-Ala-OPFP, Prl2NEt, DMF.
The Boc-thiazolidinecarboxylic acid (48) was previously synthesised by Woodward et 
al.1M by the reaction of (47) with the highly unstable tert-butyloxycarbonyl chloride. 
Designing a more facile preparation using commercially available di-tert-butyl dicarbonate 
presents two difficulties. Firstly, the nitrogen in (47) is much hindered, being bonded to a 
quaternary carbon and a tertiary carbon with a bulky electron-withdrawing carboxylate. 
Secondly, C-2 substituted thiazolidines are very susceptible to alkaline hydrolysis and 
methods of Boc introduction using strong base or even excesses of non-nucleophilic 
tertiary amines led to very low yields (<10%) of intractable mixtures containing both Boc- 
cysteine and Boc-thiazolidinecarboxylic acid (48). However, in contrast to the literature 
report,135 treatment of (47) with di-tert-butyl dicarbonate in acetonitrile containing 
equivalents of triethylamine gave only 11% yield of (48). Repeated attempts using other 
solvents and bases did not show any valuable improved yields.
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The ’H NMR spectrum of (48) showed two conformations due to restricted rotation about 
the Boc carbonyl-N bond (cis and trans conformations); this is particularly evident in the 
broad doublet and double doublet signals of the 4-H of the thiazolidine (Figure 3.2). A 
variable temperature study of the NMR spectra of (48) in DMSOd6 at 20°C and 80°C has 
been done. At 20°C, the rate of interconversion of the two conformations is slow and so the 
conformers give separate signals. Raising the temperature to 80°C causes the rate of 
exchange to increase and the separate signals for 4-H coalesces and appears as a single 
double doublet. (Figure 3.2)
A
The proton NMR spectrum  





of the two conformation of (48)
Figure 3.2 A The fu ll ]H NMR spectrum o f compound (48) at 20 °C in CDCf.  B 
selected fragment from a JH NMR spectrum o f a variable-temperature study o f (69) at 
20 °C and 80 °C in (CD3)2SO.
The carboxylic acid compound (48) was converted to its pentafluorophenyl active ester 
(49) by coupling with pentafluorophenol (PFPOH) 135 using dicyclohexylcarbodiimide
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(DCC) in ethyl acetate at 0°C. Reaction of (49) with 2-(4-nitrophenyl)ethylamine (41) 
afforded the amide (50) in 93% yield (Scheme 3.2).
Boc protecting groups are easily and rapidly removed on treatment with acid. The most 
common method involves the use of trifluoroacetic acid. This acts as the solvent and 
reagent, yielding 4he unprotected peptide as the trifluoroacetate salt. Therefore, 
deprotection of (50) was carried out with 20% trifluoroacetic acid in dichloromethane, 
affording the trifluoroacetate salt (51) in a quantitative yield. This ratio of solvents and 
reagent is very important to prevent ring-opening, since the thiazolidine ring is acid- 
sensitive. Unfortunately, attempted couplings of (51) with the pentafluorophenyl esters of 
Boc-glycine and Boc-alanine were unsuccessful; the *H NMR spectra of the crude products 
indicated that the thiazolidine ring had opened (absence of the characteristic 2,2-dimethyl 
peaks).
1A convenient synthesis pathway was to follow route A in (Scheme 3.1). The design now 
is firstly to couple the amino acids with compound (47) and, later on, attach the 
nitrophenylethylamine (NPEA) moiety (Scheme 3.3).
The presence of an electron-withdrawing carboxylate in position 4 of the ring system will 
reduce the nucleophilic character of the nitrogen atom in position 3, usually resulting in 
poor acylation yields at the N-terminus. Consequently, rapid-acting acylating agents must 
be used in an attempt to improve the coupling yield. In the literature, direct N-acylation of 
(47) with N“-Fmoc-protected amino acid fluorides (Route A, Scheme 3.1) afforded the 
corresponding product in a yield ranging from 60 to 95%.132 This is relatively high when 
compared with the yield obtained upon acylation of (47) with di-terf-butyl dicarbonate 
(<30%).
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Scheme 3.3 Chemical synthesis o f the L,R configuration self-immolative molecular 
clips (68), (69), (70) and (71). (i) Pr^NEt, DMF; (ii) PFPOH, DCC, EtOAc; (iii) 4-nitro- 
phenylethylamine hydrochloride, Et^N, CH2CI2; (iv) 20% CF3CO2H /  CH2CI2.
As a result, the next step forward is to synthesise a series of rapid-acting acylating agents. 
Acyl fluorides are versatile functional groups in organic chemistry due to the unique nature 
of the carbonyl-fluorine bond. They possess greater stability than the corresponding acid 
chlorides and are of high reactivity toward amines.136 Generally speaking, they are stable, 
rapid-acting acylating reagents for peptide bond formation. Furthermore, no significant 
loss of optical purity was observed during the conversion of acid fluorides to amides.137 A 
variety of techniques are available for the generation of these acyl fluorides, including 
halogen exchange from the corresponding acyl chloride with potassium fluoride, potassium 
hydrogen fluoride and many other reagents.138 However, there are disadvantages associated 
with those methods, such as poor yields, dangerous or toxic chemicals, forcing reaction 
conditions and costly reagents. An alternative method was the use of diethyaminosulfur
1 ' IQ 1 1 1fitrifluoride (DAST) or cyanuric fluoride. ’ Cyanuric fluoride is a very mild reagent,
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very reactive and convenient. Interestingly, a new method using [bis(2- 
methoxyethyl)amino] sulfur trifluoride was recently published.140 The acid fluorides of 
Boc-protected glycine (52), L-alanine (53), L-valine (54) and L-phenylalanine (55) were 
prepared by the treatment of the corresponding Boc-protected amino acid with cyanuric 
fluoride.136 Pyridine was found to promote the fluorination reaction, which proceeds by 
nucleophilic displacement of fluoride from the cyanuric fluoride by the carboxylate anion, 
followed by attack of the liberated fluoride at the activated carbonyl.
These crude acid fluorides were used directly in the next coupling reactions with (47), 
without any purification attempts, to avoid any possible racemisation. Coupling proceeds 
in the presence of two equivalents of base (diisopropylethylamine). The resulting Boc- 
aminoacylthiazolidinecarboxylic acids (56), (57), (58) and (59) were purified via 
chromatography which required the use of small quantities of glacial acetic acid in the 
eluant to maintain the product carboxylic acids in the electrically neutral form. 
Unfortunately, the best yield obtained was 35%. The rationale for this is the presence of 
the acid-labile protecting group (Boc), unlike the Fmoc protecting group,132 could be 
cleaved easily during work-up or purification. Compounds (56), (57), (58) and (59) were 
obtained in moderate yields, 35%, 30%, 27% and 30% respectively. Coupling of (56), (57), 
(58) and (59) with pentafluorophenol and DCC in ethyl acetate at 0°C afforded the active 
acylating agents (60), (61), (62) and (63) in 92%, 89% 93% and 92% yields, respectively. 
Consequent reaction of these compounds with 2-(4-nitrophenyl)ethylamine (41) afforded 
the required amides (64), (65), (66) and (67) in 76%, 75%, 73% and 95% yields, 
respectively. Deprotection of (64), (65), (66) and (67) with 20% trifluoroacetic acid in 
dichloromethane for 45 min afforded the trifluoroacetate salts (68), (69), (70) and (71) in 
quantitative yields.
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As for (48), the ‘H NMR spectra of BocGly(dimethylthiazolidine)CONHCH2CH2PhN02
(64) showed evidence of restricted rotation about the carbonyl-thiazolidine amide bond. 
CMe3 group were separate in the spectrum run at 20°C; singlets were observed at 5 1.32 
and at 8 1.38 in the approximate ratio of 1:11. To investigate this phenomenon, a variable 
temperature *H NMR study in (CDs^SO was carried out, with spectra being recorded at 
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Figure 3.3 lH - H  COSY NMR spectrum o f compound (64) at 20°C in (CD 3) 2 8 0 .
Assignment of the signals in the 'H NMR spectrum of (64) was confirmed with a 'H-1!! 
COSY spectrum (Figure 3.3). A cross-peak between signals at 8 2.91 (ArCI-h) and 8 3.39,
6 0
8 3.47 (NHC//2CH), a cross-peak between signals at 8 3.20 (Gly-H) and 8 3.67 (Gly-H) 
and a cross-peak between signals at 8 3.10 (5-H), 8 3.31 (5-H) was identified. 
Interestingly, a cross-peak between 8 3.31 (only one 5-H) and 8 4.79 (4-H) is identified but 
there was no cross-peak between the signals at 8 3.10 and 8 4.79, corresponding to the very 
low coupling (<0.2 Hz) between these protons arising from a dihedral angle close to 90°. 
Furthermore, a NOESY spectrum (Figure 3.4) was studied in an attempt to determine the 
conformation of the major rotamer (Figure 3.5). The spectrum showed NOE connectivities 
between signals at 8 3.31 (5-Ha) and 8 4.79 (4-H) and between signals at 8 3.67 (Gly-Ha) 
and 8 4.79 (4-H). No cross-peak was seen for 4-H to 5-Hp, confirming the assignment of 
the 5-protons. Cross-peaks for 4-H to Gly-Hp and from the thiazolidine 2,2-dimethyl 
protons to Gly-H were also absent. These data confirm that the major rotamer of (64) has 
the required Z (cis) amide conformation.
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Figure 3.5 The Z (cis) amide conformation o f  the major rotamer o f  compound (64).
Studies were also carried out on the conformations of the pentafluorophenyl esters (61) and
spectra, two distinct populations were observed for each in the ratio of 7:3. Again, the acyl- 
thiazolidine tertiary amide bond shows restricted rotation. Presumably, the major 
conformations of these synthetic intermediates still have the Z (cis) amide but NOESY 
experiments have not been carried out to confirm this. The shifts in the rotamer 
populations may be driven by the steric bulk of the pentafluorophenyl ester which could 
compete with the geminal dimethyl unit and the R group for steric repulsion (Figure 3.6). 
In contrast, the PFP esters derived from the Gly and Phe compounds (60) and (63) showed 
only one conformation. Interestingly, removing the bulky Boc group drives back the 
mixture to one conformation (vide infra).
Figure 3.6 The Z and E conformations o f  Boc-Xaa-(Me2 Thiazolidine)PFP esters.
However, since this compound was a synthetic intermediate in the overall process and the 
effect of PFP moiety will be temporary, a decision was taken to proceed into the next 
coupling step to generate the nitrophenylethyl amides.
Whereas the Gly compound (64) showed an 11:1 mixture of conformers, L-Ala compound
(65), L-Val compound (6 6 ) and L-Phe compound (67) were identified as being in only one 
conformation by *H NMR. NOESY analysis of (65) has been done to assign the 
conformation E or Z. The spectrum showed expected NOE connectivities between signals
(62), containing L-Ala and L-Val, respectively. On the bases of their NMR and 19F
B o H N
B o c H N
c o 2p f p c o 2p f p
Z E
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at 8  1.12 (Ala P-H3) and 8  7.06 (Ala-NH) and between 8  2.95 (ArCH2) and 8  7.49 (Ar 2,6- 
H2). More informatively, an NOE connectivity was seen between 8  3.84 (Ala a-H) and 8  
4.73 (4-H). Enticingly, no through-space correlations were seen between any of the methyl 
groups at position 2 and Ala P-H3 or Ala a-H. These data confirm that compound (65) 
exists in the required Z (cis) amide conformation (Figure 3.7).
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Figure 3.7 ' H -'H  NOESY NMR spectrum o
The 'H-'H COSY spectrum of (6 6 ) helped in the assignment of the H-H coupling 
relationships (Figure 3.8). The similarity of the spectra of (66) to those of (65) suggests 
that (66) also exists in the Z (cis) amide conformation. The sole conformation of (67) is 
also taken to be Z (cis). Although these are the N-Boc protected compounds, it is very 
encouraging to note that they all exist (almost) completely in the conformation that would 
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Figure 3.8 'H-'H COSY NMR spectrum o f compound (66) at 20°C in CDCI3.
The deprotected compounds (69) and (70) were identified as being in only one 
conformation by 'H NMR. 'H-'H  COSY spectra of (69) and (70) helped in the assignment 
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Figure 3.9 'H-'H COSY NMR spectrum (CD3)fiO .
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Figure 3.10 ‘ H -H  COSY NMR spectrum o f
At this point, a series of experiments was conducted to ensure that the apparent mixtures of 
conformers were indeed a mixture of conformers and not mixtures of diastereoisomers. 
Similarly, a check on the stereochemical integrity of the coupling reactions was required; 
i.e. a check that no racemisation had occurred during the various couplings reactions.
A fingerprint experiment with a tailor-made mixture of D-Ala and L-Ala amino acid 
fluorides (72) in a ratio of 3:2 was performed (Scheme 3.4). The rationale of this 
experimental mixture was to follow the consistency of the ratio through the synthetic 
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Scheme 3.4 Chemical synthesis of  D,R and L R- diastereoisomers (75) (i) Prl2NEt, 
DMF; (ii) PFP OH, DCC, EtOAc; (iii) 4-nitrophenylethylamine hydrochloride, EtsN, 
CH2Cl2.
The acid fluorides of the mixture consisting of 60% Boc-protected D-alanine and 40%Boc- 
protected alanine (D and L) (72) were prepared by the method used previously. 
Coupling of the crude mixture with (47) afforded the mixture (73) in 36% yield as a 
mixture of two diastereoisomers before purification in a ratio of 3:2 for the D,R- 
diastereoisomer and L,/?-diastereoisomer, respectively. The COSY spectrum of (73) 
highlighted the separate signals of the two diastereoisomers (Figure 3.11). The comparison 
of compounds (57) and (73) spectra confirmed that (57) was indeed the L,R stereoisomer 
only. Furthermore, the similarity of the ratio of products to the ratio of acid fluorides 
confirms that there is little or no diastereoselectivity in the coupling reaction. Coupling of 
the mixture (73) with pentafluorophenol under the usual conditions afforded the active 
acylating agent mixture (74) in 80% yield. The 19F NMR spectrum of (74) was complex 
and indicated the presence of two conformers for each of the two diastereoisomers.
X
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Figure 3.11 1H -H  COSY NMR spectrum o f  compound (73) in CDCf. A corresponds
to the L,R-diastereoisomer; B corresponds to the D,R-diastereoisomer.
Two distinct diastereoisomers in a ratio of 6:4 for the D, /?-diastereoisomer and L, R- 
diastereoisomer respectively was seen in *H NMR and 19 F spectra. From these data, it is 
clear that the two populations of (61) are not diastereoisomers but are conformers.
Coupling of the diastereomeric mixture (74) with 2-(4-nitrophenyl)ethylamine afforded 
mixture (75) in 76% yield. Interestingly, two diastereoisomers in the initial ratio 3:2 was 
identified for the (D,/Cdiastereoisomer) and (L,/?-diastereoisomer) respectively. The wide 
range melting point 69-80°C of (75) is attributed to the presence of these diastereoisomers. 
Clearly, the identification of two diastereoisomers in the spectra of the mixture (75) will 
highlight the fact that no racemisation occurred in the synthesis of the target compounds 
(64), (65), (6 6 ), and (67).
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Diastereoisomers differ in their physical and chemical properties. On this basis, it was 
important to study their effect on the rate of intramolecular cyclisation of the self- 
immolative molecular clip and, in consequence, the drug release. Thus a pure 
diastereoisomer of one of the previously studied molecular clips was needed for this study. 
The diastereoisomer of compound (6 6 ) was taken as an example. This diastereoisomer 
could either be (D,/?) or (L,S), which are enantiomers and should have identical chemical 
properties under achiral conditions. The synthesis of these diastereoisomers could be 
attained by two pathways (Scheme 3.5). Applying these two pathways in the synthesis will 
add to the body of knowledge valuable information about the ease of the synthesis in both 
pathways. Initially, since D-Cys.HCl is much more expensive than D-Val, pathway A was 
investigated. It will be interesting to compare the final output products of the two 
enantiomers.
On the basis of pathway A (Scheme 3.5), the Boc-protected D-valine acid fluoride (76) 
was prepared by the treatment of Boc-protected D-valine with cyanuric fluoride, as 
previously. The crude product was coupled directly with (47) in the presence of tertiary 
amine base. Purification via chromatography afforded compound (77) in 50% yield. It is 
noteworthy that this yield was relatively high upon comparison with the yield obtained for 
the L,^-diastereoisomer (58) and may suggest some diastereoselectivity in the coupling 
with Val, in contrast to the lack of selectivity with Ala (vide supra).
On the basis of pathway B (Scheme 3.5), compound (81) was prepared by cyclo-
173condensation of D-Cys.HCl.H2O (80) with acetone in the presence of 2,2- 
dimethoxypropane (DMP) which serves as a reactant. The crude Boc-protected L-valine 
acid fluoride (54) was coupled directly with (81). Purification via chromatography afforded 
crude compound (82) in 35% yield.
69
Pathway A Pathway B
BocHn HCl.H2r r  ^ C 0 2H
B o cH N
N H B o c
N H B o c
+ HN
N H 3 _
c f 3c o 2
(85)
Scheme 3.5 Chemical synthesis of the enantiomeric self-immolative molecular clips 
(79) and (85), according to pathways A andB, respectively, (i) (CH3)2CO, DMP; (ii) 
Pr^NEt, DMF; (iii) PFP OH, DCC, EtOAc; (iv) 4-nitrophenylethylamine hydrochloride, 
Et3N, CH2Cl2; (v) 20% CF3CO2H / C H 2CI2.
70
The 'H NMR spectra of (77) and (82) were essentially identical, as is required for 
enantiomers. However, significant differences were seen between the spectra of the 
diastereoisomers. The most marked differences were for the Val a-H ( 8  3.86 for (77) and 8  
4.50 for (58)) and 4-H ( 8  5.66 for (77) and 8  5.02 for (58)), with smaller differences being 
observed for other signals.
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Figure 3.12 1H - H  COSY NMR spectrum o f compound (84) at 20°C in CDCf.
Activation of (77) and (82) by coupling with pentafluorophenol in the presence of DCC 
afforded crude (78) and (83). Subsequent coupling with 2-(4-nitrophenyl)ethylamine (41) 
granted the amides (79) and (84) as gummy oils in 17% and 49% yields, respectively. The 
^ - 'H  COSY spectrum of (84) helped in the assignment of the 'H - ^  coupling relationship 
(Figure 3.12). Deprotection of compound (84) afforded the trifluoroacetate salt (85) in a 
quantitative yield.
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For compounds (79) and (84), two distinct sets of signals were observed in the *H NMR 
spectra with relative populations of 80% and 20% at 20°C in CDCI3, indicating that two (Z 
and E) amide conformations are present. These compounds (79) and (84) are enantiomers 
and both are diastereoisomeric to compound (6 6 ) (Figure 3.8). The identification of the 
two sets of signals in the spectra of (79) and (84) as arising from the conformers, rather 
than any racemisation, was confirmed by the fact that neither set corresponded to the 
signals from the diastereoisomer (6 6 ). Comparison of the spectra of (84) in (CD3)2SO at 
20°C and 80°C have showed line-broadening and movement towards coalescence for the 
4-H signal at the higher temperature. However, since coalescence was not complete at 
80°C, the energy barrier to rotation must be relatively high. The *H NMR spectra of 
compounds (79) and (84) were identical; this confirms that they are enantiomers (Figure 
3.13).
fi 6 4 2 0 2 ■06 4a
J f
6 6 4 Z 0
c
Figure 3.13 A and B are ]H NMR spectra o f the enantiomeric compounds (79) and 
(84) respectively in CDCI3, while C is the 1H NMR spectrum o f the diastereoisomeric 
compound (6 6 ) in CDClj.
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As a conclusion, the results of the tailor-made enantiomeric D/L-Ala mixture experiment, 
together with the synthesis of the Val-containing stereoisomers by two pathways, confirms 
that no loss of stereochemical integrity had taken place during any of the coupling 
reactions.
However, in order to increase the body of knowledge, another experiment was performed 
by substituting the amino-acid L-valine with L-leucine (Scheme 3.7) in the L,S 
diastereoisomer. The rationale for this experiment is to highlight the role of the size of the 
side-chain in forcing the clip into the reactive cis (Z) amide conformation and as a 
consequence, the rate of intramolecular cyclisation of the self-immolative molecular clip.
Previously, the acid fluorides were used for coupling with the Me2Thiazolidine moiety. 
Experiments (vide supra) to attempt to use pentafluorophenyl active esters with the 
dimethylthiazolidine nitrophenylethyl amide (51) resulted in opening of the thiazolidine 
ring (Scheme 3.2). Nevertheless, Fmoc-L-ValOPFP (87) ester141,142 coupled very 









Scheme 3.6 Chemical approach fo r  the synthesis o f (88). (i) PFPOH, DCC, EtOAc; 
(ii) Prl2NEt, DMF.
However, unlike Boc protecting group, Fmoc moiety is not acid-labile and has an excellent 
chromophore, which facilitates detection via UV. It is also not removed by the acetic acid 
which is necessary for the chromatographic purification. Unfortunately, in the synthesis 
pathway of the clip, Fmoc-protected amino-acids cannot be used in the coupling process 
due to the cyclisation that would follow Fmoc deprotection under alkaline conditions. 
However, this experiment gives valuable information about successful coupling of PFP and 
acid fluorides with the Me2thiazolidine moiety.
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Using the success of the previous model (Scheme 3.6), Boc-L-Leu was converted to its 
pentafluorophenyl ester (90)143 with DCC by the usual methodology (Scheme 3.7). 
Consequent coupling with (81) afforded (91). After simple work-up procedures, the 
preliminary !H NMR spectrum indicated that this compound is 90% pure and the 
impurities were identified to be related to DCU. On the basis of *H NMR spectroscopy, 
compound (91) ̂ exists solely as one diastereoisomer and one conformer. COSY
analysis of (91) helps in the assignment of the H-H coupling relationship. Conversion of 
(91) to the pentafluorophenyl active ester (92) was followed by coupling with the 
appropriate amine to give the nitrophenylethyl amide (93) in 58% yield. and 19F NMR 
spectroscopy indicates the presence of mainly one conformer of (92). The *H NMR 
spectrum of (93) showed the presence of two rotamers in the ratio 4:1, similar to the ratio 
seen for the corresponding Val dipeptide. Deprotection of (93) afforded the trifluoroacetate 


















Scheme 3.7 Chemical synthesis o f the L,S-diastereoisomer (94). (i) PFPOH, DCC, 
EtOAc; (ii) Prl2NEt, DMF; (iii) PFPOH, DCC, EtOAc;(iv) 4-nitrophenylethylamine 
hydrochloride, Et3N, CH2Cl2; (v) 20% CF3C 0 2H /  CH2Cl2.
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3.2 Synthesis of diketopiperazines (DKPs)
In the course of solid-phase synthesis of the peptide sequence D-Pro-D-Val-L-Pro, it has 
been found that a carboxylic acid-catalysed intramolecular aminolysis of the ester bond to 
the resin occurs at the dipeptide stage. This result accounts for the considerable loss of the 
dipeptide from the resin, which amounted for 70% during the step of coupling with Boc-D- 
Proline and DCC. However, this cyclisation was repressed by adding the carbodiimide 
reagent prior to the carboxyl component. The resulting diketopiperazine of D-valyl-L- 
proline was isolated and characterized.144 Generally speaking, DKP formation occurs as a 
disturbing reaction in the synthesis and long-term storage of peptides.121 However, DKP 
formation is known to occur easily for dipeptide esters because of the presence of alkoxy 
good leaving groups. In addition, peptides with alternating chirality form DKPs more 
easily because of the higher stability of the resulting DKPs.121 DKPs are conformationally 
constrained scaffolds with side chains that are oriented in a spatially defined manner. As an 
example, in the D/L DKPs, the amino acid side chains will lie on opposite sides of the 
plane of the cycle. It is noteworthy, as in compound (36) (Scheme 2.1 B), that the peptide 
bonds must be in the cis conformation; the cyclisation reaction is usually promoted by an 
N-alkylated residue in the first position, because of their high propensity to form a cis 
peptide bond with the preceding residue.145
In general, rates of cyclisation vary markedly with ring size;146 five and six-membered 
rings cyclize rapidly, however, four and seven-membered rings are very much slower. The 
classical explanation is usually attributed to the unfavourable strain energy, which hinders 
the formation of small rings, while this strain becomes negligible in five and six-membered 
rings. Another factor is the presence of alkyl substituents, which usually causes a large 
enhancement of the rate of cyclisation; this is the “gem-dialkyl” effect.147
Recently, an efficient novel route for the synthesis of DKPs on a solid-phase system has 
been described.148 Also solution-phase synthesis has been reported.144 The strategy now is 
to synthesise the DKPs corresponding to the self-immolative molecular clips previously 
synthesised, in order to identify the side-product (DKPs) of the intramolecular cyclisation 
process during the HPLC analysis. Retrosynthetic analysis exploits the general recognised 
propensity for dipeptide esters to form diketopiperazines, where the unprotonated nitrogen
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atom of the N-terminal amino acid can attack the carbonyl carbon atom of the ester of the 
second cyclic residue causing the formation of a six-membered ring DKPs in a good rate. 
The route of DKP synthesis will start with the pentafluorophenyl active esters of the L,R 
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R = H (95)
R = CH3 (96)
R = CH(CH3)2 (97)
R = CH2Ph (98)
(ii)
R = CH, (99)
R = CH(CH3)2 (100)
R = CH2Ph (101)
Scheme 3.8 Chemical synthesis of the authentic diketopiperazines (99), (100) and 
(101). (i) HCl /  CH2Cl2; (ii) Et3N /  CH2Cl2.
Removal of the Boc protecting group was achieved rapidly by passing hydrogen chloride 
through (60), (61), (62) and (63) in dichloromethane to afford (95), (96), (97) and (98) in 
quantitative yields. Enticingly, on the basis of *H NMR spectral analysis, these 
intermediate deprotected compounds were identified; however, by the time that the I9F 
NMR spectrum and mass spectroscopy were conducted, a hydronium ion-catalyzed 
cyclisation reaction (Scheme 3.9) had occurred, resulting in the formation of the 
corresponding DKPs. The COSY spectrum of (97) helped in the assignment of the
H-H coupling relationship. The NOESY spectrum showed the usual through-space
77
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Figure 3.14 ' H- H NOESY NMR spectrum
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The NOESY spectrum of (98) is shown (Figure 3.15). Notably, there is NOE connectivity 
between the upfield 2 -CH3 (8  1.87) and the ortho protons of the phenyl group. There is also 
connectivity between the downfield 2 -CH3 (8  1.92) and the Phe a-H (8  4.24). These data 
allow assignment of the individual singlets for the 2-methyl groups. Similarly the 
individual protons of the 5 -CH2 can be assigned because the signal for one of them (8  3.26) 
has an NOE correlation with the 4-H (8  4 53). Other NOE correlations were seen between 
the NH and Phe a-H, between NH and the phenyl protons and between NH and the Phe p-
h 2.
5













Figure 3.15 'H- H NOESY NMR spectrum
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Acid-catalysed DKP formation is due to the protonation of the carbonyl oxygen atom, 
which lowers the activation energy of the nucleophilic addition on the carbonyl carbon 
atom (102), resulting in direct formation of a cationic tetrahedral intermediate (103). This 
is the expected route for DKP formation (105) at low pH. On the other hand, base- 
catalysed formation of the DKPs (99), (100) and (101) proceeded swiftly upon stirring with 
a non-nucleophilic base (triethylamine). The unprotonated N-terminal amino group 
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Scheme 3.9 Proposed mechanism o f  acid-catalysed formation o f  diketopiperazines 
(105).
The structures of the DKPs (99), (100) and (101) were confirmed by *H NMR; the 
assignments of the signals were aided by the 'H -’H COSY spectra (Figure 3.16), (Figure 
3.17) and (Figure 3.18), respectively. It should be noted that the numbering system of the 
DKPs is different to that of the parent dipeptides; the bicycle is numbered with sulfur at 














2 . 5 -
3 . 0 -
3 . 5 -
6-H
8 a-H
1 . 53 . 5 3 . 0 2 . 5 2 . 04 . 5 4 . 0
FI (ppm)






1 . 5 -
2x(3-Me)
4-1
2 . 5 -
3 . 5 -
6 -H
4 . 5 -
8 a-H
4 . 5 3 . 5 3 . 0 2 . 5 2 . 0 1 . 5 1 . 04 . 0
FI (ppm)









1 . 5 -
PhCH 3
3 . 0 -
2x (1-H) = 3
PhCH □
4 . 5  4 . 0  3 . 5  3 . 0  2 . 5
FI (ppm]
2 . 0  1 . 5

















8 7 6 5 4 3 2
FI (ppm)
Figure 3.19 ' H- H  NOESY NMR spectrum o f  co
The detailed conformations of the DKPs were needed to understand the relative rates of 
ring-closure. The DKPs (99) and (100), derived from L-Ala and L-Val, respectively, form 
good crystals and X-ray crystal structure determinations were carried out {vide infra). 
However, the L-Phe-derived DKP (101) was a gum. The NOESY spectrum of (101) 
(Figure 3.19) showed expected NOE connectivity between 1-H (5 3.20) and 8a-H (5 4.53) 
and between 6-H (8 4.24) and NH (8 5.82). Another NOE connectivity was seen between 
the ortho protons of the phenyl group (8 7.21) and the 6-H (8 4.24) and both PhCH (8 2.82 
and 8 3.56). Notably, an NOE connectivity was seen between the upfield 3 -CH3 (8 1.87) 
and the other 1-H protons.
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In the other diastereomeric series, the DKPs (108) and (109) derived from the L^S-Val 




R = CH(CH3)2 (83) R = CH(CH3)2 (106)
R = CHCH2(CH3)2 (92) R = CHCH2(CH3)2 (107)
(ii)
H
R = CH(CH3)2 (108)
R = CHCH2(CH3)2 (109)
Scheme 3.10 Chemical synthesis o f  the authentic diketopiperazines (108) and (109). (i) 
HC l / CH 2Cl2 or 2 0 % CF3CO2H / C H 2CI2; (ii) Et^N /  CH2Cl2.
The synthesis route follows the same methodology used previously. Hydrogen chloride- 
catalysed deprotection o f compound (83) afforded (106) quantatively, whereas 
deprotection o f (92) was successfully achieved by treatment with a mixture o f 20% 
trifluoroacetic acid in dichloromethane and afforded (107) quantitavely. Subseqently, base- 
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Figure 3.20 'H-'H COSY NMR spectrum o
The 'H-'H  COSY NMR spectrum of (108) helped in the assignment of the H-H coupling 
relationships (Figure 3.20).
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3.3 Conformational studies on the DKPs derived from the 
molecular clips
The structures of the DKPs (99), (100), (101), (108) and (109), derived from L-Ala-/?- 
dimethylthiazolidinecarboxylic acid, L-Val-/?-dimethylthiazolidinecarboxylic acid, L- 
Phe-/?“dimethylthiazolidinecarboxylic acid, L-Val-S-dimethylthiazolidinecarboxylic 
acid and L-Leu-S-dimethylthiazolidinecarboxylic acid, respectively, were established 
by the conventional spectroscopic methods (vide supra). Part of the study on the rates 
of formation of the DKPs and liberation of the model drug from the clips was to 
investigate the effect of the size of the amino-acid side-chain. The bulk of the side- 
chains may influence the cyclisation / drug release in several ways. Firstly, it may 
influence the cis/trans amide conformer ratio. Secondly, steric clashes may occur 
during the ring-closure reaction steps. Since it was not clear whether having a bulky 
side-chain would increase or decrease the rate of cyclisation and drug release, the 
conformations of the product DKPs were studied to assess the extent of steric 
crowding.
X-ray crystallography, performed by Dr. Mary F. Mahon, Department of Chemistry, 
University of Bath, provided the solid-state conformations for (99) and (100). Crystals 
suitable for the diffraction studies have not yet been grown for (101), (108) and (109).
3.3.1 Intermolecular hydrogen-bonding
The structures of compounds (99) (Figure 3.21) and (100) (Figure 3.22) each contain 
one hydrogen-bond donor and two acceptors. Each shows intermolecular hydrogen- 
bonding of the N -H —*0=C type in the crystal. Only the secondary amide carbonyl is 
involved in this bonding. However, the pattern of the hydrogen bonding differs 
between the two molecules. In (99), the N-H and C =0 of one molecule bond to 
different adjacent molecules, resulting in a chain of hydrogen-bonded molecules, as 
shown in (Figure 3.21). However, in (100), the N-H  and C=0 of the secondary 
amide of one molecule form two hydrogen-bonds with the C=0 and N-H  of the 
secondary amide of one adjacent molecule, resulting in the formation of a hydrogen- 
bonded dimer (Figure 3.22).
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Figure 3.22 X-ray crystallographic structure o f  compound (100), showing the 
intermolecular hydrogen-bonding interactions.
3.3.2 Conformational analysis of the DKPs
A previously reported X-ray analysis of the symmetrical unsubstituted DKP, cyclo- 
GlyGly, indicated it adopts a planar conformation. 149 In cyclo-L-Ala-L-Ala, which 
carries two methyl groups on the same face of the ring, the DKP ring is puckered and 
has been described as a twist boat. 150 On the other hand, the opposite diastereoisomer 
cyclo-D-Ala-L-Ala, with the methyls on opposite sides, is nearly planar. 150 When one 
of the amino-acids is Pro, the conformations adopted by the DKPs deviate from 
planarity, owing to the restriction imposed by the fused pyrrolidine ring. The two 
amides individually remain planar but they do not both lie in the same plane. Thus 
cyclo-L-Pro-L-Leu and cyclo-L-Pro-L-Phe adopt boat conformations. 151,152 Crystal 
structures of DKPs containing thiazolidines, in place of the pyrrolidine of Pro, have 
not been reported.
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Figure 3.23 X-ray crystallographic view o f  the structure o f  compound (99). The red 
color refers to oxygen atom, the yellow refers to sulfur, the blue refers to nitrogen and 
the gray refers to the carbon atom.
Figure 3.23 shows a view of the structure of (99). The DKP ring is in a flattened boat 
conformation, with the thiazolidine in a half-chair. This ring conformation places the 
geminal methyl groups at position-3 in equatorial and axial positions; the 6 -methyl 
occupies a /wewfifo-equatorial position. Notably, this 6 -methyl group is remote in 
space from the geminal dimethyl unit and, indeed, from other sterically bulky groups.
A similar conformation is also likely to be adopted in solution in chloroform, since it 
is consistent with several NMR observations. The 3J  coupling constants between the 
axial 8 a-H and the 1-H protons are 10.2 Hz and 6 . 6  Hz. These are consistent with 
dihedral angles (8 a-H)-(8 a-C)-(l-C)-(lp-H) of 166° and (8 a-H)-(8 a-C)-(l-C)-(la-H) 
of 44°, according to the Karplus relationship. The axial 6 -H couples with the adjacent 
N-H by 3J  = 1.0 Hz, which corresponds with the dihedral angle of 97°. Longer-range 
couplings are also observed. A four-bond coupling V  = 1.6 Hz is seen between 8 a-H 
and the NH; the coupling path between these atoms contains four atoms in one plane 
and one terminal atom out of that plane, thus the W-arrangement is almost adopted. 
Excitingly, a five-bond coupling 5J  = 0.8 Hz was observed between the axial 8 a-H 
and the axial 6 -H. Maes et al.153 observed a similar coupling in ditryptophenaline, a 
natural product from Aspergillus flavus var. columnaris; this molecule contains a
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cyclo-L-Phe-L-Pro unit fused to a heterocycle through the Pro side-chain loop. They 
use this long-range coupling to confirm that the DKP is in a boat conformation in 
solution where the corresponding protons are axial and cis. This then confirms that the 
solution conformation of (99) has these protons axial and cis and thus the solution 
conformation is similar to the solid-state conformation shown in (Figure 3.23).
Figure 3.24 Three views o f  the X-ray crystallographic structure o f  (100). In the 
lower view, parts o f  the molecule have been omittedfor clarity.
The X-ray crystallographic study on the DKP (100) derived from L-Val-/?-dimethyl- 
thiazolidinecarboxylic acid showed this molecule to adopt a conformation similar to 
that of (99). Figure 3.24 shows three views of the structure of (100). Again, the DKP 
ring is in a boat conformation, with the thiazolidine in a half-chair. The geminal 
methyl groups at position-3 are in equatorial and axial positions; the 6-isopropyl 
occupies a /wew<7o-equatorial position. Notably, this 6-isopropyl group is remote in 
space from the geminal dimethyl unit.
The solution conformation of (100) in (CD3)2SO is similar, as shown by the ]H NMR 
spectra. The 3J  coupling constants between the axial 8a-H and the 1-H protons are 
11.7 Hz and 5.9 Hz. These are consistent with dihedral angles (8a-H)-(8a-C)-(l-C)- 
(1P-H) of 169° and (8a-H)-(8a-C)-(l-C)-(la-H) of 41°. In this case, the coupling
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between axial 6 -H and the adjacent N-H is too small to be resolved; the dihedral angle 
in the crystal structure is 98°. The five-bond coupling 5J = 1.2 Hz was observed 
between the axial 8 a-H and the axial 6 -H, which again confirms the boat 
conformation in solution.153 Looking at the conformation of the side-chain, a V  = 2.3 
Hz coupling is seen between 6 -H and the adjacent Me2CH. In the solid state, the 
corresponding dihedral angle is 70°.
The DKP (101) derived from L-Phe-R-dimethylthiazolidinecarboxylic acid was a gum
and a crystal structure could not be determined. However, the *H NMR spectra in
chloroform do give useful conformational information. The boat conformation of the
DKP ring was confirmed by the presence of the five-bond coupling V  = 0.8 Hz
between the axial 8 a-H and the axial 6 -H.153 Therefore, the PI1CH2 side-chain is in an
equatorial position and is far from the geminal dimethyl unit. The thiazolidine is
probably in the half-chair conformation, with a three-bond trans-diaxial coupling 3J  =
11.3 Hz between 8 a-H and one of the 1-H protons. The corresponding three-bond
axial-equatorial coupling between 8 a-H and the other 1-H is 3J = 5.9 Hz. A four-bond
coupling 4J = 1.6 Hz is observed between 8 a-H and NH; an identical coupling was
seen for (99). The three-bond coupling constants from the PI1-CH2 protons to the 6 -H
are 3J = 10.2 Hz and 3J = 3.9 Hz; thus the Ph cannot be antiperiplanar to the 6 -H, as a
coupling constant of 10.2 Hz is only consistent with antiperiplanar H—C—C—H. The
phenyl is either orientated towards the nitrogen or towards the carbonyl oxygen.
These data contrast with those for ditryptophenaline (vide supra), in which the two
corresponding coupling constants between PI1-CH2 and 6 -H are 3J = 4.4 Hz and 3J =
3.1 Hz; these values are used to support a conformation with Ph located over the DKP
ring.153 However, the data for (101) are consistent with the X-ray structure-derived
conformation reported for cyclo-L-Phe-L-Pro, in which the DKP is boat, CH2PI1 is
1 ̂ 2equatorial and the phenyl is antiperiplanar to the carbonyl.
No X-ray crystal structures were available for the other diasereoisomeric DKPs (108) 
and (109) but certain inferences can be drawn from NMR data. Most notable is the 
coupling of 6 -H with the adjacent NH, with 3J = 3.5 Hz for (108) and with 3J = 5 Hz 
for (109). In the crystal structure of L,R diastereoisomer (100), the dihedral angle (7- 
H)-(7 -N)-(6 -C)-(CHMe2) is 13°. Simple exchange of the hydrogen and isopropyl
9 2
groups at C-6  would give the new diastereoisomer. However, this would place the 
isopropyl pseudo-axial and the hydrogen pseudo-e,quatorial and give the (7-H)-(7-N)- 
(6 -C)-(Cf/Me2) dihedral angle as 13°; this is inconsistent with the coupling constant 
of 3.5 Hz. Consequently, the conformation of the DKP is unlikely to be boat but may 
be almost planar. Such planarity would relieve steric compression between the 
isopropyl groups and 8 a-H. The flattening effect is less in (109) Wherea the 
CH2CHMe2 group is less sterically demanding than the CHMe2 of (108). With this 
flattening of the DKP, the side-chain is moved away from the geminal dimethyl unit.
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3.4 Study on the rates o f cyclisation o f candidate molecular clips
The prodrug system comprises the polymer, the PSA-cleavable peptide, the molecular 
clip and the drug. Each of these components needs to be tested and optimised for 
efficiency independently (with the exception of the drug). In this section, the 
optimisation of the molecular clip will be discussed. Analysis has been conducted to 
evaluate the efficiency of cyclisation of the putative self-immolative molecular clips 
(68), (69), (70), (71), (85) and (94) to liberate the model drug (Scheme 3.11). For each 
clip, the Boc protecting group of the precursor was removed with trifluoroacetic acid, 
giving the clip-drug units as their trifluoroacetate salts. In these salts, the amine nitrogen 
is protonated, preventing premature cyclisation. The salts were placed in aqueous 
buffers at three different pH values, generating the free amines. The rates of cyclisation 
and liberation of the model drug (2-(4-nitrophenyl)ethylamine) were determined by 
HPLC analysis.
1
Scheme 3.11 Optimisation o f  aminoacyl dimethylthiazolidine molecular clip. (R = H  







3.4.1 Quantitation of the percentage of model drug (NPEA) released
The percentage was determined by calculating the ratio of the peak area of 
NH2XMe2Thiazolidine-NPEA at each defined time of the analysis with 'respect to the 
initial area at zero time. Representative graphs are provided to show the consistent 
decrease in the area of H2NXaa-Me2Thiazolidine-NPEA and increase in the area of 
DKPs and the model drug (NPEA). Results are reported as the time required for 50% of 
the drug to be released (half-life).
3.4.2 Results and discussion
The first fundamental step in the release study will be the analysis of the authentic 
diketopiperazines (99), (100), (101), (108), (109) and the model drug NPEA. The 
corresponding retention times (Rt) are shown in (Table 3.1).
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Standards Derivatives (R) Ret. Time (min), 37°C
pH 6.0 pH 7.0 pH 8.0
j-----, ,--- NH2.
o 2n — f t  \ — /








(100) 7.8 7.6 7.9
CH2Ph
(101) 12.3 12.9 12.5
%
R
/ ' - s
H
CH(CH3)2




Table 3,1 HPLC analysis (monitored at 225 nm) at 37°C o f the authentic 
diketopepirazines (97), (98), (99), (108) and (109) at pH  6.0, pH  7.0 and pH  8.0.
As noted in (Table 3.1), the retention times of all the authentic standards appear 
consistent. All DKPs have retention times which are independent of the pH (as expected 
for amides) and the NPEA has a slightly shorter retention time at low pH due to 
protonation. Further, the retention times of the H2NXaa-Me2Thiazolidine-NPEA 
derivatives (68), (69), (70), (71), (85) and (94) were also measured (Table 3.2) These 
derivatives have a lower retention time at lower pH because of protonation. 
Interestingly, each of these derivatives has a retention time, which is different from the 
retention time of the analytes (DKPs and NPEA) of the cyclisation process.
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8 .2 1 1 .8 15.9
ND
Table 3.2 HPLC analysis (monitored at 225 nm) at 37°C of the aminoacyl 
dimethylthiazolidinemolecular clips (6 8 ), (69), (70), (71), (85) and (94) at various pHs. 
ND (Not done).
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The rate o f cyclisation and subsequent drug release was studied at three different pHs:
A Release studies at pH  8 .0
In this first set of experiments, the chemical cyclisation of compounds (6 8 ), (69), (70), 
(71), (85) and (94) was studied at pH 8.0 (37°C) where the release rate is predicted to be 
maximal, as the proportion of unprotonated nucleophilic amine should be higher at this 
pH than at the lower pH values. The progress of the cyclisations was monitored by 
decreases in the peaks corresponding to the starting materials and increases in the peaks 
corresponding to the DKP and NPEA products. In all cases, the formations of the 
products corresponded to the consumption of the starting material since no by-products 
or intermediates were detected. It is noteworthy that each experiment has been repeated 
twice and the chromatograms were monitored at 225 nm and 275 nm in order to follow 
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Figure 3.25 Time courses o f  chemical cyclisation o f  compound (68) at pH  8.0 (37°C) 
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Figure 3.26 A plot o f  the time versus area o f  compound (6 8) and the analytes L-Gly- 
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Figure 3.27 Time courses o f  chemical cyclisation o f  compound (69) at pH  8.0 (37°C) 
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Figure 3.28 A plot o f  the time versus area o f  compound (69) and the analytes L-Gly- 
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Figure 3.29 Time courses o f  chemical cyclisation o f  compound (70) at pH  8.0 (37°C) 
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Figure 3.30 A plot o f  the time versus area o f  compound (70) and the analytes L-Val- 
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Figure 3.31 Time courses o f  chemical cyclisation o f  compound (71) at pH  8.0 (37°C) 
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Figure 3.32 A plot o f  the time versus area o f  compound (71) and the analytes L-Phe- 
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Figure 3.33 A plot o f  the time versus area o f  compound (85) and the analytes L-Val- 
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Figure 3.34 A plot o f  the time versus area o f  compound (94) and the analytes L-Leu- 
derived DKP (109) and the model drug NPEA (41) at pH  8.0 (37°C) o f  trial F, and F2.
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Since the reactions of compounds (85) and (94) are fast, some drug release has already 
occurred at the time required for the assay of the sample injected at “zero time”. 
However, estimation can be done. The corresponding tj/2 of all 
NH2XaaMe2Thiazolidine-NPEA derivatives at pH 8.0 will be summarised in (Table 
3.3).
B Release studies at pH  7.0
In this second set of experiments, the chemical intramolecular cyclisation of compounds 
(6 8 ), (69), (70), (71), (85) and (94) was studied at pH 7.0, 37°C (mimicking the 
physiological pH). The percentage of NPEA released was calculated and the ti/2 was 
determined. The following figures 3.35, 3.36, 3.37, 3.38 and 3.39 represent the graphic 
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Figure 3.35 Time courses o f  chemical cyclisation o f  compound (6 8)  at pH  7.0 (37°C) 
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Figure 3.36 Time courses o f  chemical cyclisation o f  compound (69) at pH  7.0 (37°C) 
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Figure 3.37 Time courses o f  chemical cyclisation o f  compound (70) at pH  7.0 (37°C) 
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Figure 3.38 Time courses o f  chemical cyclisation o f  compound (85) at pH  7.0 (37°C) 
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Figure 3.39 Time courses o f  chemical cyclisation o f  compound (94) at pH  7.0 (37°C) 
o f  the two trials, as monitored by consumption o f  the starting material.
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C Release studies at pH  6.0
At this pH, only compound (85) was studied, since this is the compound which cyclised 
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Figure 3.40 Time courses o f  chemical cyclisation o f  compound (85) at pH  6.0 (37°C) 
o f the two trials, as monitored by consumption o f  the starting material.
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pH 8.0 pH 7.0 pH
6.0
10-11 42 h NDMe Sk.
(68)
3-4 h 8-9 ND
26-27 ND
28-29 NDND
15-20 45-75 10 hMe_
minmin
60-90 2.5 h ND
min
Table 3.3 The approximate times required for 50% of the molecular clips to 
cyclise and release 50% of the model drug (h/2) at various pH  values in phosphate 
buffer-acetonitrile mixture.
The results presented in (Table 3.3) indicate the effect of the size of the side-chain and 
the relative configuration on the rate of DKP formation and liberation of the model drug 
(NPEA). In the design of the molecular clip, the side-chain R group of the terminal 
amino acid is designed to clash sterically with the geminal 2 ,2 -dimethyl moiety of the 
thiazolidine ring, thus forcing the clip into 100% cis (Z) amide conformation (Scheme
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3.12). Consequently, DKP formation and drug expulsion would be enhanced. As a 
result, one might expect that compounds with more bulky R group would cyclise more 
quickly. However, on the contrary, the cyclisation process was found to be slower for 
the L-aminoacyl-.ft-thiazolidines with bulky side-chains. Examination of the X-ray 
crystallographic structures of the DKPs derived from L-Ala (99) and L-Val (100) in the 
previous section (3.3) helped in the explanation of these results.
The mechanism of DKP formation is suggested in (Scheme 3.12). As one might expect, 
as the size of the R group of the amino-acids increases, the equilibrium between the two 
amide conformations Z (110) and E  (111) will be in favour of the Z conformer (110). 
Conformer (112) is also disfavoured due the steric clash between the R group and the 
drug. In compound (110), the amino group is pointed towards the carbonyl atom 
promoting cyclisation through formation of the tetrahedral intermediate (113). This then 
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Scheme 3.12 Mechanism o f  DKP formation (R= H, Me, Pr\ CH2Ph and CH2Pr‘, R ' 
= NPEA).
The intermediate (113) is expected to have a twisted-chair conformation due to the
3 * 2  •presence of four sp and two contiguous sp hybridised atoms. In this twisted-chair 
conformation, the R group in the L,R diastereoisomers (68), (69), (70) and (71) will be 
pointed upward and thus clash sterically with the “up” methyl group of the geminal
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dimethyl unit. Thus, if the formation of (113) is rate-determining, increase of the bulk of 
R will slow the overall reaction. This is the rank order observed. Therefore, the 
formation of (113) is suggested to be rate-determining. However, on the other hand, in 
the L,5 diastereoisomers (85) and (94), the R group will be pointed downward and thus 
no steric clash will exist with either of the geminal dimethyls; as a result, the rate of 
cyclization will be faster. In the L,R diastereoisomers, the rate of DKP formation 
increases as the size of the side-chain R group decreases. Interestingly, the rate of DKP 
formation is faster in the L,5 diastereoisomer as the R group of the side chain was more 
locally bulky (Val vs. Leu). The origin of this effect is not clear, as the R group is far 
from the geminal dimethyls in the intermediate but it may be connected with the 
proportion of the reactive Z-amide conformer of the starting material.
As shown in the X-ray crystallographic study, the L,R DKPs exist in a flattened boat 
conformation, having two sp3 atoms separating two sets of two trigonal sp2 atoms. In 
this conformation, the side-chain R is far from the geminal dimethyls, so the effect of 
steric bulk should be insignificant in the final elimination step leading to the DKP. 
Within the set of L,P compounds, the bulk of the R group has a profound effect on 
reaction rate, so the final elimination step cannot be rate-determining. However, 
structures of the DKPs of the L,5 diastereoisomers were not available but the ring is 
proposed to be almost planar (vide supra). This planarity again places the R group far 
from the geminal dimethyls, so the final elimination step is again unlikely be rate- 
determining.
A study of the effects of pH, buffer and temperature on the cyclisation reaction of Ala- 
Pro-NH2 to the cyclo-AlaPro DKP has been reported.121 The effect of the size of the R 
group was not studied. This report is more relevant to the present study, as the leaving 
group is an amine (ammonia), unlike many studies on DKP formation70,118 where the 
leaving group is oxygen-based and consequently a better leaving group. In Ala-Pro- 
NH2, the Pro ensured a sufficiently high cyclisation rate at all pHs. Capasso et a l 121 
considered parallel routes in which the intermediates differed in their protonation status 
at the heteroatoms concerned. The balance between the different pathways therefore 
depended on the pH of the solution and affected which step was rate-determining. 
Interestingly, only effects on steps after the formation of intermediates corresponding to 
(113) were considered. However, in our study, the side-chains R had a profound effect
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on the overall rate and this steric effect could only be exerted on the initial cyclisation 
step forming intermediate (113).
As a conclusion, increasing the size of R group in the L,R diastereoisomers would, on 
one hand, shift the equilibrium between the two conformations (Z and E) towards the 
energetically favourable Z conformation (110) and, on the other hand, slow the rate- 
determining step in DKP formation. In the other diastereoisomeric L,S series, a bulky R 
group would shift the conformational equilibrium in the starting material towards Z but 
not as effectively as in the L,R series. However, in this series, comparison of the rates of 
cyclisation of (85), (94) and (6 8 ) (as could also be considered as a member of both 
series with R = H) shows that cyclisation is faster with more bulky R groups. Since the 
R group is equatorial in the intermediate and is far from the geminal dimethyl in the 
DKP, the E —» Z interconversion may now be rate-limiting. Alternatively, large R may 
influence the relative energies of the conformations around the carbonyl— Ca bond so 
that the reacting conformer with NH2 pointed towards the secondary amide electrophile 
is more accessible with large R.
It is noteworthy that with the change of the pH from 8.0 to 7.0, the half-lives of the 
cyclisations increased by 2-4 fold. This is due to the presence of the equilibrium 
between the protonated and the unprotonated forms of the primary amine. The pKa of 
AlaProNH2 is 7.8 ;121 the pKa of these molecular clips should be similar. This pKa is 
within the pH range studied. At the three different pH values studied, the degree of 
protonation will vary markedly, consequently affecting the overall rate of cyclisation. 
At pH 6.0, where the amino group is highly protonated, the rate should be much slower, 
as seen with compound (85) (pH 8.0 ty2 = 15 min; pH 7.0 ty2 = 45 min; pH 6.0 ty2 = 10 h) 
(Table3.3).
108
3.5 Synthesis of the PSA-cleavable peptide linker
The HPLC study on the relative rates of DKP formation and expulsion of the model drug in 
the previous section showed that the clip derived from L-Val and S-dimethylthiazolidine 
cyclised most rapidly. Thus, this clip was chosen for studies on development of the PSA- 
cleavable peptide linker.
Following optimisation of the self-immolative molecular clip, the synthesis of PS A-cleavable 
peptide linker is the next target. On the basis of the literature,114 two peptide sequences 
SSKLQ and SKLQ will be synthesised and examined. Since the HPLC study highlighted the 
fact that the DKP formation from (85) was very rapid under basic conditions, this compound 











Scheme 3.13 Proposed route towards the synthesis of compound (116). (i) EtjN, CH2CI2.
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Since it is the dimethylthiazolidine that is driving the rapid cyclisation and DKP formation, a 
series of experiments was conducted to test whether it would be possible to construct a 
peptide containing D-Cys and later build the thiazolidine ring.
Generally speaking, \|/Pro derivatives are used as temporary protecting groups in peptide
chain containing N-terminal serine-derived oxazolidine (Serox) or threonine-derived
or N-carboxyanhydrides (Route B, Scheme 3.1). Interestingly, successful acid-catalyzed
(117) with 2,2-dimethoxypropane (DMP) upon refluxing (Scheme 3.14). Furthermore, it is 
noteworthy that racemization sometimes observed in the coupling of peptide derivatives, is
Scheme 3.14 Oxazolidine formation in dipeptide derivatives (Rj = H, CH3; R2 = H, CH3, 
allvl, succinimide: Axx = Ala, Val).
Consequently, the strategy now was to gain advantage of the possible recyclisation of the 
cysteine moiety to the thiazolidine ring. A model experiment using glutathione (GSH), which 
is a tripeptide composed of glutamate, cysteine and glycine was executed. The rationale of 
this experiment is to set up the conditions required for ring-closure of a cysteine moiety 
incorporated into a peptide chain (Scheme 3.15). Glutathione (119) was esterified with 
methanol in the presence of hydrogen chloride. Evaporation afforded crude (120). Consequent 
simultaneous protection of the thiol and amine moieties with benzoyl groups was an attractive 
proposition because of the ability of selective S-deprotection.154 Benzoylation of (120) was 
attempted by stirring with benzoyl chloride in the presence of excess triethylamine in 
dichloromethane. Recrystallisation afforded pure (121) as a white solid in 20% yield.
synthesis. It has been reported that coupling of amino-acid derivatives to a growing peptide
oxazolidine (Throx) results in low reaction yields. Consequently, the pre-formation of \|/Pro- 
containing dipeptides is readily accomplished by in situ N-acylation with amino acid halides
oxazolidine ring formation was achieved by the reaction of N-protected dipeptide derivatives
133suppressed by the presence of this ring system. Notably no thiazolidine ring formation from 
Aaa-Cys dipeptides has been reported.
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Scheme 3.15 Proposed route toward the chemical synthesis o f compound (123). (i) HCl, 
MeOH; (ii) PhCOCl, Et3N, CH2Cl2; (Hi) MeOH, 30°C, 48 h; (iv) (CH3)2CO, DMP, PTSA 
or TOSEC, DMAP.
Selective deprotection of the benzoyl thioester was attained by methanolysis upon stirring 
with methanol in the presence of triethyamine. Evaporation and recrystallisation afforded 
(122) as a white solid in 57% yield. All attempts of cyclocondensation failed. Several 
attempts by refluxing with acetone in the presence of 2 ,2 -dimethoxypropane, toluenesulfonic 
acid as an acid catalyst for different times were unsuccessful to drive the cyclisation process. 
The product was usually identified by !H NMR to be the starting material. Mass spectrometry 
suggested that some of the disulfide (m/z 877 for M + H) may have been formed. So far, no 
clue was known for the obstruction of the cyclisation process.
I l l
An alternative cysteine-containing unit with amide bonds on the N- and C- terminals was also 
studied. Three pathways were investigated to synthesise compounds of this type (Scheme 
3.16, 3.17, 3.18). The principle of the three pathways starts with the use of cystine, in which 
the S-S bridge linkage can be cleaved later on to yield the corresponding cysteine moieties.
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Scheme 3.16 Different routes towards the chemical synthesis of (128). (i) PhCOCl, aq. 
NaOH; (ii) H2S 04, MeOH; (iii) NH2NH2, MeOH.
On the basis of (Scheme 3.16), benzoylation of L-cystine (124)155 with benzoyl chloride 
under Schotten-Baumann conditions afforded (125) in 54% yield. The !H NMR spectrum 
indicates the presence of one signal for the two cysteine moieties in cystine, due to the 
symmetry of the compound. Consequent esterfication of (125) by boiling with sulphuric acid 
in methanol afforded (126) in a quantitative yield. It is noteworthy that compound (126) can 
be synthesised directly from L-cystine dimethyl ester dihydrochloride (127) in 67% yield, 
which is higher than that of the two-step synthesis process. Reaction of (126) with hydrazine 
hydrate156 in methanol for 16 h afforded (128) in 60% yield. The hydrazides formed could 
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Scheme 3.17 Two different approaches fo r  the synthesis of (130). (i) 1- BuNfy, -78°C, 2- 
reflwcfor 5 h; (ii) aq. NaOAc, Et2 0 , PhCOCl, 0°C, 4 h.
On the basis of (Pathway A, Scheme 3.17), L-cystine (124) was boiled under reflux with 
butylamine for 5 h and afforded crude mixture (129).155’157 Benzoylation of crude (129) with 
benzoyl chloride afforded two diastereoisomers (130) and (131). The NMR spectra of each 
of these compounds confirmed the presence of the benzoyl group, the butylamide and the 
cysteine. In these spectra, the characteristic differential signal was corresponding to the Cys 
p-H  protons, which is presented as a pair of double doublets for compound (130) and a single 
doublet for (131). Surprisingly, mass spectroscopy showed these compounds to contain only 
one sulfur per two amino-acid units. Compound (131) also showed [a]o20 + 0.0° (c 0.003, 
CHCI3), which is consistent with a meso stereoisomer. The structures (130) and (131) are 
therefore proposed for these compounds.
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However, it has been reported that disulfides undergo facile monodesulfurisation on treatment 
with an aminophosphine.158 This desulfurisation process is stereospecific in that inversion of 
configuration occurs at one of the carbon atoms a to the disulfide group. However, since the 
diastereomeric products are formed in similar amounts, a different mechanism is likely 
(Scheme 3.17). Elimination of RSS‘ would give N-benzoyldehydroalanine N-butylamide. 
RSS' would then lose one sulfur to give the thiolate which attacks the dehydroalanine in a 
Michael reaction. Since the Michael electrophile is achiral, the addition will give equal 
amounts of the R,S and R,R isomers.
We were, however, surprised to encounter that the straightforward acylation process of (126) 
by dissolving in anhydrous butylamine at -78°C and boiling under reflux for 5 h, resulting in 
the isolation of solely one diastereoisomer (130) in 8 % yield (Pathway B, Scheme 3.17).
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Scheme 3.18 Proposed chemical approach for the synthesis of (137). (i) AC2O, EtsN; (ii) 
propane-1,3-dithiol, Prl2NEt, THF; (iii) (CH3)2 0 0 , DMP, PTSA, CH2CI2.
An alternative method was based on the use of the highly expensive commercially available 
L,L-cystine bis(naphth-2-yl)amide (132). This compound was acetylated with acetic 
anhydride and afforded (133) in 92% yield as a white solid. This approach is very convenient 
because the structure is confirmed and fulfils the required features, being now appropriately 
modified on both the C- and N- terminals. Compound (133) was cleaved swiftly to (134) with 
excess propane-1,3-dithiol159 in THF. The rate of the process was considerably enhanced by 
the addition of a hindered tertiary amine (Pr^NEt), which aids in an intermediate formation of
the appropriate thiolate anions. The by-product, 1,2-dithiacyclopentane, has been reported160 
to be unstable and to give rise to intractable insoluble polymers. Cyclocondensation of (134) 
was attempted by refluxing with acetone in the presence of 2 ,2 -dimethoxypropane and 
toluenesulfonic acid or BF3 as an acid catalyst. None of the desired compound (137) was 
formed. The products identified by *H NMR were the monothioacetal (135) and the thioenol 
ether (136), both potential intermediates in the desired process. It may be possible to 
rationalise such results on the basis of lack of nucleophilicity of the amide.
As a conclusion, the concept of constructing a peptide sequence in which cysteine moiety is at 
the penultimate position with the drug attached, followed by cyclocondensation to form the 
thiazolidine ring, proved to be unsuccessful. So, an alternative approach should be considered.
The new approach will be based on the successful constructing of the aminoacyl- 
Me2Thiazolidine unit (Scheme 3.19). In this suggested route, acidolysis of (82) will be 
performed with trifluoroacetic acid in dichloromethane to afford (138). The latter would 
subsequently be coupled with BocGlnOPFP to afford (139). The rationale of this pathway is 
based on the stability of the carboxylic acid functionality toward any nucleophilic attack 
relative to the pentafluorophenyl active esters which proved to undergo' spontaneous 
intramolecular cyclization to the DKP following the deprotection process. However, an 






Scheme 3.19 Proposed chemical approach fo r the synthesis o f (138). (i) 20% CF3CO2H /  
CH2Cl2.
So far, the strategy has been to synthesise the clip or clip-drug units, then to attach the 
peptide. A new strategy was investigated in which dipeptides or oligopeptides are attached to 
the dimethylthiaproline, avoiding intermediates which may form DKPs. Direct coupling of 
the heptapeptide Ac-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-OH with 4-O-prolyl ester of dAc-VIN 
was reported (Scheme 1.3); however, the preceding experiment (Scheme 3.2) proves that 
amino-acyl coupling of compound (51) resulted in ring-opening. This, in turn will prohibit the 
possibility of initial drug and subsequent amino acid coupling to the Me2ThPro moiety.
Alternatively, a new strategy based upon the method of coupling dipeptide acid fluorides to 
Me2Thiazolidine unit was attempted. The rationale of this tactic is based upon barring the 
intramolecular cyclisation process by insertion of an amino acid moiety between the 
nucleophilic N and the electrophilic carbonyl moiety (Scheme 3.20). Generally speaking, 
dipeptide acid fluorides coupling were not reported at the time of the experiment. However, 
very recently, Carpino et al.161 have reported a new method for dipeptide acid fluoride 
generation and utilisation in the segment coupling process. It is noteworthy that the acid 
fluoride of side-chain-unprotected Gin-containing dipeptides was not reported. On the other 
hand, synthesis of acid fluorides of trityl-side-chain-protected Gin-containing dipeptides 
proved to be successful. The rationale of this route was based on the advantage of reactive 



















Scheme 3.20 Proposed chemical approach for the synthesis of (139). (i) SOCh, MeOH, 
40°C; (ii) BocGlnOH, HOBt, DCC, CH2Cl2, Pr^NEt; (iii) NaOH, MeOH; (iv) 10% PdJC, 
MeOH; (v) Cyanuric fluoride, pyridine, CH2Cl2, -10°C.
This route starts with the conventional esterification162 of (140) by stirring in MeOH with 
thionyl chloride at 40°C for 24 h. A quantitative yield of (141) was obtained. Subsequent 
coupling of Na-Boc-L-glutamine with (141) using the DCC/l-hydroxybenzotriazole 
method163 afforded (142) in 71% yield. Alkaline hydrolysis of (142) was achieved by stirring 
in methanol with sodium hydroxide for 2 h. Following evaporation of the solvent, water was 
added and neutralised to protonate the carboxylate anion which was then extracted with 
EtOAc. This process afforded a very low yield of (143). However, TLC indicated its presence 
in the aqueous layer. It may be possible to rationalise this result as being due to the high 
aqueous solubility of the polar Gin-containing dipeptides. Salting-out by the saturation of the 
aqueous layer with sodium chloride, followed by extraction with ethyl acetate, proved to 
enhance the yield. The best yield obtained for (143) was 64%. Furthermore, an alternative
118
method of ester hydrolysis with LiOH164 was not that good, because of the need to use H2O in 
the working up procedures.
However, there is a need for a versatile and facile procedure to prepare (143) in a good yield. 
Therefore, an alternative method based on the use of the benzyl ester (144) instead of (140) 
was applied. The rationale of this substitution was based upon the ease of hydrogenolysis of 
the benzyl group, from which the product can be isolated without aqueous washing.165 Thus 
coupling of Boc-L-glutamine with L-valine benzyl ester (144) using the DCC/1- 
hydroxybenzotriazole method afforded (145) in 71% yield. Debenzylation with hydrogen 
and palladium afforded (143) in 94% yield.
Attempts to convert (143) with cyanuric fluoride to its acyl fluoride in the presence of 
pyridine appeared to be positive by TLC detection but no product could be isolated. It may be 
possible that the work-up procedure drives the acid fluoride into the aqueous layer because of 
the high solubility of Gin residue. However, the solubility problem may be overcome by the 
inclusion of various protecting groups on the Gin side-chain. These derivatives are available 
commercially but are very expensive. So, it was necessary first to confirm that dipeptides can, 
in general, be converted to their acyl fluorides. Therefore, it was decided to synthesise 
analogues in which Gin was substituted with the hydrophobic phenylalanine. Interestingly, 
this substitution proved to be virtuous (Scheme 3.21). This experiment; on one hand, will 
examine the effectiveness of the concept of acid fluoride synthesis of dipeptides and, on the 
other hand, will explain the unsuccessful synthesis of Gin-containing dipeptides acid 
fluorides. The synthesis pathway starts with the coupling of Boc-L-Phe with L-ValOMe (141) 
using the DCC/1-hydroxybenzotriazole method.163 Recrystallisation afforded BocPheValOMe 
(147) in 33% yield. Subsequent alkaline hydrolysis afforded the corresponding 
BocPheValOH (148) in 8 8 % yield. Treatment of this dipeptides with cyanuric fluoride 
applying the usual methodology afforded crude (149), which coupled with 2-(4-nitrophenyl)- 
ethylamine, affording (150) in 10% overall yield. From these results, it is clear that synthesis 














Scheme 3.21 Chemical synthesis of (150).(i) BocPheOH, HOBt, DCC, CH2CI2; (ii) aq. 
NaOH, CH3OH; (iii) Cyanuric fluoride, pyridine, CH2CI2; (iv) 4-nitrophenylethylamine 
hydrochloride, Et^N, DMAP, CH2CI2.
Other coupling methods were examined in turn. The first trial was the use of the mixed 
anhydride coupling method (Scheme 3.22). Two attempts were executed. In the first attempt, 
compound (143) was stirred in dry DMF with isobutyl chloroformate166,167,168 and N- 
ethylmorpholine at -18°C under argon for 1 h, after which a solution of (81) and 
diispropylethylamine in DMF was added. The mixture was then allowed to warm gradually 
to 20°C and stirred for 16 h. Following work-up, *H NMR analysis indicated the failure of 
this coupling reaction. The next attempt was a “one-pot” process in which (143) was treated 
with 4-nitrophenyl chloroformate (Scheme 3.22), with the intention of forming the 4- 
nitrophenyl active ester.169,170 However, consequent coupling of this active ester with (81) was 
not successful. Another coupling approach based on the DCC/1-hydroxybenzotriazole
method167 was unsuccessful. Furthermore, the common coupling agent 2-ethoxy-l-
(ethoxycarbonyl)-l,2-dihydroquinoline (EEDQ) 171 was also used without any success. It is
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noteworthy that all these experiments were attempted several times, for different periods, with 
or without DMAP catalyst.
O
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Scheme 3.22 Proposed different chemical approaches for the synthesis of (139). (i) isobutyl 
chloroformate, N-ethylmorpholine, Prl2NEt, DMF, -18°C; (ii) 4-nitrophenylchloroformate, 
Pr^NEt, DMF, DMAP, -18°C; (iii) HOBt, DCC, Pr^NEt, DMF; (iv) EEDQ, Pr^NEt, DMAP, 
DMF.
In view of the reported high reactivity of pentafluorophenyl ester coupling with 
thiazolidines,172 it was worthy to test them in the dipeptide coupling process with the 
Me2thiazolidine unit. This attempt was executed despite the previous unsuccessful coupling of 
PFP esters to the thiazolidine-N-(nitrophenylethyl)amide (51) where the thiazolidine ring 
opens (Scheme 3.1). However, a model experiment was executed by using an Fmoc-protected 
amino acid to provide a good chromophore to follow. Fmoc-Val-OPFP (8 6 ) was successfully 
coupled with the 2,2-dimethylthiazolidine-4-carboxylic acid (81) (Scheme 3.6). This result 
suggests that the ring-opening may be associated with the presence of the amide and that 
coupling of dipeptide active esters with the thiazolidinecarboxylic acid should preserve the 
heterocycle.
However, the required presence of Gin in the dipeptide will lower its solubility in moderately
173polar organic solvents, probably due to hydrogen bonds through the Gin side-chain amide.
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However, solubility may be increased by the inclusion of various protecting groups on the 
Gin-side chain. These derivatives are available commercially but are very expensive.
As a part of the ongoing synthetic strategy, a new tactic was employed to circumvent the 
solubility problem of Gin. This tactic was based on the substitution of Gin with 
pyroglutamate (Pyg). Pyg can act as a lipophilic synthon for Gin.174 Interestingly, N-Boc 
protected pyroglutamate (151) undergoes a ring-opening reaction with Grignard reagents175 
and with lithium enolates through attack of these powerful nucleophiles with the ring 
carbonyl.176 Also, it has been reported that the reaction of (151) with at least two equivalents 
of an alcohol in the presence of KCN in THF opens the ring to form the Glu y-esters177 but the 
reaction time needed was long (24 h). In this reaction, alcohol nucleophile will displace the 
cyanide in the highly reactive acyl cyanide intermediate, delivering the acyclic product. 
Amines behave as good nucleophiles.174 Therefore, reaction of (151) with amines should yield 
the corresponding carboxamide derivatives. More specifically, reaction of (151) with 
ammonia in wet THF is expected to yield BocGlnOBn. On this basis, a model experiment 




Scheme 3.23 Proposed chemical synthesis of (152). (i) aq. NH3, THF.
A complete monomeric model for PSA-triggered release of NPEA was then constructed. The 
dipeptides BocPygValOPFP (157) was assembled according to the route in (Scheme 3.24). L- 
PygOH (153) contains a lactam moiety, which is responsible for the very low reactivity of the 
NH function. To introduce the Boc group to the poorly nucleophilic lactam nitrogen, it was 
first necessary to protect the carboxylic acid of (153)178’179 as the benzyl ester. This was 
achieved by alkylation of the carboxylate anion with benzyl choride. The crude ester was then 
treated with di-terr-butyl dicarbonate (B0 C2O), triethylamine and DMAP in dichloromethane 
at 0°C for 1 h and at RT for 16 h to give the BocPygOBn (151). Hydrogenolysis of (151) 
afforded (154) in 93% yield. Coupling with ValOBn (144) by the DCC/1-
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hydroxybenzotriazole method afforded the dipeptide (155) in 71% yield. Subsequent 
hydrogenolysis afforded BocPygValOH (156) in a quantitative yield. Formation of the PFP 
active ester (157) was achieved with pentafluorophenyl trifluoroacetate (TFAOPFP). This 
reagent has been shown to be particularly useful in the preparation of activated carboxylic 
acids via a mixed carboxylic-trifluoroacetic anhydride type of intermediate.180’181 Others have 
shown that TFAOPFP could be used to protect amines as the corresponding trifluoroacetyl 
derivatives. Thus, TFAOPFP can be used for one-pot protection/activation of amino-acids. 
Therefore, recently many studies were conducted, all aimed at evaluating the scope of this 
chemistry. One of the advantages of TFAOPFP over the traditional DCC/PFPOH method is 

























Scheme 3.24 Synthetic steps towards the formation of compound (157) (i) A- Benzyl 
chloride, Et3N, THF, 5 d. B- Boc20, Et3N, DMAP, CH2Cl2, 0°C; (ii) 10% Pd/C, MeOH; (iii) 
A- HOBt, DCC, CH2Cl2, 0°C, 1 h. B- L-ValOBn, Pr^NEt, DCM, 24 h;(iv) TFAPFP, pyridine, 
DMF.
The next step forward was the preparation of the molecular clip-drug portion (Scheme 3.25). 
The synthesis pathway starts with the coupling of the dipeptides active ester (157) with S-2,2- 
dimethylthiazolidine-4-carboxylic acid (81) and diisopropylethylamine in dry DMF for 16 h.
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Interestingly, the coupling reaction proceeded swiftly. Recrystallistion proved unsuccessful. 
However, chromatography afforded two compounds; (158a) in 42% and (158b) in 10% yield.
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Scheme 3,25 Synthetic steps towards the formation of compound (161). (i) Compound (81), 
Prl2NEt, DMF; (ii) TFAPFP, pyridine, DMF; (iii) 4-nitrophenylethylamine hydrochloride, 
Et3N, CH2Cl2; (iv) aq. NH3, THF.
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On the bases of *H NMR and mass spectroscopic analysis, compound (158a) and (158b) are 
diastereoisomers. Whereas the usual couplings with active esters of carbamate-protected 
(Boc, Cbz, Fmoc) single amino-acids normally occur without racemisation, coupling of active 
esters of amino-acids with amides at the nitrogen often give partly racemised products. This 
racemisation occurs through formation of intermediate oxazolidinones, in which the “a- 
proton” is highly acidic. Dipeptides, of course, have an amide bond between the two amino- ® 
acids.
The apparent difference in the NMR spectra of (158a) and (158b) can be seen with the signal 
of Val a-H, which is presented as triplet at 8  4.25 in (158a) and as double doublet at 5 4.78 in 
(158b). It was expected that the major compound (158a) would be the required Boc-L-Pyg-L- 
Val-Me2thiazolidinecarboxylic acid diastereoisomer and that the minor compound (158b) 
would be the epimer Boc-L-Pyg-D-Val-Me2thiazolidinecarboxylic acid. It was planned that 
an X-ray structure be determined for a suitably crystalline intermediate later in the sequence, 
to confirm the stereochemistry.
Subsequent reaction of (158a) by pentafluorophenyl trifluoroacetate (TFAOPFP) granted 
(159) in 93% yield, which was then coupled with 2-(4-nitrophenyl)ethylamine (41) and 
afforded (160) in a 69% yield. Crystallisation of (160) afforded large,' but severely twinned, 
crystals, which, after several efforts, were found unsuitable for X-ray analysis. Luckily, ring- 
opening of the pyroglutamine in (160) to Gin was attained successfully by stirring for 18 h 













Scheme 3.26 Synthetic steps towards the formation o f compound (164). (i) 20% CF3CO2H 
/C H 2CI2; (ii) BocLeuOSu, Et3N, DMF, THF, DMAP.
Deprotection of (161) afforded (162) quantitatively (Scheme 3.26). Compound (162) was 
then subsequently coupled through the active ester method with the hydroxysuccinimide ester 
BocLeuOSu and afforded (163) as a white solid in 92% yield. The !H NMR spectrum of this 
compound was complex but the presence of characteristic signals for the Leu a-H and Leu- 
Me2 at the expected chemical shifts and correct integration confirmed the structure. 
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Scheme 3.27 Synthetic steps towards the formation of compound (170). (i) FmocLysOPFP, 
Et3N, DMF, THF, DMAP; (ii) 10% Et2NH /  CH2Cl2; (Hi) CbzSer(Bul)OSu, Et3N, DMF, 
THF, DMAP; (iv) 20% CF3C 02H /  CH2Cl2.
The next step toward the synthesis of target (167) (Scheme 3.27) required the activation of 
the carboxylic acid of Na-Fmoc-Ne-Boc-L-Lys (165) (Scheme 3.28). Activation was granted
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with pentafluorophenol/DCC method and afforded (166) in 59%. It is noteworthy that 




Scheme 3.28 Chemical synthesis of (166). (i) PFPOH, DCC, EtOAc, THF.
The N£ side chain should be Boc protected to provide consistency for selective deprotection of 
the whole target peptide, since the next coupling step will involve the O-tert-butyl derivative 
of Ser. N° was chosen to be Fmoc-protected. This is an attractive proposition because of the
opportunity for selective deprotection. Fmoc group can be removed by treatment with
182 161 secondary amines such as piperidine and diethylamine. However, Boc group proved to
be stable under these alkaline conditions. It is important to maintain Ne protection, to avoid
any involvement of the nucleophilic amino motif in the next coupling step and also any
possible cyclisation. The coupling of Na-Fmoc-Ne-Boc-L-LysOPFP (166) with (164) gave
crystalline (167) in 95% yield (Scheme 3.27). Characteristic signals of the Fmoc moiety were
seen in the lH NMR spectrum. Removal of the Fmoc protecting group was conducted with a
10% solution of diethylamine in dichloromethane, affording (168) in a 90% yield. From here,
couplings with orthogonally protected serine derivatives were essential.
Since the cleavage of two peptide sequences (SSKLQV and SKLQV) by PSA were to be 
studied, the synthetic pathways diverged at this point. Two parallel couplings of (168) were 
granted by using CbzSer(Bul) (Scheme 3.27) and FmocSerCBu1) (Scheme 3.29).
As a part of the ongoing strategy, the side chain protection of Lys and Ser amino acids should 
possess the same characteristics. The protecting group should be cleaved swiftly under the 
same conditions. Therefore, the serine side-chain protecting group should be acid-labile, such 
as the tert-butyl (Bul) ether. On the other hand, on the way to synthesise SKLQV target (170) 
(Scheme 3.27), the Na- protecting group of serine was chosen to be Cbz. Unlike Fmoc, the 
Cbz protecting moiety is known to be stable under the alkaline conditions (pH = 7.4) under
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which the release study of the model drug by PSA will be conducted later. In addition, the 
Cbz moiety will provide a UV-detectable tag during the release study. However, in the route 
to target (174) (Scheme 3.29), one more coupling step with another Ser residue is required. 
This, in turn, suggested the use of an orthogonal protecting group which is not acid-labile and, 
at the same time, could be cleaved under mild conditions, which do not affect the integrity of 
the thiazolidine ring. The Fmoc protecting group has been proved earlier to serve these 
purposes well and can be removed swiftly without damaging the thiazolidine ring.
To achieve target (170) (Scheme 3.27), coupling of compound (168) with CbzSe^Bu^OSu 
was executed, giving crystalline (169) in 51% yield. Again, these crystals were not of good 
enough quality for X-ray analysis. Subsequent simultaneous deprotection of Lys and Ser 
protecting groups was executed with 2 0 % trifluoroacetic acid in dichloromethane and 
afforded (170) quantitatively.
The synthesis pathway to target (173) (Scheme 3.29) starts with the coupling of compound 
(168) with FmocSe^Bu^OSu, affording (171) in 62% yield. The subsequent removal of the 
Fmoc protecting group was conducted with diethylamine to give (172) in 8 8 % yield. The 
following coupling with CbzSer(Bul)OSu and FmocSe^Bu^OSu afforded (173) (Scheme 
3.29) and (175) (Scheme 2.31) in 62% and 43% yield, respectively. Consequent deprotection 
of (173) afforded (174) quantitatively.
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Scheme 3.29 Synthetic steps towards the formation of compound (174). (i)
FmocSer(Bu )OSu, Et3N, DMF, THF, DMAP;(ii) 10% Et2N/CH2Cl2 (ii) CbzSer(Bu')OSu, 









Scheme 3.30 Chemical synthesis o f compound (175). (i) FmocSer(But)OSu, Et$N, DMF, 
THF, DMAP.
In conclusion, syntheses of the CbzSKLQV and CbzSSKLQV sequences attached to the 
thiazolidine-N-nitrophenyl amide unit have been achieved in satisfactory overall yield 
through active ester couplings. These will provide substrates to test for cleavage by PSA and 
for subsequent DKP formation and release of the model drug. The success of these synthetic 
sequences was largely due to development of methods to couple dipeptides to the thiazolidine 
nitrogen and to use of Pyg as a more soluble synthon for Gin.
An alternative known pathway to solve the solubility problem of Gin during peptide synthesis 
is the use of N-side-chain-protected derivatives. These derivatives were available 
commercially but are very expensive. As a result, an alternative pathway was investigated 
briefly using the Gln(Trt) derivative (Scheme 3.31). The protecting trityl moiety is removed 
under the same conditions as tert-butyl ether and Boc. As a test of the use of Gln(Trt), a 
dipeptide was synthesized. Therefore, coupling of ValOBn (174) with Gln(Trt) was conducted 
using the DCC/l-hydroxybenzotriazole method. Chromatography afforded (176) in 54% 
















Scheme 3.31 Synthetic steps towards the formation of compound (177). (i)
FmocGln(Tr)OH, HOBt, DCC, CH2Cl2, Prl2NEt; (ii)10% Pd/C, MeOH.
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3.6 Synthesis of PSA-specific substrate analogue
The next plan was to synthesise SKLQVOMe as an analogue of the PSA-specific substrate 
SKLQ. The cleavage study of this sequence will add to the body of knowledge; on one hand, 
confirmation of the activity of the enzyme in cleaving the sequence and, on the other hand, 
the ability of the enzyme to cleave the Q— V amide bond. This will help later in 
interpretation of the release study from targets (170) and (174).
In the design of a synthetic method for target (184) (Scheme 3.33), solution-phase synthesis 
methodology was applied. The route to the pentapeptide (184) is illustrated in scheme 3.32 
and 3.33. The active ester coupling method was employed predominantly for the stepwise 
elongation process. BocGlnValOMe (142) was deprotected with trifluoroacetic acid, giving 
GlnValOMe (178). This dipeptide ester does not form the corresponding DKP readily, since it 
is in the trans peptide conformation. The remaining amino-acid units were added using 
BocLeuOSu, Na-Fmoc-Ne-Boc-L-LysOPFP and CbzSe^Bu^OSu, as before. Only one 
diastereoisomer was seen, in the NMR spectra of all intermediates, indicating that no 
racemisation had taken place during the sequence.
133
o





c f 3c o o -
(178)
(>) BocHN
CF3C O O - £
H2N ^^O
OMe
H2N ^ O  (179)
FmocHN
H2N ' ^ 0
NHBoc
Scheme 3.32 Synthetic steps toward the formation of compound (181). (i) 50% CF3CO2H /  
CH2CI2; (ii) BocLeuOSu, Et$N, DMF, THF, DMAP; (iii) FmocLysOPFP, EtjN, DMF, THF, 
DMAP
As the peptide sequence grows, in the stage of tetrapeptide (181) (Scheme 3.32) and (Scheme 
3.33), limited solubility of the product was observed. This is attributed to the trans-amide 
bond conformation adopted by the amino acids, which results in inter-molecular H-bond 
formation and consequent aggregation. However, in this synthetic pathway, limited solubility 
was an advantage because of the ability of washing solids (181) with ethyl acetate and with 
aqueous solutions to remove by-products without any loss of compound. Analysis of the 1-D 
*H NMR spectrum was difficult for the tetra- and penta-peptides. Therefore, the H-H 
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Scheme 3.33 Synthetic steps toward the formation of compound (184). (i) 10% 
EtfNHJDMF; (ii) CbzSer(But)OSu, Et3N, DMF, THF, DMAP; (iii) 30% CF3CO3H/CH2CI2.
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3.7 Assaying of the PSA-cIeavable peptide linker in the monomeric model 
prodrug.
The synthesized peptide-clip-drug models (170), (174) and the synthesized PSA substrate 
analogue (184) were assayed for PSA hydrolysis. In brief, peptide conjugates were mixed 
with PSA at a molar ratio of 100:1, respectively, in 50 mM TRIS.HC1 and 140 mM NaCl at
70pH 7.4. The reaction was incubated for different intervals at 37°C. The reactions were 
then quenched with ZnC^ (10 mM final concentration). The chromatogram was monitored 
at X-220* Results are reported as the time required for PSA to hydrolyze 50% of the initial 
substrate. The instrumentation and the chromatographic method were similar to those used 
in Section 3.4. PSA enzyme was bought from Aldrich.
The constructed models CbzSSKLQVMe2ThProNPEA and CbzSSKLQ VMe2ThPro- 
NPEA will now be evaluated for cleavage by PSA, liberating ValMe2ThProNPEA and 
hence, NPEA. Also, the PSA analogue substrate CbzSKLQVOMe will be assayed to 
evaluate the activity of the enzyme.
The first step in this study is the analysis of the authentic fragments of the peptide 
sequence CbzS KLQ V and CbzS SKLQV attached to the thiazolidine-N-nitrophenyl amide 
and the fragments of the CbzSKLQVOMe target. The corresponding retention times (Rt) 






(min), pH  
7.40, 37°C
NPEA (41) 3.9
S Val DKP (108) 6 .8
Val-thiazolidine-N-nitrophenyl amide ‘(85) ° 13.9
GlnVal-thiazolidine-N-nitrophenyl amide (162) 8 .2
LeuGlnVal-thiazolidine-N-nitrophenyl amide (164) 13.9
LysLeuGlnVal-thiazolidine-N-nitrophenyl amide (168) 8.3
CbzSerLysLeuGlnVal-thiazolidine-N-nitrophenyl amide (170) 5.4
CbzSerSerLysLeuGlnVal-thiazolidine-N-nitrophenyl amide (174) 17.4




Ret. Time (min) 
at pH 7.4, 37°C
Val-OMe (141) 4.5
Gin ValOMe (178) 3.8
LeuGlnValOMe (180) 4.5
LysLeuGln ValOMe (182) 3.9
CbzSerLysLeuGln V alOMe (184) 5.7
Table 3.5 Retention times o f the target compounds (184) and the intermediate 
fragments.
Since the retention time of the fragments Val-thiazolidine-N-nitrophenyl amide (85) and 
LeuGlnVal-thiazolidine-N-nitrophenyl amide (164) were identical, the consequence 
assaying of the cleavage site would be verified by the identification of the DKP and the 
model drug (NPEA) peaks for the target compounds (170) and (174). Also, in the target 
compound (184) similar retention times were recorded for the fragments ValOMe (141) 
and LeuGlnValOMe (180). Thus, assaying of PSA cleavage site would be by the
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identification of a ValOMe peak. It is noteworthy that different mobile phase gradients 
were unsuccessful to give different retension times for the fragments.
HPLC analysis of the incubation of (170) with PSA indicated that the enzymatic cleavage 
took place between either the LjQ or SfK amino-acid residues and not between QfV as 
was expected. However, the addition of another Ser amino acid, as in compound (174), 
proved not to make any difference, either to the rate of cleavage or to the site of cleavage. 
Interestingly, cleavage of CbzSKLQVOMe (184) also took place at LJ,Q.
The HPLC evidence showed that cleavage of (170) has taken place at LjQ or at S|K . 
However, when samples were collected from the HPLC, concentrated and subjected to 
mass spectroscopic analysis, no useful spectra could be obtained. Therefore, the specific 
site of cleavage is still uncertain.
As a conclusion, PSA enzyme proved to be active and managed to cleave the constructed 
sequences. However, the cleavage did not take place in the correct site (QjV), either in the 
constructed CbzS KLQ VThPro-NPE A and CbzSSKLQVThPro-NPEA targets or in the 
close substrate analogue CbzSKLQVOMe. Therefore, one might conclude that the 
Me2Thiazolidine moiety had no effect on the PSA specificity. On the other hand, the 
difference in the steric environments of Val and of Leu may account for this shifting in the 
site of cleavage.
The percentage cleavage of the targets (170), (174) and (184) is presented in (Figure 3.41), 
(Figure 3.42) and (Figure 3.43) respectively. From these figures it is clear that the rate of 
cleavage is relatively slow. It is noteworthy that the difference in percentage cleavage 
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Figure 3.41 A plot o f  the % cleavage o f CbzSKLQV(2,2-dimethylthiazolidine)-N- 
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Figure 3.42 A plot o f  the % cleavage o f  CbzSSKLQV(2,2-dimethylthiazolidine)-N- 
nitrophenyl amide (174) in the presence o f  PSA versus time.



















Figure 3.43 A plot o f  the % cleavage o f  CbzSKLQVOMe (184) in the presence o f  PSA 
versus time.
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As a conclusion, future work in our lab will be performed to increase the body of 
knowledge. A new target in which Val amino acid residue in the L S-diastereoisomer will 
be replaced by Leu will be synthesised. Also, another peptide sequence Ac-Hyp-Ser-Ser- 





In conclusion, synthetic strategies have been successfully investigated for the development 
of the tripartite prodrugs, CbzSSKLQVMe2ThProNPEA, CbzSKLQVMe2ThProNPEA and 
CbzSKLQVOMe.
A putative approach toward the synthesis of the self-immolative molecular clips was 
developed. Various derivatives were synthesized. The conformation of these derivatives 
was studied by various spectroscopic methods and the preferred conformation was 
determined to be the Z for all derivatives. Furthermore, no loss of stereochemical integrity 
was found to take place during any of the coupling reaction throughout the synthetic 
process. Notably, incorporation of a 2-C disubstituted thiazolidine moiety offers a simple 
and attractive means to constrain selectively in the peptide bonds, i.e. to induce cis amide.
The X-ray crystallographic studies on the DKPs (99) and (100) derived from L-Ala-/?- 
dimethylthiiazolidinecarboxylic acid and L-Val-/?-dimethylthiazolidinecarboxylic acid 
showed that the DKP ring is in a boat conformation, with the thiazolidine in a half-chair. 
The geminal methyl groups at position-3 are in equatorial and axial positions; the amino- 
acid side chain occupies a pseudo-equatorial position. This conformation was also likely to 
be adopted in solution.
The rates of intramolecular cyclization of the molecular clips and the consequent drug 
liberation were studied for the L, R and the L, S diastereoisomers. The effect of the size of 
the amino acid side chain on each series was also investigated. Interestingly, a change in 
the rate-determining step provides insights on the general effect of the size of the amino- 
acid side chain.
A PSA cleavable peptide sequence analogue has been synthesized using suitable 
orthogonal protecting groups and an effective ester coupling strategy. In addition, a novel 
synthesis of the tripartite system (peptide-clip-drug) has been realised. The six-amino acid 
peptide SSKLQjLwas document to be hydrolysed specifically by PSA to liberate the
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active drug. However, assaying of the PSA cleavage of our tripartite system realized that 
the cleavage has took place most probably between LJQ, thus no drug was released.
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Nitric oxide synthase inhibitors 
Introduction
5.1 Nitric oxide - a puzzling molecule
In 1772, Joseph Priestly discovered nitric oxide (NO) .184 This naturally occurring free 
radical has been established in large number of mammalian tissues. It is a double-edged 
sword, beneficial as a messenger or modulator for immunological self-defence but at the 
same time, potentially toxic upon excessive production.185 It plays peculiar roles and is 
involved in a myriad of biological processes including neuronal function, vascular tone and 
the cytotoxic function of macrophages.186 These roles played by NO give the prospect of 
developing of new drugs to tackle important diseases. For example, drugs that release NO, 
improve blood flow to the heart muscle due to vascular smooth muscle relaxation. Also, 
NO controls blood flow into the corpus cavemosum of the penis; this role has been 
exploited by the anti-impotence drug Viagra®. On the other hand, overproduction of NO 
leads to chronic diseases, such as rheumatoid arthritis, may contribute to brain damage and
187could led to fatal conditions, such as septic shock.
5.1.1 Biosynthesis
The biosynthesis of NO consists of two steps. First, L-arginine, the physiological substrate, 
is converted to N -hydroxyarginine in a reaction catalysed by Nitric Oxide Synthase 
(NOS). In the second step, N -hydroxyarginine is oxidised by NOS to form citrulline and 
NO .188 This five-electron-transfer reaction involves the utilisation of NADPH and O2 as 
substrates, as well as flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
tetrahydrobioterin (BH4) and haem as cofactors.189
tooThe NOSs are a family of haem-containing oxygenases. Three genetically distinct 
isoforms have been characterised. These isoforms share an overall -50% amino acid 
sequence identity with one another. They were originally isolated from neuronal, 
immunocyte and endothelial cell sources. Their nomenclature was initially based on the 
cell type from which they were originally purified, cloned and characterised; hence, the 
designations for neuronal (nNOS), immunocyte (iNOS) and endothelial (eNOS). Later on,
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it has been discovered that the different NOS isoforms have a much wider distribution than 
was previously thought. For example, nNOS is also expressed in the skeletal muscle, iNOS 
is expressed in many tissues after immunoactivation and eNOS is also expressed in brain. 
This discovery of a more general tissue distribution of the archetypal neuronal, inducible 
and endothelial NOS isoforms has led to a proposed numerical designation in order of their 
discovery (NOS1, NOS2, and NOS3, respectively) .191
NOS isoforms have also been characterised and distinguished by their Ca2+/calmodulin- 
(CaM) dependence and by whether they are expressed constitutively (eNOS) or induced 
following exposure to cytotoxins or endotoxins (iNOS) .192 nNOS and eNOS are 
constitutive and regulated by their dependence on Ca2+ concentration, while iNOS does not 
depend on Ca2+ concentration since it is tightly bound to CaM.189 The main differences 
between the constitutive and the inducible isoforms are the amount and duration of 
production of NO. The total amount of NO generated per cell by eNOS is low when 
compared with that formed by iNOS and the flux of NO generated by eNOS is of short 
duration. On the other hand, iNOS generates considerably higher concentrations of NO for 
periods of hours-to-days and is essentially unregulated, once expressed.193
Therefore, the physiological versus pathophysiological role of NO is correlated to the 
presence and activity of specific isoforms of NOS. These isoenzymes are distinct from 
each other by their amino acid sequences, thus the active site of the three isoenzymes 
might be different enough to allow selective inhibition towards a therapeutic benefit.194
NOSs have two major domains, the reductase domain (C-terminal) and the oxygenase 
domain (N-terminal). The reductase domain shows very high similarity to cytochrome 
P450 reductase and contains sequences for binding sites for NADPH, FAD and FMN. The 
oxygenase domain binds to the haem and BH4. The oxygenase and reductase domain are 
joined by a calmodulin-binding site, which serves as a ‘switch’. The shuttle of electrons 
from NADPH to the oxygenase domain depends on Ca2+/CaM184 (Figure 5.1).
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Figure 5.1 Domains and cofactors o f NO synthase.
5.1.2 Chemical biology
L-arginine is bound near the haem cofactor, the iron of which is bound to NOS through the 
sulfur (S) of the active-site cysteine. The haem iron is then reduced to the ferrous form 
(Fe2+) by an electron transfer from NADPH. One O2 is bound to the haem and a second 
electron is delivered from NADPH, via flavin, to form a perferryl haem species. This is a 
potent hydroxylating agent, reacting with the arginine to form NG-hydroxy arginine. 195
Further reaction of this intermediate takes place with the original haem cofactor, which 
again receives one electron from NADPH and binds O2. This electron is later delivered 
from the intermediate as H; this radical then attacks the peroxyhaem species in the 
resulting intermediate radical, leading to the formation of L-citrulline, NO, and water
(H2O) (Figure 5.2) . 1,5
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Figure 5.2 Proposed mechanism for the synthesis of NO. 195
5.1.3 Nitric oxide: the good, superoxide the bad, and peroxynitrite the ugly
In biological media, NO reacts with superoxide anion radical (0 2 *“) to produce peroxy­
nitrite (ONOO~), which is not a free radical but a highly potent oxidant. This peroxynitrite 
induces peroxidation of lipids, disrupts protein structure through nitration of tyrosine, 
oxidises -SH residues in proteins, depletes antioxidants and causes breaks in DNA 
strands. 196 This modification has considerable effects on protein and enzyme function and 
contributes to pathophysiological dysfunction.
5.1.4 Isoenzyme-specific inhibitors
It is hoped that NOS inhibitors will offer a high degree of potency and selectivity to 
suppress specific NOS isoform activity. For example, selective nNOS inhibitors might help
187to alleviate ischaemic brain damage and might be useful in the treatment of septic 
shock, 193 chronic inflammatory diseases such as rheumatoid arthritis, adverse immune 
reactions associated with transplantation187 and cancer. 197
5.1.5 NOS inhibitors
NOS inhibitors are usually classified into two main categories, amino-acid derivatives and 
non-amino-acid derivatives (Figure 5.3).
5.1.5.1 Amino-acid-based NOS inhibitors
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Figure 5.3 Structures of amino-acid and non-amino-acic inhibitors of NOS.
A Guanidino amino-acids (185)
These are analogues of the NOS substrate L-arginine and have minimal selectivity.189
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B Amidino amino-acids (186)
These are analogues of the NOS substrate L-arginine and show higher degrees of 
selectivity. It has been noticed that none of the saturated derivatives shows significant 
isofomr selectivity while, in contrast, the unsaturated derivative (vinyl-L-NIO) showed a 
marked selectivity for nNOS and could be classified as a potent mechanism-based 
inactivator of nNOS.193
C Amino-acid isothioureas (187)
Griffith and Furfine have reported that these NOS inhibitors are potent with selective 
inhibition for nNOS.189 S-methyl- and S-ethyl-L-citrulline are reversible and time- 
dependent inhibitors. Obviously, the proposed mechanisms for this time-dependence is not 
yet understood.198 Also, the sulphur, which replaces the guanidium nitrogen atom, binds in 
close proximity to haem iron.
D Acetamidine lysine derivative (188)
This compound resembles an amidino-amino-acid. However, the carboxylate group is 
replaced by vicinal glycol. Halliman et al.199 found that additional iNOS selectivity (with a 
slight penalty in potency) resulted from this replacement. Interestingly, inversion of the 
stereochemical configuration at the secondary alcohol abolishes NOS inhibitory activity.
E Citrullines (189)
Urea citrullines are inactive as inhibitors. However, the thiourea derivatives are potent and 
bind to the active site of the enzyme through the sulfur atom in close proximity to haem.
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5.1.5.2 Non-amino-acid-based NOS inhibitors
A N-(3-(Aminomethyl)benzyl)acetamidine (1400W) (190)
This is a monoamidine monoamine analogue.193 It is the most selective iNOS inhibitor 
reported to date, with an irreversible or an extremely slowly reversible mechanism-based 
inactivation.198 The inhibition was dependent on NADPH and its binding was competitive 
with L-arginine. The amidine moiety of 1400W binds in the guanidine-binding pocket of 
the substrate site.198 Studies showed that 1400W had a similar toxicity profile to the bis- 
isothioureas. However, such toxic effects appeared only after exceeding a relatively high 
threshold plasma concentration of drug and not at normal doses.198
B ARL17477 (191)
This is a heterocyclic substituted amidine, which is reported to be the most selective nNOS 
inhibitor at present (IC50 = 35 nM against rat nNOS), being at least 100-fold selective for 
nNOS over eNOS and iNOS.193
C Isothioureas (193)
They are non-amino-acid analogues of L-arginine. The simple alkyl derivative were 
extremely potent,194 with little isoform selectivity. Their binding is competitive with L- 
arginine and is reversible. However, the acetylenic isothiourea, S-propargylisothiourea, 
shows NADPH-dependent mechanism-based inactivation. The pharmacological use of 
(iso)thioureas is limited due to their acute toxicity.193
D Indazoles (194)
7-Nitroimidazole is a selective nNOS inhibitor. This selectivity may be due to differences 
in its uptake or metabolism in different tissues or to its mode of inhibition, since it 
competes with BH4 and L-arginine binding. Thus its nNOS selectivity could be attributed 
to the relatively low concentrations of the substrate and BH4 in certain tumours.187
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5.1.6 Structure-activity relationships (SARs)
The NOS enzymes interact with the guanidinium region of L-arginine throughout NO 
biosynthesis (Figure 5.4). Therefore, the first NOS inhibitors reported bind to the 
oxygenase domain and interact with the guanidinium region of L-arginine-binding site 
within NOS.193Also, it has been found that several modifications to the guanidino group 
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Figure 5.4 Models fo r binding o f  the substrate; B the potent with little isoform 
selectivity thiocitrulline; C the potent non-isoform-selective NS-(4,5-dihydrothiazol-2- 
yl)ornithine; D the iNOS selective inhibitor 1400W; E, F, G and H  a proposed potential 
analogue.
NOS inhibitors.189
Aspects of the SARs underlying the isoform selectivity can be gleaned from examination 
of the structure and possible mode of binding in the active sites of known inhibitors. 
1400W is a highly potent NOS inhibitor with a selectivity of 5000 for iNOS versus 
eNOS.200 This finding constitutes the largest selectivity reported for iNOS. Some features 
in its structure were the benzene ring (which may fit in a hydrophobic pocket) and the
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absence of the amino-acid carboxylate. In respect of the aromatic ring, (±)-6 -
cyclohexylmethyl-2-iminopiperidine with its iNOS-selectivity supports the hydrophobic
ring role;201 also one may speculate that the function of the benzene ring is to maintain the
correct relative conformation of the acetamidine and the amine groups which bind to the
haem iron and in a cation-binding pocket, respectively.
' ©
The role of the carboxylate anion is more debatable. When the CO2" is removed from the
202dihydrothiazole C, inhibitory potency was diminished ca. 10-fold. When the amidine
189group was joined directly to the benzene ring (6 -atom bridge) in 1400W, it shows nNOS 
inhibition selectivity.
5.1.7 Role in tumours
In the 1950s, Tomlinson and Gray observed that the diffusion limitation of O2 led to the 
presence of hypoxic cells in tumours.53 In general, hypoxia usually resulted from two 
mechanisms: diffusion-limited or chronic hypoxia (resulting from reduced oxygen 
diffusion from regions distant from the tumour blood vessels) and acute hypoxia (due to 
the transient occlusion of blood vessels). Hypoxic cells are about three times more resistant 
to radiotherapy than normoxic cells and tumour hypoxia has been purported to be an 
important biological factor in the failure of radical radiotherapy to achieve local control. 
Therefore, to enhance tumour sensitivity to radiotherapy, methods to enhance tumour 
blood supply, thus increasing the amount of oxygen delivered to the tumour, have been 
investigated.
NO, as a vasoactive agent, was generally thought to enhance tumour blood flow and so 
increase the amount of oxygen delivered to tumours; this would enhance the sensitivity of 
tumour cells to radiotherapy by decreasing the hypoxic state. However, NOS inhibitors 
actually increase tumour hypoxia and induce 3-5 fold increases in tumour resistance to 
radiotherapy.
Actually, the potential effect of vasodilators on tumour perfusion is a controversial topic, 
when the vascular bed in tumour and normal tissue are in parallel, an increase in the blood 
flow in normal tissue due to vasodilatation would shunt away the blood flow to the tumour. 
This effect is called the “steal” effect. In contrast, when the blood vessels in tumours and
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normal tissue are in series, changes in perfusion would be similar because the blood, which 
leaves normal tissue vascular bed directly, flows into tumours. However, in many tumours, 
series and parallel types may be mixed or combined, and so modification of tumour 
perfusion vary depending on the relative contribution of both types.203
However, in human ttfmoure, high NOS activities have been identified in comparison with 
surrounding tissue. Also, the expression of NOS is related to tumour grade. So, inhibition 
of NOS decreases tumour blood flow, increases tumour hypoxia and consequently stops 
tumour growth. Also, increase in tumour hypoxia is a target in itself, as it will allow 
increased activation of bioreductive prodrugs of cytotoxins and NOS inhibitors.204 Many of 
these compounds undergo bioreductive metabolism of an aromatic nitro compound into the 
active amine derivative.205
5.2 Aim
To design and synthesis a novel NOS inhibitors with isoform selectivity, based on 
information from known substrates and previously synthesised inhibitors.
5.3 Research proposal
Most of the NOS inhibitors described to date are analogues of the substrate L-arginine. 
These inhibitors bind to the guanidinium region of the arginine-binding site and are 
competitive inhibitors with reported potency but little isoform selectivity. However, the 
amino-acid moiety is not a requirement for either selectivity or potency.198
The target compounds will illustrate the possibility of switching isoform selectivity 
through subtle changes in the spatial relationship between the haem-ligating headgroup and 
the remote functionalities. Inhibitors containing a rigid planar benzene ring are 
known.198,206 An attractive approach would be the synthesis of a new target in which the 
benzene ring is replaced with the approximately isosteric thiophene. This rigidity 
introduced would then maximise the interaction with the enzyme binding site and, more 
importantly, differentiate between various NOS isoforms.
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Information from potent but non-isoform-selective NOS inhibitors suggested that thiourea 
is good head groups for haem-iron-binding. Therefore, the design would be a hybrid of the 
aromaticity of the 1400W and the thiourea functionality of the L-thiocitrulline inhibitor; 
each carries the C0 2 Me motif in a “meta-like” arrangement with thiourea on the thiophene 
seeking for better potency and selectivity than the lead compounds.
The structures of the designed target compounds are shown in (Figure 5.5). In fact, we will 
explore whether the isoform selectivity shown by 1400W could be translated into 
analogous compounds carrying sulfur haem-ligating head group.
(195) (196) (197)
Rj = Thiourea head group 
R2 = C 0 2Me
Figure 5.5 Proposed structure of the target compounds
5.4 Discussion
5.4.1 2,5-Disubstituted thiophenes
Retrosynthetic analysis suggested that one of the key intermediates in the synthesis of the 
targets would be 2,5-bis(aminomethyl)thiophene, which is reported in the literature207to be 
synthesised from 2,5-bis(hydroxymethyl)thiophene (200) (Scheme 5.1).
Alcohols are mostly prepared from carbonyl compounds by reduction with metal hydrides,
20ftsuch as LiAIFU, LABH4, and NaBtU. L1AIH4 is one of the few reagents that can reduce a 
carboxylic acid directly. Reduction of commercially available thiophene-2,5-dicarboxylic 
acid (198) with LiAHi* gave the diol with great difficulty, owing to its considerable 
solubility in water, which impeded the work-up. Treatment of (198) with borane.THF 
complex, which is a selective reducing agent for carboxylic acids,209 afforded only an
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unidentifiable solid product. As an alternative to direct reduction, acids are often converted 
into alcohols by a two-step process: esterification and reduction using milder reducing 
agent. Consequently, compound (198) was esterified with a large excess of methanol and 
catalytic H2SO4 to afford compound (199) (74%). Treatment of (199) with four equivalents 
of LiBfL* in dry THF, followed by quench with acetic acid and acetylation in situ with 
acetyl chloride and triethylamine, gave a mixture of two compounds. The acetylation 
enabled isolation of the very water-soluble alcohols from the boron residues as their 
acetate esters. Removal of the protecting acetates with methanol and ammonia, afforded a 
mixture of compounds which were then separated by chromatography to afford the mono­
alcohol (201) and the required diol (200) in low yields. Use of greater excesses of LiBFU 
and longer reaction times did not improve the proportion of (2 0 0 ) produced.
H02C ^ / S\ ^ C 0 2H Me02C ^ / S\ ^ C 0 2Me
\ J  q> r \ J
(198) (199)
(ii)
O H C ^ /S\^ -C H O  / - ^ / SV - ' C° 2Me
°y) r HO \_J ° H 
(202) (200) (201)
Scheme 5.1 Chemical synthesis of compound (200). (i) H2SO4, MeOH; (ii) A- L1BH4, 
Dry THF, B- CH3COCI, Et3N, C-MeOH, NH3; (iv)NaBH4, THF.
An alternative method was the direct reduction of thiophene-2,5-dicarboxaldehyde (202),
210which is available commercially but is expensive, using the milder reagent NaBH4 
afforded the diol (200) in 76% yield (Scheme 5.1).
The Mitsunobu reaction provides a convenient route for the synthesis of amines from 
alcohols through the intermolecular reaction between alcohols and phthalimide on
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treatment with diethyl azodicarboxylate (DEAD) and triphenylphosphine under dry
conditions.211 Indeed, the literature preparation of 2,5-bis(aminomethyl)thiophene used this 
method207 However, prolonged treatment of (200) with two equivalents of DEAD, 
phthalimide and triphenylphosphine failed to give the required bis(phthalimide). The 
Mitsunobu reaction is very sensitive to traces of water. However, the starting diol (200) is 
highly viscous and hygroscopic oil which resisted rigorous drying and this 'may explain the 
lack of reaction (Scheme 5.1).
























Scheme 5.2 Chemical synthesis of compound (206). (i) SOCI2, DMF; (ii) NH3, THF;
(iii) POCh; (iv) .1 -BH3.Me2S, Dry THF, MeOH; 2- CH3COCL
In another approach (Scheme 5.2), the two nitrogens of the target diamine were introduced
at the amide oxidation level. The dicarboxylic acid (198) was converted to the bis(acid
chloride) (203) with thionyl chloride / DMF. Treatment of crude (203) with ammonia gave
the diamide (204) in 74% yield as a white solid. Reduction of (204) was attempted using
LiAlH4 but the diamide was found to be insoluble in the solvents (THF, diethyl ether, 1,2-
dimethoxyethane, etc.), which are compatible with this reagent. An attempt to extract the
diamine into solution in 1,2-dimethoxyethane using a Soxhlet apparatus for several days
was not successful. Alternatively, the diamide (204) was converted to the corresponding
dinitrile (205) by dehydration with refluxing POCI3. This dinitrile (205) is much less polar
than the the diamide (204) and was readily soluble in THF. However, reduction using
LiAlFL* failed due to the highly polar nature of the diamine product, which impeded
isolation from inorganic lithium aluminium salts. As a result, reduction using borane-
212methyl sulfide complex, one of the most efficient reagents for the reduction of nitriles,
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was used. Treatment of (205) with BH3.Me2S, followed by acetylation of the diamine in 
situ, afforded the diacetamide (206) in 9% yield. Interestingly, the diacetamide (206) was 



















Scheme 5.3 Chemical synthesis of compound (212). (i) Butyllithium, THF, 0°C;(ii) 
EtC>2CCl, THF, 0°C; (iii) N-bromosuccinimide, aq. HCIO4, hexane; (iv) CF3CONH2, 
KOBu, THF; (v) NaOH, H20, MeOH
After these several unsuccessful attempts to synthesise 2,5-bis(aminomethyl)thiophene, 
new synthetic pathway was investigated (Scheme 5.3). This pathway, although longer, 
differentiated the 2- and 5- substituents at an early stage. The commercially available 2- 
methylthiophene (207) was converted to the thienylmetallo compound (208); abstraction of 
the relatively acidic thiophene 2 -proton by butyl lithium would give an appropriate 
nucleophile for the reaction with a reactive carbonyl electrophile. Lithiation of (207) with 
butyl lithium at 0°C, followed by quench with ethyl chloroformate (a reactive carboxy 
electrophile equivalent) gave the required ester (209) in 6 8 % optimised yield. A similar 
lithiation of (207) with butyl lithium, followed by quenching with methyl chloroformate, 
afforded a mixture of products. Thus the precise nature of the trapping electrophile was 
important.213
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A radical bromination214 of (209) by treatment with one equivalent of N-bromosuccinimide 
afforded a mixture of ethyl 5-bromomethylthiophene-2-carboxylate (210), ethyl 4-bromo- 
5-methylthiophene-2-carboxylate and ethyl 4-bromo-5-bromomethylthiophene-2- 
carboxylate, in addition to the starting material. Changes in reaction time, solvent and 
radical initiating agent did not divert the reaction towards side-chain bromination 
particularly: As the Rf values of these materials are very similar, separation by column 
chromatography gave pure (210) in the low yield of 13%.
N-Alkylation of the potassium salt of trifluoroacetamide is an alternative to the Gabriel 
synthesis of primary and secondary amines.215 These methods were of similar scope but 
removal of the blocking trifluoroacetyl group is relatively easy. Treatment (210) with the 
potassium salt of trifluoroacetamide (strong nucleophile) gave the N-alkyltrifluoro- 
acetamide (211) in 62% yield. The trifluoroacetamide group was then hydrolysed with 
NaOH to the corresponding amine. However, under these alkaline conditions, the ester in
(211) also hydrolysed to the corresponding carboxylic acid salt. In the same reaction flask, 
reaction of resulting amine with benzyl chloroformate was carried out using the Schotten- 
Baumann technique. In this way, the Cbz protecting group was introduced for the amine. 
The carboxylic acid salt was converted to the corresponding acid upon acidification of the 
aqueous layer. Compound (212) was isolated in excellent yield.
Compound (212) (Scheme 5.4) was esterified with methanol in the presence of H2SO4 to 
afford compound (213) in (8 8 %). The Cbz protecting group of (213) was cleaved by 
treatment with hydrogen bromide to give the amine salt (214). The corresponding free 
amine was then converted to the isothiocyanate (215) by treatment with two equivalents of 
thiophosgene in the presence of CaCC>3. Ammonia was added across of the electrophilic 
isothiocyanate to give the thiourea (216) in excellent yield. Treatment of (212) with 
BH3.THF complex afforded a mixture of (217) and (218). The alcoholic compound (217) 
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Scheme 5,4 Chemical synthesis o f compound (216). (i) H2SO4, MeOH; (ii) 30% HBr in 
AcOH; (iii) SCCl2, CaC03, H20 , CHCI3; (iv) NH3, CH2Cl2; (v) BH3.THF complex,, THF, 
AcOH.
5.4.2 2,4-Disubstituted thiophenes
Retrosynthetic analysis suggested that 3-methylthiophene (219) (Scheme 5.5) would be an 
ideal starting material, by analogy with the 2,5-disubstituted series. Detty and Hays217 have 
reported two direct approaches for formylation of (219) which usually afford mixture of 
2,3- and 2,4-disubstituted products. The ratio of the isomers depends on the bulkiness of 







Scheme 5.5 Chemical synthesis of compound (222a) and (222b). (i) Butylithium, DMF, 
Et2 0 ; (ii)Ag2 0 , aq. NaOH; (iii) MeOH, H2SO4; (iv) Butyllithium, Me0 2 CCl, THF, 0°C.
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Firstly, standard Vilsmeier reactions led predominantly to the 2,3-disubstituted product 
(220b). For 3-methylthiophene, the preferential site of attack by the electrophilic species is 
the 2-position, leading predominantly to 2,3-disubstituted products. However, it has been 
shown that, as the steric bulk of the 3-substituent increases, more of the 2,4-disubstituted
217products are formed and the 2,3:2,4 ratio decreases. Secondly, lithiation, followed by 
treatment with dimethylformamide appears to have the opposite regioselectivity and to 
afford mainly the required (220a) isomer. In contrast to the literature report, about 
successful separation of the two isomers via chromatography on silica gel, the mixture of 
(220a) and (220b) could not be separated preparatively using various eluant systems.
Thus the sequence proceeded with the mixture of the two isomers. Compounds (220a,b) 
were oxidised by silver oxide to the corresponding acids (221a,b). These were esterified 
with excess methanol and H2SO4 to afford a mixture of compounds (222a,b) (Scheme 5.5). 
Interestingly, this new lithiation approach also provided a direct synthesis of (222a,b), in 
that the lithiated 3-methylthiophene reacted with methyl chloroformate to give the isomeric 
esters in approximately the same ratio as of the aldehydes formed by DMF quench of the 
anion. However, attempts using ethyl chloroformate gave a complex mixture, in contrast to 





Figure 5.6 Chemical synthesis o f compound (224). (i) N-Bromosuccinimide, 
Dibenzoyl peroxide, CCU; (ii) CF3CO2H, KOBu\ THF.
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Side-chain bromination of (222a) was achieved in <50% yield by treatment with one 
equivalent of N-bromosuccinimide (NBS), using dibenzoyl peroxide218 as radical initiator. 
(Scheme 5.6). However, a mixture of unreacted starting material, ring-brominated 
products, and side-chain brominated (and polybrominated) products were produced. 
Repeated attempts using two equivalents of NBS gave higher percentages of ring- 
brominated products. Separation of the mixture via chromatography afforded 4.5% of 
(223). Treatment with the potassium salt of trifluoroacetamide produced a mixture of 
unreacted starting material, the required secondary amide (224) and the dialkylated 
trifluoroacetamide (225). Separation by chromatography afforded (224) in 35% yield and 
(225) in 5% yield (Scheme 5.6). Repeated experiments used a combination of nucleophile 
and increasing the mixing time, but neither consumed all the starting material, or avoided 
dialkylation. As a result of the previous low isolated yield of pure (223), treatment of crude 
(223) with the potassium salt of trifluoroacetamide was investigated and gave an improved 
overall yield of (224). As expected, the contaminating methyl 3-bromomethylthiophene-2- 
carboxylate did not react with this nucleophile, allowing easier separation from the product 
amide (224).
The simultaneous removal of the trifluoroacetyl blocking group'and reduction of the ester 
was attempted using LiBHU. Ninhydrin indicated the formation of a primary amine but, on 
work-up, nothing was found in the organic layer. However, the aqueous layer contained a 
trace of (226) (Scheme 5.7) as white solid mixed with inorganic salts, as shown by NMR.
As for the 2,5-disubstituted series, hydrolysis of the trifluoroacetamide and the ester was 
carried out simultaneously using sodium hydroxide. In the same reaction flask, a Schotten- 
Baumann reaction was carried out using benzyl chloroformate, giving, after acid work-up, 
the Cbz compound (227) in 82% yield. This was esterified with methanol and H2SO4 to 
give the ester (228) in high yield. As before, the protecting Cbz group of (228) was cleaved 
quantitatively upon treatment with hydrogen bromide in acetic acid. Compound (229) 
was then converted to the isothiocyanate (230) with thiophosgene in the presence of 
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Scheme 5.7 Chemical synthesis o f  compound (231). (i) 1- NaOH, H2Ot MeOH, 2- 
Bn02CCl; (ii) H2S 0 4, MeOH; (iii) 30% HBr in AcOH; (vi) SCCl2, C aC03, H20, CHCl3; (v) 
NH3, CH2Cl2; (vi) LiBH4, THF.
5.5 Biological Evaluation and conclusion
Neither (216) nor (231) showed any inhibitory effect against iNOS or cNOS. In contrast, 
they showed significant stimulatory effects on iNOS, as shown in (Table 5.1) below; this 
stimulation was evident only without preincubation o f the enzyme with the agents. These 
compounds have been evaluated by Dr Claire Goodyer according to the method published 
previously.204,219
The biochemical origin and mechanism o f this stimulation is unclear, although a similar 
but weaker stimulation was reported by Ulhaq et a l 204 for S-2-amino-5-(3-nitro-l,2,4- 
triazol-l-yl)pentanoic acid hydrochloride, S-2-nitro-5-(3-nitro-l,2,4-triazol-l-yl)pentanoic 
acid hydrochloride and S-2-amino-5-(2-cyanoimidazol-l-yl)pentanoate hydrochloride on
' i f l  i \iNOS and nNOS and similar stimulatory values were reported recently by Goodyer et al. 
for N-(4-aminophenylmethyl)thiourea, 3-(thioureidomethyl)benzoic acid, and 4- 
(thiouridomethyl)benzoic acid. Goodyer el al have also reported that introduction o f an N'-
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(2 -hydroxyethyl) motif into the methoxyarylthiourea targets introduce an increase in the 
stimulatory values for the iNOS isoform at a preincubation time o f zero.
Furthermore, 3-phenyl-3,4-dihydro-1-isoquinolinamine has been reported to be a weak 
inhibitor o f iNOS and nNOS. However, analogues compounds 6-phenyl-4-amino-6,7- 
dihydrothienopyridines, in which the benzo ring has been replaced by a thieno ring fusion 
are potent iNOS and nNOS inhibitors.221
Compound
%  Inhibition of iNOS %  Inhibition of cNOS




-62 ±2 4 ± 3 1 ± 4 - 3 ± 3
HtN
2 231
- 37 ±27 8±  11 - 6 ± 1 - 6 ± 7
Table 5.1 Inhibition results fo r  compounds (216) and (231) against hiNOS and rat 
brain cNOS at 100 pM  concentration, Values are expressed as means ± SEM (n=2). T=0 
refers to no pre-incubation o f  the compound with the enzyme. T=10 refers to a ten-minute 
pre-incubation time o f  the compound with the enzyme.
From the previous reports on this marked NOS stimulation effects o f some compounds, 
one might expect that these compounds interact with the active site o f the enzyme through 
more than one binding site under different conditions; binding to one site would have a 
stimulatory effect while binding to the other would have inhibitory effect. The binding to 
the allosteric stimulatory site is expected to be fast, this would then explain the stimulation 
effects reported without preincubation.
Interestingly, these compounds may have some therapeutic value in increasing NO 
biosynthesis. However, the reported switch in this stimulation effect after incubation to a 
weak inhibition effect may hinder their use in clinical trial.
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Experimental
6.1 HPLC instrumentation and conditions
The chromatographic equipment comprised a Dionex autosampler (Model AS1 -  100 / AS1 
-  100T), Dionex pump (Model P 580), Dionex column thermostat for HPLC and GPC 
(Model 585) and a Dionex UV/VIS detector (Model UVD 170S/340S).
6.2 HPLC Chromatographic conditions
A C.i8 Hypersil (Thermoquest BDS) column (250 x 4.6 mm) was used. The mobile phase 
was composed of a mixture (65/35, v/v) of acetonitrile and 0.066 M phosphate buffer, 
adjusted to pH 6.0, pH 7.0, and pH 8.0 with 19 M potassium hydroxide using a Hanaa pH 
meter (Model 210). The phosphate buffer was filtered in a Vacuubrand GmbH vacuum 
system (Model ME 4) with a Schleicher and Schuell filter membrane (pore size and 
diameter of 0.45 and 47mm). The flow rate during the assays was 0.8 ml min' 1 and 
detection being accomplished at X = 275 nm and X = 225 nm. The incubations and analyses 
were carried out at 37°C. The times between injections varied depending on the speed of 
drug release.
6.3 Spectroscopic instrumentation
NMR spectra were recorded on Varian GX270 or EX400 spectrometers of samples in 
CDCI3, unless otherwise stated. 19F NMR spectra were referenced to CFCI3. IR spectra 
were recorded on a Perkin-Elmer 782 spectrometer as KBr discs, unless otherwise stated. 
Mass spectra were obtained using fast atom bombardment (FAB) ionisation in the positive 
ion mode, unless otherwise stated. Chromatography was performed with silica 33-70 pm.
6.4 Experimental abbreviations and conditions
DCC refers to dicyclohexylcarbodiimide, THF refers to tetrahydrofuran, DMF refers to 
dimethylformamide, HOBt refers to 1-hydroxybenzotriazole, DMAP refers to 4- 
dimethylaminopyridine. THF was dried with Na. Solutions in organic solvents were dried 
with MgSC>4. Solvents were evaporated under reduced pressure. The aqueous NaHCC>3 and 
brine were saturated. Experiments were conducted at ambient temperature, unless
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otherwise stated.
/?-2,2-DimethyItetrahydrothiazole-4-carboxylic acid hydrochloride (47)
HC1.HN
HO
L-Cys.HCl.H2O (3.5 g, 20 mmol) and 2,2-dimethoxypropane (50 mL) was boiled under 
reflux in acetone (250 mL) for 6  h. The resulting solid was collected by filtration to afford 
47 (3.45 g, 87%) as a white solid: mp 125-130°C (lit135 mp 165-168°C); IR vmax 3412 
(NH), 2600, (OH), 1744 (C=0) cm'1; NMR (D20 )  6 H 1.58 (3 H, s, Me), 1.59 (3 H, s, Me),
3.31 (1 H, dd, J = 12.1, 8.2 Hz, 5-H), 3.45 (1 H, dd, J  = 12.1, 8.2 Hz, 5-H), 4.63 (1 H, t, J 




Pr^NEt (722 mg, 5.6 mmol) was stirred with 47 (1.0 g, 5.1 mmol) and di-f-butyl 
dicarbonate (1.45 g, 6 .6  mmol) in dry MeCN (10 ml) for 2 d. The evaporation residue, in 
Et2 0 , was filtered through Celite®. The evaporation residue was dissolved in CH2CI2 and 
washed with aq. H2SO4 (100 mM, cold), H2O and brine. Drying, evaporation of the organic 
layer and recrystallisation of the residue (hexane) afforded 48 (150 mg, 11%) as a white 
solid: mp 112-114°C (lit135 mp 114-114.5°C); NMR (CDC13; 20°C) 5 h  1.43 (4.5 H, brs) 
and 1.53 (4.5 H, brs) (Bu'), 1.80 (4.5 H, m) and 1.87 (1.5 H, brs) (2 x  Me), 3.1-3.28 (2 H, 
m, 5-H2), 4.83 (1 H, m) and 4.98 (1 H, m) (4-H); NMR ((CD3)2SO; 20°C) 6 H 1.35 (5.4 H, 
brs) and 1.43 (3.6 H, brs) (Bu1), 1.70 (brs) and 1.73 (brs) and 1.75 (brs) (2 x  Me), 3.03 (d, J 
= 12.1 Hz) and 3.34 (m) (5-H2), 4.67 (0.6 H, dd, J  = 4.0, 12.1 Hz) and 4.74 (0.4 H, brd, J =
5.0 Hz) (4-H); NMR ((CD3)2SO; 80°C) 5H 1.41 (9 H, s, Bu'), 1.73 (3 H, s, 2-Me), 1.77 (3
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H, s, 2-Me), 3.05 (1 H, dd, 7 = 12.1, 3.0 Hz, 5-H), 3.35 (1 H, dd, 7 = 12.1, 6.9 Hz, 5-H),




Compound 48 (1.10 g, 4.2 mmol) was stirred with pentafluorophenol (850 mg, 4.6 mmol) 
and DCC (850 mg, 4.6 mmol) in EtOAc (10 mL) at 0°C under N2 for 3 h. The mixture was 
filtered. The solvent was evaporated from the combined filtrate and EtOAc washings. The 
residue, in hexane, was filtered. Evaporation afforded 49 (1.62 g, 90%) as white needles: 
mp 107-109°C (lit135 mp 104-105°C); NMR 5H 1.46 (6.3 H, s, Bu'), 1.52 (2.7 H, s, Bu'),
1.80 (0.9 H, s, 2-Me), 1.83 (3 H, s, 2-Me), 1.90 (2.1 H, s, 2-Me), 3.28 (0.7 H, brd, 7 = 12.5 
Hz, 5-H), 3.41 (0.3 H, m, 5-H), 3.47 (1 H, dd, 7 =  12.5, 7.0 Hz, 5-H), 4.05 (0.3 H, m, 5-H), 
5.18 (0.7 H, dd, 7 = 6 .6 , 1.6 Hz, 4-H), 5.26 (0.3 H, dd, J = 6 .6 , 2.3 Hz, 4-H); NMR 8 F -
162.2 (0.3 F, m, 4 ’-F), -161.8 (0.7 F, m, 4 ’-F), -157.8 (0.6 F, dd, 7 = 2 1 .1 , 17.2 Hz, 3’,5’- 
F2), -157.3 (1.4 F, dd, 7 =  21.1, 17.2 Hz, 3 \5 ’-F2), -152.6 (1.4 F, d, 7 =  17.2 Hz, 2’,6’-F2), - 




4-Nitrophenylethylamine hydrochloride (85 mg, 420 pmol) was stirred with Et3N (85 mg, 
840 jiimol) and 49 (180 mg, 420 jimol) in CH2C12 (2.0 mL) for 2 h. Evaporation and 
chromatography (CHCI3 /  MeOH 9:1) afforded 50 (160 mg, 93%) as a viscous yellow oil:
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IR (Nujol) vmax 3325 (NH), 1681 (C=0), 1519 (N 02), 1346 (N 02) cm'1; NMR 6 H 1.43 (9 
H, s, Bu'), 1.70 (3 H, s, 2-Me), 1.75 (3 H, s, 2-Me), 2.95 (2 H, m, ArCH2), 3.23 (2 H, m, 5- 
H2), 3.53 (1 H, m) and 3.68 (1 H, m) (NHC//2), 4.74 (1 H, m, 4-H), 7.42 (2 H, d, J = 8 .6  
Hz, Ar 2,6-H2), 8.18 (2 H, d, J = 8 .6  Hz, Ar 3,5-H2); NMR 5c 19.6,28.7, 36.0,40. 7, 67.5,
82.0, 93.7, 110.0, 124.0, 129.9, 146.9, 171.3; MS m/z 410.1764 (M + H) (Ci9H28N30 5S 
requires 410.1750), 354 (M -Me2C=CH2), 336 (M - Bu'O), 310 (M - Boc); Found; H, 6.59; * 




Compound 50 (1.30 g, 3.2 mmol) was stirred with CF3CO2H (20 mL) and CH2CI2 (10 mL) 
for 2 h. Evaporation afforded 51 (1.35 g, quant.) as a highly hygroscopic viscous oil: NMR 
5h 1.82 (3 H, s, 2-Me), 1.93 (3 H, s, 2-Me), 2.97 (2 H, m, ArCH2), 3.20 (1 H, dd, /  = 1'2.5,
6.2 Hz, 5-H), 3.59 (1 H, dd, J = 12.5, 8.2 Hz, 5-H), 3.64 (2 H, m, NHCtf2), 5.22 (1 H, dd, J 
= 8.2, 6.2 Hz, 4-H), 7.35 (2 H, d, J = 8 .6  Hz, Ar 2,6-H2), 7.56 (1 H, brt, /  = 5.9 Hz, NH), 
8.15 (2 H, d, J = 8 .6  Hz, Ar 3,5-H2), 9.76 (3 H, br, N+H2); MS m/z 310.1238 (M + H) 
(C14H20N3O3S requires 310.1225).
tert-Butyl N-(fluorocarbonylmethyl)carbamate (52)
B ocH N '^u^
O
BocGlyOH (1.0 g, 5.7 mmol) was stirred with pyridine (450 mg, 5.7 mmol) in dry CH2CI2 
(30 mL) and added slowly to cyanuric fluoride (1.54 g, 11.4 mmol) in dry CH2CI2 (10 mL), 
then stirred for 3 h. The mixture was washed with ice-water (3 x 50 mL). Drying and 
evaporation afforded crude 52 (800 mg): NMR 8 h 1-47 (9 H, s, Bu1), 4.11 (2 H, t, J = 5.5 





BocValOH (2.5 g, 11 mmol) was stirred with pyridine (910 mg, 11.5 mmol) in dry CH2CI2 
(30 mL) and added slowly to cyanuric fluoride (3.1 g, 23.0 mmol) in dry CH2CI2 (30 mL). 
Stirring continued under nitrogen at -10°C for 2 h. The mixture was washed with ice-water 
(3 x 100 mL). Drying and evaporation afforded crude 54 (2.22 g) as a white solid: mp 38- 
42°C (lit136 mp 36-38°C); NMR 8 H 0.99 (3 H, d, J = 7.0 Hz, Val-Me), 1.04 (3 H, d, J = 6 .6  
Hz, Val-Me), 1.46 (9 H, s, Bu'), 2.25 (1 H, m, Val p-H), 4.40 (1 H, dd, J = 8 .6 ,4 .7  Hz, Val 
a-H), 4.96 (1 H, brd, NH); NMR 8f  32.29 (1 F, s, C 0 2F)
tert-Butyl S-N-(l-fluorocarbonyl-2-phenylethyl)carbamate (55)
NHBoc '
BocPheOH (2.5 g, 9.4 mmol) was Stirred with pyridine (744 mg, 9.4 mmol) in dry CH2CI2 
(30 mL) and added slowly to cyanuric fluoride (2.54 g, 18.80 mmol) in dry CH2CI2 (30 
mL). The mixture was stirred under nitrogen at -10°C for 2 h. The mixture was washed 
with ice-water (3 x  100 mL). Drying and evaporation afforded crude 55 (1.53 g, 57 %): 
NMR 5h 1.42 (9 H, s, Bu'), 3.15 (1 H, dd, J = 14.4, 6.0 Hz, Phe p-H), 3.17 (1 H, dd, J = 
14.4, 6.0 Hz, Phe P-H), 4.74 (1 H, brd, J  = 6.0 Hz, Phe a-H), 4.86 (1 H, d, J = 6 .6  Hz, 






BocGlyF53 (810 mg, 4.6 mmol) was stirred with 47 (1.00 g, 5.1 mmol) and Pr'2NEt (1.24 g,
9.6 mmol) in dry DMF (100 mL) for 3 h. The evaporation residue, in EtOAc, was washed 
with cold 5% aq. citric acid and brine. Drying, evaporation and chromatography (EtOAc / 
Et2 0  / AcOH 13:6:1) afforded 56 (560 mg, 35%) as a pale buff solid: mp 152-155°C: IR 
vmax 3385 (NH), 2933 (OH), 1748 (C=0), 1672 (C=0), 1625 (amide I), 1539 (amide II) 
cm'1; NMR ((CD3)2SO) 6 H 1.38 (9 H, s, Bu'), 1.74 (3 H, s, 2-Me), 1.76 (3 H, s, 2-Me), 3.28 
(2 H, m, 5-H2), 3.50 (1 H, dd, J = 17.0, 6.2 Hz) and 3.87 (1 H, dd, J = 17.0, 5.5 Hz) (Gly- 
H2), 5.10 (1 H, m, 4-H), 6.78 (1 H, t, J = 6  Hz, NH); MS m/z 319.1339 (M + H) 
(Ci3H23N20 5S requires 319.1328), 263 (M - Me2C=CH2); Found: C, 47.80; H, 6.72; N, 
8.85; Ci3H22N2O5S0.5H2O requires C, 47.99; H, 6.51; N, 8.61%.
tert-Butyl S-N-(l-(fluorocarbonyl)ethyl)carbamate (53) and R-2,2-dimethyl-3-(N-(l,l- 
dimethylethoxycarbonyl)-L-alanyI)tetrahydrothiazole-4-carboxylic acid (57)
BocAlaOH (2.0 g, 11 mmol) was stirred with pyridine (840 mg, 10.6 mmol) in dry CH2C12 
(30 mL) and added slowly to cyanuric fluoride (2.86 g, 21.1 mmol) in dry CH2C12 (30 mL). 
Stirring continued for 3 h. The mixture was washed with ice-water (3 x  100 mL). Drying 
and evaporation afforded crude 53 (1.74 g) as a white solid. This material (1.74 g, 9.1 
mmol) was stirred with 47 (2.0 g, 10 mmol) and Pr2NEt (2.5 g, 19 mmol) in dry DMF 
(100 mL) for 16 h. The evaporation residue, in EtOAc, was washed with cold 5% aq. citric 
acid and brine. Drying, evaporation and chromatography (EtOAc / Et20  / AcOH 49:49:2) 
afforded 57 (680 mg, 30% from 47) as a pale yellow solid: mp 93-94°C: IR vmax 3338 





Hz, Ala P-H3), 1.40 (9 H, s, Bu'), 1.81 (3 H, s, 2-Me), 1.92 (3 H, s, 2-Me), 3.24 (1 H, dd, J 
= 12.1, 5.5 Hz, 5-H), 3.45 (1 H, d, J =12.1 Hz, 5-H), 4.53 (1 H, qn, J = 6 .8  Hz, Ala a-H), 
4.85 (1 H, d, /  = 5.1 Hz, 4-H), 5.68 (1 H, d, J = 7.8 Hz, NH); MS m/z 333.1489 (M + H) 





BocValF (1.61 g, 6 .8  mmol) was stirred with 47 (1.50 g, 7.6 mmol) and Pr^NEt (1.87 g,
14.4 mmol) in dry DMF (100 mL) for 16 h. The evaporation residue, in EtOAc, was 
washed with cold 5% aq. citric acid, cold H2O and brine. Drying, evaporation and 
chromatography (hexane / EtOAc / AcOH 70:29:1) afforded 58 (730 mg, 27%) as a 
gummy solid: IR Vmax 3338 (NH), 1705 (C=0), 1655 (amide I), 1534 (amide II) cm'1; 
NMR 5h 0.90 (3 H, d, J = 7.0 Hz, Val-Me), 1.0 (3 H, d, 7 = 6 .6  Hz, Val-Me), 1.39 (9 H, s, 
Bu'), 1.82 (3 H, s, 2-Me), 1.88 (1 H, m, Val P-H), 1.92 (3 H, s, 2-Me), 3.21 (1 H, dd, 7 =
12.1, 5.3 Hz, 5-H), 3.44 (1 H, d, 7=12.1 Hz, 5-H), 4.50 (1 H, dd, J = 9.4, 5.5 Hz, Val a-H),
5.02 (1 H, d, J  = 5.3 Hz, 4-H), 5.60 (1 H, d, J = 9.4 Hz, NH), 8.52 (1 H, br, OH); MS m/z 






BocPheF (1.53 g, 5.4 mmol) was stirred with 47 (1.20 g, 6.0 mmol) and Pr^NEt (1.47 g,
11.4 mmol) in dry DMF (100 mL) for 16 h. The evaporation residue, in EtOAc, was 
washed with cold 5% aq. citric acid and brine. Drying, evaporation and chromatography
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(EtOAc / AcOH 99:1) afforded 59 (920 mg, 30%) as a pale yellow gum: NMR 5h 1.29 (9 
H, s, Bu'), 1.68 (3 H, s, 2-Me), 1.77 (3 H, s, 2-Me), 2.80 (1 H, dd, 7 =  13.3, 7.1 Hz, Phe 0- 
H), 2.88 (1 H, dd, 7 =  13.3, 6.1 Hz, Phe P-H), 2.97 (1 H, dd, 7 =  11.7, 5.9 Hz, 5-H), 3.12 (1 
H, d, 7 =  11.7 Hz, 5-H), 4.34 (1 H, ddd, 7 = 9.0, 7.1, 6.1 Hz, Phe a-H), 4.68 (1 H, d, 7 =  5.9 
Hz, 4-H), 6.50 (1 H, d, 7 = 9.0 Hz, NH), 7.26 (5 H, m, Ph-H5); MS m/z 409.1812 (M + H) 






Compound 56 (450 mg, 1.4 mmol) was stirred with pentafluorophenol (290 mg, 1.6 mmol) 
and DCC (330 mg, 1.6 mmol) in EtOAc (5.0 mL) at 0°C under N2 for 3 h. The mixture 
was filtered (Celite®) and the solid was washed with cold EtOAc. The evaporation residue, 
in hexane, was kept at 4°C for 16 h and filtered. Evaporation gave 60 (700 mg, 92%) as a 
colourless oil: NMR 8H 1.45 (9 H, s, Bur), 1.88 (3 H, s, 2-Me), 1.92 (3 H, s, 2-Me), 3.45 (1 
H, dd, 7 = 12.5, 5.5 Hz, 5-H), 3.51 (1 H, d, 7 = 12.1 Hz, 5-H), 3.67 (1 H, dd, 7 = 17.2, 3 
Hz) and 4.13 (1 H, dd, 7 = 17.2, 6 .6  Hz) (Gly-H2), 5.20 (1 H, d, 7 = 5.3 Hz, 4-H), 5.37 (1 
H, br, NH); NMR 5F -161.3 (2 F, m, 3’,5’-F2), -156.4 (1 F, t, 7 = 21.4 Hz, 4 ’-F), -152.0 (2 
F, d, 7 = 16.8 Hz, 2’,6’-F2); MS m/z 485.1185 (M + H) (Ci9H22F5N20 5S requires 







Compound 57 (400 mg, 1.2 mmol) was stirred with pentafluorophenol (240 mg, 1.3 mmol) 
and DCC (270 mg, 1.3 mmol) in EtOAc (10 mL) at 0°C under N2 for 3 h. The mixture was 
filtered (Celite®) and the solid was washed with cold EtOAc. The evaporation residue, in 
hexane, was kept at 4°C for 16 h and filtered. Evaporation gave 61 (530 mg, 89%) as a 
colourless oil: NMR 5H 1.36 (2.1 H, d, J = 6 .6  Hz, Ala P-H3), 1.37 (0.9 H, d, J = 6 .6  Hz, 
Ala P-H3), 1.39 (6.3 H, s, Bu'), 1.43 (2.7 H, s, Bu'), 1.85 (2.1 H, s, 2-Me), 1.94 (2.1 H, s, 2- 
Me), 2.05 (0.9 H, s, 2-Me), 2.09 (0.9 H, s, 2-Me), 3.33 (0.3 H, dd, J = 12.7, 2.9, 5-H), 3.40 
(0.7 H, dd, J = 12.5, 5.5 Hz, 5-H), 3.46 (0.3 H, m, 4-H), 3.49 (0.7 H, d, J = 12.1 Hz, 4-H),
4.39 (0.7 H, qn, /  = 7 Hz, Ala a-H), 4.79 (0.3 H, qn, J = 7 Hz, Ala a-H), 5.19 (0.7 H, d, J 
= 5.5 Hz, 4-H), 5.24 (0.3 H, br, NH), 5.40 (0.7 H, d, J = 7.8 Hz, NH), 5.57 (0.3 H, dd, J = 
6 .6 , 3.1 Hz, 4-H); NMR 8 F -161.7 (0.6 F, m, 3 \5 ’-F2), -161.6 (1.4 F, dt, / =  21.0, 18.4 Hz, 
3’,5’-F2), -157.1 (0.3 F, t, /  = 21.0 Hz, 4 ’-F), -156.7 (0.7 F, t, J = 21.0 Hz, 4 ’-F), -151.9 
(0.6 F, d, J =  17.1 Hz, 2’,6’-F2), -150.8 (1.4 F, d, J =  17.1 Hz, 2 \6 ’-F2); MS m/z 499.1335 






Compound 58 (500 mg, 1.4 mmol) was stirred with pentafluorophenol (280 mg, 1.5 mmol) 
and DCC (320 mg, 1.5 mmol) in EtOAc (10 mL) at 0°C under N2 for 3 h. The mixture was
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filtered (Celite®) and the solid was washed with cold EtOAc. The evaporation residue, in 
hexane, was kept at 4°C for 16 h and filtered. Evaporation gave 62 (680 mg, 93%) as a 
colourless oil: IR v max 3440 (NH), 1718 (C=0), 1669 (amide I), 1521 (amide II) cm'1; 
NMR 5h 0.94 (2.1 H, d, 7 = 6 .6  Hz, Val-Me), 0.99 (2.1 H, d, 7 = 6 .6  Hz, Val-Me), 1.03 
(0.9 H, d, 7 = 7.0 Hz, Val-Me), 1.10 (0.9 H, d, 7 = 7.0 Hz, Val-Me), 1.33 (6.3 H, s, Bu'), 
1.43 (2.7 H, s, Bu'), 1.86 (2.1 H, s, 2-Me), 1.91 (0.°7 H, m, Val P-H), 1.95 (2.1 H, s, 2-Me),
1.99 (1.8 H, s, 2 x 2-Me), 3.32 (0.3 H, dd, 7 = 12.5, 3.5 Hz, 5-H), 3.40 (0.7 H, dd, 7 =  12.1,
5.1 Hz, 5-H), 3.44 (0.3 H, d, 7 = 12.5, 6.4 Hz, 5-H), 3.50 (0.7 H, d, 7 =  12.1 Hz, 5-H), 4.28 
(0.7 H, dd, 7 = 9.0, 6.2 Hz, Val a-H), 4.54 (0.3 H, dd, 7 = 9.8, 6.2 Hz, Val a-H), 5.12 (0.3 
H, d, 7 = 10.2 Hz, NH), 5.24 (0.7 H, d, 7 = 9.0 Hz, NH), 5.38 (0.7 H, d, 7 = 5.1 Hz, 4-H), 
5.62 (0.3 H, dd, 7 =  6.4, 3.5 Hz, 4-H); NMR 8F-161.9 (1.4 F, dd, 7 = 22.4, 18.4 Hz, 3’,5’- 
F2), -161.6 (0.6 F, dd, 7 = 21.0, 17.1 Hz, 3’,5’-F2), -157.1 (0.7 F, dt, 7  = 22.4 Hz, 4 ’-F), -
152.6 (0.3 F, d, 7 =  17.1 Hz, 4 ’-F), -151.8 (0.6 F, d, 7 =  17.1 Hz, 2 ’,6’-F2), -150.3 (1.4 F, d, 
7 =  18.4 Hz, 2 \6 ’-F2); MS m/z 527.1660 (M + H) (C22H28F5N20 5S requires 527.1639), 471 






Compound 59 (400 mg, 1.0 mmol) was stirred with pentafluorophenol (150 mg, 800 (imol) 
and DCC (170 mg, 810 jumol) in EtOAc (10 mL) at 0°C under N2 for 3 h. The mixture was 
filtered (Celite®) and the solid was washed with cold EtOAc. The evaporation residue, in 
hexane, was kept at 4°C for 16 h and filtered. Evaporation gave 63 (390 mg, 92%) as a 
white solid: mp 35-36°C: IR 3442 (NH), 1792 (C=0), 1716 (C=0), 1659 (amide I), 
1523 (amide II) cm’1; NMR 5H 1.39 (9 H, s, Bu'), 1.77 (3 H, s, 2-Me), 1.86 (3 H, s, 2-Me),
2.40 (1 H, dd, J = 12.5,5.5 Hz, 5-H), 2.89 (1 H, dd, J = 12.5,10.9 Hz, Phe p-H), 3.00 (1 H, 
d, ] =  12.5 Hz, 5-H), 3.25 (1 H, dd, 12.5, 3.9 Hz, Phe P-H), 4.37 (1 H, d, /  = 5.5 Hz, 4-H), 
4.51 (1 H, m, Phe a-H), 5.42 (1 H, d, J = 7.8 Hz, NH), 7.33 (5 H, m, Ph-H5); NMR 6 F -
172
161.8 (2 F, dd, J = 21.0, 17.1 Hz, 3 \5 ’-F2), -156.9 (1 F, t, J  = 21.0 Hz, 4 ’-F), -150.7 (1 F, 
d, J = 18.4 Hz, 2’,6’-F2); MS m/z 575.1635 (M + H) (C26H28F5N2O5S requires 575.1639), 






4-Nitrophenylethylamine hydrochloride (270 mg, 1.3 mmol) was stirred with Et3N (270 
mg, 2.7 mmol) and 60 (650 mg, 1.3 mmol) in CH2CI2 (5.0 mL) for 2 h. Evaporation and 
chromatography (EtOAc) afforded 64 (470 mg, 76%) as a white solid: mp 65-66°C; NMR 
((CD3)2SO) 5h 1.38 (9 H, s, Bu'), L72 (3 H, s, 2-Me), 1.74 (3 H, s, 2-Me), 2.91 (2 H, t, J =
7.4 Hz, ArCH2), 3.10 (1 H, d, J = 12.9 Hz, 5-H), 3.20 (1 H, dd, J = 16.4, 5.5 Hz, Gly-H),
3.31 (1 H, m, 5-H), 3.39 (1 H, m) and 3.47 (1 H, m) (NHC//2), 3.67 (1 H, dd, 7 =  16.4, 5.5, 
Gly-H), 4.79 ( lH ,d ,7 =  5.5 Hz, 4-H), 6.67 (1 H, t, J  = 5.5 Hz, Gly-NH), 7.50 (2 H, d, J = 
8 .8  Hz, Ar 2,6-H2), 8.07 (1 H, t, J = 5.5 Hz, NH), 8.13 (2 H, d, J = 8 .8  Hz, Ar 3,5-H2); MS 
m/z 467.1943 (M + H) (C2iH3iN40 6S requires 467.1964), 411 (M - Me2C=CH2), 393 (M - 






4-Nitrophenylethylamine hydrochloride (210 mg, 1.1 mmol) was stirred with Et3N (210 
mg, 2.1 mmol) and 61 (530 mg, 1.1 mmol) in CH2CI2 (5.0 mL) for 2 h. Evaporation and 
chromatography (EtOAc / hexane 4:1) afforded 65 (380 mg, 75%) as a white solid: mp 
156-158°C: IR vraax 3319 (NH), 1696 (C=0), 1657 (C=0), 1601 (amide I), 1520 (amide II)
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cm'1; NMR ((CD3)2SO) 5H 1.12 (3 H, d, /  = 7.0 Hz, Ala p-H3), 1.37 (9 H, s, Bu'), 1.61 (3 
H, s, 2-Me), 1.71 (3 H, s, 2-Me), 2.95 (2 H, m, ArCH2), 3.24 (1 H, dd, J =12.1, 5.5 Hz, 5- 
H), 3.32 (2 H, m, 5-H and ArCH2CH), 3.53 (1 H, m, ArCH2CH), 3.84 (1 H, m, Ala a-H),
4.73 (1 H ,d , / =  5.5 Hz, 4-H), 7.06 (1 H, d, J =5.9 Hz, NH), 7.49 (2 H, d, J  = 8 .8  Hz, Ar
2,6-H2), 8.13 (2 H, d, / =  8 .8  Hz, Ar 3,5-H2) 8.13 (1 H, br, NH); MS m/z 481.2142 (M + H) 






4-Nitrophenylethylamine hydrochloride (230 mg, 1.1 mmol) was stirred with Et3N (230 
mg, 2.3 mmol) and 62 (600 mg, 1.1 mmol) in CH2C12 (7.0 mL) for 2 h. Evaporation and 
chromatography (EtOAc / hexane 1:1) afforded 6 6  (420 mg, 73%) as a white solid: mp 
233.8°C (DSC); IR Vmax 3331 (NH), 1700 (C=0), 1653 (amide I), 1519 (amide II) cm'1; 
NMR 6 h 0.95 (3 H, d, J =  6 .6  Hz, Val-Me), 1.01 (3 H, d, J =  6 .6  Hz, Val-Me), 1.44 (9 H, s, 
Bu*), 1.65 (3 H, s, 2-Me), 1.81 (3 H, s, 2-Me), 1.87 (1 H, m, Val p-H), 3.02 (2 H, m, 
ArCH2), 3.12 (1 H, dd, J = 12.1, 5.5 Hz, 5-H), 3.50 (1 H, m, ArCH2Ci/), 3.63 (1 H, d, J =
12.1 Hz, 5-H), 3.75 (1 H, m, Val a-H), 3.79 (1 H, m, ArCH2Cfl), 4.67 (1 H, d, J =5.5 Hz,
4-H), 4.90 (1 H, d, J = 7.8 Hz, NHBoc), 7.38 (2 H, d, J = 8 .8  Hz, Ar 2,6-H2), 7.98 (1 H, br, 
NtfCH2), 8.14 (2 H, d, J = 8 .8  Hz, Ar 3,5-H2); MS m/z 509.2434 (M + H) (C ^ H ^ O e S  







4-Nitrophenylethylamine hydrochloride (160 mg, 800 pmol) was stirred with Et3N (158 
mg, 1.6 mmol) and 63 (450 mg, 800 jimol) in CH2CI2 (5.0 mL) for 2 h. Evaporation and 
chromatography (EtOAc / hexane 1:1) afforded 67 (410 mg, 95%) as a white solid: mp 45- 
46°C: IR vmax 3442 (NH), 1699 (C=0), 1652 (amide I), 1518 (amide H) cm'1; NMR 6 H 1-43 
(9 H, s, Bu'), 1.58 (3 H, s, 2-Me), 1.60 (3 H, s, 2-Me), 2.30 (1 H, dd, 7 =  11.7, 5.9 Hz, Phe 
P-H), 2.89 (2 H, m, Phe P-H + 5-H), 2.97 (2 H, t, J  = 7.0 Hz, ArCH2), 3.20 (1 H, d, J =
11.7 Hz, 5-H), 3.41 (1 H, m, ArCH2C7/), 3.69 (1 H, m, ArCH2OT), 3.74 (1 H, d, J = 5.5 
Hz, 4-H), 4.13 (1 H, m, Phe a-H), 4.98 (1 H, d, J = 5.9 Hz, Phe NH), 7.18 (2 H, m, Phe 
2’,6’-H2), 7.33 (3 H, m, Phe 3’,4 \5 ’-H3), 7.35 (2 H, d, J =  8 .8  Hz, Ar 2,6-H2), 8.10 (2 H, d, 
J = 8 .8  Hz, Ar 3,5-H2), 8.10 (1 H, m, NH); MS m/z 557.2433 (M + H) (C28H37N4O6S 




Compound 64 (50 mg, 110 pmol) was stirred in CF3CO2H (400 pL) and CH2CI2 (1.6 mL) 
for 45 min. Evaporation afforded 6 8  (53 mg, quant.) as a highly hygroscopic colourless 
gum: NMR ((CD3)2SO) 5H 1.76 (3 H, s, 2-Me), 1.78 (3 H, s, 2-Me), 2.90 (2 H, t, J  = 6 .6  
Hz, ArCH2), 3.18 (1 H, m, Gly-H), 3.20 (d, J = 12.3 Hz, 5-H), 3.34 (1 H, dd, J = 12.3, 5.9 
Hz, 5-H), 3.42 (2 H, brq, NHCH2\  3.89 (1 H, m, Gly-H), 4.85 (1 H, d, J = 6.1 Hz, 4-H), 
7.50 (2 H, d, J = 8 .8  Hz, Ar 2,6-H2), 8.02 (3 H, br, N+H3), 8.15 (2 H, d, J = 8 .8  Hz, Ar 3,5- 
H2), 8.26 (1 H, t, J = 6.2 Hz, NH); MS m/z 367.1448 (M + H) (Q e H ^ C ^ S  requires
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Compound 65 (20 mg, 40 jumol) was stirred with CF3CO2H (200 |nL) and CH2CI2 (800 (iL) 
for 20 min. Evaporation afforded 69 (quant.) as a pale buff solid: mp 119-121°C: IR vmax 
3410 (NH), 1655 (C=0), 1600 (amide I), 1517 (amide II) cm'1; NMR ((CD3OD) 5H 1.34 (3 
H, d, 7 = 6 .6  Hz, Ala P-H3), 1.69 (3 H, s, 2-Me), 1.72 (3 H, s, 2-Me), 2.85 (1 H, dt, 7 = 
12.9, 6 .6  Hz) and 2.89 (1 H, dt, 7 = 12.9, 6 .6  Hz) (ArCH2), 3.10 (1 H, dd, 7=12.9, 1.6 Hz,
5-H), 3.33 (2 H, m, 5-H, NC//H), 3.54-3.61 (1 H, dt, 7 =  13.7, 6 .6  Hz, NC#H), 3.68 (1 H, 
q, 7 = 7.0 Hz, Ala a-H), 4.74 (1 H, dd, 7 = 5.9, 1.6 Hz, 4-H), 7.39 (2 H, d, 7 = 9.0 Hz, Ar




Compound 6 6  (70 mg, 140 jumol) was stirred in CF3CO2H (600 |iL) and CH2CI2 (2.4 mL) 
for 15 min. Evaporation afforded 70 (quant.) as a highly hygroscopic viscous oil: NMR 
((CD3)2SO) 8 h 0.95 (3 H, d, 7 = 6 .6  Hz, Val-Me), 1.00 (3 H, d, 7 = 6 .6  Hz, Val-Me), 1.80 
(3 H, s, 2-Me), 1.82 (3 H, s, 2-Me), 2.10 (1 H, m, Val 0-H), 2.98 (2 H, t, 7 = 7.0 Hz, 
AiCH2), 3.32 (1 H, dd, 7 = 12.3, 2.3 Hz, 5-H), 3.45 (1 H, dd, 7 = 12.3, 5.9 Hz, 5-H), 3.53 
(3 H, m, NCH2 and Val a-H), 4.95 (1 H, dd, 7 =5.9, 2.3 Hz, 4-H), 7.57 (2 H, d, 7 = 8 .6  Hz,
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Ar 2,6-H2), 8.16 (3 H, br, N+H3), 8.23 (2 H, d, J = 8 .6  Hz, Ar 3,5-H2), 8.33 (1 H, t, J = 5.9 
Hz, NH); MS m/z 409.1911 (M + H) (Ci9H29N40 4S requires 409.1910).
R-2,2-Dimethyl-N-(2-(4-nitrophenyl)ethyI)-3-(L-phenylalanyI)tetrahydrothiazoIe-4- 
carboxamide trifluoroacetate (71)
Compound 67 (5 mg, 9 jumol) was stirred in CF3C 02H (100 pL) and CH2C12 (400 pL) for 
15 min. Evaporation afforded 71 (quant.) as a highly hygroscopic viscous oil: 
NMR((CD3)OD) 5h 1.64 (3 H, s, 2-Me), 1.70 (3 H, s, 2-Me), 2.55 (1 H, dd, J = 12.5, 5.9 
Hz, 5-H), 2.90 (2 H, t, J = 7.0 Hz, ArCH2), 2.95 (1 H, dd, 7 =  13.3, 8 .6  Hz, Phe |3-H), 3.08 
(1 H, d, J = 12.5 Hz, 5-H), 3.10 (1 H, dd, /  = 13.3, 5.6 Hz, Phe p-H), 3.42 (2 H, m, 
ArCH2C//2), 4.08 (1 H, m, Phe a-H), 4.20 (1 H, d, J  = 5.9 Hz, 4-H), 7.27 (2  H, m, Phe 
2’,6’-H2), 7.36 (3 H, m, Phe 3’,4’,5’-H3), 7.50 (2 H, d, J =  8 .6  Hz, Ar 2,6-H2), 8.18 (2 H, d, 
J  = 8 .6  Hz, Ar 3,5-H2), 8.23 (1 H, t, J = 6 .6  Hz, NH), 8.38 (3H, br, N+H3); MS m/z 
457.1907 (M + H) (C23H29N40 4S requires 457.1910).
/?-2,2-DimethyI-3-(N-(l,l-dimethylethoxycarbonyl)-D-alanyl)tetrahydrothiazole-4- 






Boc 73a Boc 73b
A mixture of Boc(D-Ala)F 72a (308 mg, 1.6 mmol) and Boc(L-Ala)F 72b (132 mg, 700 
pmol) was stirred with xx (500 mg, 2.5 mmol) and Et3N (480 mg, 4.8 mmol) in dry DMF 
(50 mL) for 16 h. The evaporation residue, in EtOAc, was washed with cold 5% aq. citric 
acid and brine. Drying and evaporation afforded a mixture of 73a and 73b (300 mg, 36%) 
as a white solid: IR vmax 3316 (NH), 1748 (C=0), 1718 (C=0), 1643 (amide I), 1660
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(amide I), 1540 (amide II), 1512 (amide II) c m 1; NMR SH 1.30 (1.2 H, d, J = 2.7 Hz, Ala 
P-H3 (L,R-diastereoisomer)), 1.32 (1.8 H, d, J = 3.1 Hz, Ala P-H3 (D,R-diastereoisomer)),
1.40 (3.6 H, s, Bu' (L^-diastereoisomer)), 1.42 (5.4 H, s, Bur (D,R-diastereoisomer)), 1.81 
(1.2 H, s, 2-Me (L,R-diastereoisomer)), 1.84 (1.8 H, s, 2-Me (D,R-diastereoisomer)), 1.87 
(1.8 H, s, 2-Me (D,R-diastereoisomer)), 1.91 (1.2 H, s, 2-Me (L,R-diastereoisomer)), 3.23 
(0!4 H, dd, J = 11.7, 5.3 Hz, 5-H (L,R-diastereoisomer)), 3.34 (0.6 H, dd, J = 12.1, 5.3 Hz,
5-H (D,R-diastereoisomer)), 3.40 (0.6 H, d, J = 12.1 Hz, 5-H (D,R-diastereoisomer)), 3.45 
(0.4 H, d, J  = 11.7 Hz, 5-H (L,R-diastereoisomer)), 4.25 (0.6 H, qn, J = 6 .6  Hz, Ala a-H  
(D,R-diastereoisomer)), 4.53 (0.4 H, qn, J = 7.0 Hz, Ala a-H (L,R-diastereoisomer)), 4.87 
(0.4 H, d, J = 5.3 Hz, 4-H (L^-diastereoisomer)), 5.36 (0.6 H, d, J = 8 .6  Hz, NH (D,R- 
diastereoisomer)), 5.59 (0.6 H, d, J = 5.3 Hz, 4-H (D,/?-diastereoisomer)), 5.79 (0.4 H, d, J 
= 8.2 Hz, NH (L,/?-diastereoisomer); MS m/z 333.1494 (M -I- H) (C14H25N2O5S requires 
333.1484), 277 (M - Me2C=CH2).
Pentafluorophenyl -2,2-dimethy 1-3-(N-( 1,1-dimethylethoxycarbonyl)-D-alanyl)tetra- 








Mixture (73a and 73b) (250 mg, 800 jimol) was stirred with pentafluorophenol (160 mg, 
900 pmol) and DCC (180 mg, 900 pmol) in EtOAc (5.0 mL) at 0°C under N2 for 3 h. The 
mixture was filtered (Celite®) and the solid was washed with cold EtOAc. The evaporation 
residue, in hexane, was kept at 4°C for 16 h and filtered. Evaporation gave 74a and 74b 
(320 mg, 80%) as a colourless gum; NMR 5h 1.30 (2.1 H, d, J = 6 .6  Hz, Ala-Me (D,R- 
diastereoisomer)), 1.37 (0.9 H, d, J = 6 .6  Hz, Ala-Me (L,R-diastereoisomer)), 1.39 (2.7 H, 
s, Bu' (L^?-diastereoisomer)), 1.43 (6.3 H, s, Bu' (D,R-diastereoisomer)), 1.85 (0.9 H, s, 2- 
Me (L^-diastereoisomer)), 1.87 (2.1 H, s, 2-Me (D,R-diastereoisomer)), 1.89 (2.1 H, s, 2- 
Me (D,R-diastereoisomer)), 1.94 (0.9 H, s, 2-Me (L,R-diastereoisomer)), 3.37 (0.3 H, dd, J 
= 12.5, 3.5 Hz, 5-H (L,R-diastereoisomer)), 3.40 (0.7 H, dd, J = 12.5, 5.7 Hz, 5-H (D,R-
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diastereoisomer)), 3.49 (1 H, d, 7 =12.5 Hz, 5-H), 4.22 (0.7 H, qn, 7 = 7.0 Hz, Ala a-H  
(D,R-diastereoisomer)), 4.38 (0.3 H, m, Ala a-H (L,/?-diastereoisomer)), 5.01 (0.7 H, d, 7 
= 9.0 Hz, NH (D,^-diastereoisomer)), 5.19 (0.7 H, d, 7 = 5.7 Hz, 4-H (D,R- 
diastereoisomer)), 5.58 (0.3 H, d, 7 = 3.5 Hz, 4-H (L,R-diastereoisomer)), 6.13 (0.3 H, d, 7 
= 3.9 Hz, NH (L,R-diastereoisomer)); NMR 5F-163.8 (2 F, t, 7 =  21.0 Hz, 3’,5’-F2), -162.1 
(2 F, t, 7 =  21.0 Hz, 3’,5’-F2), -161.5 (2 F, m, .3 \5 ’-F2), -161.1 (2 F, t, 7 =  22.4 Hz, 3’,5’- 
F2), 156.4 (1 F, t, 7 = 21.0 Hz, 4 ’-F), -156.6 (1 F, t, 7 = 21.0 Hz, 4 ’-F), 157.1 (1 F, t, 7 =
21.0 Hz, 4 ’-F), -157.8 (1 F, t, 7 = 21.0 Hz, 4 ’-F), -150.9 (2 F, d, 7 = 17.1 Hz, 2 ’,6’-F2), -
151.9 (2 F, d, 7 =  17.1 Hz, 2’,6’-F2) -152.1 (2 F, d, 7 =  18.4 Hz, 2’,6’-F2), -152.6 (2 F, d, 7 
= 17.1 Hz, 2’,6’-F2); MS m/z 499.1340 (M + H) (C ^ H ^ sN ^ sS  requires 499.1326), 443 
(M - Me2C=CH2), 425 (M - Bu'O).
/?-2,2-Dimethyl-3-(N-(l,l-dimethylethoxycarbonyI)-D-alanyl)-N-(2-(4-nitrophenyl)- 
ethyl)tetrahydrothiazole-4-carboxamide (75a) and R-2,2-dimethyl-3-(N-(l,l-dimethyl- 
ethoxycarbonyl)-L-alanyl)-N-(2-(4-nitrophenyl)ethyl)tetrahydrothiazole-4- 
carboxamide (75b)
4-Nitrophenylethylamine hydrochloride (120 mg, 600 pmol) was stirred with Et3N (120 
mg, 1.20 mmol) and 74a and 74b (300 mg, 600 pmol) in CH2C12 (3.0 mL) for 2 h. 
Evaporation and chromatography (EtOAc / hexane 4:1) afforded 75a and 75b (220 mg, 
76%) as a white solid: mp 69-80°C: NMR ((CD3)2SO) 8 H 0.93 (1.8 H, d, 7 = 6 .6  Hz, Ala- 
Me (D,R-diastereoisomer)), 1.11 (1.2 H, d, 7 = 6 .6  Hz, Ala-Me (L,R-diastereoisomer)),
1.36 (3.6 H, s, Buf (L,R-diastereoisomer)), 1.37 (5.4 H, s, Bu' (D,/?-diastereoisomer)), 1.59 
(1.2 H, s, 2-Me (L,R-diastereoisomer)), 1.68 (1.8 H, s, 2-Me (D,R-diastereoisomer)), 1.70 
(1.8 H, s, 2-Me (D,R-diastereoisomer)), 1.71 (1.2 H, s, 2-Me (L,R-diastereoisomer)), 2.88 
(0.8 H, m, ArCH2 (L,R-diastereoisomer)), 2.95 (1.2 H, m, ArCH2 (D,R-diastereoisomer)), 
3.00-4.00 (5 H, m, 5-H2, ArCH2C^2, Ala a-H), 4.72 (0.4 H, d, 7 = 4.1 Hz, 4-H (L,R- 
diastereoisomer)), 5.25 (0.6 H, d, 7 = 4.3 Hz, 4-H (D,/?-diastereoisomer)), 7.05 (0.4 H, d, 7 
= 5.9 Hz, NH (L,R-diastereoisomer)), 7.13 (0.6 H, d, 7 = 7.4 Hz, NH (D ,R- 
diastereoisomer)), 7.49 (0.8 H, d, 7 = 8.2 Hz, Ar 2,6-H2 (L7?-diastereoisomer)), 7.51 (1.2
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H, d, J = 8 .6  Hz, Ar 2 ,6 -H2 (D,R-diastereoisomer)), 8.13 (2 H, d, J = 8 .6  Hz, Ar 3 ,5 -H2), 
8.17 (1 H, d, /  = 5.9 Hz, Ala NH); MS m/z 481.2128 (M + H) (C22H33N4O6S requires 





BocD-Val F (270 mg, 1.1 mmol) was stirred with 47 (250 mg, 1.1 mmol) and Pr^NEt (310 
mg, 2.4 mmol) in dry DMF (10 mL) for 16 h. The evaporation residue, in EtOAc, was 
washed with cold 5% aq. citric acid, cold H2O and brine. Drying, evaporation and 
chromatography (hexane / EtOAc / AcOH 49:49:2) afforded 77 (200 mg, 50%) as a 
colourless gum: IR (film) Vmax 3329 (NH), 1714 (C=0), 1657 (amide I), 1462 (amide II) 
cm'1; NMR 8 H 0.92 (3 H, d, J = 6.4 Hz, Val-Me), 0.94 (3 H, d, J = 6.4 Hz, Val-Me), 1.43 
(9 H, s, Bur), 1.85 (3 H, s, 2-Me), 1.89 (3 H, s, 2-Me), 2.05 (1 H , m, Val 0-H), 3.27 (1 H, 
dd, J -  12.1, 5.7 Hz, 5-H), 3.40 (1 H, d, /  = 12.1 Hz, 5-H), 3.86 (1 H, t, J = 9.8 Hz, Val a- 
H), 5.42 (1 H, d, J = 9.8 Hz, NH), 5.66 (1 H, d, J = 5.7 Hz, 4-H); MS m/z 361.1810 (M + 




Compound 77 (200 mg, 560 pmol) was stirred with pentafluorophenol (113 mg, 610 pmol) 
and DCC (126 mg, 610 pmol) in EtOAc (10 mL) at 0°C under N2 for 3 h. The mixture was 
filtered (Celite®) and the solid was washed with cold EtOAc. The evaporation residue, in 
hexane, was kept at 4°C for 16 h and filtered. Evaporation gave 78 (120 mg, 41%) as a
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colourless oil; NMR 8 H 0.89 (2.1 H, d, J = 6 .8  Hz, Val-Me), 0.98 (2.1 H, d, J = 6 .8  Hz, 
Val-Me), 1.04 (0.9 H, d, 7 = 7.0 Hz, Val-Me), 1.10 (0.9 H, d, J =  7.0 Hz, Val-Me), 1.45 
(6.3 H, s, Bu'), 1.48 (2.7 H, s, Bu'), 1.89 (3 H, s, 2-Me), 1.93 (3 H, s, 2-Me), 2.02 (1 H, m, 
Val P-H), 3.30 (1 H, m, 5-H), 3.54 (1 H, dd, J  = 12.5, 6.2 Hz, 5-H), 3.83 (1 H, t, J = 9.0, 5- 
H), 5.03 (0.7 H, d, 7 = 9.8, Hz, 4-H), 5.08 (0.3 H, d, 7 = 9.0 Hz, 4-H), 5.62 (0.3 H, m, Val 






4-Nitrophenylethylamine hydrochloride (46 mg, 230 pmol) was stirred with Et3N (47 mg, 
460 pmol) and 78 (120 mg, 230 pmol) in CH2CI2 (2 mL) for 2 h. Evaporation and 
chromatography (EtOAc / hexane 1:1) afforded 79 (20#mg, 17%) as a colourless gum: IR 
(film) Vniax3320 (NH), 1702 (C=0), 1655 (amide I), 1514 (amide II) cm'1; NMR 8H0.83 (3 
H, d, 7 = 6 .6  Hz, Val-Me), 0.92 (3 H, d, 7 = 6 .6  Hz, Val-Me), 1.42 (7.2 H, s, Bu'), 1.55 (1.8 
H, s, Bu'), 1.79 (2.4 H, s, 2-Me), 1.81 (2.4 H, s, 2-Me), 1.88 (0.6 H, s, 2-Me), 1.91 (0.6 H, 
s, 2-Me), 1.92 (1 H, m, Val P-H), 2.97 (2 H, t, 7 = 7.0 Hz, ArCH2), 3.04 (1 H, d, 7 = 12.5 
Hz, 5-H), 3.36 (1 H, dd, 7 = 12.5, 6 .6  Hz, 5-H), 3.44 (1 H, m, ArCH2Ctf), 3.80 (1 H, m, 
ArCH2C//), 3.86 ( l H , t , / =  9.2 Hz, Val a-H), 4.85 (1 H, d, 7 = 9.2 H, ValNH), 5.07 (0.2 
H, d, J = 6 .6  Hz, 4-H), 5.36 (0.8 H, d, J = 6 .6  Hz, 4-H), 6.03 (0.2 H, br, N/fCH2), 6.41 (0.8 
H, br, NtfCH2), 7.35 (0.4 H, d, J = 8 .8  Hz, Ar 2,6-H2), 7.40 (1.6 H, d, J  = 8 .6  Hz, Ar 2,6- 
H2), 8.15 (0.4 H, d, J = 8 .8  Hz, Ar 3,5-H2), 8.17 (1.6 H, d, J = 8 .6  Hz, Ar 3,5-H2); MS m/z 
509.2437 (M + H) (C24H37N4O6S requires 509.2434).
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S-2,2-DimethyItetrahydrothiazole-4-carboxylic acid hydrochloride (81)
HC1.HN
OH
D-Cys.HCl.H2O (2.00 g, 10 itimol) and 2,2-dimethoxypropane (30 mL) were boiled under 
reflux in acetone (200 mL) for 4 h. The resulting solid was collected by filtration to afford 
81 (2.15 g, 78%) as a white solid: mp 166-170°C (lit135 mp 165-168°C); IR vm„  3412 
(NH), 2600, (OH), 1743 (C=0) cm'1; NMR (D20 )  5H 2.06 (6  H, s, 2 x  Me), 2.92 (1 H, dd, 






BocValF53 (1.08 g, 4.6 mmol) was stirred with 81 (1.00 g, 5.1 mmol) and Pr^NEt (1.24 g,
9.6 mmol) in dry DMF (100 mL) for 16 h. The evaporation residue, in EtOAc, was washed 
with cold 5% aq. citric acid, cold H2O and brine. Drying, evaporation and chromatography 
(hexane /  EtOAc /AcOH 70:28:2) afforded 82 (630 mg, 35%) as a colourless gummy solid: 
: IR 3434 (NH), 2970 (OH), 1723 (C=0), 1605 (amide I), 1513 (amide II) cm'1; NMR 
5h 0.87-0.95 (6  H, m, 2 x Val-Me), 1.43 (9 H, s, Bu'), 1.85 and 1.88 (6  H, s, 2 x 2-Me),
2.00 (1 H, m, Val p-H), 3.20-3.50 (2 H, m, 5-H + Val a-H), 3.85 (1 H, t, J = 10.0 Hz, 5-H),
5.36 (1 H, d, /  = 10.02 Hz, 4-H), 5.68 (0.7 H, d, / =  5.1 Hz, NH), 8.63 (1 H, br, OH); MS 







Compound 82 (500 mg, 1.4 mmol) was stirred with pentafluorophenol (280 mg, 1.5 mmol) 
and DCC (320 mg, 1.5 mmol) in EtOAc (10 mL) at 0°C under N2 for 3 h. The mixture was 
filtered (Celite®) and the solution was washed with cold EtOAc. The evaporation residue, 
in hexane, was kept at 4°C for 16 h and filtered. Evaporation gave 83 (500 mg, 68%) as a 
colourless oil: NMR 6H 0.88 (3 H, d, J  = 6.6 Hz, Val-Me), 0.97 (3 H, d, J  = 6.6 Hz, Val- 
Me), 1.45 (9 H, s, Bu*), 1.88 (3 H, s, 2-Me), 1.92 (3 H, s, 2-Me), 3.55 (1 H, dd, J  = 12.5,
6.6 Hz, 5-H), 3.82 (1 H, dd, J =  12.5, 9.8 Hz, 5-H), 5.08 (1 H, dd, J  = 9.8, 6,6 Hz, 4-H), 
5.61 and 5.66 (1 H , 2 x d , 7 =  4.5 Hz, Val a-H), 6.22 (1 H, brd, J =  4.5 Hz, NH); MS m/z 






4-Nitrophenylethylamine hydrochloride (80 mg, 400 pmol) was stirred with Et3N (80 mg, 
800 pmol) and 83 (200 mg, 400 pmol) in CH2CI2 (3.0 mL) for 2 h. Evaporation and 
chromatography (EtOAc / hexane 1:1) afforded 84 (100 mg, 49%) as an oil: IR vmax 3323 
(NH), 1698 (C=0), 1605 (amide I), 1520 (amide II) cm'1; NMR 8 h 0.83 (3 H, d, J  = 6 .6  
Hz, Val-Me), 0.92 (3 H, d, J =  6 .6  Hz, Val-Me), 1.42 (7.2 H, s, Bu*), 1.55 (1.8 H, s, Bu*),
1.80 (2.4H, s), 1.82 (2.4 H, s), 1.89 (0.6 H, s) and 1.91 (0.6 H, s) (2-Me2), 1.95 (1 H, m, 
Val p-H), 2.81 (1.6 H, dt, J =  14.1 7.0 Hz, ArCH2), 3.04 (0.8 H, d, J =  12.5 Hz, 5-H), 3.46 
(1 H, dd, J =  12.5, 6.4 Hz, 5-H), 3.44 (1 H, m, ArCH2C//), 3.77 (1 H, m, Ai CH2CH), 3.86
183
(1 H, t, /  = 9.4 Hz, Val a-H), 4.92 (1 H, d, /  = 9.4 Hz, Val NH), 5.07 (0.2 H, d, J = 6.4 Hz,
4-H), 5.36 (0.8 H, d, J = 6.4 Hz, 4-H), 6.09 (0.2 H, br, NHCH2), 6.47 (0.8 H, t, J = 5.5 Hz, 
NHCH2), 7.35 (0.4 H, d, /  = 8 .6  Hz, Ar 2,6-H2), 7.40 (1.6 H, d, J = 8.4 Hz, Ar 2,6-H2), 
8.13 (0.4 H, d, J = 8.4 Hz, Ar 3,5-H2), 8.16 (1.6 H, d, J = 8 .6  Hz, Ar 3,5-H2); MS m/z 





CF3CO2 N 0 2
Compound 84 (5 mg, 9.8 pmol) was stirred in CF3C0 2H (100 pL) and CH2C12 (400 pL) 
for 15 min. Evaporation afforded 85 (quant.) as a highly hygroscopic viscous oil: NMR 
((CD3)2SO) 5h 0.82 (3 H, d, J = 7.4 Hz, Val-Me), 0.84 (3 H, d, J = 7.0 Hz, Val-Me), 1.80 
(6  H, s, 2 x 2-Me), 2.02 (1 H, m, Val p-H), 2.88 (2 H, t, J = 7.0 Hz, ArCH2), 3.08 (1 H, d, J 
= 12.1 Hz, 5-H), 3.38 (2 H, m, ArCH2C7/2), 3.52 (1 H, dd, J = 12.1, 5.3 Hz, 5-H), 4.60 (1 
H, m, Val a-H), 5.05 (1 H, d, J =5.3 Hz, 4-H), 7.49 (2 H, d, /  = 8 .6  Hz, Ar 2,6-H2), 8.15 (2 
H, d, J = 8 .6  Hz, Ar 3,5-H2), 8.23 (1 H, t, J = 5.9 Hz, NH); MS m/z 409.1911 (M + H) 
(Ci9H29N40 4 S requires 409.1910).





FmocValOH (2.0 g, 5.9 mmol) was stirred with pentafluorophenol (1.20 g, 6.5 mmol) and 
DCC (1.34 g, 6.5 mmol) in EtOAc (20 mL) at 0°C under N2 for 4 h for 16 h. The mixture 
was filtered (Celite®) and the solid was washed with cold EtOAc. Evaporation afforded 87 
(2.10 g, 70%) as a white solid: mp 114-117°C (lit141 mp 122-123°C); NMR 5H 1.03 (3 H, 
d, J = 6 .6  Hz, Val-Me), 1.10 (3 H, d, J = 6 .6  Hz, Val-Me), 2.40 (1 H, m, Val p-H), 4.24 (1
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H, t, 7 = 6 .6  Hz, CtfCH20 ), 4.46 (2 H, d, 7 = 6 .6  Hz, CH20 ), 4.67 (1 H, dd, 7 = 9.4, 5.1 
Hz, Val a-H), 5.27 (1 H, d, 7 = 9.4 Hz, NH), 7.30 (2 H, t, 7 = 7.4 Hz, Ar-H2), 7.38 (2 H, t, 7 
= 7.4 Hz, Ar-H2), 7.58 (2 H, d, 7 = 7.4 Hz, Ar-H2), 7.75 (2 H, d, 7 = 7.4 Hz, Ar-H2); NMR 
6f -161.2 (2 F, t, 7 = 20.9 Hz, 3’,5’-F2), -156.6 (1 F, t, 7 =  20.9 Hz, 4 ’-F), -151.5 (2 F, d, 7 




Compound 87 (1.16 g, 2.3 mmol) was dissolved in dry THF (10 mL) and added slowly to a 
solution of compound 81 (495 mg, 2.5 mmol) and Pr'2NEt (970 g, 7.5 mmol) in dry DMF 
(30 mL) at 0°C under N2 for 3 h. The mixture was then gradually warmed to 20°C and 
stirred for 16 h. The evaporation residue, in EtOAc, was washed with cold 5% aq. citric 
acid and brine. Drying, evaporation and chromatography (petroleum ether / EtOAc /AcOH 
25:25:1) afforded 8 8  (600 mg, 50%) as a white solid: mp 95-97°C; 0.92 (3 H, d, 7 = 7.0 
Hz, Val-Me), 0.94 (3 H, d, 7 = 6 .6  Hz, Val-Me), 1.84 (3 H, s, 2-Me), 1.89 (3 H, s, 2-Me), 
2.10 (1 H, m, Val P-H), 3.25 (1 H, dd, 7 = 12.1, 5.3 Hz, 5-H), 3.35 (1 H, d, 7 =12.5 Hz, 5-
H), 3.90 (1 H, t, 7 = 9.8 Hz, Val a-H), 4.20 (1 H, t, 7 = 7.0 Hz, CtfCH20 ), 4.37 (1 H, dd, 7 
= 10.7, 7.0 Hz, CHO), 4.45 (1 H, dd, 7 = 10.7, 7.0 Hz, CHO), 5.43 (1 H, d, 7 = 10.1 Hz, 
NH), 5.52 (1 H, d, 7 = 5.3 Hz, 4-H), 7.28 (2 H, t, 7 = 7.4 Hz, Ar-H2), 7.38 (2 H, t, 7 = 7.4 
Hz, Ar-H2), 7.54 (2 H, d, 7 = 6 .6  Hz, Ar-H2), 7.75 (2 H, d, 7 = 7.4 Hz, Ar-H2); MS m/z 
483.1951 (M + H) (C26H3iN20 5S requires 483.1954).
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N-(l,l-DimethylethoxycarbonyI)-L-leucine pentafluorophenyl ester (90)
BocHN
BocLeuOH (2.00 g, 8.0 mmol) was stirred with pentafluorophenol (1.62 g, 8 .8  mmol) and 
DCC (1.82 g, 8 .8  mmol) in dry EtOAc (20 mL) at 0°C under N2 for 3 h. The mixture was 
filtered (Celite®) and the solid was washed with cold EtOAc. The filtrate was kept at 4°C 
for 16 h and filtered (Celite®). Evaporation gave 90 (2.50 g, 79%) as a solid: mp 49-53°C 
(lit143 mp 48-50°C); NMR 5H 1.02 (6  H, d, J = 6.3 Hz, 2 x Leu-Me), 1.47 (9 H, s, Bu'), 1.67 
(1 H, m, Leu P-H), 1.8 (2 H, m, Leu P-H, Leu y-H), 4.41 (0.1 H, m, Leu a-H), 4.62 (0.9 H, 
m, Leu a-H), 5.75 (0.1 H, br, NH), 4.92 (0.9 H, d, / =  8.2 Hz, NH); NMR 8 f  -162.1 (1.8 F, 
t, J = 21 Hz, 3 \5 ’-F2), -161.9 (0.2 F, t, J = 21.0 Hz, 3 \5 ’-F2), -157.6 (0.9 F, t, J = 22.4 Hz, 
4 ’-F), -157.4 (0.1 F, t, /  = 22.4 Hz, 4 ’-F), -152.7 (0.2 F, d, J = 19.7 Hz, 2’,6’-F2), -152.2 






Compound 90 (1.5 g, 3.8 mmol) was stirred with 81 (833 mg, 4.2 mmol) and Pr'2NEt (1.63 
g, 12.6 mmol) in dry DMF (40 mL) for 16 h. The evaporation residue, in EtOAc, was 
washed with cold 5% aq. citric acid, cold H20  and brine. Drying and evaporation afforded 
crude 91 (2.4 g) as a gummy oil: NMR 5h 0.81-0.90 (6  H, m, 2 x Leu-Me), 1.40 (9 H, s, 
Bu'), 1.50-1.60 (2 H, m, Leu p-H2, Leu y-H), 1.83 (3 H, s, 2-Me), 1.86 (3 H, s, 2-Me), 3.28 
(2 H, m, 5-H2), 4.17 (1 H, m, Leu a-H), 5.30 (1 H, d, J = 5.90 Hz, NH), 5.70 (1 H, m, 4-H); 






Compound 91 (1.50 g, 4.0 mmol) was stirred with pentafluorophenol (812 mg, 4.4 mmol) 
and DCC (908 mg, 4.4 mmol) in EtOAc (10 mL) at 0°C under N2 for 3 h. The mixture was 
filtered (Celite®) and the solid was washed with cold EtOAc. The filtrate was kept at 4°C 
for 16 h and filtered (Celite®). Evaporation gave crude 92 (2.3 g) as a pale yellow oil: 
NMR 8 h 0.88 (3 H, d, J = 6.4 Hz, Leu-Me), 0.90 (3 H, d, J = 6.4 Hz, Leu-Me), 1.44 (9 H, 
s, Bu'), 1.55-1.65 (2 H, m, Leu P-H2, Leu y-H), 1.86 (3 H, s, 2-Me), 1.91 (3 H, s, 2-Me), 
3.47 (1 H, dd, J = 12.1, 9.4 Hz, 5-H), 3.54 (1 H, dd, 7 =  12.7, 4.8 Hz, 5-H), 4.17 (1 H, dt, J 
= 2.7, 8.7 Hz, Leu a-H), 4.96 (1 H, d, J = 9.4, 4.8 Hz, 4-H), 6.17 (1 H, d, J = 8.5 Hz, NH); 
NMR 5f -161.5 (2 F, t, J =  17.1 Hz, 3’,5’-F2), -156.6 (1 F, t, / =  22.4 Hz, 4 ’-F), -152.1 (2 
F, d, J = 18.4 Hz, 2’,6’-F2). MS m/z 541.1797 (M + H) (C23H3oN2 0 5F5S requires 






4-Nitrophenylethylamine hydrochloride (375 mg, 1.85 mmol) was stirred with Et3N (375 
mg, 3.7 mmol) and 92 (1.00 g, 1.85 mmol) in CH2CI2 (5 mL) for 16 h. Evaporation and 
chromatography (EtOAc / hexane 1:1) afforded 93 (640 mg, 58%) as a white solid: mp 
108-109°C; NMR 8H0.84 (2.4 H, d, /  = 6.4 Hz, Leu-Me), 0.90 (2.4 H, d, J = 6.4 Hz, Leu- 
Me), 0.98 (1.2 H, d, J = 6.4 Hz, 2 x Leu-Me), 1.41 (7.2 H, s, Bu'), 1.43 (1.8 H, s, Bu'), 
1.60-1.70 (3 H, m, Leu p-H2, Leu y-H), 1.78 (2.4 H, s, 2-Me), 1.80 (2.4 H, s, 2-Me), 1.84
187
(0.6 H, s, 2-Me), 1.85 (0.6 H, s, 2-Me), 2.97 (2 H, t, /  = 7.0 Hz, ArCH2), 3.05 (1 H, d, /  = 
12.3 Hz, 5-H), 3.45 (2 H, m, ArCH2Ctf, 5-H), 3.85 (1 H, m, ArCH2Ctf), 4.11 (0.8 H, m, 
Leu a-H), 4.30 (0.2 H, m, Leu a-H), 4.81 (0.8 H, d, J = 8 .6  Hz, LeuNH), 4.92 (0.2 H, d, J 
= 8 .6  Hz, LeuNH), 5.30 (0.2 H, d, J = 7.0 Hz, 4-H), 5.42 (0.8 H, d, /  = 7.0 Hz, 4-H), 6.15 
(1 H, t, J = 5.1 Hz, NtfCH2), 7.41 (2 H, d, J = 8 .6  Hz, Ar 2,6-H2), 8.15 (0.4 H, d, /  = 8 .6  
Hz, Ar 3,5-H2), 8.19 (1.6 H, d, /  = 8 .6  Hz, Ar 3,5-H2); MS m/z 523:2596 (M + H) 






Compound 93 (5 mg, 9.6 pmol) was stirred in CF3C0 2H (100 pL) and CH2C12 (400 pL) 
for 15 min. Evaporation afforded 94 (quant.) as highly hygroscopic viscous oil: NMR 
(CD3OD) 5h 0.90 (3 H, d, J = 4.7 Hz, Leu-Me), 0.98 (3 H, d, J  = 4.3 Hz, Leu-Me), 1.60- 
1.70 (3 H, m, Leu p-H2, Leu y-H), 1.89 (3 H, s, 2-Me), 1.92 (3 H, s, 2-Me), 2.95-3.07 (3 
H, m, 5-H, AiCH2), 3.38-3.52 (2 H, m, ArCH2C//, 5-H), 3.70 (1 H, m, ArCH2OT), 3.95 (1 
H, m, Leu a-H), 5.08 (1 H, d, J = 6.2 Hz, 4-H), 7.52 (2 H, d, /  = 7.2 Hz, Ar 2,6-H2), 8.20 





HC1 was bubbled through 61 (90 mg, 180 pmol) in CH2C12 (5.0 mL) for 30 min.
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Evaporation afforded 96 (quant.) as a highly hygroscopic yellow solid: IR Vmax 3423 (NH), 
1793 (C=0), 1670 (amide I), 1521 (amide II) cm'1; NMR ((CD3)2SO) 8H 1.20 (3 H, d, 7 =
7.0 Hz, Ala p-H3), 1.74 (3 H, s, 2-Me), 1.77 (3 H, s, 2-Me), 3.17 (1 H, dd, 7 =  12.1, 10.2 
Hz, 5-H), 3.25 (1 H, dd, 7 =  12.1, 6 .6  Hz, 5-H), 4.10 (1 H, q, 7 = 7.0 Hz, Ala a-H), 4.68 (1 
H, dd, 7 = 10.2,6 .6  Hz, 4-H), 6.30 (3 H, br, N+H3); MS m/z 215 (M -  C6F50).
Pentafluorophenyl R-2,2-dimethyl-3-(L-vaIinyl)tetrahydrothiazole-2-carboxylate 
hydrochloride (97)
HC1 was bubbled through 62 (150 mg, 300 pmol) in CH2CI2 (5.0 mL) for 1 h. Evaporation 
afforded 97 (120 mg, 90%) as a white wax: IR Vmax 3433 (NH), 1790 (C=0), 1667 (amide
I), 1520 (amide II) cm’1; NMR ((CD3)2SO) 5H 0.82 (3 H, d, 7 = 6 .6  Hz, Val-Me), 0.99 (3 
H, d, 7 = 7.4 Hz, Val-Me), 1.75 (6  H, s, 2 x Me), 2.29-2.37 (1 H, d septet, 7 = 2.3, 7.0 Hz, 
Val p-H), 3.13 (1 H, dd, 7 =  11.5, 10.2 Hz, 5-H), 3.22 (1 H, dd, 7=11.5, 6.2 Hz, 5-H), 3.89 
(1 H, m, Val a-H), 4.60-4.64 (1 H, dd, 7 = 10.2, 6.2, Hz, 4-H), 5.94 (3 H, br, N+H3); NMR 
8 f  -171.5 (IF, tt, 7 = 23.7, 6 .8  Hz, 4 ’-F2), -165.1 (2 F, dd, 7 = 23.7, 19.6 Hz, 3’,5’-F2), -




HC1 was bubbled through 63 (130 mg, 230 pmol) in CH2CI2 (6.0 mL) for 1.5 h. 
Evaporation afforded 98 (quant.) as a colourless highly hygroscopic viscous oil: IR Vmax
189
3434 (NH), 1791 (C=0), 1669 (amide I), 1520 (amide H) c m 1; NMR ((CD3)2SO) 6 H 1.66 
(3 H, s, 2-Me), 1.74 (3 H, s, 2-Me), 2.75 (1 H, t, 7 = 11.3 Hz, 5-H), 3.04 (1 H, dd, 7 = 14.1,
4.5 Hz) and 3.06 (1 H, dd, 7 =  14.1,4.5 Hz) (Phe P-H2), 3.13 (1 H, dd, 7=  11.3, 5.7 Hz, 5- 
H), 4.34 (1 H, t, 7 = 4.5 Hz, Phe a-H), 4.46 (3 H, br, N ^ ) ,  4.60 (1 H, dd, 7 = 11.3, 5.7 Hz,
4-H), 7.25 (5 H, m, Ph-H5) 8.31 (1 H, s, NH); NMR 6 F -171.5 (2 F, tt, 7 = 22.4, 6 .6  Hz, 4 ’- 
F2), -165.1 (1 F, dd, 7 = 22.4, 19.7 Hz, 3’,5’-F2), -161.8 (2 F, dd, 7 = 19.7, 6 .6  Hz, 2 ’,6 ’- 
F2), MS m/z 475.1131 (M + H) (C2iH20F5N2O3S requires 475.1115), 291 (M -  C6F50).
6S,8aR-3,3,6-TrimethyltetrahydrothiazoIo[3,4-fl]pyrazine-5,8-dione (99)
V-NH
Compound 96 (190 mg, 480 jumol) was stirred with Et3N (97 mg, 1.0 mmol) in CH2CI2 
(5.0 mL) for 5 min. Evaporation and chromatography (EtOAc) afforded 99 (15 mg, 15%) 
as a white solid: mp 155.8°C (DSC): IR 3436 (NH), 1693 (C=0), 1652 (C=0) cm'1; 
NMR 8 h 1.46 (3 H, d, J = 7.0 Hz, 6 -Me), 1.85 (3 H, s, 3-Me), 1.89 (3 H, s, 3-Me), 3.25 (1 
H, dd, J = 12.5, 6 .6  Hz, 1-H), 3.30 (1 H, dd, J  = 12.5, 10.2 Hz, 1-H), 4.07 (1 H, ddq, J = 
0.8, 1.3, 7.0 Hz, 6 -H), 4.57 (1 H, dddd, J = 10.2, 6 .6 , 1.3, 0.8 Hz, 8 a-H), 7.28 (1 H, br, 
NH); MS m/z 368 (M + mNBA), 215.0862 (M + H) (C9H15N2O2S requires 215.0854); 
Found C, 50.43; H, 6.55; N, 12.9; C9H14N 2O2S requires C, 50.45; H, 6.58; N, 13.07%.
6S,8aR-3,3-Dimethyl-6-(l-methylethyl)tetrahydrothiazolo[3,4-a]pyrazine-5,8-dione
(100)
Compound 97 (90 mg, 190 pmol) was stirred with Et3N (39 mg, 380 pmol) in CH2CI2 (3.0 
mL) for 10 min. Evaporation and chromatography (EtOAc) afforded 100 (40 mg, 87 %) as 
a white solid: mp 186.4°C (DSC): IR (film) 3213 (NH), 1692 (C=0) cm'1; NMR
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((CD3)2SO) 8 h 0.83 (3 H, d, 7 = 7.0 Hz, CHMe), 1.0 (3 H, d, 7 = 7.0 Hz, CHMe), 1.76 (3 H, 
s, 3-Me), 1.77 (3 H, s, 3-Me), 2.34 (1 H, dseptet, 7 = 7.0, 2.3 Hz, C//Me2), 3.14 (1 H, dd, 7 
= 11.7, 10.2 Hz, 1-H), 3.23 (1 H, dd, 7=11.7, 5.9 Hz, 1-H), 3.34 (1 H, br, NH), 3.89 (1 H, 
dd, 7 = 2.3, 1.2 Hz, 6 -H), 4.64 (1 H, ddd, 7 = 10.2, 5.9, 1.2 Hz, 8 a-H); MS m/z 396 (M +





Compound 98 (80 mg, 170 pmol) was stirred with Et3N (34.0 mg, 340 pmol) in CH2C12 
(3.0 mL) for 1.5 h. Evaporation and chromatography (EtOAc) afforded 101 (40 mg, 81%) 
as a colourless gum: IR (film) Vmax 3377 (NH), 1794 (C=0), 1688 (C=0) cm'1; NMR 5h 
1.87 (3 H, s, 3-Me), 1.92 (3 H, s, 3-Me), 2.82 (1 H, dd, 7 = 14.4, 10.2 Hz, PhCH), 3.19 (1 
H, dd, 7 = 12.1, 10.3 Hz, 1-H), 3.26 (1 H, dd, 7 = 12.1, 5.9 Hz, 1-H), 3.56 (1 H, dd, 7 =
14.4, 3.9 Hz, PhCH), 4.24 (1 H, ddd, 7 = 10.3, 3.9, 0.8 Hz, 6 -H), 4.53 (1 H, dddd, 7 = 10.3,
5.9, 1.6, 0.8 Hz, 8 a-H), 5.82 (1 H, s, NH), 7.21-7.37 (5 H, m, Ph-H5); MS m/z 291.1169 (M 
+ H) (Ci5Hi8N20 2S requires 291.1167).
Pentafluorophenyl S-2,2-dimethyl-3-(N-(L-valinyl)tetrahydrothiazole-2-carboxylate 
hydrochloride (106)
HC1 was bubbled through 83 (110 mg, 200 pmol) in CH2C12 (5.0 mL) for 30 min. 
Evaporation afforded 106 (quant) as a pale yellow gummy solid: IR vmax 3412 (NH) cm'1; 
NMR ((CD3)2SO) 8 h 0.88 (3 H, d, 7 = 6 .6  Hz, Val-Me), 0.92 (3 H, d, 7 = 7.0 Hz, Val-Me),
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1.78 (3 H, s, 2-Me), 1.82 (3 H, s, 2-Me), 2.06 (1 H, m, Val P-H), 3.11 (1 H, dd, 7 = 11.7, 
10.9 Hz, 5-H), 3.22 (1 H, dd, 7 =11.7, 5.5 Hz, 5-H), 3.32 (3 H, br, N*H3), 4.64 (1 H, dd, 7 =
10.9, 5.5 Hz, 4-H), 5.19 (1 H, m, Val a-H); NMR 8p-171.46 (2 F, m, 3 \5 ’-F2), -165.12 (1 
F, dt, 7 = 23.7 Hz, 4 ’-F), -161.53 (2 F, dd, 7 = 19.7, 6 .6  Hz, 2 \6 ’-F2); MS m/z 427 (M + H), 




Compound 106 (90 mg, 190 pmol) was stirred with Et3N (39 mg, 380 pmol) in CH2C12 
(3.0 mL) for 10 min. Evaporation and chromatography (EtOAc) afforded 108 (28 mg, 
61%) as a white solid: mp 180-182°C: NMR ((CD3)2SO) 8H0.88 (3 H, d, J = 6 .6  Hz, 6 - 
CMe), 0.91 (3 H, d, J = 6 .6  Hz, 6 -CMe), 1.78 (3 H, s, 3-Me), 1.82 (3 H, s, 3-Me), 2.07 (1 
H, m, 6 -CH), 3.11 (1 H, dd, J = 11.7, 10.7 Hz, 1-H), 3.23 (1 H, dd, 7=11.7, 5.5 Hz, 1-H), 
3.40 (1 H, dd, 7 = 5.9, 3.5 Hz, 6 -H), 4.64 (1 H, dd, 7 = 10.7, 5.5 Hz, 8 a-H), 8.90 (1 H, d, 7 
= 3.5 Hz, NH); MS m/z 396 (M + mNBA), 243.1176 (M + H) (CnHi9N20 2S requires 




trifluoroacetate (107) and 6S,8aS-3,3-Dimethyl-6-isopropylmethyltetrahydro- 
thiazolo[3,4-a]pyrazine-5,8-dione (109)
(107) (109)
Compound 92 (700 mg, 1.30 mmol) was stirred with CF3CO2H (1 mL) and CH2CI2 (4 mL) 
for 20 min. Evaporation afforded 107 (quant.) as a gummy solid. This material (554 mg, 1 
mmol) was stirred with Et3N ( 2 0 2  mg, 2  mmol) in CH2CI2 (3.0 mL) for 30 min. 
Evaporation and chromatography (EtOAc) afforded 109 (150 mg, 59%) as a white solid: 
mp 153-155°C: NMR 8 H 0.95 (3 H, d, J = 6 .6  Hz, CHCtf3), 1-00 (3 H, d, J = 6 .6  Hz, 
CHC/73), 1.60-1.78 (3 H, m, 6-CHCH2CH), 1.88 (3 H, s, 3-Me), 1.89 (3 H, s, 3-Me), 3.23 
(1 H, dd, J = 12.1, 10.7 Hz, 1-H), 3.32 (1 H, dd, J =12.1, 5.7 Hz, 1-H), 3.87 (1 H, dt, 7 =
10.0, 5.0 Hz, 6 -H), 4.55 (1 H, dd, J = 10.7, 5.7 Hz, 8 a-H), 6.29 (1 H, br, NH); MS m/z 
257.1316 (C12H21N2O2S requires 257.1324).
N-(N-(L-y-glutamyl)-L-cysteinyI)glycine dimethyl ester hydrochloride (120), N-(S- 






HC1 was bubbled through glutathione 119 (1.5 g, 4.89 mmol) in MeOH (60 mL) for 1.5 h. 
The mixture was then stirred for 24 h. Evaporation afforded crude 120 as a white solid. 
This material (1.75 g, 5.19 mmol) was stirred with benzoyl chloride (1.82 g, 13 mmol) and
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Et3N (2.10 g, 21 mmol) in CH2CI2 (10 mL) under N2 for 3 h. The organic layer was 
washed with H2O and aq. HC1 (1 M). Drying, evaporation and recrystallisation (EtOAc) 
afforded 121 (680 mg, 24 %) as a white solid: mp 189-192°C: IR 3278 (NH), 1750 
(C=0), 1662 (amide I), 1638 (amide I), 1581 (amide II), 1545 (amide II) cm'1; NMR 
((CD3)2SO) 6h 1.99 (1 H, m, Glu P-H), 2.12 (1 H, m, Glu P-H), 2.32 (2 H, t, 7 = 7.8 Hz, 
Glu y-H2), 3.52. (1 H, dd, 7 = 13.3, 8 .6  Hz, Cys P-H), 3.61 (3 H, s, C 0 2Me), 3.65 (3 H, s, 0 
C 0 2Me), 3.82 (1 H, dd, 7 = 13.3, 5.3 Hz, Cys P-H), 3.84 (1 H, dd, 7 = 17.2, 5.9 Hz) and 
3.86 (1 H, dd, 7 = 17.2, 5.9 Hz) (Gly-H2), 4.43 (1 H, m, Glu a-H), 4.61 (1 H, dt, 7 = 5.3,
8 .6  Hz, Cys a-H), 7.45-7.92 (10 H, m, Ar), 8.36 (1 H, d, 7 =  8 .6  Hz, Cys-NH), 8.51 (1 H, t,
7 = 5.9 Hz, Gly-NH), 8.79 (1 H, d, 7 = 7.4 Hz, Glu-NH); MS m/z 544.17636 (M + H) 
(C26H30N3O8S requires 544.17536), Found C, 56.90; H, 5.34; N, 7.62; C26H30N3O8S 0.25 
H20  requires C, 56.98; H, 5.42; N, 7.67%.
N-(N-(N-Benzoyl-y-glutamyl)-L-cysteinyl)glycine dimethyl ester (122)
SH
P h ^ N ^  ^  ^C02Me
O
Compound 121 (100 mg, 180 pmol) in MeOH (10 mL) was stirred at 30°C for 48 h. The 
evaporation residue was recrystallised (hexane) to afford 122 (55 mg, 57%) as a white 
solid: 203-205°C; NMR ((CD3)2SO) 6 H 1.99 (1 H, m, Glu P-H), 2.09 (1 H, m, Glu P-H), 
2.31 (2 H, m, Glu y-H2), 2.82 (1 H, dd, 7=  13.5, 8 .6  Hz, Cys p-H), 3.10 (1 H, dd, 7 =  13.5,
4.7 Hz, Cys p-H), 3.63 (3 H, s, Me), 3.64 (3 H, s, Me), 3.82 (2 H, d, 7 = 5.9 Hz, Gly-H2),
4.45 (1 H, m, Glu a-H), 4.60 (1 H, dt, 7 = 4.7, 8 .6  Hz, Cys a-H), 7.48-7.89 (5 H, m, Ph- 
H5), 8.28 (1 H, d, 7 = 8 .6  Hz, Cys-NH), 8.46 (1 H, t, 7 = 5.9 Hz, Gly-NH), 8.82 (1 H, d, 7 =





L-cystine hydrochloride 124 (2.50 g, 10.4 mmol) was stirred with benzoyl chloride (2.92 g, 
21 mmol) and NaOH (2.10 g, 52.5 mmol) in H20  (20 mL) for 20 h. The aq. phase was 
washed twice with Et20 , acidified (1 M aq. HC1), filtered and washed with hot H20 .  
Drying under vacuum afforded 125 (2.50 g, 54%) as a white solid: mp 179-181°C (lit155 
mp 178-180°C); NMR ((CD3)2SO) 8 H 3.08 (2 H, dd, J = 13.7, 9.4 Hz, 2 x  P-H), 3.39 (2 H, 
dd, J = 13.7, 3.9 Hz, 2 x p-H), 4.69 (2 H, ddd, J  = 9.4, 7.8, 3.9 Hz, 2 x  a-H), 7.43-7.84 (10 
H, m, 2 x  Ph-Hs), 8.65 (2 H, d, J = 7.8 Hz, 2 x NH).
N,N'-Dibenzoyl-L-cystine dimethyl ester (126)
M e02C
Compound 125 (500 mg, 1.1 mmol) was boiled under reflux with H2SC>4 (1.0 mL) in 
MeOH (100 mL) for 24 h. Aq. NaHC03 was added until no further bubbling occurred. The 
evaporation residue was washed with H20 . Drying under vacuum afforded 126 (530 mg 
quant.) as a white solid: mp 170-173°C (lit222 mp 168-169°C); NMR ((CD3)2SO) 8H3.13 (2
HN C 02Me
H, dd, J = 13.7, 9.8 Hz, 2 x  p-H), 3.27 (2 H, dd, /  = 13.7, 4.7 Hz, 2 x p-H), 3.64 (6  H, s, 2 
x Me), 4.74 (2 H, ddd, J = 9.8, 7.8, 4.7 Hz, 2 x  a-H), 7.42-7.81 (10 H, m, 2 x  Ph-H5), 8.91 







Compound 126 (500 mg, 1.1 mmol) was stirred with hydrazine hydrate (820 mg, 25 mmol) 
in MeOH (10 mL) for 16 h. The filtered solid was washed with MeOH. Drying afforded 
128 (300 mg, 60%) as a white solid: mp 205-207°C (lit223 mp 206-207°C);; NMR 8 h 3.02 
(2 H, dd, J = 13.3, 9.8 Hz, 2 x  0-H), 3.20 (2 H, dd, J = 13.3, 5.1 Hz, 2 x p-H), 4.73 (2 H, 
ddd, J = 9.8, 8.2, 5.1 Hz, 2 x a-H), 7.44 (2 H, t, J = 7.4 Hz, 2 x Ph 4-H), 7.52 (4 H, t, /  =
7.4 Hz, 2 x Ph 3,5-H2), 7.85 (4 H, d, J = 7.4 Hz, 2 x 2,6-H2), 8.62 (2 H, d, J = 8.2 Hz, 2 x  
PhCONH), 9.37 (2 H, br, 2 x NHNH2); MS m/z 477.1370 (M + H) (C20H25N6O2S2 requires 
477.1379).




L,L-Cystine dimethyl ester dihydrochloride 124 (5.0 g, 15 mmol) was dissolved in 
anhydrous butylamine (100 mL) at -78°C. The solution was warmed to ambient 
temperature and heated under reflux for 5 h. Evaporation afforded a sticky yellow solid 
which was dissolved in MeOH and acidified (HC1). Evaporation afforded crude 129 (14.8 
g) as a yellow viscous oil; MS m/z 351.1874 (M + H) (ChH3iN4 0 2S2 requires 351.1888).
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Crude 128 (14.7 mmol) was stirred with NaOAc (10 g) in H2O (100 mL) and Et2 0  (100 
mL). Benzoyl chloride (9.1 g, 65 mmol) was added at 0°C and the mixture was stirred 
vigorously for 4 h. The Et2 0  layer was separated. Drying, evaporation and chromatography 
(EtOAc / hexane 1:1) afforded 130 (500 mg, 951 pmol) as a white solid mp 154-156°C: 
[a ]D20 + 40.63° (c 3.2 x 10'3, CHC13); IR 3286 (NH), 1634 (amide I), 1602 (amide I), 
1557 (amide II), 1540 (amide II) cm'1; NMR 6H0.90 (6  H, t, J = 7.0 Hz, 2 x Me), 1.41 (4 
H, sextet, J = 7.0 Hz, 2 x Ctf2Me), 1.58 (4 H, quintet, J = 7.0 Hz, 2 x NHCH2Gtf2), 3.01 (2 
H, dd, 7 = 14.8, 6.2 Hz, 2 x  1-H), 3.07 (2 H, dd, 7 =  14.8, 6.2 Hz, 2 x 1-H ), 3.33 (4 H, m, 2 
x NHCtf2), 5.43 (2 H, q, 7 = 6.2 Hz, 2 x  2-H), 7.46-7.58 (8  H, m, 2 x Ar 3,4,5-H3 + 2 x  
NH), 7.85 (4 H, m, 2 x Ar 2,6-H2), 7.96 (2 H, t, 7 = 5.5 Hz, 2 x  NHBu); MS m/z 527.2696 
(M + H) (C28H39N4O4S requires 527.2692); Found: C, 62.30; H, 7.32; N, 10.37; 
C28H38N4O4S requires C, 63.85; H, 7.27; N, 10.63%. Further elution gave the other 
diastereoisomer 131 (310 mg, 589 pmol) as a white solid: mp 178-180°C: [(x] d 20 +  0.0° (c 
0.003, CHCI3); IR 3287 (NH), 1633 (amide I), 1602 (amide I), 1560 (amide II), 1532 
(amide II) cm'1; NMR 5H0.93 (6  H, t, J = 7.4 Hz, 2 x  Me), 1.40 (4 H, sextet, J = 7.4 Hz, 2 
x Ctf2Me), 1.56 (4 H, quintet, J = 7.4 Hz, 2 x  NCH2Ctf2), 3.14 (4 H, d, J = 6.2 Hz, 2 x 1- 
H2), 3.33 (4 H, m, 2 x NCH2), 4.90 (2 H, q, J = 6.2 Hz, 2 x  1-H), 7.33 (2 H, t, J = 5.5 Hz, 2 
x NHBu), 7.44 (6  H, m, 2 x Ph 3,5-H2 + 2 x  NH), 7.53 (2 H, m, 2 x Ph 4-H), 7.81 (4 H, m, 






L,L-Cystine bis(naphth-2-yl)amide (500 mg, 1.0 mmol) was stirred with AC2O (7 mL) and 
Et3N (206 mg, 2.0 mmol) for 16 h. The evaporation residue was washed with H2O. Drying 
under vacuum afforded 133 (0.54 g, 92%) as a white solid: mp 250-252°C; IR Vmax 3289 
(NH), 1647 (amide I), 1604 (amide I), 1536 (amide II), 1505 (amide II) cm"1; NMR 
((CD3)2SO) 8 h 1.91 (6  H, s, 2 x Me), 3.03 (2 H, dd, J = 13.3, 8.4 Hz, 2 x P-H), 3.25 (2 H, 
dd, J  = 13.3, 5.9 Hz, 2 x p-H), 4.78 (2 H, dt, J = 8.4, 5.9 Hz, 2 x a-H), 7.40 (2 H, dt, J =
1.2 Hz, 7.0 Hz) and 7.46 (2 H, dt, /  = 1.2, 7.0 Hz) (2 x Ar 6,7-H2), 7.63 (2 H, dd, J  = 8 .6 ,
2.0 Hz, 2 x Ar 3-H), 7.85 (6  H, m, 2 x Ar 4,5,8-H3), 8.29 (2 H, d, J  = 2.0 Hz, 2 x  Ar 1-H),
8.45 (2 H, d, J = 7.8 Hz, 2 x  NHAc), 10.41 (2 H, s, 2 x  NH); MS m/z 575.1782 (M + H) 
(C3oH31N40 4S2 requires 575.1787); Found: C, 60.70; H, 5.31; N, 9.18; C30H30N4O4S2 1.0 






Compound 133 (250 mg, 0.44 mmol) was boiled under reflux with propane-1,3-dithiol 
(480 mg, 4.4 mmol) and Pr2NEt (142 mg, 1.1 mmol) in THF (10 mL) for 48 h. The 
evaporation residue, in CH2CI2, was washed twice with cold aqueous H2S 0 4 (1 M) and 
brine and was dried. The evaporation residue was washed with hexane and dried to afford
198
134 (190 mg, 150%) as a white solid: mp 204-207°C; IR Vmax 3271 (NH), 1646 (amide I), 
1542 (amide II), 1508 (amide II) cm'1; NMR 6 H 1.94 (1 H, dd, J = 10.5, 7.0 Hz, SH), 2.15 
(3 H, s, Me), 2.81 (1 H, ddd, J = 10.5, 7.4, 3.7, Hz, P-H), 3.24 (1 H, ddd, J = 1A, 7.0, 3.7 
Hz, P-H), 4.80 (1 H, dt, J = 3.7, 7.0 Hz, a-H), 6.61 (1 H, d, J = 6 .6  Hz, NHAc), 7.47 (3 H, 
.m, Ar-H3), 7.79 (3 H, m, Ar-H3), 8.19 (1 H, d, J = 2.0 Hz, Ar 1-H), 8.74 (1 H, brs, CONH); 
MS m/z 288.0932 (M) (Q sH i^ C ^ S  requires 288.0932).
N-Acetyl-S-(l-methoxy-l-methylethyl)cysteine naphth-2-yIamide (135) and N-acetyl- 
S-(l-methylethenyl)cysteine naphth-2-ylamide (136)







Compound 134 (50 mg, 0.17 mmol) was boiled under reflux in 2,2-dimethoxypropane (70 
ml), 4-methylbenzenesulfonic acid hydrate (8.0 mg, 40 pmol) and CH2CI2 (3 mL) for 3 h, 
after which CH2CI2 (20 mL) and H2O (10 mL) were added. The organic layer was 
extracted and washed with H2O. Drying, evaporation and chromatography (EtOAc / 
hexane 9:1) afforded 135 (30 mg, 54%) as a colourless oil; NMR §h2.03 (3 H, s, Me), 2.10 
(3 H, s, COMe), 3.17 (1 H, dd, J = 14.1, 7.4 Hz, p-H), 3.30 (1 H, dd, J = 14.1, 6.2 Hz, P- 
H), 4.87 (1 H, dd, J = 7.4, 6.2 Hz, a-H), 5.04 (1 H, brs, =CH), 5.13 (1 H, s, =CH), 6.59 (1 
H, d, J  = 7.0 Hz, AcNH), 7.45 (3 H, m, Ar 3,6,7-H3), 7.75 (3 H, m, Ar 4,5,8-H3), 8.19 (1 
H, d, 7 =  2.0 Hz, Ar 1-H), 8.85 (1 H, brs, NH); MS m/z 361.1589 (M + H) (Ci9H25N20 3S 
requires 361.1586). Further elution gave 136 (30 mg, 49%) as a white solid: mp 137- 
138°C; NMR 6 H 1.56 (3 H, s, Me), 1.58 (3 H, s, Me), 2.09 (3 H, s, COMe), 3.03 (1 H, dd, J 
= 13.7, 6.2 Hz, P-H), 3.10 (1 H, dd, J = 13.7, 6.2 Hz, P-H), 4.93 (1 H, dt, J  = 7.8, 6.2 Hz, 
a-H), 7.01 (1 H, d, J = 7.8 Hz, AcNH), 7.39 (2 H, m, Ar 6,7-H2), 7.46 (1 H, dd, J = 9.0,
2.0 Hz, Ar 3-H), 8.2 (1 H, d, 7 =  1.6 Hz, Ar 1-H), 9.2 (1 H, brs, NH); MS m/z 361.1589 (M 
+ H) (Ci9H24N20 3S requires 361.1586).
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L-Valine methyl ester hydrochloride (141)
HC1.H2N
o
L-Valine (10.0 g, 85.5 mmol) was stirred with SOCI2 (50 mL) in MeOH (500 mL) at 40°C 
for 24 h. Evaporation afforded 141 (11.1 g, 78%) as a white solid: mp 166-169°C (lit162 
mp 171-173°C); NMR ((CD3)2SO) 5H 0.93 (3 H, d, J =  7.0 Hz, Val-Me), 0.98 (3 H, d, J =
7.0 Hz, Val-Me), 2.19 (1 H, m, Val p-H), 3.74 (3 H, s, OMe), 3.84 (1 H, m, Val a-H), 8.61 
(3 H, br, hTHs).




N-(l,l-Dimethylethoxycarbonyl)-L-glutamirie (2.78 g, 11.3 mmol) was stirred with HOBt 
(1.68 g, 12.4 mmol) and DCC (3.49 g, 16.9 mmol) in CH2CI2 (150 mL) at 0°C for 1 h. 
Pr^NEt (2.92 g, 22.6 mmol) was added, followed by 141 (1.89 g, 11.3 mmol) in CH2CI2 
(50 mL) and the mixture was stirred for 24 h. The mixture was kept at 4°C for 16 h and 
filtered (Celite®). The filtrate was washed with aq. citric acid (10%), aq. NaHC03 and 
H20 . Drying, evaporation and chromatography (EtOAc —> EtOAc/MeOH 1:1) afforded 
142 (2.90 g, 71%) as a white solid: mp 145-148°C; NMR 5H 0.93 (3 H, d, J = 6 .6  Hz, Val- 
Me), 0.96 (3 H, d, J = 6 .6  Hz, Val-Me), 1.43 (9 H, s, Bu1), 2.04 (2 H, m, Gin p-H2), 2.21 
(1 H, m, Val P-H), 2.42 (2 H, t, /  = 6 .6  Hz, Gin y-H2), 3.73 (3 H, s, OMe), 4.26 (1 H, brq, J 
= 7.4 Hz, Gin a-H), 4.48 (1 H, dd, /  = 8.4, 5.1 Hz, Val a-H), 5.59 (1 H, d, J = 7.4 Hz, Gln- 
NH), 5.84 (1 H, s, CONH), 6.40 (1 H, s, CONH), 7.59 (1 H, d, J = 8.4 Hz, Val NH); MS 
m/z 741 (2M + Na), 719 (2M + H), 382 (M + Na), 360.2142 (M + H) (Ci6H30N3O6 requires 







Compound 142 (890 mg, 2.5 mmol) was stirred with NaOH (2.0 g, 50 mmol) in MeOH (30 
mL) for 2 h. H2O (10 mL) was added and MeOH was evaporated. The aqueous solution 
was brought into neutrality with cold aq. citric acid ( 1 0 %) and extracted several times with 
EtOAc. Also, the aqueous layer was saturated with NaCl and extracted further with EtOAc. 
Drying and evaporation of the combined extracts afforded 143 (550 mg, 64%) as a white 
solid: mp 86-89°C (lit224mp not reported); NMR ((CD3)2SO) 8 h 0.87 (6  H, d, /  = 7.0 Hz, 2 
x Val-Me), 1.37 (9 H, s, Bul), 1.66 (1 H, m, Gin P-H), 1.83 (1 H, m, Gin P-H), 2.10 (3 H, 
m, Gin y-H2,Val P-H), 3.94 (1 H, dt, J = 8 .6 , 5.5 Hz, Gin a-H), 4.15 (1 H, dd, J = 8 .6 , 5.5 
Hz, Val a-H), 6.76 (1 H, s, CONH), 6.94 (1 H, d, J = 8.2 Hz, Gin NH), 7.25 (1 H, s, 
CONH), 7.75 (1 H, d, J = 8 .6  Hz, Val NH); MS m/z 346.1975 (M + H) (Q 5H28N3O6 
requires 346.1978).




BocPheOH (10.0 g, 37.7 mmol) was stirred with HOBt (5.10 g, 37.7 mmol) and DCC 
(7.80 g, 37.7 mmol) in CH2C12 (250 mL) at 0°C for 1 h. Compound 141 (6.30 g, 37.7 
mmol) in CH2CI2 ( 1 0 0  mL) was added in the presence of Et3N (7.60 g, 75.4 mmol) and the 
mixture was stirred for 48 h. The mixture was kept at 4°C for 16 h and filtered through 
Celite®. The solution was washed with 10% aq. citric acid, aq. NaHCC>3 and H2O. Drying, 
evaporation and recrystallisation (EtOAc / hexane) afforded 147 (4.50 g, 33%) as a white 
solid: mp 115-118°C (lit22S mp 115-117°C); NMR 8H 0.84 (3 H, d, J = 7.0 Hz, Val-Me), 
0.87 (3 H, d, J = 7.0 Hz, Val-Me), 1.42 (9 H, s, Bu'), 2.11 (1 H, d septet, J = 5.0, 7.0 Hz,
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Val p-H), 3.07 (2 H, d, J = 7.0 Hz, Phe P-H2), 3.68 (3 H, s, OMe), 4.34 (1 H, brq, J = 6 .6  
Hz, Phe a-H), 4.46 (1 H, dd, J = 8 .8 , 5.1 Hz, Val a-H), 4.99 (1 H, br, Phe NH), 6.34 (1 H, 





Compound 147 (1.0 g, 2.6 mmol) was stirred with NaOH (1.0 g, 26 mmol) in MeOH (15 
mL) and H20  (15 mL) for 1 h. The mixture was concentrated and EtOAc (25 mL) was 
added. The mixture was brought into neutrality with cold 10% aq. citric acid and extracted 
with EtOAc. Drying and evaporation afforded 148 (850 mg, 8 8 %) as a white solid: mp 77- 
78°C (lit226 mp 77-78°C); NMR 8 H 0.84 (3 H, d, 7 = 7.0 Hz, Val-Me), 0.91 (3 H, d, J = 7.0 
Hz, Val-Me), 1.4 (9 H, s, Bu'), 2.17 (1 H, d septet, J = 4.7, 6.7 Hz, Val p-H), 3.07 (2 H, m, 
Phe P-H2), 4.34 (1 H, m, Phe a-H), 4.46 (1 H, dd, J  = 8.4 ,4 .7  Hz, Val a-H), 5.10 (1 H, br, 










BocPheValOH (148) (200 mg, 55 pmol) was stirred with pyridine (44 mg, 55 pmol) in dry 
CH2C12 (5 mL) and added slowly to cyanuric fluoride (222 mg, 165 pmol) in dry CH2C12 
(5 mL). The mixture was stirred under nitrogen at -10°C for 2 h. The mixture was washed 
with ice-water (3 x 20 mL). Drying and evaporation afforded crude 149 (40 mg, 14 %). 
This material (550 pmol) was dissolved in CH2C12 (3 mL) and added to 4- 
nitrophenylethylamine hydrochloride (168 mg, 830 pmol), Et3N (172 mg, 1.7 mmol) and 
DMAP in CH2C12 (3 mL) under N2. The mixture was stirred for 16 h and the evaporation
202
residue was washed with EtOAc (3mL) to afford 150 (100 mg, 36%) as a buff solid: mp 
202-203°C; NMR ((CD3)2SO) 6 H 0.76 (6  H, d, 7 = 6.7 Hz, 2 x Val-Me), 1.28 (9 H, s, Bu‘), 
1.85 (1 H, m, Val p-H), 2.71 (1 H, dd, 7 =  13.5, 10.6 Hz, Phe p-H), 2.85 (2 H, t, 7 = 7.0 Hz, 
ArCH2), 2.91 (1 H, dd, 7 = 13.5, 4.1 Hz, Phe P-H), 3.34 (2 H, m, NCH2), 4.07 (1 H, dd, 7 = 
9.1, 7.0 Hz, Val a-H), 4.17 (1 H, ddd, 7 = 10.3, 8.5, 4.1 Hz, Phe a-H), 7.03 (1 H, d, 7 = 8.5 
Hz, Phe NH), 7.12-7.26 (5 H, m, Ph-H5), 7.47 (2 H, d, 7 = 8 .8  Hz, Ar 2,6-H2), 7.64 (1 H, d, 
7 = 8 .8  Hz, Val NH), 8.06 (1 H, t, 7 = 5.9 Hz, NH), 8.11 (2 H, d, 7 = 8 .8  Hz, Ar 3,5-H2); 





lS-2-pyrrolidinone-5-carboxylic acid 153 (5.0 g, 39 mmol) was boiled under reflux with 
Et3N (3.92 g, 39 mmol) and benzyl choride (5.4 g, 43 mmol) in THF (50 mL) for 5 d. 
After cooling, H20  (50 mL) was added and the THF was evaporated. The evaporation 
residue was extracted with CH2C12 (3 x  50mL). Drying and evaporation afforded the crude 
benzyl pyroglutamate as oil. The oil was stirred with Et3N (3.92 g, 38.8 mmol), Boc20  
(16.9 g, 77.6 mmol) and DMAP (2.8 g, 39 mmol) in CH2C12 (150 mL) at 0°C for 1 h and at 
20°C for 16 h. The evaporation residue, in CH2C12, was washed with cold 5% aq.citric acid 
and brine. Drying and evaporation afforded 151 (9.0 g, 72%) as buff solid: mp 62-65C 
(lit.179 mp 57-59°C); NMR 8H 1.41 (9 H, s, Bul), 2.05 (1 H, ddt, 7 =  12.8, 10.3, 3.3 Hz, Pyg 
P-H), 2.32 (1 H, ddt, 7 = 12.8, 9.8, 9.4 Hz, Pyg P-H), 2.47 (1 H, ddd, 7 = 17.6, 9.4, 3.5 Hz, 
Pyg y-H), 2.60 (1H, ddd, 7 = 17.5, 10.3, 9.8 Hz, Pyg y-H), 4.62 (1 H, dd, 7 = 9.4, 3.3 Hz, 




Compound 151 (15.0 g, 47 mmol) was stirred with 10% Pd/C (450 mg) in MeOH (300 
mL) under H2 for 6  h. Filtration (Celite®) and evaporation afforded 154 (10.0 g, 93%) as a 
white solid: mp 65-67°C (lit.178mp 77-80°C); NMR ((CD3)2SO) 6 H 1.42 (9 H, s, Bu‘), 1.90
N-(S-l-(l,l-Dimethylethoxycarbonyl)pyrrolidine-2-carbonyI)-L-valine phenybnethyl 
ester (155)
Compound 154 (10.0 g, 43.7 mmol) was stirred with HOBt (6.50*g, 48.1 mmol) and DCC 
(9.92 g, 48.1 mmol) in CH2C12 (200 mL) at 0°C for 1 h. L-ValOBn (16.60 g, 43.7 mmol) 
in CH2C12 (50 mL) was added in the presence of Pr'2NEt (11.30 g, 87.4 mmol) and the 
mixture was stirred for 24 h. The mixture was kept at 4°C for 16 h and filtered (Celite®). 
The solution was washed cold 5% aq. citric acid, aq. NaHCC>3 and H20 . Drying, 
evaporation and chromatography (EtOAc) afforded 155 (13.0 g, 71%) as a white solid: mp 
96-98°C; NMR 6H 0.87 (3 H, d, /  = 7.0 Hz, Val-Me), 0.93 (3 H, d, J = 7.0 Hz, Val-Me), 
1.51 (9 H, s, Bul), 2.20 (3 H, m, Val P-H, Pyg P-H2), 2.46 (1 H, ddd, / =  17.6, 8.5, 3.5 Hz, 
Pyg y-H), 2.73 (1 H, dt, J = 17.6, 10.5 Hz, Pyg y-H), 4.57 (1 H, dd, J = 7.8, 3.1 Hz, Pyg a- 
H), 4.60 (1 H, dd, J = 9.0, 4.7 Hz, Val a-H), 5.14 (1 H, d, /  = 12.1 Hz) and 5.20 (1 H, d, J 
= 12.1 Hz) (CH2Ph), 6.46 (1 H, d, /  = 9.0 Hz, Val NH), 7.35 (5 H, m, Ph-H5); MS m/z 859 
(2 M + Na), 837 (2 M + H), 737 (2 M + H - Boc), 441 (M + Na), 419.2192 (M + H) 
(C22H3iN20 6 requires 410.2182), 319 (M -  Boc).
Boc o









Compound 155 (7.50 g, 17.9 mmol) was stirred with 10% Pd/C (400 mg) in MeOH (300 
mL) under H2 for 16 h. Filtration (Celite®) and evaporation afforded 156 (5.60 g, quant.) 
as a white solid: mp 152-155°C; NMR ((CD3)2SO) 6 H 0.91 (3 H, d, /  = 7.0 Hz, Val-Me), 
0.92 (3 H, d, /  = 7.0 Hz, Val-Me), 1.39 (9 H, s, Bul), 1.80 (1 H, m, Pyg p-H), 2.10 (1 H, 
octet, J = 7.0 Hz, Val p-H), 2.2-2.4 (3 H, m, Pyg p,y-H3), 4.16 (1 H, dd, J = 8.2, 7.0 Hz, 
Val a-H), 4.68 (1 H, dd, J = 9.0, 2.3 Hz, Pyg a-H), 8.32 (1 H, d, J = 8 .6  Hz, NH); MS m/z 
679 (2 M + Na), 657 (2 M + H), 557 (2 M + H - Boc), 351 (M + Na), 329.1721 (M + H) 







Compound 156 (200 mg, 610 pmol) was stirred with pentafluorophenyl trifluoroacetate 
(188 mg, 671 pmol) and pyridine (53 mg, 671 pmol) in dry DMF for 1 h. The mixture was 
diluted with EtOAc (20 mL) and washed with cold 5% aq. citric acid and 5% aq. NaHC03. 
Drying and evaporation afforded 157 (250 mg, 83%) as a highly colourless viscous oil; 
NMR 5h 1.05 (3 H, d, J = 7.0 Hz, Val-Me), 1.07 (3 H, d, J = 6 .6  Hz, Val-Me), 1.52 (9 H, s, 
Bu‘), 2.26 (2 H, m, Val p-H, Pyg p-H), 2.42 (1 H, m, Pyg p-H), 2.50 (1 H, m, Pyg y-H), 
2.75 (1 H, m, Pyg y-H), 4.62 (1 H, dd, J = 7.8,3.1 Hz, Pyg a-H), 4.89 (1 H, dd, J = 8 .6 ,5.1 
Hz, Val a-H), 6.64 (1 H, d, J = 8 .6  Hz, NH); NMR 6P -161.2 (2 F, dd, J = 20.9, 18.0 Hz, 
3’,5’-F2), -156.4 (1 F, t, J = 20.9 Hz, 4 ’-F), -151.6 (2 F, d, J  = 18.0 Hz, 2’,6’-F2); MS m/z 
495.1571 (M + H) (C2iH24N206F5 requires 495.1555), 395 (M -  Boc), 494 (M + Na).
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S-N-(N-(S-l-(l,l-Dimethylethoxycarbonyl)pyrroIidine-2-carbonyl)valyl)-2,2- 
dimethyltetrahydrothiazole-4-carboxylic acid (158a and b)
NBoc
O
Compound 157 (750 mg, 1.52 mmol) was stirred with 81 (326 mg, 1.65 mmol) and Pr^NEt 
(640 mg, 4.95 mmol) in dry DMF (100 mL) for 16 h. The evaporation residue, in EtOAc, 
was washed with cold 5% aq. citric acid and brine. Drying, evaporation and 
chromatography (EtOAc / AcOH 49:1) afforded 158a (300 mg, 42%) as a white solid: mp 
166-168°C; NMR 5H 0.92 (3 H, d, J = 6 .6  Hz, Val-Me), 0.95 (3 H, d, J = 6 .6  Hz, Val-Me), 
1.50 (9 H, s, B u \  1.83 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me), 2.00-2.16 (2 H, m, Val P-H, 
Pyg p-H), 2.25 (1 H, m, Pyg p-H), 2.45 (1 H, ddd, J = 17.7, 9.4, 2.7 Hz, Pyg y-H), 2.69 (1
H, dt, J = 17.7, 9.8 Hz, Pyg y-H), 3.26 (1 H, dd, J = 12.1, 5.9 Hz, 5-H), 3.39 (1 H, d, J = 
12.1 Hz, 5-H), 4.25 (1 H, t, /  = 9.4 Hz, Val a-H), 4.55 (1 H, dd, J = 9.0, 2.0 Hz, Pyg a-H), 
5.54 (1 H, d, J = 5.1 Hz, 4-H), 6.83 (1 H, d, /  = 9.4 Hz, Val-NH); MS m/z 472.2129 (M + 
HHC21H34N3O7S requires 472.2117), 372 (M -  Boc), 625 (M + mNBA + H), 742 ( 2 x (M 
-Boc)). Minor peaks were observed corresponding to a rotamer. Further elution gave 158b 
(70 mg, 10%) as a white solid: mp 149-151°C; NMR 5h 0.93 (3 H, d, / =  6 .6  Hz, Val-Me),
I.01 (3 H, d, J = 6 .6  Hz, Val-Me), 1.50 (9 H, s, Bul), 1.83 (3 H, s, 2-Me), 1.87 (3 H, s, 2- 
Me), 1.95 (2 H, m, Val P-H, Pyg P-H), 2.45 (1 H, m, Pyg p-H), 2.48 (1 H, ddd, J = 17.4,
9.4, 2.7 Hz, Pyg y-H), 2.70 (1 H, dt, J  = 17.4, 9.8 Hz, Pyg y-H), 3.26 (1 H, dd, J = 11.7, 5.5 
Hz, 5-H), 3.43 (1 H, d, /  = 11.7 Hz, 5-H), 4.52 (1 H, dd, J = 9.4, 2.7 Hz, Pyg a-H), 4.78 (1 
H, dd, J = 9.4, 6 .6  Hz, Val a-H), 5.02 (1 H, d, J = 5.5 Hz, 4-H), 7.07 (1 H, d, J = 9.4 Hz, 





Compound 158a (100 mg, 212 pmol) was stirred with pentafluorophenyl trifluoroacetate 
(65 mg, 233 pmol) and pyridine (18 mg, 233 pmol) in dry DMF (1 mL) for 1 h. The 
mixture was diluted with EtOAc (20 mL) and washed with cold 5% aq. citric acid and 5% 
aq. NaHC0 3 . Drying, evaporation and recrystallisation (EtOAc / hexane) afforded 159 
(125 mg, 93%) as a white solid: mp 150-152°C; NMR 5H 0.92 (3 H, d, /  = 6 .6  Hz, Val- 
Me), 0.96 (3 H, d, J = 6 .6  Hz, Val-Me), 1.54 (9 H, s, Bul), 1.87 (3 H, s, 2-Me), 1.92 (3 H, s, 
2-Me), 2.15 (2 H, m, Val P-H, Pyg P-H), 2.26 (1 H, m, Pyg P-H), 2.50 (1 H, ddd, J = 17.2,
9.0, 2.7 Hz, Pyg y-H), 2.71 (1 H, ddd, J = 17.2, 10.5, 9.4 Hz, Pyg y-H), 3.46 (2 H, m, 5- 
H2), 4.12 (1 H, t, J = 8 .6  Hz, Val a-H), 4.58 (1 H, dd, / =  9.0, 2.3 Hz, Pyg a-H), 6.14 (1 H, 
dd, J = 4.3, 2.3 Hz, 4-H), 6.83 (1 H, d, J = 8 .6  Hz, Val NH); NMR 6 F -161.1 (2 F, dd, J =
21.0, 18.4 Hz, 3’,5’-F2), -156.4 (1 F, t, J = 21.0 Hz, 4 ’-F), -151.4 (2 F, d, J = 17.1 Hz, 
2’,6’-F2); MS m/z 1298 (2 M + Na), 1276 (2 M + H), 660.1779 (M + Na) 




4-Nitrophenylethylamine hydrochloride (426 mg, 2.1 mmol) was stirred with Et3N (425 
mg, 4.2 mmol) and 159 (1.34 g, 2.1 mmol) in CH2C12 (10 mL) for 5 h. Evaporation and 
chromatography (EtOAc) afforded 160 (900 mg, 69%) as a buff solid: mp 115-117°C; 
NMR 5h 0.77 (3 H, d, J = 6 .6  Hz, Val-Me), 0.83 (3 H, d, J = 6 .6  Hz, Val-Me), 1.43 (9 H, 
s, Bul), 1.70 (3 H, s, 2-Me), 1.74 (3 H, s, 2-Me), 1.9-2.2 (3 H, m, Val P-H, Pyg p-H2), 2.36
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(1 H, ddd, J  = 17.6, 9.4, 2.7 Hz, Pyg y-H), 2.57 (1 H, m, Pyg y-H), 2.90 (2 H, t, J  = 7.4 Hz, 
ArCH2), 2.93 (1 H, d, J = 12.5 Hz, 5-H), 3.28 (1 H, dd, J = 12.5, 6 .6  Hz, 5-H), 3.40 (1 H, 
m, NHC7/), 3.65 (1 H, m, NHC7/), 4.13 (1 H, t, J = 8.2 Hz, Val a-H), 4.46 (1 H, dd, J = 
9.0, 2.0 Hz, Pyg a-H), 5.24 (1 H, t, J = 6 .6  Hz, 4-H), 6.39 (1 H, d, J = 8.2 Hz, Val NH), 
6.50 (1 H,.t, J = 5.9 Hz, NtfCH2), 7.31 (2 H, d, J = 8.4 Hz, Ar 2,6-H2), 8.08 (2 H, d, J = 8.4 








Compound 160 (100 mg, 162 pmol) was stirred in aq. NH3 (35%, 1.0 mL) and THF (10 
mL) for 18 h. Evaporation afforded 161 (quant.) as a white solid: mp 95-97°C; NMR 8 h 
0.84 (3 H, d, J = 6 .6  Hz, Val-Me), 0.91 (3 H, d, J = 6 .6  Hz, Val-Me), 1.42 (9 H, s, Bul), 
1.77 (3 H, s, 2-Me), 1.79 (3 H, s, 2-Me), 2.0 (3 H, m, Val p-H, Gin p-H2), 2.25 (1 H, m, 
Gin y-H), 2.35 (1 H, m, Gin y-H), 2.95-3.00 (3 H, m, 5-H, ArCH2), 3.37 (1 H, dd, / =  12.5, 
6.2 Hz, 5-H), 3.45 (1 H, m, NHCH)t 3.75 (1 H, m, NHCtf), 4.11 (2 H, m, Val a-H, Gin a- 
H), 5.35 (1 H, d, J = 6.2 Hz, 4-H), 5.50 (1 H, d, J = 7.4 Hz, NH), 5.69 (1 H, s, CONH), 
6.21 (1 H, s, CONH), 6.50 (1 H, brt, NtfCH2), 7.27 (1 H, d, J = 8.2 Hz, NH), 7.38 (2 H, d, 
J = 8 .6  Hz, Ar 2,6-H2), 8.16 (2 H, d, /  = 8 .6  Hz, Ar 3,5-H2); MS m/z 637.3020 (M + H) 
(C29H45N60 8S requires 637.3021), 537 (M -B oc).
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S-2,2-Dimethyl-3-(N-(L-glutaminyl)-L-valyl)-N-(2-(4-
nitrophenyl)ethyl)tetrahydrothiazole-4-carboxamide trifluoroacetate salt (162)
CF3CO2
Compound 161 (300 mg, 472 pmol) was stirred in CF3CO2H (900 pL) and CH2CI2 (3.6 
mL) for 1 h. Evaporation and trituration with Et2 0  afforded 162 (300 mg, 98%) as a white
J = 8 .8  Hz, Ar 3,5-H2); MS m/z 537.2495 (M + H) (C24H37N60 6S requires 537.2493).
S-2,2-dimethyl-3-(N-(N-(N-(Dimethylethoxycarbonyl)-L-Leucyl)-L-glutaminyl)-L- 
valyl)-N-(2-(4-nitrophenyl)ethyl)tetrahydrothiazole-4-carboxamide (163)
N-(l,l-Dimethylethoxycarbonyl)-L-leucine N-hydroxysuccinimide ester (157 mg, A ll  
pmol) in dry THF (2.0 mL) and added to compound 162 (310 mg, 477 pmol), Et3N (97 
mg, 954 pmol) and DMAP (1 mg) in dry DMF (1.5 mL) at 0°C and the mixture was stirred 
for 30 min. The mixture was then gradually warmed to 20°C and stirred for 24 h. The 
evaporation residue, in EtOAc, was washed with cold 5% aq. citric acid, H2O and brine. 
Drying, evaporation and recrystallisation (EtOAc / hexane) afforded 163 (330 mg, 92%) as 
white solid: mp 109-111°C; NMR (CD3OD) 8H0.85 (3 H, d, J = 6 .6  Hz, Val-Me), 0.86 (3
solid: mp 108-110°C; NMR (CD3OD) 8H 0.89 (3 H, d, J = 6 .6  Hz, Val-Me), 0.91 (3 H, d, J 
= 6 .6  Hz, Val-Me), 1.77 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me), 2.10 (3 H, m, Val P-H, Gin P- 
H2), 2.40 (2 H, m, Gin y-H2), 2.99 (3 H, m, 5-H, ArCH2), 3.37 (1 H, dd, J  = 12.5, 6.2 Hz,
5-H), 3.51 (2 H, m, NHCH2), 3.96 (1 H, t, J = 6 .6  Hz, Gin a-H), 3.98 (1 H, d, J = 8 .6  Hz, 




H, d, J = 6 .6  Hz, Val-Me), 0.93 (3 H, d, J  = 6 .6  Hz, Leu-Me), 0.95 (3 H, d, J  = 6 .6  Hz, 
Leu-Me), 1.45 (9 H, s, Bul), 1.52 (2 H, t, /  = 7.0 Hz, Leu P-H2), 1.79 (3 H, s, 2-Me), 1.88 
(3 H, s, 2-Me), 1.70-2.10 (4 H, m, Val P-H, Leu y-H, Gin P-H2), 2.30 (2 H, m, Gin y-H2), 
2.94-3.04 (3 H, m, 5-H, ArCH2), 3.42 (1 H, dd, J = 12.1, 5.9 Hz, 5-H), 3.55 (2 H, brq, J =
5.5 Hz, NHCH2), 3.95 (1 H, t, J = 9.0 Hz, Val a-H), 4.04 (1 H, t, J = 7.4 Hz, Leu a-H), 
4.30 (1 H, brq, J = 6 .6 'Hz, Gin a-H), 5.21 (1 H, d, J = 5.9 Hz, 4-H), 7.50 (2 H, d, J = 8 .6  
Hz, Ar 2,6-H2), 8.07 (1 H, t, /  = 5.5 Hz, NtfCH2), 8.16 (2 H, d, J = 8 .6  Hz, Ar 3,5-H2), 
8.18 (2 H, m, 2 x NH); MS m/z 772 (M + Na), 750.3860 (M + H) (C35H56N7O9S requires 
750.3901), 650 (M -B oc).
S-2,2-Dimethyl-3-(N-(N-(L-Leucyl)-L-glutaminyl)-L-valyI)-N-(2-(4- 
nitrophenyl)ethyl)tetrahydrothiazole-4-carboxamide (164)
Compound 163 (300 mg, 401 pmol) was stirred in CF3C0 2H (900 pL) and CH2C12 (3.6 
mL) for 30 min. Evaporation and trituration with Et20  afforded 164 (300 mg, 98%) as a 
white solid: mp 121-123°C; NMR (CD3OD) 6H 0.76 (3 H, d, J = 7.0 Hz, Val-Me), 0.77 (3
H, d, J = 6 .6  Hz, Val-Me), 1.00 (3 H, d, J = 5.5 Hz, Leu-Me), 1.01 (3 H, d, J = 5.5 Hz, 
Leu-Me), 1.54-1.74 (3 H, m, Leu P-H2, Leu y-H), 1.70 (3 H, s, 2-Me), 1.79 (3 H, s, 2-Me),
I.82-2.04 (3 H, m, Val P-H, Gin P-H2), 2.20 (2 H, m, Gin y-H2), 2.89 (2 H, t, J = 6 .6  Hz, 
ArCH2), 2.91 (1 H, d, J = 12.1 Hz, 5-H), 3.30 (1 H, dd, J = 12.1, 5.9 Hz, 5-H), 3.50 (2 H, 
m, NHCtf2), 3.80 (1 H, brt, J = 8.2 Hz, Leu a-H), 3.87 (1 H, d, J = 9.4 Hz, Val a-H), 4.31 
(1 H, t , y  = 7.8 Hz, Gin a-H), 5.20 (1 H, d, /  = 5.9 Hz, 4-H), 7.40 (2 H, d, /  = 9.0 Hz, Ar 
2,6-H2), 7.97 ( l H , t , / =  5.5 Hz, N/fCH2), 8.06 (2 H, d, J = 9.0 Hz, Ar 3,5-H2), 8.26 (1 H, 







Na-Fmoc-Ne-Boc-L-Lysine (1.0 g, 2.1 mmol) was stirred with pentafluorophenol (432 mg,
2.3 mmol) and DCC (483g, 2.3 mmol) in EtOAc (5 mL) and THF (5 ml) at 0°C under N2 
for 4 h for 16 h. The mixture was filtered (Celite®) and the precipitate was washed with 
cold EtOAc. Evaporation afforded 166 (2.10 g, 70%) as a white solid: mp 102-104°C (lit181 
mp 99-101°C); NMR 5H 1.43 (9 H, s, Bul), 1.50-2.05 (8  H, m, Lys (3-H2, Lys y-H2, Lys 5- 
H2, Lys £-H2), 4.23 (1 H, t, J = 7.0 Hz, C//CH20), 4.41 (1 H, dd, J = 10.5, 7.0 Hz, CHO), 
4.49 (1 H, dd, J = 10.5, 7.0 Hz, CHO), 4.61 (1 H, br, NH), 4.69 (1 H, q, J = 7.8 Hz, Lys a- 
H), 5.57 (1 H, d, J = 7.0 Hz, NH), 7.29 (2 H, t, J = 7.4 Hz, Ar-H2), 7.38 (2 H, t, J = 7.4 Hz, 
At-H2), 7.58 (2 H, d, /  = 7.4 Hz, Ar-H2), 7.74 (2 H, d, J = 7.4 Hz, Ar-H2); NMR SF -161.7  
(2 F, t, J = 20.7 Hz, 3’,5’-F2), -157.1 (1 F, t, J = 20.7 Hz, 4 ’-F), -152.2 (2 F, d, J = 18.4 







Compound 166 (290 mg, 380 pmol) in dry THF (1.5 mL) was stirred with compound 164
211
(241 mg, 380 pmol), Et3N (77 mg, 760 pmol) and DMAP (1 mg) in dry DMF (1.5 mL) at 
0°C for 30 min. The mixture was then gradually warmed to 20°C and stirred for 16 h. The 
evaporation residue, in EtOAc, was washed with cold 5% aq. citric acid, H2O and brine. 
Drying and recrystallisation (EtOAc / hexane) afforded 167 (395 mg, 95%) as a white 
solid: mp 72-75°C; NMR 6 H 0.75-0.85 (12 H, m, 2 x Val-Me, 2 x Leu-Me), 0.92 (2 H, t,
7.4 Hz, Lys e-H2), 1.20-1.40 (6  H, m, Lys P-H2, Lys y-H2, Lys 5-H2), 1.43 (9 H, s, Bul), 
1.50-1.65 (3 H, m, Leu P-H2, Leu y-H), 1.73 (3 H, s, 2-Me), 1.83 (3 H, s, 2-Me), 1.90-2.10 
(3 H, m, Val P-H, Gin P-H2), 2.30 (2 H, m, Gin y-H2), 2.78 (2 H, brd, CH20 ), 2.89-3.03 (4 
H, m, 5-H2, AtCH2), 3.35 (1 H, m, NHCtfCH2), 3.65 (1 H, m, NHCtfCH2), 4.04 (1 H, t, J 
= 9.0 Hz, CHCH20), 4.15-4.50 (4 H, m, Val a-H , Gin a-H, Leu a-H, Lys a-H), 5.11 (1 
H, m, 4-H), 7.24-7.55 (8  H, m, Ar-H8), 7.72 (2 H, d, /  = 7.4 Hz, Ar 2,6-H2), 8.10 (2 H, d, J 






Compound 167 (250 mg, 227 pmol) was stirred in CH2C12 (4.5 mL) and diethylamine (500 
pL) for 30 min. The evaporation residue was washed with Et20  and dried to afford 
168(180 mg, 90%) as a white solid: mp 100-103°C; NMR (CD3OD) 0.85 (3 H, d, J = 6 .6  
Hz, Val-Me), 0.86 (3 H, d, /  = 6 .6  Hz, Val-Me), 0.92 (3 H, d, /  = 6 .6  Hz, Leu-Me), 0.96 
(3 H, d, /  = 6 .6  Hz, Leu-Me), 1.40-1.65 (18 H, m, Bul, Lys p-H2, Lys y-H2, Lys 5-H2, Leu 
P-H2, Leu y-H), 1.79 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me), 1.90-2.12 (3 H, m, Val P-H, Gin 
P-H2), 2.30 (2 H, m, Gin y-H2), 2.96-3.04 (6  H, m, Lys 8-H2, 5-H2, ArCH2), 3.40 (1 H, m, 
NHCtfCH2), 3.55 (1 H, m, NHCJ7CH2), 3.92-4.42 (4 H, m, Val a-H , Gin a-H, Leu a-H, 
Lys a-H), 5.24 (1 H, d, J = 5.4 Hz, 4-H), 7.50 (2 H, d, J = 8 .6  Hz, Ar 2,6-H2), 8.15 (2 H, d,
2 1 2
J = 8 .6  Hz, Ar 3,5-H2); MS m/z 878.4831 (M + H) (C41H68N9O10S requires 878.4810), 778 








CbzSer(Bu4)OSu (13.3 mg, 34 pmol) in dry THF (700 pL) was added to compound 168 
(30 mg, 34 pmol), Et3N (6.9 mg, 6 8  pmol) and DMAP (1 mg) in dry DMF (300 pL) at 0°C 
and the mixture was stirred for 30 min. The mixture was then gradually warmed to 20°C 
and stirred for 16 h. The evaporation residue, in EtOAc, was washed with cold 5% aq. 
citric acid, H2O and brine. Drying and recrystallisation (EtOAc / hexane) afforded 169 (20 
mg, 51%) as a white solid: mp 128-130°C; NMR (CD3OD) 0.84 (3 H, d, J = 6 .6  Hz, Val- 
Me), 0.86 (3 H, d, J = 6 .6  Hz, Val-Me), 0.89 (3 H, d, /  = 6.2 Hz, Leu-Me), 0.90 (3 H, d, J 
= 6.2 Hz, Leu-Me), 1.20 (9 H, s, SerOBu4), 1.42 (9 H, s, Boc Bu4), 1.45-1.75 (9 H, m, Lys 
p-H2, Lys y-H2, Lys 5-H2, Leu P-H2, Leu y-H), 1.79 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me),
1.90-2.15 (3 H, m, Val P-H, Gin P-H2), 2.30 (2 H, m, Gin y-H2), 2.96-3.04 (4 H, m, Lys e- 
H2, AtCH2), 3.42 (1 H, dd, / =  12.5, 5.9 Hz, 5-H), 3.55 (3 H, m, 5-H, NHCtf2), 3.76 (1 H, 
m, Ser p-H), 3.85 (1 H, m, Ser p-H), 3.95 (1 H, d, J = 9.4 Hz, Val a-H), 4.15-4.44 (4 H, m, 
Gin a-H, Leu a-H, Lys a-H, Ser a-H), 5.09 (1 H, d, / =  12.5 Hz) and 5.14 (1 H, d, J = 12.5 
Hz) (CH2Ph), 5.21 (1 H, d, /  = 5.9 Hz, 4-H), 7.36 (5 H, m, Ph-H5), 7.51 (2 H, d, J = 8 .8  
Hz, Ar 2,6-H2), 8.06 (1 H, brt, J = 7 Hz, NH), 8.16 (2 H, d, J = 8 .8  Hz, Ar 3,5-H2); MS m/z 









H3N + c f 3c o 2
Compound 169 (5.0 mg, 4.3 pmol) was stirred in CF3CO2H (100 pL) and CH2CI2 (400 pL) 
for 2 h. Evaporation and trituration with Et2 0  afforded 170 (4.7 mg, 98%) as a white solid: 
mp 107-109°C; NMR (CD3OD) 0.84 (3 H, d, 7 = 6 .6  Hz, Val-Me), 0.85 (3 H, d, 7 = 6 .6  
Hz, Val-Me), 0.90 (3 H, d, 7 = 6.2 Hz, Leu-Me), 0.95 (3 H, d, 7 = 6.2 Hz, Leu-Me), 1.45- 
1.70 (9 H, m, Lys p-H2, Lys y-H2, Lys 6 -H2, Leu p-H2, Leu y-H), 1.78 (3 H, s, 2-Me), 1.88 
(3 H, s, 2-Me), 1.90-2.15 (3 H, m, Val P-H, Gin P-H2), 2.30 (2 H, t, 7 = 7.4 Hz, Gin y-H2), 
2.39 (2 H, t, 7 = 7.0 Hz, ArCH2), 2.98 (2 H, t, 7 = 6.5 Hz, Lys e-H2), 3.03 (1 H, 7 = 12.1 
Hz, 5-H), 3.41 (1 H, dd, 7 =  12.1, 5.5 Hz, 5-H), 3.55 (2 H, m, NHCH2), 3.75 (1 H, m, Ser 
p-H), 3.85 (1 H, m, Ser P-H), 3.95 (1 H, d, 7 = 9.4 Hz, Val a-H), 4.20-4.40 (4 H, m, Gin a- 
H, Leu a-H, Lys a-H, Ser a-H), 5.07 (1 H, d, J = 12.5 Hz) and 5.12 (1 H, d, J = 12.5 Hz) 
(CH2Ph), 5.21 (1 H, d, J =  5.5 Hz, 4-H), 7.36 (5 H, m, Ph-H5), 7.51 (2 H, d, J =  8 .8  Hz, Ar 
2,6-H2), 8.06 (1 H, brt, 7 = 7  Hz, NH), 8.16 (2 H, d, 7 = 8 .8  Hz, Ar 3,5-H2); MS m/z 










FmocSeitBu^OSu (44 mg, 91 pmol) in dry THF (500 pL) was added to compound 168 (80 
mg, 91 pmol), Et3N (18.4 mg, 182 pmol) and DMAP (1 mg) in dry DMF (500 pL) at 0°C 
and the mixture was stirred for 30 min. The mixture was then gradually warmed to 20°C 
and stirred for 16 h. The evaporation residue, in EtOAc, was washed with cold 5% aq. 
citric acid, H2O and brine. Drying and recrystallisation (EtOAc / hexane) afforded 171 (70 
mg, 62%) as a white solid: mp 184-186°C; NMR (CD3OD) 0.85 (3 H, d, J = 6 .6  Hz, Val- 
Me), 0.86 (3 H, d, J = 6 .6  Hz, Val-Me), 0.90 (3 H, d, /  = 6.2 Hz, Leu-Me), 0.95 (3 H, d, J 
= 6.2 Hz, Leu-Me), 1.18 (9 H, s, SerOBu1), 1.43 (9 H, s, Boc Bu*), 1.45-1.75 (9 H, m, Lys 
P-H2, Lys y-H2, Lys 8 -H2, Leu P-H2, Leu y-H), 1.79 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me),
1.90-2.15 (3 H, m, Val P-H, Gin P-H2), 2.30 (2 H, m, Gin y-H2), 2.96-3.02 (4 H, m, ArCH2, 
Ser P-H2), 3.15-3.25 (2 H, m, 5-H2), 3.55 (2 H, m, Lys e-H2), 3.62 (2 H, m, NHCH2), 3.94 
(1 H, d, J = 9.4 Hz, CRCH2O), 4.21-4.35 (5 H, m, Gin a-H, Leu a-H, Lys a-H, Ser a-H, 
fluorene 9-H), 5.20 (1 H, d, J = 5.1 Hz, 4-H), 7.30 (2 H, t, /  = 7.4 Hz, Ar-H2), 7.39 (2 H, t, 
J = 7.4 Hz, Ar-H2), 7.50 (2 H, d, /  = 8 .6  Hz, Ar 2,6-H2), 7.66 (2 H, J = 7.4 Hz, Ar-H2), 
7.80 (2 H, J = 7.4 Hz, Ar-H2),8.16 (2 H, d, J = 8 .6  Hz, Ar 3,5-H2); MS m/z 1243.6437 (M 







Compound 171 (70 mg, 56 pmol) was stirred in CH2CI2 (1350 pL) and diethylamine (150 
pL) for 30 min. The evaporation residue was washed with Et2 0  and dried to afford 172 (50 
mg, 8 8 %) as a white solid: mp 94-96°C; NMR (CD3OD) 0.85 (3 H, d, J = 6 .6  Hz, Val- 
Me), 0.86 (3 H, d, J = 6 .6  Hz, Val-Me), 0.92 (3 H, d, J  = 6.2 Hz, Leu-Me), 0.96 (3 H, d, J 
= 6;2 Hz, Leu-Me), 1.31 (9 H, s, SerOBu1), 1.44 (9 H, s, Boc Bu‘), 1.45-1.75 (9 H, m, Lys 
P-H2, Lys y-H2, Lys 8 -H2, Leu P-H2, Leu y-H), 1.78 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me),
1.90-2.15 (3 H, m, Val P-H, Gin P-H2), 2.30 (2 H,t, J  = 7.0 Hz, Gin y-H2), 2.96-3.05 (5 H, 
m, 5-H, ArCH2, Ser P-H2), 3.42 (1 H, dd, J = 12.1, 5.3 Hz, 5-H), 3.55 (2 H, m, Lys s-H2), 
3.58-3.55 (2 H, m, NHCH2), 3.95 (1 H, d, J = 9.0 Hz, Val a-H), 4.20-4.40 (4 H, m, Gin a- 
H, Leu a-H, Lys a-H, Ser a-H), 5.21 (1 H, d, J = 5.3 Hz, 4-H), 7.51 (2 H, d, J = 8 .6  Hz, Ar 









CbzSer(Bul)OSu (9.8 mg, 25 pmol) in dry THF (700 pL) was added to compound 172 (25 
mg, 25 pmol), Et3N (5.1 mg, 50 pmol) and DMAP (1 mg) in dry DMF (300 pL) at 0°C and 
the mixture was stirred for 30 min. The mixture was then gradually warmed to 20°C and 
stirred for 16 h. The evaporation residue, in EtOAc, was washed with cold 5% aq. citric 
acid, H2O and brine. Drying and recrystallisation (EtOAc / hexane) afforded 173 (20 mg, 
62%) as a white solid: mp 202-205; NMR (CD3OD) 0.86 (3 H, d, J = 6 .6  Hz, Val-Me),
0.89 (3 H, d, J = 6 .6  Hz, Val-Me), 0.91 (3 H, d, J = 5.9 Hz, Leu-Me), 0.95 (3 H, d, J = 5.9 
Hz, Leu-Me), 1.20 (18 H, s, 2 x SerOBu1), 1.42 (9 H, s, Boc Bul), 1.45-1.75 (9 H, m, Lys 
P-H2, Lys y-H2, Lys 5-H2, Leu P-H2, Leu y-H), 1.80 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me),
1.90-2.15 (3 H, m, Val P-H, Gin P-H2), 2.30 (2 H, m, Gin y-H2), 2.96-3.04 (4 H, m, Lys e- 
H2, ArCH2), 3.45-3.8 (8  H, m, 5-H2, NHCf/2, 2 x Ser p-H2), 3.95 (1 H, d, J = 9.4 Hz, Val 
a-H), 4.15-4.80 (6  H, m, Gin a-H, Leu a-H, Lys a-H, 2 x  Ser a-H), 5.09 (2 H, m,CH2Ph), 
5.21 (1 H, d, J = 5.5 Hz, 4-H), 7.35 (5 H, m, Ph-H5), 7.51 (2 H, d, J = 8 .8  Hz, Ar 2,6-H2),
8.16 (2 H, d, J = 8 .8  Hz, Ar 3,5-H2); MS m/z 1199.6588 (M - Boc) (13Ci12C57H92NiiOi4S 









c f 3c o 2
Compound 173 (5.0 mg, 3.9 pmol) was stirred in CF3CO2H (100 pL) and CH2CI2 (400 |iL) 
for 2 h. Evaporation afforded 174 (quant.) as a highly hygroscopic gummy solid. NMR 
(CD3OD) 0.86 (3 H, d, J = 6 .6  Hz, Val-Me), 0.89 (3 H, d, J = 6 .6  Hz, Val-Me), 0.91 (3 H, 
d, J = 5.9 Hz, Leu-Me), 0.95 (3 H, d, J = 5.9 Hz, Leu-Me), 1.20 (18 H, s, 2 x SerOBu1), 
1.42 (9 H, s, Boc Bul), 1.45-1.75 (9 H, m, Lys P-H2, Lys y-H2, Lys 8 -H2, Leu P-H2, Leu y- 
H), 1.80 (3 H, s, 2-Me), 1.88 (3 H, s, 2-Me), 1.90-2.15 (3 H, m, Val P-H, Gin P-H2), 2.30 
(2 H, m, Gin y-H2), 2.96-3.04 (4 H, m, Lys e-H2, ArCH2), 3.45-3.8 (8  H, m, 5-H2, NHC//2, 
2 x Ser P-H2), 3.95 (1 H, d, J = 9.4 Hz, Val a-H), 4.15-4.80 (6  H, m, Gin a-H, Leu a-H, 
Lys a-H, 2 x Ser a-H), 5.09 (2 H, m,CH2Ph), 5.21 (1 H, d, J = 5.5 Hz, 4-H), 7.35 (5 H, m, 








FmocSer(Bul)OSu (12.0 mg, 25 pmol) in dry THF (700 pL) was added to compound 172 
(25 mg, 25 pmol), Et3N (5.1 mg, 50 pmol) and DMAP (1 mg) in dry DMF (300 pL) at 0°C
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and the mixture was stirred for 30 min. The mixture was then gradually warmed to 20°C 
and stirred for 16 h. The solid evaporation residue was washed with Et2 0 , cold 5% aq. 
citric acid and H2O. Drying afforded 175 (15 mg, 43%) as a white solid: mp 168-170°C; 
MS m/z 1164 (M -  Fmoc).
N-(Na-(Fluoren-9-yImethoxycarbonyI)-N8-(triphenylmethyl)-L-glutaminyl)-L-valine 
phenylmethyl ester (176)
FmocGln(Trt)OH (2.99 g, 4.9 mmol) was stirred with HOBt (730 mg, 5.4 mmol) and DCC 
( 1 .11  g, 5.4 mmol) in CH2CI2 (50 mL) at 0 °C for 1 h. L-Valine benzyl ester (1 .8 6  g, 4.9 
mmol) in CH2CI2 (50 mL) was added in the presence of Pr^NEt (1.27 g, 9.8 mmol) and the 
mixture was stirred for 24 h. The mixture was kept at 4°C for 16 h and filtered (Celite®). 
The solution was washed cold 5% aq. citric acid, aq. NaHCC>3 and H2O. Drying, 
evaporation and chromatography (EtOAc / hexane 2:3) afforded 176 (2.10 g, 54%) as a 
white solid: mp 110-113°C; NMR 6 H 0.72 (3 H, d, J = 6 .6  Hz, Val-Me), 0.82 (3 H, d, J = 
6 .6  Hz, Val-Me), 1.95 (1 H, m, Gin P-H), 2.10 (2 H, m, Val P-H, Gin p-H), 2.52 (2 H, brt, 
J = 6.2 Hz, Gin y-H2), 4.19 (2 H, m, Gin a-H, CHCH20 ), 4.34 (2 H, m, CHCtf20 ), 4.40 (1 
H, dd, J = 7.8, 4.7 Hz, Val a-H), 5.03 (1 H, d, J = 12.1 Hz) and 5.13 (1 H, d, J = 12.1 Hz) 
(CH2Ph), 5.89 (1 H, d, J = 7.0 Hz, Gin NH), 6.90 (1 H, s, CONHTr), 7.30 (21 H, m, 4 x  
Ph-Hs, NH), 7.37 (4 H, m, Ar-R), 7.56 (2 H, d, J = 7.6 Hz, Ar-H2), 7.73 (2 H, d, J = 7.6 
Hz, Ar-H2) MS m/z 800.3701 (M + H) (C51H50N3O6 requires 800.3700), 621 (M -  
fluoreneCH2), 243 (PI13C), 179 (fluorene-CH2).
11 = n  11










Compound 176(1.0 g, 1.2 mmol) was stirred with 10% Pd/C (40 mg) in MeOH (50 mL) 
and under H2 for 24 h. Filtration (Celite®) and evaporation afforded 177 (500 mg, 56%) as 
a white solid: mp 120-122°C; NMR (CD3OD) 6 H 0.94 (3 H, d, J = 7.0 Hz, Val-Me), 0.96 
(3 H, t, J =  7.0 Hz, Val-Me), 1.84 (1 H, m, Gin P-H), 2.04 (1 H, m, Val P-H), 2.16 (1 H, m, 
Gin P-H), 2.45 (2 H, m, Gin y-H2), 4.20 (2 H, m, a-H, CHCH20 ), 4.31 (1 H, d, J = 5.1 Hz, 
a-H), 4.38 (2 H, d, J = 7.0 Hz, CHC//20 ), 7.17-7.31 (17 H, m, 3 x Ph-H5, Ar-H2), 7.36 (2 
H,'t, J = 7.3 Hz, Ar-H2), 7.64 (2 H, d, J = 7.3 Hz, Ar-H2), 7.78 (2 H, d, J = 7.3 Hz, Ar-H2); 
MS m/z 710.3230 (M + H) (C44H44N 30 6 requires 710.3233), 531 (M -  fluoreneCH2), 488 
(M -  Fmoc), 243 (Ph3C), 179 (fluorene-CH2).







Compound 142 (1.00 g, 2.8 mmol) was stirred in CF3C 0 2H (3 mL) and CH2C12 (3 mL) for 
45 min. Evaporation afforded crude 178 (quant.) as a highly hygroscopic yellow viscous 
oil: NMR ((CD3)2SO) 6H 0.85 (6  H, d, J = 7.0 Hz, 2 x Val-Me), 1.88 (2 H, brq, J  = 5.7 Hz, 
Gin p-H2), 2.00 (1 H, m, Val P-H), 2.20 (2 H, t, J = 7.4 Hz, Gin y-H2), 3.59 (3 H, s, OMe), 
3.87 (1 H, brq, J = 5.7 Hz, Gin a-H), 4.16 (1 H, dd, J = 7.8, 5.9 Hz, Val a-H), 6.93 (1 H, s, 









N-(l,l-Dimethylethoxycarbonyl)-L-leucine N-hydroxysuccinimide ester (1.14 g, 3.5 
mmol) in dry THF (5 mL) was added to 178 (1.29 g, 3.5 mmol), Et3N (708 mg, 7 mmol) 
and DMAP (1 mg) in dry DMF (5 mL) at 0°C during 30 min. The mixture was then 
gradually warmed to 20°C and was stirred for 24 h. The evaporation residue, in EtOAc, 
was washed with cold aq. citric acid (5%) and brine. Drying, evaporation and 
chromatography (EtOAc —» EtOAc/MeOH 1:1) afforded 179 (900 mg, 54%) as a white 
solid: mp 135-139°C; NMR 8H 0.83-0.87 (12 H, m, 2 x  Val-Me, 2 x  Leu-Me), 1.34 (9 H, 
s, Bul), 1.41 (1 H, m, Leu P-H), 1.57 (1 H, m, Leu y-H), 1.70 (2 H, m, Gin P-H, Leu P-H), 
1.85 (1 H, m, Gin P-H), 2.03 (1 H, m, Val P-H), 2.08 (2 H, m, Gin y-H2), 3.62 (3 H, s, 
OMe), 3.94 (1 H, dt, J = 8.2, 6 .6  Hz, Leu a-H), 4.14 (1 H, dd, J = 7.8, 5.9 Hz, Val a-H),
4.34 (1 H, dt, J = 7.8, 5.5 Hz, Gin a-H), 6.77 (1 H, s, CONH), 6.95 (1 H, d, J = 8.2 Hz, 
Leu-NH), 7.25 (1 H, s, CONH), 7.82 (1 H, d, J = 7.8 Hz, Gin NH), 8.12 (1 H, d, J = 7.8 
Hz, Val NH); MS m/z 495.2793 (M + Na) (C22H40N4O7 requires 495.2795), 395 (M + Na -  
Boc).
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Compound 179 (650 mg, 1.4 mmol) was stirred in CF3CO2H (2 mL) and CH2CI2 (2 mL) 
for 2 h. Evaporation afforded 180 (quant.) as a highly hygroscopic colourless viscous oil: 
NMR ((CD3)2SO) 5h 0.85-0.87 (12 H, m, 2 x  Val-Me, 2 x Leu-Me)„ 1.26 (1 H, m, Leu p-
+ H) (C17H33N4O5 requires 373.2451).
N-(N-(N-(N-(NE-(l,l-Dimethylethoxycarbonyl)-Na-(fluoren-9-ylmethoxy carbonyl)- 
L-lysyl)-L-leucyl)-L-glutaminyl)-L-valine methyl ester (181)
Compound 166 (700 mg, 1.10 mmol) in dry THF (5 mL) was added to 180 (826 mg, 1.7 
mmol), Et3N (344 mg, 3.4 mmol) and DMAP (1 mg) in dry DMF (3 mL) at 0°C during 30 
min. The mixture was then slowly warmed to 20°C and stirred for 16 h. The evaporation 
residue was washed with EtOAc, cold aq. citric acid (5%) and H2O. Drying afforded 181 
(600mg, 6 8 %) as a white solid: mp 200-202°C; NMR ((CD3)2SO) 5h 0.80-0.86 (12 H, m, 2 
x Val-Me, 2 x Leu-Me), 1.35 (9 H, s, Bul), 1.44-1.52 (6  H, m, Lys p,y,5-H6), 1.54 (1 H, m,
H), 1.62 (1 H, m, Leu y-H), 1.73 (2 H, m, Gin p-H, Leu p-H), 1.85 (1 H, m, Gin P-H), 2.04 
(1 H, m, Val P-H), 2.15 (2 H, m, Gin y-H2), 3.62 (3 H, s, OMe), 3.80 (1 H, m, Leu a-H),
4.16 (1 H, dd, J = 8.2, 6.2 Hz, Val a-H), 4.42 (1 H, dt, / =  7.8, 5.5 Hz Gin a-H), 6.82 (1 H, 
s, CONH), 7.31 (1 H, s, CONH), 8.14 (3 H, br, N+H3), 8.28 (1 H, d, /  = 8.2 Hz, Val NH), 








Gin P-H), 1.57 (1 H, m, Gin P-H), 2.05 (1 H, m, Val P-H), 2.22 (2 H, m, Gin y-H2), 2.88 (2 
H, m, Lys e-H2), 3.61 (3 H, s, OMe), 3.94-4.32 (7 H, m, Leu a-H, Gin a-H, Val a-H, Lys 
a-H, fluorene 9-H, CH20 ), 6.77 (2 H, m, CONH, NH), 7.23 (1 H, s, CONH), 7.30 (2 H, t, 7 
= 7.4 Hz, Ar-H2), 7.39 (2 H, t, 7 = 7.4 Hz, Ar-H2), 7.46 (1 H, d, 7 = 8.2 Hz, NH), 7.69 (2 H, 
t, 7 = 7.4 Hz Ar-H2), 7.86 (2 H, d, 7 = 7.4 Hz, Ar-H2), 7.89 (1 H, d, 7 = 8.2 Hz, NH), 7.94 








Compound 181 (52 mg, 64 pmol) was stirred in DMF (900 pL) and diethylamine (100 pL) 
for 30 min. The evaporation residue was washed with Et20  and dried to afford 182 (35 mg, 
91%) as a white solid: mp 162-165°C; NMR (CD3OD) 5H 0.94-0.98 (12 H, m, 2 x  Val-Me, 
2 x  Leu-Me), 1.38-1.62 (17 H, m, Bu\ Lys p,y,S-H6, Gin P-H2), 1.76 (1 H, m, Leu y-H), 
1.95 (1 H, m, Leu P-H), 2.08-2.20 (2 H, m, Val P-H, Leu p-H), 2.35 (2 H, t, J = 7.4 Hz, 
Gin y-H2), 3.04 (2 H, t, J = 6 .6  Hz, Lys e-H2), 3.37 (1 H, t, J = 6 .6  Hz, Lys a-H), 3.72 (3 H, 
s, OMe), 4.31 (1 H, d, J = 5.9 Hz, Val a-H), 4.38 (1 H, t, J = 7.4, Gin a-H), 4.45 (1 H, dd, 








O v. O s .  o
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NHBoc
CbzSeitBu^OSu (19 mg, 48 pmol) in dry THF (700 pL) was added to 182 (29 mg, 48 
pmol), EtsN (9.8 mg, 96 pmol) and DMAP (1 mg) in dry DMF (300 pL) at 0°C. The 
mixture was stirred at 0°C for 30 min and at 20°C for 72 h. The evaporation residue, in 
EtOAc, was washed with cold aq. citric acid (5%) and H2O and was dried to afford 183 (30 
mg, 6 8 %) as a white solid: mp 234-236°C; NMR ((CD3)2SO) 6 H 0.83-0.87 (12 H, m, 2 X 
Val-Me, 2 X Leu-Me), 1.10 (9 H, s, CH20 B u \  1.25-2.11 (21 H, C 0 2Bu\ Val p-H, Gin p- 
H2, Leu P,Y-H3, Lys P,y,5-H6), 2.85 (2 H, t, J = 6.2 Hz, Gin y-H2), 3.32 (2 H, m, 
C//2OBul), 3.44 (2 H, t, J = 5.5 Hz, Lys e-H2), 3.63 (3 H, s, OMe), 4.10-4.24 (5 H, Val <x- 
H, Gin a-H, Leu a-H, Lys a-H, Ser a-H), 5.02 (1 H, d, /  = 12.5 Hz) and 5.06 (1 H, d, J = 
12.5 Hz) (CH2Ph), 6.72-8.06 (13 H, m, 8  x  NH, Ph-H5); MS m/z 878.5264 (M + H) 
(C43H72N7 0 i2 requires 878.5239).
N-(N-(N-(N°-(N-Phenylmethoxycarbonyl)-L-serinyI)-L-lysyl)-L-leucyl)-L- 
glutaminyl)-L-valine methyl ester trifluoroacetate salt (184)
CF3GO2 +NH3





for 4 h. Evaporation afforded 184 (quant.) as a highly hygroscopic colourless gum: NMR
Thiophene-2,5-dicarboxylic acid 198 (900 mg, 5.2 mmol) was boiled under reflux with 
H2SO4 (2.0 mL) in MeOH (150 mL) for 48 h. The evaporation residue, in CH2CI2, was 
washed with H2O, aq. NaHCOs and brine. Drying and evaporation afforded 199 (770 mg, 
74%) as a white solid: mp 147-149°C (lit226 mp 147-151°C); NMR 8 h 3.92 (6  H, s, 2 x  
Me), 7.74 (2  H, s, 3,4-H2).
2,5-Bis(hydroxymethyl)thiophene (200)
NaBH4 (590 mg, 16 mmol) was stirred with 202 (1.0 g, 7.1 mmol) in H2O (14 mL) and 
THF (15 mL) for 24 h. The evaporation residue, in CH2CI2, was extracted with H2O. The 
aqueous layer was saturated with NaCl and extracted with Et2 0 . Drying and evaporation 
afforded 200 (780 mg, 76%) as a pale buff viscous oil: NMR ((CD3)2SO) 5h 4.55 (4 H, d, J
((CD3)2SO) 5h 0.83 (3 H, d, J = 6 .6  Hz, Val-Me), 0.87 (3 H, d, /  = 6.2 Hz, Leu-Me), 0.89 
(6  H, d, J = 5.9 Hz) (Val-Me, Leu-Me), 1.25-1.80 (10 H, m, Lys p,y,5-H6, Leu P-H2, Gin 
P-H, Val p-H), 1.85 (1 H, m, Gin P-H), 2.04 (1 H, nonet, J = 6.2 Hz, Leu y-H), 2.11 (2 H, 
brt, 7 = 7 Hz, Gin y-H2), 2.85 (2 H, m, Lys £-H2), 3.57 (2 H, brd, J = 5.5 Hz, Ser p-H2),
3.63 (3 H, s, C 0 2Me), 4.11 (1 H, brq, / =  7.4 Hz, Ser a-H), 4.15 (1 H, dd, J =  8.1, 6.2 Hz), 
4.20-4.35 (3 H, m, Gin a-H, Leu a-H, Lys a-H), 5.00 (1 H, d, /  = 12.5 Hz) and 5.04 (1 H, 
d, /  = 12.5 Hz) (CH2Ph), 6.81 (1 H, s), 7.28 (1 H, s) (CONH2), 7.32 ( 6  H, m, Ser NH, 
Ph-Hs), 7.65 (3 H, br, NH3), 7.91 (1 H, d, J = 5.9 Hz, NH), 7.93 (1 H, d, J = 7.4 Hz, NH),
8.04 (1 H, d, J = 7.8 Hz, Val NH), 8.10 (1 H, d, J  = 8.2 Hz, NH); MS m/z 722.4099 (M + 
H) (C34H56N7O10 requires 722.4089).
Dimethyl thiophene-2,5-dicarboxylate (199)
M e02C S C 0 2Me





LiBH4 (300 mg, 14 mmol) was added to 199 (500 mg, 2.5 mmol) in dry THF under Ar and 
the mixture was stirred for 2 d. AcOH was added dropwise until no further bubbling was 
observed. Acetyl chloride (2.0 mLJ was added to the evaporation residue, followed by 
Et3N (1.0 mL). The mixture was stirred for 16 h. The evaporation residue, in CH2CI2, was 
washed with H2O and dried. The evaporation residue was stirred with MeOH (15 mL) and 
aq. NH3 (35%, 5.0 mL) for 16 h. Evaporation and chromatography (EtOAc / hexane 1:1) 
afforded 201 (150 mg, 34%) as a pale buff oil: IR (Nujol) 2854 (OH), 1702 (C=0) 
cm'1; NMR 5h 3.80 (3 H, s, Me), 4.68 (2 H, d, J  = 5.8 Hz, CH2), 5.75 (1 H, t, J = 5.8 Hz, 
OH), 7.02 (1 H, dd, J  = 3.7, 0.9 Hz, 4-H), 7.66 (1 H, d, J = 3.7 Hz, 3-H); MS (El) mJz 
172.0188 (M) (C7H80 3S requires 172.0194), 141 (M - CH2OH), 113 (M - C 0 2Me); Found: 
H, 4.77. C7H8O3S requires H, 4.68%.
Thiophene-2,5-dicarbonyl chloride (203)
Thiophene-2,5-dicarboxylic acid 198 (1.00 g, 5.8 mmol) was boiled under reflux with 
DMF (30 fiL) in SOCI2 (3.45 g, 29 mmol) for 16 h. Evaporation afforded 203 (1.21 g, 
quant.): NMR 5H 8.01 (2 H, s,- 3,4-H2).
Thiophene-2,5-dicarboxamide (204)
Compound 203 (6.44 g, 38 mmol) in THF (25 mL) was added dropwise to aq. NH3 (35%, 
50 mL). The solid was collected by filtration, washed with H2O and dried to afford 204 
(4.78 g, 74%) as a white solid: mp >350°C (lit.226 no mp given); NMR ((CD3)2SO) 5h 7.55
O O
o o
(2 H, s, 2 x  NH), 7.68 (2 H, s, Hz, 3,4-H2), 8.07 (2 H, s, 2 x  NH).
226
Thiophene-2,5-dicarbonitrile (205)
N = C C = N
Compound 204 (4.70 g, 30 mmol) was boiled under reflux in POCI3 (13 mL) for 3 h. 
CH2CI2 (100 mL) was added, followed by aq. NaHCC>3 (CAUTION). The organic layer
was washed with aq. NaHC0 3 . Drying and evaporation afforded 205 (2.05 g, 51%) as a 
white solid: mp 102-103°C (lit.227 mp 103°C); IR vmx 2361 (CN) cm'1; NMR 5H 7.67 (2 H, 
s, 3,4-Hj).
2,5-Bis(acetamidomethyl)thiophene (206)
BH3.Me2S in THF (2.0 M, 50 mL, 100 mmol) was added dropwise to 205 (1.00 g, 7.5 
mmol) in dry THF (45 mL) at reflux. The mixture was boiled under reflux for 30 h and 
cooled to 20°C. MeOH (28 mL) was added and stirring continued for 30 h. Acetyl chloride 
(15.0 mL) was added to the evaporation residue, followed by Et3N (1.0 mL). The mixture 
was stirred for 16 h. The evaporation residue, in EtOAc, was extracted with H2O. The 
aqueous layer was saturated with NaCl and extracted with EtOAc. Drying, evaporation and 
chromatography (CHCI3 /  MeOH 13:1) afforded 206 (150 mg, 9%) as a white solid: mp 
142-144°C; IR 3254 (NH), 1648 (amide I), 1543 (amide II) cm'1; NMR (CD3OD) 6 H
1.94 (6  H, s, 2 x  Me), 4.44 (4 H, s, 2  x CH2), 6.78 (2 H, s, 3,4-H2); MS m/z 227.0855 (M + 
H) C10H15N2O2S requires 227.0854); Found: C, 53.10; H, 6.34; C10H14N2O2S requires C, 
53.08; H, 6.24%.
Ethyl 5-methylthiophene-2-carboxylate (209)
2-Methylthiophene (20.0 g, 204 mmol) was added slowly to butyl lithium (220 mmol) in 
dry THF (400 mL) at 0°C and the mixture was stirred at 0°C for 3 h before being added 
slowly to ethyl chloroformate (28.2 g, 260 mmol) in THF (200 mL) at 0°C. The mixture 
was stirred at 20°C for 16 h, and then poured onto ice. The organic layer was washed with 
H2O, aq. HC1 (1 M), aq. NaHCC>3, and H2O. Drying, evaporation and distillation gave 209
NHCOCH3CH3COHN
227
(23 g, 6 8 %) bp~i 120°C (lit228. bp5 87-89°C); NMR 5H 1.33 (3 H, t, 7 = 7.0 Hz, CH2Ctf3), 
2.48 (3 H, brs, 5-Me), 4.30 (2 H, q, 7 = 7.0 Hz, CH2), 6.72 (1 H, dq, 7 = 3.7, 1.2 Hz, 4-H), 
7.57(1 H, d, 7 =  3.7Hz, 3-H).
Ethyl 5-bromomethylthiophene-2-carboxylate (210)
Compound 209 (1.00 g, 5.9 mmol) was stirred with N-bromosuccinimide (1.08 g, 6.1 
mmol) and aq. HCIO4 (60%, 30 pL) in hexane (3.0 mL) for 24 h. The evaporation residue, 
in EtOAc, was washed with saturated aq. sodium sulphite solution. Drying, evaporation 
and chromatography (hexane / EtOAc 9:1) afforded 210 (160 mg, 11%) as a colourless oil: 
NMR 5h 1.37 (3 H, t, 7 = 7.0 Hz, Me), 4.35 (2 H, q, 7 = 7.0 Hz, OCH2), 4.68 (2 H, s, 
CH2Br), 7.08 (1 H, dt, 7 = 3.9, 0.8 Hz, 4-H), 7.63 (1 H, d, 7 = 3.9 Hz, 3-H); MS m/z 




Trifluoroacetamide (410 mg, 3.6 mmol) in dry THF (2.0 mL) was added slowly to KOBuf 
(410 mg, 3.6 mmol) in dry THF (2.0 mL). The mixture was stirred for 1 h, then added 
slowly to 210 (130 mg, 520 pmol) in dry THF (3.0 mL). The mixture was stirred for 15 h. 
The evaporation residue, in CH2C12, was washed with H20 , aq. HC1 (1 M) and H20 . 
Drying and evaporation afforded 211 (90 mg, 62%) as a pale yellow solid: mp 65-66°C: IR 
Vmax 3333 (NH), 1719 (C=0), 1683 (C=0) cm'1; NMR 6 H 1.37 (3 H, t, J = 7.0 Hz, Me),
4.34 (2 H, q, J = 7.0 Hz, OCH2), 4.72 (2 H, d, J  = 5.9 Hz, CH2N), 7.03 (1 H, dt, J = 3.9, 0.8 
Hz, 4-H), 7.67 (1 H, d, J = 3.5 Hz, 3-H); NMR 6 F -76.2 (3 F, s, CF3); MS m/z 282.0413 (M 
+ H) (C10H11F3NO3S requires 282.0412); Found C, 42.90; H, 3.49; N, 4.98; C10H10F3NO3S 
requires C, 42.68; H, 3.59; N, 4.98%.
228
5-(Benzyloxycarbonylaminomethyl)thiophene-2-carboxylic acid (212)
^ / s \ _ . c o 2H
CbzHN \\  /T
Compound 211 (3.50 g, 12.0 mmol) was boiled under reflux with NaOH (3.93 g, 98 mmol)
in H2O (50 mL) and MeOH (50 mL) for 16 h. The MeOH was evaporated. Benzyl chloro- 
* ©
formate (5.10 mL, 36 mmol) was added at 0°C and the mixture was stirred vigorously for 4 
h. The mixture was washed with Et2 0 . The aqueous layer was acidified (aq. HC1) and 
extracted with EtOAc. Drying and evaporation afforded 212 (3.33 g, 92%) as a yellow 
solid: mp 142-145°C; IR Vmax 3344 (NH), 2700 (OH), 1694 (C=0), 1547 (CONH), 1528 
c m 1; NMR ((CD3)2SO) 8 H 4.36 (2 H, d, J = 6.2 Hz, CH2N), 5.04 (2 H, s, CH20 ), 6.98 (1 
H, d, J = 3.5 Hz, 4-H), 7.3 (5 H, m, Ph-H5), 7.55 (1 H, d, J  = 3.5 Hz, 3-H), 8.02 (1 H, t, J = 
6  Hz, NH); MS m/z 292.0644 (M + H) (Q 4H14NO4S requires 292.0640); Found: C, 57.50; 
H, 4.41; N, 4.63; C14H13NO4S requires C, 57.70; H, 4.50; N, 4.81%.
Methyl 5-(benzyloxycarbonylaminomethyl)thiophene-2-carboxylate (213)
C0 2 Me
CbzHN ^  H
Compound 212 (500 mg, 1.7 mmol) was boiled under reflux with H2SO4 (1.0 mL) in 
MeOH (50 mL) for 2 d. Aq. NaHC03 was added until no further bubbling occurred. The 
suspension was filtered. The evaporation residue was washed with H2O and dried to afford 
213(460 mg, 8 8 %) as a white solid: mp 80-83°C; NMR 8 H 3.87 (3 H, s, Me), 4.55 (2 H, d, 
J = 5.9 Hz, CH2N), 5.14 (2 H, s, CH20 ), 5.23 (1 H, br, NH), 6.95 (1 H, d, J = 3.5 Hz, 4-H), 
7.31-7.36 (5 H, m, Ph-H5), 7.64 (1 H, d, J = 3.5 Hz, 3-H); MS m/z 398 (M + glycerol + H), 
306.0813 (M + H) (Ci5Hi6N04S requires 306.0800), 259 (M - C 02Me); Found C, 58.99; 
H, 5.00; N, 4.52; Q 5H15NO4S requires C, 58.98; H, 4.95; N, 4.59%.
Methyl 5-(aminomethyl)thiophene-2-carboxylate hydrobromide (214)
y— S\ ^  C02Me
h 3n  + f
Br -
Compound 213 (100 mg, 330 pmol) in AcOH (1.0 mL) was stirred with HBr in AcOH 
(30%, 1.0 mL) for 20 min. The evaporation residue was washed (10 x) with Et2 0  and dried
229
to afford 214 (83 mg, quant.) as a white solid: mp 212-215°C; NMR ((CD3)2SO) 8 h 3.83 (3 
H, s, Me), 4.31 (2 H, s, CH2), 7.30 (1 H, d, J = 3.9 Hz, 4-H), 7.76 (1 H, d, J = 3.9 Hz, 3-H), 
8.26 (3 H, br, N+Hs); MS m/z 325 (M + mNBA + H), 172.0437 (M + H) (C7HioN02S
Compound 214 (210 mg, 830 pmol) was stirred with CaCC>3 (90 mg, 870 pmol) and 
thiophosgene (200 mg, 1.7 mmol) in H20  (1.5 mL) and CHCI3 (10 mL) for 20 h. The 
solvent was evaporated from the organic layer. Chromatography (hexane / EtOAc 7:3) 
afforded 215 (110 mg, 62%) as a colourless oil: IR (Nujol) Vmax 2074 (NCS), 1711 (C=0) 
cm-1; NMR 5H 3.87 (3 H, s, Me), 4.85 (2 H, s, CH2), 7.03 (1 H, dt, J = 3.9, 0.8 Hz, 4-H),
7.76 (1 H, d, J = 3.9 Hz, 3-H); MS m/z 367 (M + mNBA + H), 214.0003 (M + H) 
(C8H8N 0 2S2 requires 213.9997), 182 (M - S); Found: C, 44.90; H, 3.32; N, 6.55. 
C8H7N 0 2S2 requires C, 45.05; H, 3.31; N, 6.57%.
Methyl 5-(thioureidomethyl)thiophene-2-carboxylate (216)
NH3 was passed through 215 (60 mg, 280 pmol) in CH2C12 at 0°C for 20 min. The mixture 
was stirred for 3 h at 0°C. Evaporation afforded 216 (65 mg, quant.) as a white solid: mp 
131-132°C: IR 3398 (NH), 1703 (C=0), 1277 (C=S) cm'1; NMR (CD3OD) 5 3.84 (3 
H, s, Me), 4.93 (2 H, d, J  = 5.9 Hz, CH2N), 7.06 (1 H, dt, J =3.7, 0.7 Hz, 4-H), 7.65 (1 H, 
d, 7  = 4.0 Hz, 3-H); MS m/z 231.0255 (M + H) (C8HnN2OS2 requires 231.0262).
5-(Benzyloxycarbonylaminomethyl)thiophene-2-methanol (217)
BH3.THF (1.0 M, 1.0 mL, 1.0 mmol) was added to 212 (100 mg, 340 pmol) in dry THF 
(2.0 mL) and the mixture was stirred for 18 h. AcOH was added dropwise until no further
requires 172.0432); Found H, 4.01; N, 5.56; C7H9N0 2S requires H, 4.00; N, 5.56%.
Methyl 5-(isothiocyanatomethyl)thiophene-2-carboxylate (215)
C 02Me




bubbling occurred. Evaporation and chromatography (EtOAc / hexane 4:1) afforded 217 
(50 mg, 53%) as a pale yellow solid: mp 76-78°C; NMR 8 h 4.50 (2 H, d, J = 5.9 Hz, 
CH2N), 4.77 (2 H, s, Ctf2OH), 5.13 (2 H, s, PhCH2), 6.84 (2 H, s, 3,4-H2), 7.36-7.38 (6  H, 
m, NH + Ph-H5); MS m/z 278.0856 (M + H) (Ci4Hi6N04S requires 278.0851); Found C, 
60.30; H, 5.61; N, 4.84; Ci4Hi5N 0 4S requires C, 60.63; H, 5.45; N, 5.05%.
4-Methylthiophene-2-carboxaldehyde (220a) and 3-methylthiophene-2-carbox- 
aldehyde (220b)
C—H
220a \  220b
3-Methylthiophene 219 (10.0 g, 102 mmol) was added slowly to butyl lithium (2.0 M, 55 
mL, 110 mmol) in dry Et20  (175 mL) at 0°C and the mixture was stirred for 3 h at 0°C, 
before being added slowly to N,N-dimethylformamide (10.2 g, 140 mmol) in dry Et20  (35 
mL) at 0°C. The mixture was stirred for 16 h and poured onto ice. The organic layer was 
washed with H20 , aq. HC1 (1 M), aq. NaHCC>3, and with H20 . Drying, evaporation and 
distillation gave a mixture of 220a and 220b (12.6 g, 61%) as a colourless liquid: NMR 8 h 
2.32 (2.3 H, s, Me (235a)), 2.58 (0.7 H, s, Me (235b)), 6.97 (0.22 H, d, /  = 5.2 Hz, 4-H 
(235b)), 7.36 (0.78 H, d, / =  1.3 Hz, 5-H (235a)), 7.58 (0.78 H, d, J = 1.3 Hz, 3-H (235a)),
7.63 (0.22 H, d, /  = 5.2 Hz, 5-H (235b)), 9.86 (0.78 H, d, / =  1.3 Hz, CHO (235a)), 10.04 
(0.22 H, d, J = 1.3 Hz, CHO (235b)).
4-Methylthiophene-2-carboxylic acid (221a) and 3-methyIthiophene-2-carboxylic acid 
(221b)
Ag20  (4.6 g, 20 mmol) was stirred with 220a,b (2.5 g, 20 mmol) and aq. NaOH (3.2 g, 80 
mmol) in H20  (50 mL) for 16 h. The mixture was filtered, acidified (aq. HC1) and 
extracted with CH2C12. Drying, evaporation and recrystallisation (hexane) afforded a 
mixture of 221a and 221b (2.30 g, 82%) as white crystals; mp 118-120°C (lit229 mp 123-
231
124°C for 221a); NMR 8 H 2.30 (2.7 H, s, Me (221a)), 2.57 (0.3 H, s, Me (221b)), 6.95 (0.1 
H, d, J = 4.7 Hz, 4-H (221b)), 7.13 (0.9 H, m, 5-H (221a)), 7.48 (1 H, d, /  = 5.1 Hz, 5-H
(221b)), 7.69 (0.9 H, d, /  = 1.6 Hz, 3-H (221a)); MS m/z 143.0169 (M + H) (C6H70 2S 
requires 143.0167).
Methyl 4-methylthiophene-2-carboxylate (222a) and methyl 3-riiethylthiophene-2- 
carboxylate (222b)
3-Methylthiophene 219 (5.0 g, 51 mmol) was added slowly to butyl lithium (2.0 M in 
THF, 28 mL, 56 mmol) in dry THF (100 mL) at 0°C and the mixture was stirred for 3 h at 
0°C, before being added slowly to methyl chloroformate (6.33 g, 67 mmol) in dry THF (20 
mL) at 0°C. The mixture was stirred for 16 h and poured onto ice. The organic layer was 
washed with H20 , aq. HC1 (1 M), aq. NaHCC>3 and with H20 . Drying, evaporation and 
distillation (ca. 1 torr) afforded a mixture of 222a and 222b (5.00 g, 62%) as a colourless 
oil: NMR 5H 2.28 (2.4 H, s, Me (237a)), 2.56 (0.6 H, s, Me (237b)), 3.86 (3 H, s, OMe), 
6.91 (0.2 H, d, J =  5.1 Hz, 4-H (237b)), 7.13 (0.8 H, m, 5-H (237a)), 7.38 (0.2 H, d, / =  5.1 
Hz, 5-H(237b)), 7.60 (1 H, d, J = 1.6 Hz, 3-H (237a)).
Methyl 4-bromomethylthiophene-2-carboxylate (223)
Dibenzoyl peroxide (80 mg, 330 pmol) was boiled under reflux with 222a,b (2.48 g, 16 
mmol) in CCI4 (40 mL) for 1 h. N-Bromosuccinimide (2.83 g, 16 mmol) was added and 
the mixture was boiled under reflux for 16 h. During this reflux, additional dibenzoyl 
peroxide (50 mg, 210 pmol) was added every 10 min for 1 h and then every 30 min 
(twice). Evaporation and chromatography (hexane / EtOAc 9:1) gave 223 (170 mg, 4.5%) 
as a pale buff oil; NMR 5H 3.89 (3 H, Me), 4.46 (2 H, s, CH2), 7.49 (1 H, d, J = 1.6 Hz, 5- 
H), 7.80 (1 H, d, / =  1.6 Hz, 3-H).





Methyl 4-(trifluoroacetamidomethyl)thiophene-2-carboxylate (224) and N,N-bis((2-
methoxycarbonylthien-4-yl)methyl)trifluoroacetamide (225)
M e02C S. S. C 0 2Me
C
/ S\ ^ - C 0 2Me \\ / /  X_J
- N -
A
f 3c f 3c  o
Trifluoroacetamide (570 mg, 5.1 mmol) in dry THF (2.0 mL) was stirred with KOBuf (570 
mg, 5.1 mmol) in dry THF (2.0 mL) for 1 h. Compound 223 (170 mg, 720 pmol) in dry 
THF (2.0 mL) was added slowly and the mixture was stirred for 15 h. The evaporation 
residue, in CH2CI2, was washed with H2O, aq. HC1 (1 M) and H2O. Drying, evaporation 
and chromatography (CHCI3 / EtOAc 19:1) afforded 225 (10 mg, 3%) as a pale yellow 
solid: mp 63-65°C; IR (film) 1711, 1603, 1541 c m 1; ■h NMR 6 H 3.89 (3 H, s, Me), 
3.90 (3 H, s, Me), 4.50 (2  H, s, CH2), 4.54 (2  H, s, CH2), 7.34 (1 H, brs, 5-H), 7.36 (1 H, 
brs, 5-H), 7.57 (1 H, d, J = 1.6 Hz, 3-H), 7.60 (1 H, d, 7 = 1.6 Hz, 3-H); NMR 5P -68.67 (3 
F, s, CF3); MS m/z 422.0340 (M + H) (C16H15F3NO5S2 requires 422.0344). Further elution 
gave 224 (70 mg, 36%) as a pale yellow solid: mp 80-83°C; IR Vmax 3305 (NH), 1703 
(CF3C=0), 1562 (amide) cm'1; NMR 6 H 3.89 (3 H, s, Me), 4.53 (2 H, d, J = 5.8 Hz, CH2), 
6.61 (1 H, br, NH), 7.45 (1 H, m, 5-H), 7.71 (1 H, d, J = 1.7 Hz, 3-H); NMR 8 F -76.2 (3 F, 
s, CF3); MS m/z 268.0255 (M + H) (C9H90 3F3NS requires 268.0246).
4-(Benzyloxycarbonylaminomethyl)thiophene-2-carboxylic acid (227)
Compound 224 (200 mg, 750 pmol) was boiled under reflux with NaOH (300 mg, 7.5 
mmol) in H2O (3.0 mL) and MeOH (3.0 mL) for 16 h. The MeOH was evaporated. Benzyl 
chloroformate (380 mg, 2.2 mmol) was added at 0°C and the mixture was stirred 
vigorously for 4 h, before being washed with EtOAc. The aqueous layer was acidified (aq. 
HC1) and extracted with EtOAc. Drying, evaporation and chromatography (EtOAc) 
afforded 227 (180 mg, 82%) as a white solid: mp 149-151°C; NMR ((CD3)2SO) 8 H 4.08 (2 
H, d, J = 5.7 Hz, CH2N), 5.02 (2 H, s, CH20 ), 7.33-7.36 (5 H, m, Ph-H5), 7.57 (1 H, m, 5- 
H), 7.60 (1 H, d, J = 1.2 Hz, 3-H), 7.82 (1 H, t, J = 5.7 Hz, NH); MS m/z 315.0503 (M +
CbzNH
233




Compound 227 (500 mg, 1.70 mmol) was boiled under reflux with H2SO4 (1.00 mL) and 
MeOH (50 mL) for 2 d. Aq. NaHCOs was added until no further bubbling occurred. The 
evaporation residue in CHCI3 was washed with H2O. Drying and evaporation afforded 228 
(430 mg, 82%) as a white solid: mp 64-65°C; NMR 8 h 3.88 (3 H, s, Me), 4.35 (2 H, d, J  = 
5.9 Hz, CH2N), 5.13 (3 H, m, CH20  + NH), 7.34-7.38 (6  H, m, Ph-H5 +5-H), 7.71 (1 H, br, 
3-H); MS m/z 306.0809 (M + H) (Q 5H16NO4S requires 306.0800).
Methyl 4-(aminomethyl)thiophene-2-carboxylate hydrobromide (229)
Compound 228 (280 mg, 920 pmol) in AcOH (2.8 mL) was stirred with HBr in AcOH 
(30%, 2.8 mL) for 20 min. The evaporation residue was washed with Et2 0  (10 x) and dried 
to afford 229 (230 mg, quant.) as a white solid: mp 203-205°C; NMR ((CD3)2SO) 8 h 3.85 
(3 H, s, Me), 4.08 (2 H, s, CH2), 7.95 (1 H, d, J = 1.6 Hz, 5-H), 7.97 (1 H, m, 3-H), 8.13 (3 
H, br, N+Hs); MS m/z 172.0439 (M + H) C7H10NO2S requires 172.0432); Found C, 33.20; 
H, 3.88; N, 5.44; C7H9NO2S.HBr requires C, 33.33; H, 4.00; N, 5.56%.
Methyl 4-(isothiocyanatomethyl)thiophene-2-carboxylate (230)
Compound 229 (200 mg, 790 pmol) was stirred with CaCOs (90 mg, 900 pmol) and thio- 
phosgene (180 mg, 1.6 mmol) in H2O (2.0 mL) and CHCI3 (10 mL) for 20 h. The solvent
234
was evaporated from the organic layer. Chromatography (CH2CI2) afforded 230 (104 mg, 
62%) as a white solid: mp 69-70°C: IR 2115 (NCS), 1711 (C=0) cm'1; NMR 5H 3.90 
(3 H, s, Me), 4.71 (2 H, s, CH2), 7.48 (1 H, dt, J = 2.0, 0.8 Hz, 5-H), 7.75 (1 H, d, J  = 2.0 
Hz, 3-H); MS m/z 214 (M + H); Found C, 45.30; H, 3.37; N, 6 .6 6 . C8H7NO2S2 requires C, 




NH3 was bubbled through 230 (60 mg, 280 pmol) in CH2CI2 (3.0 mL) at 0°C for 20 min. 
The mixture was stirred for 3 h at 0°C. Evaporation afforded 231 (61 mg, 95%) as a white 
solid: mp 131-132°C: NMR 5H 3.87 (3 H, s, Me), 4.64 (2 H, br, CH2), 5.98 (2 H, br, NH2),
6.77 (1 H, br, NH), 7.46 (1 H, br, 5-H), 7.72 (1 H, d, J = 1.6 Hz, 3-H); MS m/z 231.0272 . 
(M + H) (C8H11N2O2S2 requires 231.0262).
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X-ray crystallography data for compound (99)
Identification code h03mt2
Empirical formula Ci8 H2 8  N4  O 4  S 2
Formula weight 428.56
Temperature 150(2) K
W avelength 0 .71073 A
Crystal system Orthorhombic
Space group P 2i2 12 1
Unit cell dim ensions Q> II O) __L o> 0 0 >0 p II CO 0 0
b = 6.5280(1 )A 3 = 90°
c = 25.9050(5)A  y = 90°
Volume 1041.70(3) A3
Z 2
Density (calculated) 1.366 Mg/m3
Absorption coefficient 0 .287  mm ' 1
F(000) 456
Crystal size 0.40 x 0 .20 x 0 .10 mm
Theta range for data collection 4 .06  to 27.86°
Index ranges -8 <=h<= 8 ; -8 <=k<=8 ; -34<=l<=34
Reflections collected 15756
Independent reflections 2475 TR(int) = 0.04701
Reflections observed (>2a) 2180
Data C om pleteness 0.995
Absorption correction None
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2 4 7 5 /1  /1 3 6
Goodness-of-fit on F2 1.037
Final R indices [l>2c(l)l R 1 = 0 .0298 wR 2  = 0 .0697
R indices (all data) R 1 = 0 .0386 wR 2  = 0.0730
Absolute structure parameter 0 .0 2 (8 )
Largest diff. peak and hole 0.192 and -0.219 eA ' 3
Table A Crystal data and structure refinement fo r  (99)
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Atom X V z U(eq)
S(1) 19880(1) 2692(1) 955(1) 35(1)
0 (1 ) 14950(2) 7933(2) 906(1) 34(1)
0 (2 ) 21026(2) 7010(2) 2314(1) 24(1)
N(1) 17551(2) 5845(2) 1243(1) 2 2 ( 1 )
N(2) 17848(2) 8451(2) 2072(1) 2 2 ( 1 ) •
C(1 ) 20840(3) 4194(3) 1494(1) 33(1)
C(2 ) 18808(2) 5215(2) 1698(1) 2 1 ( 1 )
C(3) 19330(2) 6993(2) 2055(1) 19(1)
C(4) 15752(2) 8259(2) 1808(1) 2 2 ( 1 )
0 (5 ) 16054(2) 7355(2) 1269(1) 23(1)
0 (6 ) 18110(3) 4797(3) 747(1) 26(1)
0 (7 ) 14612(3) 10305(2) 1787(1) 32(1)
0 (8 ) 16140(3) 3858(3) 480(1) 37(1)
0(9) 19314(3) 6294(3) 398(1) 38(1)
Table B Atomic coordinates ( x  1(f) and equivalent isotropic displacement 
parameters (A2 x 1(f) fo r  (99).
S(1)-C(1) 1.8054(16) S(1)-C(6) 1.8360(16)
0(1)-C (5) 1.2209(17) 0(2)-C (3) 1.2423(17)
N(1)-C(5) 1.3518(18) N(1)-C(2) 1.4682(18)
N(1)-C(6) 1.4963(19) N(2)-C(3) 1.3194(18)
N(2)-C(4) 1.4658(17) C(1)-C(2) 1.513(2)
C(2)-C(3) 1.519(2) C(4)-C(7) 1.510(2)
C(4)-C(5) 1.527(2) C(6)-C(9) 1.524(2)
C(6 )-C(8 ) 1.525(2)
C(1)-S(1)-C(6) 90.90(7) C(5)-N(1)-C(2) 121.58(12)
C(5)-N(1)-C(6) 122.23(12) C(2)-N(1)-C(6) 116.12(11)
C(3)-N(2)-C(4) 122.18(12) C(2)-C(1)-S(1) 103.74(11)
N(1)-C(2)-C(1) 106.26(12) N(1)-C(2)-C(3) 112.72(12)
C(1)-C(2)-C(3) 111.94(12) 0(2)-C(3)-N(2) 123.89(13)
0(2)-C(3)-C(2) 120.96(12) N(2)-C(3)-C(2) 115.14(11)
N(2)-C(4)-C(7) 110.53(12) N(2)-C(4)-C(5) 110.57(11)
C(7)-C(4)-C(5) 111.43(12) 0(1)-C(5)-N(1) 124.52(13)
0(1)-C(5)-C(4) 121.17(13) N(1)-C(5)-C(4) 114.25(12)
N(1)-C(6)-C(9) 109.19(13) N(1)-C(6)-C(8) 112.97(13)
C(9)-C(6)-C(8) 112.10(14) N(1)-C(6)-S(1) 103.05(10)
C(9)-C(6)-S(1) 111.43(11) C(8)-C(6)-S(1) 107.77(12)
Table C Bond lengths [A] and angles [°] for (99).
2 5 9
Atom U 1 1 U22 U33 U23 U13 U12
S(1) 42(1) 34(1) 28(1) - 1 1 ( 1 ) -5(1) 1 2 (1 )
0 ( 1 ) 35(1) 44(1) 23(1) - 1 ( 1 ) - 1 1 ( 1 ) 1 2 (1 )
0 (2 ) 2 1 ( 1 ) 27(1) 23(1) 0 (1 ) -6 ( 1 ) 0 (1 )
N(1) 23(1) 27(1) 15(1) - 1 ( 1 ) -3(1) 5(1)
N(2) 2 2 (1 ) 24(1) 2 0 ( 1 ) . -4(1) -4(1) 2 (1 )
0 (1 ) 33(1) 38(1) 28(1) - 1 1 (1 ) -9(1) 15(1)
C(2 ) 23(1) 2 2 ( 1 ) 18(1) 1 (1 ) -3(1) 2 (1 )
0 (3 ) 2 0 (1 ) 2 2 ( 1 ) 15(1) 2 (1 ) 1 (1 ) 0 (1 )
C(4) 18(1) 25(1) 2 2 ( 1 ) - 1 ( 1 ) -3(1) 2 (1 )
0 (5) 2 0 (1 ) 27(1) 2 1 ( 1 ) 0 (1 ) -2 (1 ) 0 (1 )
0 (6 ) 28(1) 32(1) 19(1) -3(1) 0 ( 1 ) 5(1)
0 (7 ) 30(1) 32(1) 34(1) -4(1) -6 (1 ) 1 1 (1 )
0 (8 ) 40(1) 44(1) 28(1) - 1 1 (1 ) -8 (1 ) - 1 ( 1 )
0 (9 ) 43(1) 47(1) 24(1) 1 (1 ) 8 ( 1 ) 0 (1 )
Table D  Anisotropic displacement parameters (A2 x 1(f) fo r  (99).
Atom X y z U(eq)
HO A) 21509 3309 1761 39
HOB) 21917 5225 1380 39
H(2) 17946 4179 1895 25
H(4) 14826 7296 2 0 1 2 26
H(7A) 14357 . 10801 2139 48
H(7B) 13220 10152 1608 48
H(7C) 15520 11291 1601 48
H(8 A) 15349 2993 725 56
H(8 B) 16622 3026 187 56
H(8 C) 15183 4953 356 56
H(9A) 18395 7491 331 57
H(9B) 19664 5620 70 57
H(9C) 20659 6733 567 57
H(2A) 18100(30) 9490(20) 2281(6) 34(5)
Table E  Hydrogen coordinates ( x 1(f) and isotropic displacement 




X ray crystallography data for (100).
Identification code c:\backup\helix\h03mt1\maxus\h03mt1
Empirical formula C11 H 18N 2 0 2 S
Formula weight 242 .33
Temperature 150(2) K
W avelength 0.71073 A
Crystal system Triclinic
S p ace group f > 1
Unit cell dim ensions a = 5.7440(2)A  a  = 91 .399(1)°
b = 9 .7410(3)A P = 94.980(1)°
c = 11.0190(4)A y = 98.341 (2 )°
Volume 607.29(4) A3
Z 2
Density (calculated) 1.325 Mg/m3
Absorption coefficient 0.255 mm * 1
F(000) 260
Crystal size 0.15 x 0 .10 x 0 .10 mm
Theta range for data collection 3.60 to 27.45°
Index ranges -7<=h<=7; -12<=k<=12; -14<=l<=14
Reflections collected 9382
Independent reflections 5031 fR(int) = 0.03911
Reflections observed (>2c) 4185
Data C om pleteness 0.995
Absorption correction None
Refinement method Full-matrix least-sguares on F2
Data / restraints /  parameters 5031 /  5 / 3 0 7
Goodness-of-fit on F2 1.040
Final R indices [l>2c(l)l R1 = 0 .0364 wR 2  = 0 .0760
R indices (all data) R1 = 0 .0513 wR 2  = 0 .0818
Absolute structure parameter 0.04(5)
Largest diff. peak and hole 0.253  and -0.242 eA ‘ 3
Table A Crystal data and structure refinement for (100).
#
2 6 1
Atom X y z U(eq)
S(1-) -9021(1) 277(1) 1115(1) 41(1)
S(2) 7979(1) 8935(1) 3652(1) 44(1)
0 ( 1 ) -5675(3) 2800(2) -1902(1) 33(1)
0 (2 ) <r2545(3) 3226(2) 2675(1) 38(1)
0 (3 ) 3262(2) 7082(2) 6512(1) 32(1)
0 (4 ) 1924(2) 5777(2) 1723(1) 32(1)
N(1) -6397(3) 2 2 1 1 (2 ) 30(2) 24(1)
N(2) -2802(3) 4267(2) 852(2) 26(1)
N(3) 4474(3) 7449(2) 4619(2) 25(1)
N(4) 1301(3) 5194(2) 3657(2) 28(1)
0 (1 ) -6584(4) 1304(2) 2027(2) 40(1)
0 (2 ) -6079(4) 2628(2) 1333(2) 27(1)
C(3) -3621(4) 3395(2) 1687(2) 27(1)
C(4) -4282(3) 4493(2) -258(2) 2 2 ( 1 )
0 (5 ) -5490(3) 3088(2) -811(2) 24(1)
0 (6 ) -7800(3) 820(2) -318(2) 25(1)
0(7 ) -2893(3) 5391(2) -1146(2) 26(1)
0 (8 ) -2186(4) 6874(2) -621(2) 35(1)
0(9 ) -753(4) •4796(2) -1524(2) 34(1)
0 (1 0 ) -6224(4) -162(2) -743(3) 43(1)
0 ( 1 1 ) -9875(4) 926(2) -1239(2) 35(1)
0 (1 2 ) 6219(4) 7524(3) 2745(2) 38(1)
0 (13) 3874(3) 7331(2) 3302(2) 27(1)
0(14) 2282(3) 6019(2) 2845(2) 26(1)
0(15) 1557(3) 5417(2) 4975(2) 25(1)
0(16) 3138(3) 6746(2) 5431(2) 25(1)
0 (17) 6241(4) 8673(2) 4999(2) 27(1)
0(18) 2479(3) 4190(2) 5623(2) 24(1)
0(19) 5015(4) 4075(2) 5375(2) 34(1)
C(20) 869(4) 2825(2) 5317(2) 34(1)
0 (2 1 ) 5057(4) 9940(2) 5230(2) 37(1)
C(22) 7926(4) 8414(3) 6087(2) 36(1)
Table B Atomic coordinates ( x 1(f) and equivalent isotropic displacement 
parameters (A2 x 1(f) fo r  (100).
2 6 2
S(1)-C(1) 1.809(2) S(1)-C(6) 1.841(2)
S(2)-C(12) 1.806(2) S(2)-C(17) 1.862(2)
0(1)-C (5) 1 .2 2 0 (2 ) 0(2)-C (3) 1.231(3)
0(3)-C (16) 1 .2 2 1 (2 ) 0(4)-C (14) 1.246(3)
N(1)-C(5) 1.361(2) N(1)-C(2) 1.471(3)
N(1)-C(6) 1.496(3) N(2)-C(3) 1.336(3)
N(2)-C(4) 1.467(3) N(3)-C(16) 1.362(3)
N(3)-C(13) 1.460(3) N(3)-C(17) 1.476(3)
N(4)-C(14) 1.325(3) N(4)-C(15) 1.455(3)
C(1)-C(2) 1.520(3) C(2)-C(3) 1.512(3)
C(4)-C(5) 1.528(3) C(4)-C(7) 1.528(3)
C(6)-C(10) 1.501(3) C(6)-C(11) 1.513(3)
C(7)-C(9) 1.518(3) C(7)-C(8) 1.529(3)
C(12)-C(13) 1.517(3) C(13)-C(14) 1.507(3)
C(15)-C(16) 1.517(3) C(15)-C(18) 1.542(3)
C(17)-C(21) 1.519(3) C(17)-C(22) 1.524(3)
C(18)-C(20) 1.518(3) C(18)-C(19) 1.525(3)
C(1)-S(1)-C(6) 92.23(9) C(12)-S(2)-C(17) 94.65(10)
C(5)-N(1)-C(2) 120.37(17) C(5)-N(1)-C(6) 122.32(18)
C(2)-N(1)-C(6) 117.28(15) C(3)-N(2)-C(4) 121.13(17)
C(16)-N(3)-C(13) 123.40(16) C(16)-N(3)-C(17) 121.71(17)
C(13)-N(3)-C(17) 112.77(16) C(14)-N(4)-C(15) 126.99(19)
C(2)-C(1)-S(1) 104.30(15) N(1)-C(2)-C(3) 111.25(16)
N(1)-C(2)-C(1) 106.46(18) C(3)-C(2)-C(1) 112.11(18)
0(2)-C(3)-N(2) 124.70(19) 0(2)-C(3)-C(2) 121.33(18)
N(2)-C(3)-C(2) 113.96(18) N(2)-C(4)-C(5) 109.06(15)
N(2)-C(4)-C(7) 111.94(15) C(5)-C(4)-C(7) 113.85(17)
0(1)-C(5)-N(1) 123.56(19) 0(1)-C(5)-C(4) 123.13(17)
N(1)-C(5)-C(4) 113.28(18) N(1)-C(6)-C(10) 110.46(16)
N(1)-C(6)-C(11) 111.90(17) C(10)-C(6)-C(11) 1 1 2 .6 (2 )
N(1)-C(6)-S(1) 102.78(14) C(10)-C(6)-S(1) 111.58(15)
C(11)-C(6)-S(1) 107.05(14) C(9)-C(7)-C(8) 110.92(18)
C(9)-C(7)-C(4) 113.38(17) C(8)-C(7)-C(4) 110.52(17)
C(13)-C(12)-S(2) 104.01(16) N(3)-C(13)-C(14) 115.18(17)
N(3)-C(13)-C(12) 105.50(17) C(14)-’C(13)-C(12) 113.04(18)
0(4)-C(14)-N(4) 123.3(2) 0(4)-C (14)-C (13) 118.41(19)
N(4)-C(14)-C(13) 118.27(19) N(4)-C(15)-C(16) 114.60(16)
N(4)-C(15)-C(18) 111.65(17) C(16)-C(15)-C(18) 108.37(16)
0(3)-C(16)-N(3) 123.51(18) 0(3)-C (16)-C (15) 118.77(17)
N(3)-C(16)-C(15) 117.55(17) N(3)-C(17)-C(21) 111.07(17)
N(3)-C(17)-C(22) 113.04(18) C(21)-C(17)-C(22) 111.47(19)
N(3)-C(17)-S(2) 103.06(14) C(21)-C(17)-S(2) 109.87(15)
C(22)-C(17)-S(2) 107.93(15) C(20)-C( 18)-C( 19) 110.95(18)
C(20)-C(18)-C(15) 112.25(17) C(19)-C(18)-C(15) 112.18(16)
Table C Bond lengths [A] and angles [°] for (100).
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Atom U 1 1 U2 2 U33 U23 U13 U12
S(1) 46(1) 38(1) 31(1) 4(1) 5(1) -17(1)
S(2) 36(1) 54(1) 37(1) - 1 0 (1 ) 1 2 ( 1 ) -17(1)
0 (1 ) 41(1) 34(1) 19(1) 1 ( 1 ) 1 ( 1 ) -9(1)
0 (2 ) 47(1) 37(1) 23(1) 5(1) -9(1) -13(1)
0 (3 ) 36(1) 34(1) 25(1) -5(1) 3(1) - 1 ( 1 )
0 (4 ) 36(1) 35(1) 24(1) - 1 (1 ) -5(1) 0 (1 )
N(1) 26(1) 2 2 (1 ) 2 1 (1 ) 1 (1 ) 0 (1 ) -6 ( 1 )
N(2) 27(1) 25(1) 2 2 (1 ) 2 (1 ) -5(1) -6 ( 1 )
N(3) 24(1) 24(1) 23(1) -3(1) - 1 (1 ) -3(1)
N(4) 30(1) 24(1) 25(1) 1 (1 ) -7(1) -5(1)
C(1 ) 50(2) 39(2) 24(1) 5(1) - 1 (1 ) -14(1)
C(2 ) 30(1) 27(1) 2 0 (1 ) 0 (1 ) 1 (1 ) -3(1)
0(3) 34(1) 24(1) 23(1) -4(1) 1 (1 ) - 1 ( 1 )
C(4) 23(1) 2 0 ( 1 ) 2 2 (1 ) 1 (1 ) 2 (1 ) 1 (1 )
0 (5) 2 1 ( 1 ) 25(1) 24(1) 3(1) 0 (1 ) 2 (1 )
0 (6 ) 24(1) 2 2 (1 ) 27(1) - 1 (1 ) 3(1) -4(1)
0 (7) 26(1) 23(1) 26(1) 4(1) -4(1) -3(1)
0 (8 ) 46(1) 2 2 (1 ) 34(1) 4(1) 3(1) -4(1)
0 (9) 32(1) 38(1) 32(1) 3(1) 7(1) - 1 ( 1 )
0 (1 0 ) 37(1) 30(1) 60(2) -8 (1 ) 5(1) 1 (1 )
0 (1 1 ) 33(1) 32(1) 37(1) 2 (1 ) -6 (1 ) -7(1)
0 (1 2 ) 32(1) 45(2) 32(1) -8 (1 ) 3(1) -9(1)
0(13) 28(1) 26(1) 24(1) 0 (1 ) 0 (1 ) 1 (1 )
0 (14) 2 2 (1 ) 26(1) 28(1) 0 (1 ) -2 ( 1 ) 3(1)
0(15) 23(1) 27(1) 23(1) -2 ( 1 ) - 1 (1 ) 1 (1 )
0(16) 2 1 ( 1 ) 28(1) 24(1) 0 (1 ) 0 ( 1 ) 3(1)
0(17) 27(1) 27(1) 25(1) -4(1) 4(1) -5(1)
0(18) 2 1 ( 1 ) 27(1) 2 2 (1 ) 0 (1 ) 2 (1 ) 4(1)
0(19) 27(1) 39(1) 38(1) 6 (1 ) 7(1) 9(1)
C(20) 31(1) 29(1) 43(1) 6 (1 ) 4(1) 4(1)
0 (2 1 ) 38(1) 27(1) 46(2) - 1 (1 ) 7(1) 3(1)
C(22) 30(1) 36(1) 40(2) -7(1) -6 (1 ) 0 ( 1 )
Table D Anisotropic displacement parameters (A2 x 1(f) for (100).
Atom X y z U(eq)
H(1A) -7029 1510 2853 48
H(1B) -5187 814 2 1 0 2 48
H(2) -7261 3250 1507 32
H(4) -5552 5011 - 6 26
H(7) -3976 5436 -1900 31
H(8 A) -1089 6872 1 1 2 52
H(8 B) -3600 7247 -408 52
H(8 C) -1418 7455 -1228 52
H(9A) 300 4676 -798 51
H(9B) 93 5433 -2068 51
H(9C) -1269 3894 -1951 51
H(10A) -5547 180 -1484 64
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H(10B) -7148 -1084 -916 64
H(10C) -4948 - 2 2 2 -104 64
H(11A) -9295 1195 - 2 0 2 2 53
H(11B) -10780 1626 -948 53
H(11C) -10893 24 -1342 53
H(12A) 6009 7767 1879 45
H(12B) 6964 6669 2799 45
H(13) 3043 8132 3066 32
H(15) -51 5471 5237 30 *
H(18) 2485 4381 6520 28
H(19A) 5574 3336 5857 51
H(19B) 6027 4958 5601 51
H(19C) 5073 3856 4506 51
H(20A) 832 2596 4444 51
H(20B) -730 2909 5523 51
H(20C) 1468 2087 5786 51
H(21 A) 3920 10046 4535 55
H(21B) 6257 10769 5332 55
H(21C) 4232 9821 5970 55
H(22A) 7095 8385 6828 55
H(22B) 9271 9164 6176 55
H(22C) 8495 7526 5956 55
H(2A) -1510(30) 4820(20) 1030(20) 28(6)
H(4A) 210(30) 4540(20) 3323(19) 26(6)
Table E  Hydrogen coordinates ( x 1(f) and isotropic displacement 
parameters (A2 x 1(f) fo r  (100).
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